Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17

17 March Virtual

Sunday, 14. March 2021

Non-Profit Symposium
08:30 - 10:00 Auditorium 2
IS02 - Latest developments in hematopoietic cell transplantation - Sorbonne University (ATERHIT) non-profit s
Chair: Arnon Nagler, IL
Chair: Bipin Savani, US
IS2-1 Haplo transplant for AML 08:30 - 08:48
Speaker: Arnon Nagler, IL

IS2-2 Haplo transplant for the elderly 08:48 - 09:06

Speaker: Didier Blaise, FR

IS2-3 Monoclonal antibodies in ALL 09:06 - 09:24

Speaker: Eolia Brissot, FR

IS2-4 Monoclonal antibodies in Hodgkin lymphoma 09:24 - 09:42

Speaker: Ali Bazarbachi, LB

IS2-5 Allogeneic transplantation after CAR T-cell therapy 09:42 - 10:00

Speaker: Bipin Savani, US

Non-Profit Symposium
08:30 - 10:00 Auditorium 3
IS03 - Multiple myeloma in 2021: the IFM global perspective - IFM non-profit symposium
Chair: Mohamad Mohty, FR
Chair: Jean-Luc Harousseau, FR
IS3-1 Introduction 08:30 - 08:32
Speaker: Mohamad Mohty, FR

IS3-2 What's new for induction prior to ASCT? 08:32 - 08:53

Speaker: Philippe Moreau, FR

IS3-3 What's new in the elderly setting? 08:53 - 09:14

Speaker: Thierry Facon, FR

IS3-4 Monoclonal antibodies for relapse after ASCT 09:14 - 09:35

Speaker: Mohamad Mohty, FR

IS3-5 Requirements for functional cure in myeloma 09:35 - 09:56

Speaker: Jean-Luc Harousseau, FR

IS3-6 Conclusion 09:56 - 09:58

Speaker: Mohamad Mohty, FR

Non-Profit Symposium
08:30 - 10:00 Auditorium 4
IS04 - Dilemma in allogeneic hematopoietic transplantation for myelofibrosis - SFGM-TC non-profit symposium
Chair: Jacques Olivier Bay, FR
Chair: Thierry Guillaume, FR
IS4-1 Impact of HSCT in ruxolitinib area 08:30 - 08:50

1 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

Speaker: Marie Robin, FR

IS4-2 Transplantation with an alternative donor: Results and 08:50 - 09:10

perspectives
Speaker: Nicolaus Kröger, DE

IS4-3 Liver specificities in myelofibrosis and impact on 09:10 - 09:30

transplantation procedure
Speaker: Audrey Payance, FR

IS4-4 Q&A 09:30 - 10:00

Industrial Theatre
08:30 - 18:45 IT
Industry Theatre sessions

Industrial Theatre
08:30 - 18:45 IT
IT1 - Kite as innovators in CAR T-cell therapy manufacturing and delivery - Kite-Gilead Industry Theatre sessio
This session is available throughout the whole congress
Chair: Dick Sundh, AU

Industrial Theatre
08:30 - 18:45 IT
IT2 - Developing the Future of CAR-T Cell Therapy Today - Novartis Industry Theatre session
This session is available throughout the whole congress
Chair: Amir Hefni, GB
Chair: David Kuzan, US
Chair: Carolin Barth, CH

Industrial Theatre
08:30 - 18:45 IT
IT3 - Amicus Blue in Children and Adolescents with GVHD - Fresenius Kabi Industry Theatre session
This session is available throughout the whole congress
Chair: Volker Witt, AT

Data Management
08:30 - 18:45 On-Demand Library
DM07 - Education session 7
This session is available in our on-demand library throughout the whole congress
DM7-1 Minimal residual disease (MRD) -
Speaker: Johannes Schetelig, DE

Oral Session
08:30 - 18:45 On-Demand Library
OS01 - Oral session 1: Hematopoietic Stem Cells, Mobilization and Engineering
This session is available in our on-demand library throughout the whole congress
OS1-1 MGTA-145, IN COMBINATION WITH PLERIXAFOR IN A PHASE 1 08:30 - 08:30
CLINICAL STUDY, MOBILIZES LARGE NUMBERS OF

2 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

HEMATOPOIETIC STEM CELLS AND A GRAFT WITH POTENT

IMMUNOSUPPRESSIVE PROPERTIES
Speaker: Kevin Goncalves, US

OS1-2 EFFICACY AND SAFETY OF PEGFILGRASTIM FOR CD34+ CELL 08:30 - 08:30
MOBILIZATION IN HEALTHY VOLUNTEERS
Speaker: Hideki Goto, JP

OS1-3 THE IMPACT OF PLATELET RECOVERY ON SURVIVAL IN 08:30 - 08:30

CHILDREN UNDERGOING HEMATOPOIETIC STEM CELL
TRANSPLANTATION
Speaker: Rumesh Chandar, IN

OS1-4 THE IMPACT OF CD3 AND CD34 CELL DOSE ON GRAFT 08:30 - 08:30
REJECTION AND GRAFT VERSUS HOST DISEASE IN
CHILDREN UNDERGOING UNRELATED PERIPHERAL BLOOD
STEM CELL TRANSPLANTATION
Speaker: Satish Meena, IN

OS1-5 OUTCOME AND IMMUNE RECONSTITUTION AFTER 08:30 - 08:30

TCR??/CD19 CELL DEPLETED HEMATOPOIETIC STEM CELL
TRANSPLANTATION FROM HAPLOIDENTICAL RELATED
DONOR IN ADULT LEUKEMIA – A SINGLE CENTRE
EXPERIENCE
Speaker: Lucia Prezioso, IT

OS1-6 THE PREVALENCE OF ANTI-HLA ANTIBODIES IN THE FIRST 08:30 - 08:30

100 HAPLOIDENTICAL HEMATOPOIETIC STEM CELL
TRANSPLANTATION IN PEDIATRIC PATIENTS: A SINGLE-
CENTER EXPERIENCE
Speaker: Muhammad Ameen, SA

OS1-7 POST-TRANSPLANT OUTCOMES OF CHILDREN WITH 08:30 - 08:30

PRIMARY HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS
TREATED WITH EMAPALUMAB
Speaker: Michael Jordan, US

OS1-8 WHITE MATTER DEVELOPMENT IN NEONATES WITH 08:30 - 08:30

INFANTILE KRABBE DISEASE
Speaker: Maria Escolar, US

Data Management
08:30 - 18:45 On-Demand Library
DM05 - Education session 5
This session is available in our on-demand library throughout the whole congress
DM5-1 Hematopoietic Cell Transplantation-Comorbidity Index ‘Sorror -
Score’
Speaker: Bronwen Shaw, US

3 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

Oral Session
08:30 - 18:45 On-Demand Library
OS03 - Oral session 3: CARs II
This session is available in our on-demand library throughout the whole congress
OS3-1 CD19 CAR T THERAPY IN CHILDREN WITH R/R ALL: ADAPTIVE 08:30 - 08:30
SPLIT DOSING IMPROVES SAFETY AND MAINTAINS EFFICACY
OF THE APPROACH
Speaker: Olga Molostova, RU

OS3-2 CYTOKINE RELEASE SYNDROME IN PATIENTS WITH 08:30 - 08:30

RELAPSED/REFRACTORY MULTIPLE MYELOMA TREATED
WITH CILTACABTAGENE AUTOLEUCEL IN THE PHASE 1B/2
CARTITUDE-1 STUDY
Speaker: Andrzej Jakubowiak, US

OS3-3 PHARMACOLOGY AND EFFICACY OF KTE-X19 BY PRIOR 08:30 - 08:30

BRUTON TYROSINE KINASE INHIBITOR EXPOSURE OR
MANTLE CELL LYMPHOMA (MCL) MORPHOLOGY IN PATIENTS
WITH RELAPSED/REFRACTORY MCL IN ZUMA-2
Speaker: Michael L. Wang, US

OS3-4 REAL WORLD OF EXPERIENCE AXICABTAGENE CILOLEUCEL 08:30 - 08:30

FOR THE TREATMENT OF RELAPSED OR REFRACTORY
LARGE B-CELL LYMPHOMA IN SPAIN
Speaker: Mi Kwon, ES

OS3-5 HUMORAL RESPONSE TO PNEUMOCOCCAL ANTIGENS 08:30 - 08:30

DECLINES AFTER CD19-TARGETED CAR T CELL THERAPY
Speaker: Dasom Lee, US

OS3-6 DECREASED NEUROPROTECTIVE ANALYTES ON DAY OF 08:30 - 08:30

INFUSION OF CHIMERIC ANTIGEN RECEPTOR (CAR) T CELLS
ARE ASSOCIATED WITH NEUROTOXICITY
Speaker: Madhavi Lakkaraja, US

OS3-7 COMPARISON OF TWO KINDS OF ANTI-THYMOCYTE 08:30 - 08:30

GLOBULIN ON OUTCOMES OF HAPLOIDENTICAL STEM CELL
TRANSPLANTATION FOR REFRACTORY/RELAPSED AND HIGH-
RISK B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA AFTER CAR-
T THERAPY
Speaker: Zhao-Yanli Zhao, CN

OS3-8 THIRD-GENERATION GD2.CAR T-CELLS INCORPORATING 08:30 - 08:30

CD28.4-1BB COSTIMULATORY DOMAINS FOR TREATMENT OF
GD2+ SARCOMAS
Speaker: Antonio Camera, IT

Educational
08:30 - 18:45 On-Demand Library
E09 - Allogeneic HSCT in MDS and MPN
This session is available in our on-demand library throughout the whole congress
E9-1 Definition of graft failure/relapse after allo-HCT in myelofibrosis -
Speaker: Donal McLornan, GB

4 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

E9-2 Allogeneic HSCT in patients with therapy-related MDS/AML -

Speaker: Marie Robin, FR

E9-3 The role of maintenance therapy after allogeneic HSCT in MDS -

Speaker: Francesco Onida, IT

On Demand Library
08:30 - 18:45 On-Demand Library
On Demand Library

Oral Session
08:30 - 18:45 On-Demand Library
OS04 - Oral session 4: Cellular Therapy, Gene Therapy and New Drugs I
This session is available in our on-demand library throughout the whole congress
OS4-1 INTERIM RESULTS OF BETIBEGLOGENE AUTOTEMCEL GENE 08:30 - 08:40
THERAPY IN PEDIATRIC PATIENTS WITH TRANSFUSION-
DEPENDENT ?-THALASSEMIA (TDT) TREATED IN THE PHASE 3
NORTHSTAR-2 (HGB-207) AND NORTHSTAR-3 (HGB-212)
STUDIES
Speaker: Isabelle Thuret, FR

OS4-2 NARSOPLIMAB (OMS721), A MASP-2 INHIBITOR, FOR THE 08:40 - 08:50

TREATMENT OF ADULT HEMATOPOIETIC STEM CELL
TRANSPLANT-ASSOCIATED THROMBOTIC
MICROANGIOPATHY (HSCT-TMA): SUBGROUP ANALYSES
Speaker: Alessandro Rambaldi, IT

OS4-3 CRISPR-BASED REPLACEMENT OF THE ENDOGENOUS T- 08:50 - 09:00

CELL REPERTOIRE WITH NOVEL, HIGH-AVIDITY, NATURAL T
CELL RECEPTORS TO WT1 FOR THE TREATMENT OF ACUTE
MYELOID LEUKEMIA
Speaker: Eliana Ruggiero, IT

OS4-4 CLINICAL TRIAL UPDATE: EX-VIVO AUTOLOGOUS STEM CELL 09:00 - 09:10
GENE THERAPY IN MPSIIIA
Speaker: Jane Louise Kinsella, GB

OS4-5 EXOGENOUS M-CSF PROTECTS FROM LETHAL A. FUMIGATUS 09:10 - 09:20

PULMONARY INFECTION EARLY AFTER HEMATOPOIETIC
STEM CELL TRANSPLANTATION
Speaker: Dalia Sheta, DE

OS4-6 REAL-WORLD EFFECTIVENESS AND SAFETY OF 09:20 - 09:30

BLINATUMOMAB IN EUROPE: 3-YEAR RESULTS IN RELAPSED
OR REFRACTORY PHILADELPHIA CHROMOSOME-NEGATIVE
BCP-ALL PATIENTS INCLUDING THOSE WITH LATE FIRST
RELAPSE
Speaker: Alessandro Rambaldi, IT

OS4-7 GENERATION OF HSPC-DERIVED CD16A-ENGINEERED NK 09:30 - 09:40

CELLS WITH ADVANCED ANTIBODY-DEPENDENT CELLULAR
CYTOTOXICITY
Speaker: Paulien van Hauten, NL

5 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

OS4-8 IMPROVEMENTS IN FATIGUE AND PHYSICAL FUNCTION 09:40 - 09:50

EVALUATED THROUGH CHANGES IN CLINICAL OUTCOMES IN
PAROXYSMAL NOCTURNAL HEMOGLOBINURIA: POST-HOC
ANALYSES FROM THE PEGASUS STUDY

Oral Session
08:30 - 18:45 On-Demand Library
OS07 - Oral session 7: Stem Cell Source and Donors
This session is available in our on-demand library throughout the whole congress
OS7-1 FUNCTIONAL MISMATCHING FOR HLA-DP REDUCES RELAPSE 08:30 - 08:40
RISK AFTER UNRELATED HEMATOPOIETIC CELL
TRANSPLANTATION: A STUDY FROM THE CELLULAR
THERAPY AND IMMUNOBIOLOGY WORKING PARTY OF THE
EBMT
Speaker: Annalisa Ruggeri, ES

OS7-2 POST-TRANSPLANT CYCLOPHOSPHAMIDE IN ONE-ANTIGEN 08:40 - 08:50

MISMATCHED UNRELATED DONOR TRANSPLANTATION
VERSUS HAPLOIDENTICAL TRANSPLANTATION: A
RETROSPECTIVE STUDY ON BEHALF OF THE ACUTE
LEUKEMIA WORKING PARTY OF THE EBMT
Speaker: Giorgia Battipaglia, IT

OS7-3 HLA EVOLUTIONARY DIVERGENCE (HED) INFLUENCES 08:50 - 09:00

OUTCOMES OF ALLOGENEIC HSCT FROM UNRELATED
DONOR (UD) IN PEDIATRIC PATIENTS AND YOUNG ADULTS
AFFECTED BY MALIGNANT DISORDERS
Speaker: Pietro Merli, IT

OS7-4 MANAGEMENT OF DONOR-SPECIFIC ANTIBODIES IN 09:00 - 09:10

HAPLOIDENTICAL TRANSPLANT: MULTICENTER EXPERIENCE
FROM THE MADRID GROUP OF HEMATOPOIETIC
TRANSPLANT
Speaker: Rebeca Bailén, ES

OS7-5 LONG TERM OUTCOMES AFTER INTRABONE UNRELATED 09:10 - 09:20

UMBILICAL CORD BLOOD TRANSPLANT IN PATIENTS WITH
HEMATOLOGICAL MALIGNANCIES: A EUROCORD, CTIWP-
EBMT ANALYSIS
Speaker: Jacopo Peccatori, IT

OS7-6 INFERIOR CLINICAL OUTCOMES IN RECIPIENTS OF 09:20 - 09:30

CRYOPRESERVED GRAFTS FOLLOWING REDUCED INTENSITY
ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION: A
SINGLE CENTER REPORT
Speaker: Andriyana Bankova, US

OS7-8 CLINICAL RESULTS OF PERIPHERAL BLOOD STEM CELL 09:30 - 09:40

TRANSPLANTATION WITH CRYOPRESERVED GRAFTS
DURING THE COVID19 PANDEMIC
Speaker: Maximilian Christopeit, DE

6 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

Oral Session
08:30 - 18:45 On-Demand Library
OS20 - Oral session 20: Aplastic Anemia, Autoimmune Disorders, and others
This session is available in our on-demand library throughout the whole congress
OS20-1 HLA EVOLUTIONARY DIVERGENCE INFLUENCES 08:30 - 08:40
CHARACTERISTICS AND OUTCOMES OF PATIENTS WITH
APLASTIC ANEMIA AND PAROXYSMAL NOCTURNAL
HEMOGLOBINURIA
Speaker: Simona Pagliuca, US

OS20-2 OUTCOME OF NON-MYELOABLATIVE AUTOLOGOUS 08:40 - 08:50

HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR
MULTIPLE SCLEROSIS: A SINGLE CENTER SUMMARY OF 511
PATIENTS
Speaker: Richard K Burt, US

OS20-3 EARLY MORBIDITY OF AUTOLOGOUS HAEMATOPOIETIC 08:50 - 09:00

STEM CELL TRANSPLANTATION IN MULTIPLE SCLEROSIS- A
REAL WORLD EXPERIENCE
Speaker: Varun Mehra, GB

OS20-4 THE GENOMIC LANDSCAPE OF MYELOID NEOPLASMS 09:00 - 09:10

ARISING FROM APLASTIC ANEMIA AND PAROXYSMAL
NOCTURNAL HEMOGLOBINURIA
Speaker: Carmelo Gurnari, US

OS20-5 HIGH-DOSE IMMUNOSUPPRESSIVE THERAPY WITH 09:10 - 09:20

AUTOLOGOUS HEMATOPOIETIC STEM CELL
TRANSPLANTATION (AHSCT) IN MULTIPLE SCLEROSIS:
CHANGING APPROACHES IN SINGLE-CENTER EXPERIENCES
Speaker: Alexey Polushin, RU

OS20-6 HLA MUTATIONS IN PAROXYSMAL NOCTURNAL 09:20 - 09:30

HEMOGLOBINURIA: A POSSIBLE ALTERNATIVE MECHANISM
OF IMMUNE ESCAPE
Speaker: Carmelo Gurnari, US

OS20-7 HEMATOPOIETIC STEM CELL TRANSPLANT AS TREATMENT 09:30 - 09:40

OF REFRACTORY MYASTHENIA GRAVIS
Speaker: Claudia Lucía Sossa Melo, CO

OS20-8 IMPACT OF AHSCT ON FERTILITY IN MULTIPLE SCLEROSIS 09:40 - 09:50

PATIENTS
Speaker: Alice Mariottini, IT

Oral Session
08:30 - 18:45 On-Demand Library
OS17 - Oral session 17: Acute Leukemia II
This session is available in our on-demand library throughout the whole congress
OS17-1 TRENDS AND PREDICTIVE FACTORS FOR OUTCOME OF 08:30 - 08:30
RELAPSED PHILADELPHIA POSITIVE ACUTE LYMPHOBLASTIC
LEUKEMIA AFTER ALLOGENEIC HEMATOPOIETIC CELL
TRANSPLANTION: IMPROVEMENT OF SURVIVAL IN RECENT

7 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

YEARS
Speaker: Ali Bazarbachi, LB

OS17-2 HOST IMMUNE GENETIC VARIATIONS INFLUENCE THE RISK 08:30 - 08:30
OF DEVELOPING ACUTE MYELOID LEUKAEMIA: RESULTS
FROM THE NUCLEAR CONSORTIUM
Speaker: José Sánchez Maldonado, ES

OS17-3 COMPARISON OF HAPLOIDENTICAL PERIPHERAL BLOOD 08:30 - 08:30

CELL TRANSPLANTATION USING POST-TRANSPLANT
CYCLOPHOSPHAMIDE WITH DOUBLE CORD BLOOD
TRANSPLANTATION IN ADULTS WITH ACUTE LEUKEMIA
Speaker: Annalisa Ruggeri, ES

OS17-4 REAL-LIFE EXPERIENCE OF SORAFENIB MAINTENANCE 08:30 - 08:30

AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL
TRANSPLANTATION FOR FLT3-ITD AML REVEALS HIGH
RATES OF TOXICITY-RELATED TREATMENT INTERRUPTION
Speaker: Sarah Morin, CH

OS17-5 VENETOCLAX COMBINED WITH HYPOMETHYLATING AGENT 08:30 - 08:30

(HMA) IS SAFE AND EFFECTIVE MAY BE A GOOD BRIDGE TO
TRANSPLANT IN HIGH-RISK ACUTE MYELOID LEUKEMIA
Speaker: Vincenzo Federico, IT

OS17-6 TKI MAINTENANCE AFTER STEM-CELL TRANSPLANTATION 08:30 - 08:30

FOR FLT3-ITD POSITIVE ACUTE MYELOID LEUKEMIA: A
SYSTEMATIC REVIEW AND META-ANALYSIS
Speaker: Nico Gagelmann, DE

OS17-7 STEM CELL TRANSPLANTATION FROM A HAPLOIDENTICAL 08:30 - 08:30

DONOR FOR PEDIATRIC PATIENTS WITH ACUTE
MYELOGENOUS LEUKEMIA: A RETROSPECTIVE NATIONWIDE
STUDY
Speaker: Charlotte Nazon, FR

OS17-8 COMPREHENSIVE GERIATRIC ASSESSMENT, ALLOGENEIC 08:30 - 08:30

HSCT AND SURVIVAL IN AML PATIENTS 65-75 YEARS OLD
Speaker: Gabriele Magliano, IT

Oral Session
08:30 - 18:45 On-Demand Library
OS16 - Oral session 16: Acute Leukemia I
This session is available in our on-demand library throughout the whole congress
OS16-1 IMPACT OF CO-OCCURRING CYTOGENETIC ABNORMALITIES 08:30 - 08:40
ON TRANSPLANT OUTCOME OF TP53 MUTANT ACUTE
MYELOID LEUKAEMIA: REPORT FROM THE ALWP OF THE
EBMT
Speaker: Justin Loke, GB

OS16-2 IMPACT OF CYTOGENETIC CLASSIFICATION IN ALLO-HCT IN 08:40 - 08:50

PATIENTS WITH ACUTE MYELOID LEUKEMIA SECONDARY TO
MYELODYSPLASTIC SYNDROME: A JOIN STUDY BY THE
ALWP AND THE CMWP

8 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

Speaker: Eolia Brissot, FR

OS16-3 THE IMPACT OF CYTOGENETIC RISK ON OUTCOME OF NON-T 08:50 - 09:00

CELL DEPLETED HAPLOIDENTICAL STEM CELL
TRANSPLANTATION IN RELAPSED/REFRACTORY AML: A
STUDY FROM THE ALWP / EBMT
Speaker: Arnon Nagler, IL

OS16-4 NON-T DEPLETED HAPLOIDENTICAL STEM CELL 09:00 - 09:10

TRANSPLANTATION IN AML PATIENTS ACHIEVING FIRST
COMPLETE REMISSION AFTER ONE VS TWO INDUCTION
COURSES: A STUDY FROM THE ALWP/EBMT
Speaker: Arnon Nagler, IL

OS16-5 PREVALENCE AND OUTCOME OF CNS RELAPSE AFTER 09:10 - 09:20

ALLOGENEIC HEMATOPOIETIC STEM CELL
TRANSPLANTATION IN PATIENTS SUFFERING FROM AML AND
ALL. A STUDY FROM THE ALWP-EBMT
Speaker: Sabine Blum, CH

OS16-6 IMPACT OF ALLOGENIC TRANSPLANTATION IN THE 09:20 - 09:30

TREATMENT OF SECONDARY ACUTE MYELOID LEUKEMIAS.
COMPARISON BETWEEN MYELOABLATIVE VS REDUCE
INTENSITY CONDITIONINGS
Speaker: Claudia Núñez-Torrón, ES

OS16-7 THE DISEASE BURDEN PRIOR TO ALLOGENEIC 09:30 - 09:40

HEMATOPOIETIC STEM CELL TRANSPLANT IS MORE
RELEVANT IN PATIENTS WITH DE NOVO LEUKEMIA COMPARE
TO PATIENTS WITH SECONDARY LEUKEMIA
Speaker: Claudia Núñez-Torrón, ES

OS16-8 PROGNOSIS OF PATIENTS WITH ACUTE LYMPHOBLASTIC 09:40 - 09:50

LEUKEMIA RELAPSING AFTER AN ALLOGENEIC STEM CELL
TRANSPLANTATION. STUDY OF 132 PATIENTS
Speaker: Christelle Ferra Coll, ES

Working Party Session

08:30 - 18:45 On-Demand Library
IDWP - Infectious Diseases Working Party Session
This session is available in our on-demand library throughout the whole congress
IDWP-1 IDWP update -
Speaker: Rafael de la Cámara, ES

IDWP-2 Current scientific proposals of IDWP -

Speaker: Dina Averbuch, IL

IDWP-3 CMV T-cell immunity monitoring: is it time to incorporate it in -

clinical practices?
Speaker: Roy Chemaly, US

IDWP-4 What is new in the field of Gram-negative infections in SCT -

patients?
Speaker: Dina Averbuch, IL

9 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

IDWP-5 Seasonal human coronaviruses vs SARS-CoV-2 in allogeneic -

hematopoietic stem cell transplantation
Speaker: Jose Luis Piñana, ES

IDWP-6 Hepatitis C and hepatitis E in SCT -

Speaker: Malgorzata Mikulska, IT

IDWP-7 Central nervous system (CNS) complications following HSCT -

Speaker: Martin Schmidt-Hieber, DE

Educational
08:30 - 18:45 On-Demand Library
E08 - New challenges in infectious complications
This session is available in our on-demand library throughout the whole congress
E8-1 T-cell therapy for infections in SCT patients: An experimental -
treatment or a real choice for the practice?
Speaker: Patrizia Comoli, IT

E8-2 Infectious complications with new drugs in Hematology -

Speaker: Georg Maschmeyer, DE

E8-3 The blood virome of HSCT Recipients: Much more than viremia -
by CMV, EBV, HH6V and adenovirus
Speaker: Marie-Celine Zanella, CH

Oral Session
08:30 - 18:45 On-Demand Library
OS18 - Oral session 18: Myeloproliferative Neoplasms and Myelodysplastic Syndromes
This session is available in our on-demand library throughout the whole congress
OS18-1 GENOMIC CONFIGURATION OF TP53 MUTATIONS IN PATIENTS 08:30 - 08:30
WITH MYELOID NEOPLASIA
Speaker: Carmelo Gurnari, US

OS18-2 RETROSPECTIVE ANALYSIS EVALUATING THE EFFECT OF 08:30 - 08:30

AGE ON OUTCOMES AFTER ALLOGENEIC HEMATOPOIETIC
CELL TRANSPLANTATION IN CHRONIC MYELOMONOCYTIC
LEUKEMIA. A STUDY OF THE EBMT-CMWP
Speaker: Alicia Rovó, CH

OS18-3 CHANGE IN IPSS-R BETWEEN DIAGNOSIS AND TRANSPLANT 08:30 - 08:30

AND TRANSPLANT OUTCOME IN PATIENTS WITH MDS. A
RETROSPECTIVE ANALYSIS FROM THE CHRONIC
MALIGNANCIES WORKING PARTY
Speaker: Christof Scheid, DE

OS18-4 ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION IN 08:30 - 08:30

PATIENTS WITH THERAPY-RELATED MYELOID NEOPLASM
AFTER BREAST CANCER TREATMENT: A STUDY OF THE
CHRONIC MALIGNANCIES WORKING PARTY OF THE EBMT
Speaker: Mitja Nabergoj, CH

OS18-5 IMPACT OF PRIOR JAK-INHIBITOR THERAPY WITH 08:30 - 08:30

10 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

RUXOLITINIB ON OUTCOME AFTER ALLOGENEIC STEM CELL

TRANSPLANTATION FOR MYELOFIBROSIS. A LARGE EBMT-
CMWP STUDY
Speaker: Nicolaus Kröger, DE

OS18-6 ADDITIONAL CHROMOSOMAL ABERRATIONS IN CML 08:30 - 08:30

PATIENTS UNDERGOING ALLOGENEIC HEMATOPOIETIC STEM
CELL TRANSPLANTATION
Speaker: Elena Morozova, RU

OS18-7 DONOR AGE, CD34 CELL DOSE AND NON-BLAST CRISIS ARE 08:30 - 08:30
PROGNOSTIC FACTORS FOR OUTCOME AFTER STEM CELL
TRANSPLANTATION IN PATIENTS WITH ADVANCE PHASE CML
Speaker: Christian Niederwieser, DE

OS18-8 OUTCOMES OF ALLOGENEIC HEMATOPOIETIC STEM CELL 08:30 - 08:30

TRANSPLANTATION IN PATIENTS WITH MYELOFIBROSIS
TREATED WITH RUXOLITINIB IN THE PRE-TRANSPLANT
PERIOD
Speaker: Anna Czyz, PL

Special Session
08:30 - 18:45 On-Demand Library
SS09 - How to get published
This session is available in our on-demand library throughout the whole congress
SS9-1 BMT: Official journal of the EBMT -
Speaker: Hillard Lazarus, US

SS9-2 How to get published -

Speaker: Mohamad Mohty, FR

Oral Session
08:30 - 18:45 On-Demand Library
OS21 - Oral session 21: Multiple Myeloma
This session is available in our on-demand library throughout the whole congress
OS21-1 MICROENVIRONMENT IMMUNE RECONSTITUTION PATTERNS 08:30 - 08:30
CORRELATE WITH OUTCOMES AFTER AUTOLOGOUS
TRANSPLANT IN MULTIPLE MYELOMA
Speaker: Harsh Parmar, US

OS21-2 AUTOLOGOUS HEMATOPOIETIC CELL TRANSPLANTATION 08:30 - 08:30

FOR RELAPSED MULTIPLE MYELOMA PERFORMED WITH
STEM CELLS RE-MOBILISED FOLLOWING A PRIOR AUTO-HCT
– A RETROSPECTIVE STUDY ON BEHALF OF EBMT CMWP
Speaker: Joanna Drozd-Soko?owska, PL

OS21-3 ISATUXIMAB PLUS CARFILZOMIB AND DEXAMETHASONE 08:30 - 08:30

VERSUS CARFILZOMIB AND DEXAMETHASONE IN RELAPSED
MULTIPLE MYELOMA PATIENTS WHO PREVIOUSLY
UNDERWENT TRANSPLANTATION: IKEMA SUBGROUP
ANALYSIS
Speaker: Mohamad Mohty, FR

11 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

OS21-4 AUTOLOGOUS-ALLOGENEIC VS AUTOLOGOUS TANDEM 08:30 - 08:30

STEM CELL TRANSPLANTATION AND MAINTENANCE WITH
THALIDOMIDE FOR PATIENTS WITH MULTIPLE MYELOMA
(MM) AND AGE <60 YEARS: A PROSPECTIVE PHASE II-
STUDY
Speaker: Nicolaus Kröger, DE

OS21-5 ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION 08:30 - 08:30

FOLLOWED BY BORTEZOMIB IN MULTIPLE MYELOMA: FINAL
RESULTS OF A PROSPECTIVE TRIAL HIGHLIGHTING A
STRONG PROGNOSTIC ROLE OF MEASURABLE RESIDUAL
DISEASE
Speaker: Jean Roy, CA

OS21-6 ACCEPTABLE TOXICITY AND GOOD HEMATOLOGICAL AND 08:30 - 08:30

RENAL RESPONSES AFTER AUTOLOGOUS HEMATOPOIETIC
STEM CELL TRANSPLANTATION IN MYELOMA PATIENTS WITH
RENAL INSUFFICIENCY: A PROSPECTIVE SFGM-TC STUDY
Speaker: laurent Garderet, FR

OS21-7 COAST (OP-501): FIRST IN MAN PHASE I MULTICENTER STUDY 08:30 - 08:30
EVALUATING OPD5 AS A MYELOABLATIVE CONDITIONING
REGIMEN IN RELAPSED REFRACTORY MULTIPLE MYELOMA
(RRMM)
Speaker: Sergio Giralt, US

OS21-8 CHARACTERISTICS AND TREATMENT PATTERNS OF TRIPLE- 08:30 - 08:30

CLASS-EXPOSED PATIENTS WITH RELAPSED/REFRACTORY
MULTIPLE MYELOMA WHO PARTICIPATED IN CLINICAL
TRIALS OF DARATUMUMAB
Speaker: Katja Weisel, DE

Oral Session
08:30 - 18:45 On-Demand Library
OS02 - Oral session 2: CARs I
This session is available in our on-demand library throughout the whole congress
OS2-1 CARTITUDE-1: PHASE 1B/2 STUDY OF CILTACABTAGENE 08:30 - 08:40
AUTOLEUCEL, A B-CELL MATURATION ANTIGEN–DIRECTED
CHIMERIC ANTIGEN RECEPTOR T CELL THERAPY, IN
RELAPSED/REFRACTORY MULTIPLE MYELOMA
Speaker: Deepu Madduri, US

OS2-2 PROPHYLACTIC CORTICOSTEROID USE WITH 08:40 - 08:50

AXICABTAGENE CILOLEUCEL (AXI-CEL) IN PATIENTS WITH
RELAPSED/REFRACTORY LARGE B CELL LYMPHOMA (R/R
LBCL)
Speaker: Olalekan O. Oluwole, US

OS2-3 MATCHING-ADJUSTED INDIRECT COMPARISON (MAIC) OF 08:50 - 09:00

LISOCABTAGENE MARALEUCEL (LISO-CEL) VERSUS
AXICABTAGENE CILOLEUCEL (AXI-CEL) AND
TISAGENLECLEUCEL IN RELAPSED/REFRACTORY LARGE B-
CELL LYMPHOMA

12 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

Speaker: David Maloney, US

OS2-4 STRATEGIES TO INCREASE CAR T-CELL SAFETY AND TO 09:00 - 09:10

PREVENT EPITOPE MASKING IN CAR+ B-CELL LEUKEMIA
BLASTS
Speaker: Concetta Quintarelli, IT

OS2-5 CONTRIBUTION OF AGE AND THE HCT-CI TO PREDICT CRS 09:10 - 09:20
AND ICANS SEVERITY IN NHL PATIENTS RECEIVING CD19
CAR T-CELL THERAPY
Speaker: Jordan Gauthier, US

OS2-6 OUTCOMES OF TREATMENT WITH THE CHIMERIC ANTIGEN 09:20 - 09:30

RECEPTOR (CAR) T CELL THERAPY LISOCABTAGENE
MARALEUCEL (LISO-CEL) IN THE NONUNIVERSITY SETTING:
INITIAL RESULTS FROM THE OUTREACH STUDY
Speaker: John E. Godwin, US

OS2-7 BUILDING OF THE G0-CAR-T INITIATIVE TO PROMOTE USE OF 09:30 - 09:40

DATA COLLECTED FROM PATIENTS TREATED WITH CAR-T
CELLS AT EU OR EBMT AFFILIATED PROGRAMS
Speaker: Christian Chabannon, FR

OS2-8 ENGINEERED CAR.CD123 NK CELLS AS AN INNOVATIVE “OFF 09:40 - 09:50

THE SHELF” STRATEGY TO TREAT CD123POS CHILDHOOD
ACUTE MYELOID LEUKAEMIA
Speaker: Simona Caruso, IT

Data Management
08:30 - 18:45 On-Demand Library
DM09 - Education session 9
This session is available in our on-demand library throughout the whole congress
DM9-1 Follow up forms - How to get a chronological overview of the -
patient history and follow up
Speaker: Elena Ferrer Martínez del Peral, ES

Oral Session
08:30 - 18:45 On-Demand Library
OS09 - Oral session 9: Graft versus Host Disease II
This session is available in our on-demand library throughout the whole congress
OS9-1 GLUCAGON-LIKE-PEPTIDE-2 (GLP-2) ANALOGUE 08:30 - 08:30
TEDUGLUTIDE FOR GRAFT-VERSUS-HOST DISEASE IN
HUMANS
Speaker: Robert Zeiser, DE

OS9-2 RUXOLITINIB VS BEST AVAILABLE THERAPY IN PATIENTS 08:30 - 08:30

WITH STEROID-REFRACTORY/DEPENDENT CHRONIC GRAFT-
VS-HOST DISEASE (CGVHD): SUBGROUP ANALYSES OF
OVERALL RESPONSE RATE IN THE PHASE 3 REACH3 TRIAL
Speaker: Franco Locatelli, IT

OS9-3 DISCONTINUATION OF SYSTEMIC IMMUNOSUPPRESSIVE 08:30 - 08:30

13 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

THERAPY: NEW GOAL OF CHRONIC GVHD TREATMENT?

Speaker: Ivan Moiseev, RU

OS9-4 A PHASE 2, PROSPECTIVE, RANDOMISED, OPEN-LABEL 08:30 - 08:30

STUDY OF DEFIBROTIDE FOR THE PREVENTION OF ACUTE
GRAFT-VERSUS-HOST DISEASE (AGVHD) AFTER
ALLOGENEIC HAEMATOPOIETIC CELL TRANSPLANTATION
(HCT)
Speaker: Michelle Hudspeth, US

OS9-5 THE IMPACT OF GVHD ON OUTCOMES AFTER ADULT SINGLE 08:30 - 08:30
CORD BLOOD TRANSPLANTATION IN EUROPEAN AND
JAPANESE POPULATIONS: THE EUROCORD/ALWP EBMT AND
JSHCT/JDCHCT COLLABORATIVE STUDY
Speaker: Junya Kanda, JP

OS9-6 EARLY RECONSTITUTION OF CD6+ T CELLS AFTER 08:30 - 08:30

HEMATOPOIETIC CELL TRANSPLANTATION IDENTIFIES A
SUITABLE TARGET FOR ACUTE GRAFT-VERSUS-HOST
DISEASE TREATMENT USING ANTI-CD6 MONOCLONAL
ANTIBODY ITOLIZUMAB
Speaker: Benedetta Rambaldi, US

OS9-7 MICROBIAL-DERIVED METABOLITES INDUCE EPITHELIAL 08:30 - 08:30

RECOVERY VIA THE STING PATHWAY IN MICE AND MEN AND
PROTECT FROM GRAFT-VERSUS-HOST DISEASE
Speaker: Erik Thiele Orberg, DE

OS9-8 ASSOCIATION OF GENE POLYMORPHISMS IN 08:30 - 08:30

CYCLOPHOSPHAMIDE METABOLISM PATHWAY WITH
COMPLICATIONS AFTER HAPLOIDENTICAL HEMATOPOIETIC
STEM CELL TRANSPLANTATION
Speaker: Paula Muñiz, ES

Oral Session
08:30 - 18:45 On-Demand Library
OS13 - Oral session 13: Transplant Complications I
This session is available in our on-demand library throughout the whole congress
OS13-1 FINAL PRIMARY RESULTS FROM THE DEFIFRANCE REGISTRY 08:30 - 08:30
STUDY: EFFECTIVENESS AND SAFETY OF DEFIBROTIDE FOR
TREATMENT OF HEPATIC VENO-OCCLUSIVE
DISEASE/SINUSOIDAL OBSTRUCTION SYNDROME AFTER
HAEMATOPOIETIC CELL TRANSPLANTATION
Speaker: Mohamad Mohty, FR

OS13-2 ASSOCIATION OF PRE-EXISTING COMORBIDITIES WITH 08:30 - 08:30

OUTCOME OF ALLOGENEIC STEM CELL TRANSPLANTATION.
A RETROSPECTIVE ANALYSIS FROM THE EBMT
Speaker: Olaf Penack, DE

OS13-3 DEFIBROTIDE PROPHYLAXIS FOR VENO-OCCLUSIVE 08:30 - 08:30

DISEASE/SINUSOIDAL OBSTRUCTION SYNDROME (VOD/SOS)
AFTER HAEMATOPOIETIC CELL TRANSPLANTATION (HCT):

14 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

ANALYSIS OF A MULTICENTRE, MULTINATIONAL,

PROSPECTIVE, OBSERVATIONAL REGISTRY STUDY (EBMT
PASS)
Speaker: Mohamad Mohty, FR

OS13-4 EBMT PASS: OUTCOMES OF DEFIBROTIDE-TREATED 08:30 - 08:30

PATIENTS WITH ANICTERIC/ICTERIC VENO-OCCLUSIVE
DISEASE/SINUSOIDAL OBSTRUCTION SYNDROME (VOD/SOS)
AFTER HAEMATOPOIETIC CELL TRANSPLANTATION (HCT)
Speaker: Mohamad Mohty, FR

OS13-5 EASIX SCORE PREDICTS OVERALL SURVIVAL, NON-RELAPSE 08:30 - 08:30

MORTALITY AND THE RISK OF INTENSIVE CARE UNIT
ADMISSION AT PRE-TRANSPLANT EVALUATION
Speaker: Marta Peña Domingo, ES

OS13-6 THE INCIDENCE OF SEVERE ORAL MUCOSITIS AND TASTE 08:30 - 08:30
DISTURBANCE IN PATIENTS UNDERGOING DIFFERENT
CONDITIONING REGIMENS IN HEMATOPOIETIC STEM CELL
TRANSPLANTATION
Speaker: Midori Nakagaki, AU

OS13-7 IMPACT OF SIROLIMUS/TACROLIMUS-BASED GRAFT-VERSUS- 08:30 - 08:30

HOST-DISEASE PROPHYLAXIS ON THE DEVELOPMENT OF
EARLY AND LATE TRANSPLANT-ASSOCIATED THROMBOTIC
MICROANGIOPATHY
Speaker: Aldo A Acosta-Medina, US

OS13-8 RISK FACTORS FOR SINUSOIDAL OBSTRUCTION SYNDROME 08:30 - 08:30

OF THE LIVER AFTER ALLOGENEIC HEMATOPOIETIC STEM
CELL TRANSPLANTATION IN CHILDHOOD
Speaker: Bernd Gruhn, DE

Oral Session
08:30 - 18:45 On-Demand Library
OS14 - Oral session 14: Transplant Complications II
This session is available in our on-demand library throughout the whole congress
OS14-1 PREGNANCY AND PREGNANCY OUTCOMES AFTER 08:30 - 08:30
HEMATOPOIETIC STEM CELL TRANSPLANTATION DURING
CHILDHOOD: A CROSS-SECTIONAL SURVEY OF THE EBMT
PEDIATRIC WP
Speaker: Tamara Diesch, CH

OS14-2 ONE THOUSAND VOICES ADDRESS PATIENT ENGAGEMENT IN 08:30 - 08:30

HEMATOPOIETIC STEM CELL TRANSPLANTATION AND CELL
THERAPY: RESULTS OF A SURVEY FROM THE EBMT
Speaker: Helene Schoemans, BE

OS14-3 CHRONIC KIDNEY DISEASE TEN YEARS AFTER PEDIATRIC 08:30 - 08:30
ALLOGENEIC HEMATOPOIETIC STEM CELL
TRANSPLANTATION
Speaker: Gertjan Lugthart, NL

OS14-4 NEUROLOGIC COMPLICATIONS AFTER ALLOGENEIC STEM 08:30 - 08:30

15 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

CELL TRANSPLANTATION: ANALYSIS OF RISK FACTORS. A

SINGLE CENTER STUDY OVER 20 YEARS OF FOLLOW-UP

OS14-5 AN UPDATED SYSTEMATIC REVIEW OF STUDIES ON 08:30 - 08:30

DEFIBROTIDE PROPHYLAXIS FOR VENO?OCCLUSIVE
DISEASE/SINUSOIDAL OBSTRUCTION SYNDROME (VOD/SOS)
Speaker: Selim Corbacioglu, DE

OS14-6 PROGNOSTIC BIOMARKER SIGNATURE FOR HEPATIC VENO- 08:30 - 08:30

OCCLUSIVE DISEASE/SINUSOIDAL OBSTRUCTION SYNDROME
(VOD/SOS) IN RECIPIENTS OF MYELOABLATIVE (MA)
ALLOGENEIC HAEMATOPOIETIC CELL TRANSPLANTATION
(HCT)
Speaker: Santosh Putta, US

OS14-7 OUTCOME AFTER ADMISSION TO INTENSIVE CARE UNIT (ICU) 08:30 - 08:30
IN HEMATOPOIETIC TRANSPLANT RECIPIENTS: SINGLE
CENTRE EXPERIENCE
Speaker: Isabel Iturrate, ES

OS14-8 DISTRIBUTION AND IMPACT OF ACUTE KIDNEY INJURY IN AT- 08:30 - 08:30
HOME ALLOGENEIC BONE MARROW TRANSPLANTATION
MODELS
Speaker: Marta Garcia-Recio, ES

Oral Session
08:30 - 18:45 On-Demand Library
OS10 - Oral session 10: COVID-19
This session is available in our on-demand library throughout the whole congress
OS10-1 A PHASE I DOSE-ESCALATION SINGLE CENTER STUDY TO 08:30 - 08:40
EVALUATE THE SAFETY OF ALLOGENIC MEMORY T CELLS
CONTAINING SARS-COV-2 SPECIFIC LYMPHOCYTES AS
ADOPTIVE THERAPY IN COVID19
Speaker: Antonio Pérez-Martínez, ES

OS10-2 THE IMPACT OF COVID-19 ON UNRELATED AND DONOR CORD 08:40 - 08:50
PROVISION TO UK TRANSPLANT CENTRES DURING THE 1ST
WAVE OF THE PANDEMIC: UK ALIGNED REGISTRY STUDY
Speaker: Angharad Pryce, GB

OS10-3 IMPACT OF SARS-COV-2 ON DELIVERY OF CAR T CELL 08:50 - 09:00

THERAPY IN EUROPE: A SURVEY FROM THE CELLULAR
THERAPY AND IMMUNOBIOLOGY WORKING PARTY OF THE
EBMT
Speaker: Sara Ghorashian, GB

OS10-4 OUTCOME OF COVID 19 IN ALLOGENEIC STEM CELLS 09:00 - 09:10

TRANSPLANT PATIENTS: THE SINGLE CENTER EXPERIENCE
FROM A SEVERELY AFFECTED AREA (BERGAMO)
Speaker: Maria Caterina Mico', IT

OS10-5 ALLOGENEIC STEM CELL TRANSPLANTATION IN ACUTE 09:10 - 09:20

LEUKEMIA PATIENTS AFTER COVID-19 INFECTION

16 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

Speaker: Maximilian Christopeit, DE

OS10-6 INFLUENCE OF THE SARS-COV-2 PANDEMIC ON BONE 09:20 - 09:30

MARROW TRANSPLANTATION CENTERS AND THE
PROTOCOLS ADOPTED IN BRAZIL BETWEEN MAY AND JUNE
2020
Speaker: Fernando Barroso Duarte, BR

OS10-7 CRYOPRESERVATION OF ALLOGENEIC HEMATOPOIETIC 09:30 - 09:40

PROGENITOR CELLS IN THE CURRENT SARS-Cov-2
PANDEMIC: EXPERIENCE OF A SINGLE CENTRE
Speaker: Dolores Moreno, ES

OS10-8 IMPACT OF COVID-19 PANDEMIC ON RELEASE OF FRENCH 09:40 - 09:50

CORD BLOOD UNITS. ON BEHALF THE AGENCY OF
BIOMEDICINE, EUROCORD AND THE SFGM-TC
Speaker: Hanadi Rafii - El Ayoubi, FR

Lab Technicians Day

08:30 - 18:45 On-Demand Library
LT1 - Lab Technicians Day: Specialized cell processing
This session is available in our on-demand library throughout the whole congress
LT1-1 Bone marrow processing: Techniques and results -
Speaker: Boris Calmels, FR

LT1-2 Technical aspects and performance TCRab/CD19 depletion -

Speaker: Kasper Westinga, NL

LT1-3 Donor selection and GMP-compliant manufacturing of virus- -

specific T-cells
Speaker: Britta Eiz-Vesper, DE

Oral Session
08:30 - 18:45 On-Demand Library
OS05 - Oral session 5: Cellular Therapy, Gene Therapy and New Drugs II
This session is available in our on-demand library throughout the whole congress
OS5-1 HEMATOPOIETIC STEM CELL GENE THERAPY FOR 08:30 - 08:40
MUCOPOLYSACCHARIDOSIS TYPE I, HURLER (MPS-IH):
BIOLOGICAL EFFICACY AND PRELIMINARY EVIDENCE OF
EARLY CLINICAL RESPONSE
Speaker: Maria Ester Bernardo, IT

OS5-2 OVERALL SURVIVAL BY BEST OVERALL RESPONSE WITH 08:40 - 08:50

TABELECLEUCEL IN PATIENTS WITH EPSTEIN-BARR VIRUS-
DRIVEN POST-TRANSPLANT LYMPHOPROLIFERATIVE
DISEASE AFTER ALLOGENEIC HEMATOPOIETIC CELL
TRANSPLANT
Speaker: Susan Prockop, US

OS5-3 RESOLUTION OF SERIOUS VASO-OCCLUSIVE PAIN CRISES: 08:50 - 09:00

RESULTS FROM THE ONGOING PHASE 1/2 HGB-206 GROUP C
STUDY OF LENTIGLOBIN FOR SICKLE CELL DISEASE (SCD)

17 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

GENE THERAPY
Speaker: Markus Mapara, US

OS5-4 DURABLE CLINICAL OUTCOMES FOLLOWING 09:00 - 09:10

BETIBEGLOGENE AUTOTEMCEL (BETI-CEL) GENE THERAPY
WITH UP TO 6 YEARS OF FOLLOW-UP IN PATIENTS WITH
TRANSFUSION-DEPENDENT ?-THALASSEMIA (TDT)
Speaker: Franco Locatelli, IT

OS5-5 OPEN LABEL DOSE ESCALATION TRIAL OF AB-205 (E-CEL® 09:10 - 09:20
CELLS) IN ADULTS WITH SYSTEMIC LYMPHOMA
UNDERGOING HIGH-DOSE THERAPY AND AUTOLOGOUS
HEMATOPOIETIC CELL TRANSPLANTATION (HDT-AHCT)
Speaker: Carolyn Mulroney, US

OS5-6 IMMUNOTHERAPY IN ACUTE LEUKEMIA: A GITMO (GRUPPO 09:20 - 09:30

ITALIANO TRAPIANTO MIDOLLO OSSEO) SURVEY ON
EFFICACY AND TOXICITY OF DONOR LYMPHOCYTE
INFUSIONS AFTER ALLOGENEIC STEM CELL
TRANSPLANTATION
Speaker: Francesca Patriarca, IT

OS5-7 MONITORING PATIENT SARS-COV-2-T-CELL IMMUNE 09:30 - 09:40

RESPONSES AND GENERATING SARS-COV-2-SPECIFIC T
CELLS FROM CONVALESCENT DONORS; IMPLICATIONS FOR
THE IDENTIFICATION OF HIGH-RISK PATIENTS AND
TREATMENT WITH T-CELL IMMUNOTHERAPY
Speaker: Anastasia Papadopoulou, GR

OS5-8 NORMALISED LYSOSOMAL ACID LIPASE ACTIVITY CAN BE 09:40 - 09:50

ACHIEVED IN WOLMAN FIBROBLASTS VIA BOTH DIRECT
TRANSDUCTION AND CROSS-CORRECTION MECHANISMS
USING A LENTIVIRAL-MEDIATED GENE THERAPY APPROACH
Speaker: Jane E Potter, GB

Paed4-2 EARLY SAFETY AND EFFICACY RESULTS WITH A SINGLE 09:50 - 10:00
DOSE OF AUTOLOGOUS CRISPR-CAS9-MODIFIED CD34+
HEMATOPOIETIC STEM AND PROGENITOR CELLS IN
TRANSFUSION-DEPENDENT ?-THALASSEMIA AND SICKLE
CELL DISEASE
Speaker: Selim Corbacioglu, DE

Oral Session
08:30 - 18:45 On-Demand Library
OS19 - Oral session 19: Lymphoma and Chronic Lymphocytic Leukemia
This session is available in our on-demand library throughout the whole congress
OS19-1 INTERIM ANALYSIS (IA) OF ZUMA-12: A PHASE 2 STUDY OF 08:30 - 08:30
AXICABTAGENE CILOLEUCEL (AXI-CEL) AS FIRST-LINE
THERAPY IN PATIENTS WITH HIGH-RISK LARGE B-CELL
LYMPHOMA (LBCL)
Speaker: Catherine Thieblemont, FR

OS19-2 LONG-TERM SURVIVAL AND GRADUAL RECOVERY OF B 08:30 - 08:30

18 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

CELLS IN PATIENTS WITH REFRACTORY LARGE B CELL

LYMPHOMA (LBCL) TREATED WITH AXICABTAGENE
CILOLEUCEL (AXI-CEL)
Speaker: Caron A. Jacobson, US

OS19-3 PRIMARY ANALYSIS OF ZUMA-5: A PHASE 2 STUDY OF 08:30 - 08:30

AXICABTAGENE CILOLEUCEL (AXI-CEL) IN PATIENTS WITH
RELAPSED/REFRACTORY (R/R) INDOLENT NON-HODGKIN
LYMPHOMA (INHL)
Speaker: Caron A. Jacobson, US

OS19-4 ONE-YEAR FOLLOW-UP OF ZUMA-2, THE MULTICENTER, 08:30 - 08:30

REGISTRATIONAL STUDY OF KTE-X19 IN PATIENTS WITH
RELAPSED/REFRACTORY (R/R) MANTLE CELL LYMPHOMA
(MCL)
Speaker: Michael L. Wang, US

OS19-5 VALIDATION OF GWAS-IDENTIFIED VARIANTS FOR CHRONIC 08:30 - 08:30

LYMPHOCYTIC LEUKEMIA: A STUDY IN THE CONTEXT OF THE
CRUCIAL CONSORTIUM
Speaker: Antonio José Cabrera-Serrano, ES

OS19-6 EVALUATION OF AUTOLOGOUS AND ALLOGENEIC 08:30 - 08:30

HEMATOPOIETIC CELL TRANSPLANTATION (HCT) IN
PATIENTS WITH HIGH-RISK ANAPLASTIC LARGE CELL
LYMPHOMA (ALCL)
Speaker: Natalie L. Smith, US

OS19-7 ECONOMIC ASPECTS OF STEM CELL TRANSPLANTATION BY 08:30 - 08:30

PATIENTS WITH RELAPSED DIFFUSE B-CELL LYMPHOMA
(DLBCL) IN A GERMAN TERTIARY HOSPITAL
Speaker: Bernhard Alexander Mörtl, DE

OS19-8 LONG TERM OUTCOMES OF ALLOGENEIC 08:30 - 08:30

TRANSPLANTATION IN LYMPHOMA: A SINGLE CENTRE
EXPERIENCE
Speaker: Alexander Glover, GB

Oral Session
08:30 - 18:45 On-Demand Library
OS15 - Oral session 15: Conditioning Regimens
This session is available in our on-demand library throughout the whole congress
OS15-1 BENDAMUSTINE-BASED CONDITIONING PRIOR TO 08:30 - 08:40
AUTOLOGOUS HEMATOPOIETIC CELL TRANSPLANT
IMPROVES OUTCOMES IN PATIENTS WITH ELAPSED-
REFRACTORY NON-HODGKIN LYMPHOMA
Speaker: Sylvie Lachance, CA

OS15-2 MICROBIOTA INJURY IS CONDITIONING REGIMEN- 08:40 - 08:50

DEPENDENT IN ALLOGENEIC HEMATOPOIETIC CELL
TRANSPLANTATION RECIPIENTS
Speaker: Roni Shouval, US

OS15-3 THE IMPACT OF PULMONARY FUNCTION IN PATIENTS 08:50 - 09:00

19 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

UNDERGOING AUTOLOGOUS STEM CELL TRANSPLANTATION

Speaker: Jesus Duque-Afonso, DE

OS15-4 HIGH INCIDENCE OF GVHD WITH TBF CONDITIONING IN 09:00 - 09:10

HEMATOLOGIC MALIGNANCIES: A SINGLE CENTER
EXPERIENCE
Speaker: Khalid Halahleh, JO

OS15-5 THIOTEPA BUSULFAN AND FLUDARABINE (TBF) PATIENTS 09:10 - 09:20

WITH ACUTE MYELOID LEUKEMIA IN COMPLETE REMISSION
:A RETROSPECTIVE ANALYSIS ON 221 PATIENTS AND 369
CONTROLS
Speaker: Federica Sora, IT

OS15-6 IMPACT OF THE ADDITION OF ANTITHYMOCYTE GLOBULIN TO 09:20 - 09:30

POST-TRANSPLANT CYCLOPHOSPHAMIDE IN
HAPLOIDENTICAL TRANSPLANTATION WITH PERIPHERAL
BLOOD COMPARED TO POST-TRANSPLANT
CYCLOPHOSPHAMIDE ALONE
Speaker: Giorgia Battipaglia, IT

OS15-7 HEMATOPOIETIC CELL TRANSPLANTATION COMORBIDITY 09:30 - 09:40

INDEX (HCT-CI) AND OUTCOME AFTER NON-MYELOABLATIVE
ALLOGENEIC STEM CELL TRANSPLANTATION IN ACUTE
MYELOID LEUKEMIA (AML) PATIENTS OLDER THAN 60 YEARS
Speaker: Donata Backhaus, DE

OS15-8 SEQUENTIAL FLAMSA-BU VERSUS FLUBU2 IN PATIENTS WITH 09:40 - 09:50

ACTIVE RELAPSED OR REFRACTORY ACUTE MYELOID
LEUKEMIA: A STUDY FROM THE ACUTE LEUKEMIA WORKING
PARTY OF THE EBMT
Speaker: Eduardo Rodríguez-Arbolí, ES

Oral Session
08:30 - 18:45 On-Demand Library
OS12 - Oral session 12: Infectious Diseases II
This session is available in our on-demand library throughout the whole congress
OS12-1 NOCARDIOSIS FOLLOWING HEMATOPOIETIC CELL 08:30 - 08:30
TRANSPLANTATION: 20 YEARS' EXPERIENCE. THE
INTERNATIONAL STUDY OF INFECTIOUS DISEASES WORKING
PARTY OF EBMT AND FRANCO-BELGIAN NOCARDIA STUDY
GROUP
Speaker: Dina Averbuch, IL

OS12-2 COLONIZATION-GUIDED PROTOCOL FOR EMPIRICAL 08:30 - 08:30

ANTIBIOTIC THERAPY IN ALLO-HSCT RECIPIENTS: FIRST
RESULTS OF A SINGLE CENTER PROSPECTIVE STUDY
Speaker: Marina Popova, RU

OS12-3 COLONIZATION BY MULTIDRUG-RESISTANT GRAM-NEGATIVE 08:30 - 08:30

BACTERIA IN EARLY PHASE OF HEMATOPOIETIC STEM CELL
TRANSPLANTATION
Speaker: Yuliya Rogacheva, RU

20 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

OS12-4 FAVOURABLE OUTCOME AND NO INCREASED RISK OF GVHD 08:30 - 08:30

IN PATIENTS DEVELOPING C.DIFFICILE INFECTION AFTER
HEMATOPOIETIC STEM CELL TRANSPLANTS
Speaker: Chiara Rosignoli, IT

OS12-5 CLINICAL IMPACT OF DE-ESCALATION/DISCONTINUATION OF 08:30 - 08:30

ANTIBIOTICS PRIOR TO NEUTROPHIL RECOVERY IN
PATIENTS UNDERGOING HEMATOPOIETIC STEM CELL
TRANSPLANTATION: A SINGLE-CENTRE EXPERIENCE
Speaker: Anke Verlinden, BE

OS12-6 COLONIZATION WITH MULTIDRUG-RESISTANT BACTERIA AND 08:30 - 08:30

DISEASE RISK INDEX ARE TWO INDEPENDENT FACTORS
THAT AFFECT THE SURVIVAL OF PATIENTS AFTER
ALLOGENEIC HAEMATOPOIETIC STEM CELL
TRANSPLANTATION
Speaker: Anna Czyz, PL

OS12-7 IMPACT OF FLUOROQUINOLONE PROPHYLAXIS IN 08:30 - 08:30

ALLOGENEIC HEMATOPOIETIC STEM CELL
TRANSPLANTATION; SINGLE CENTER EXPERIENCE
Speaker: Eshrak Al-Shaibani, CA

OS12-8 STRONG INFLAMMATORY CYTOKINE RESPONSE AFTER 08:30 - 08:30

HAPLOIDENTICAL HEMATOPOIETIC STEM CELL
TRANSPLANTATION WITH POST-TRANSPLANT
CYCLOPHOSPHAMIDE RELATES TO HUMAN HERPESVIRUS 6
REACTIVATION
Speaker: Kenichiro Takeda, JP

Oral Session
08:30 - 18:45 On-Demand Library
OS11 - Oral session 11: Infectious Diseases I
This session is available in our on-demand library throughout the whole congress
OS11-1 POLYMORPHISMS WITHIN THE TNFSF4 AND MAPKAPK2 LOCI 08:30 - 08:40
INFLUENCE THE RISK OF INVASIVE ASPERGILLOSIS: A TWO-
STAGE CASE CONTROL STUDY IN THE CONTEXT OF THE
ASPBIOMICS CONSORTIUM
Speaker: Ana Moniz-Díez, ES

OS11-2 THE ASSOCIATION BETWEEN CYTOMEGALOVIRUS AND 08:40 - 08:50

INVASIVE FUNGAL INFECTIONS IN ALLOGENEIC
HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS: A
SYSTEMATIC REVIEW AND META-ANALYSIS
Speaker: Nipat Chuleerarux, TH

OS11-3 IMMUNE RECONSTITUTION DURING CMV PROPHILAXIS BY 08:50 - 09:00

LETERMOVIR: A SINGLE CENTER EXPERIENCE
Speaker: Ilaria Cutini, IT

OS11-4 LETERMOVIR PROPHYLAXIS FOR CYTOMEGALOVIRUS 09:00 - 09:10

REACTIVATION IN ALLOGENEIC STEM CELL
TRANSPLANTATION: A MULTICENTER ITALIAN REAL-WORLD

21 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

EXPERIENCE
Speaker: Massimo Martino, IT

OS11-5 PREVENTION OF INVASIVE FUNGAL INFECTION IN HAPLO 09:10 - 09:20

TRANSPLANTATION WITH POST-TRANSPLANTATION
CYCLOPHOSPHAMIDE. UNIVERSAL FLUCONAZOLE
PROPHYLAXIS AND A MOULD DIAGNOSTIC-DIRECTED
APPROACH. RESULTS IN 112 PATIENTS
Speaker: Amado Karduss -Urueta, CO

OS11-6 PATTERN OF FUNGAL INFECTIONS DURING THE INITIAL 100 09:20 - 09:30
DAYS IN CHILDREN UNDERGOING HEMATOPOIETIC STEM
CELL TRANSPLANTATION FROM A TERTIARY REFERRAL
CENTER IN INDIA
Speaker: Harika Varla, IN

OS11-7 THE MANAGEMENT OF CLOSTRIDIOIDES DIFFICILE 09:30 - 09:40

INFECTIONS IN PATIENTS AFTER ALLOGENEIC
HEMATOPOIETIC CELL TRANSPLANTATION: THE RESULTS OF
THE INFECTIOUS DISEASES WORKING PARTY EBMT SURVEY
Speaker: Agnieszka Piekarska, PL

OS11-8 CLINICAL DIAGNOSTIC AND THERAPEUTIC STRATIFICATION 09:40 - 09:50

OF INVASIVE FUNGAL DISEASE IN ADULT PATIENTS WITH
HEMATOLOGY MALIGNANCIES: A REAL-WORLD
OBSERVATIONAL STUDY
Speaker: Sizhou Feng, CN

Industry Symposium
08:30 - 18:45 On-Demand Library
IS38 - CMV management in high-risk patients - Biotest Industry Symposium
This session is available in our on-demand library throughout the whole congress
Chair: Fabio Ciceri, IT
IS38-1 A scoring system to define patients at high risk for CMV -
Speaker: Ibrahim Yakoub-Agha, FR

IS38-2 How to manage CMV high-risk patients -

Speaker: Michele Malagola, IT

IS38-3 The immunological benefits of CMV-specific immunoglobulins -

Speaker: Javier Carbone, ES

Lab Technicians Day

08:30 - 18:45 On-Demand Library
LT2 - Lab Technicians Day: Cell product testing, validation and characterization
This session is available in our on-demand library throughout the whole congress
LT2-1 Quality control assessment of ATMP phenotype and -
functionality using flow cytometry
Speaker: Willemijn Hobo, NL

LT2-2 Flow cytometry-based CD34 enumeration -

Speaker: Harry Dolstra, NL

22 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

LT2-3 Flow cytometric in-process and quality control for CAR T cell -
manufacturing
Speaker: Ulrike Köhl, DE

Data Management
08:30 - 18:45 On-Demand Library
DM06 - Education session 6
This session is available in our on-demand library throughout the whole congress
DM6-1 Response in Multiple Myeloma -
Speaker: Meral Beksac, TR

Workshop
08:30 - 18:45 On-Demand Library
W14 - In the absence of a matched-sibling, who's the best alternative allogeneic donor?
This session is available in our on-demand library throughout the whole congress
W14-1 A matched unrelated donor -
Speaker: Bronwen Shaw, US

W14-2 A haploidentical donor -

Speaker: Mi Kwon, ES

W14-3 When to choose cord blood -

Speaker: Filippo Milano, US

W14-4 Do we have to challenge our current donor hierarchy for -

patients with hemoglobinopathies?
Speaker: Selim Corbacioglu, DE

Workshop
08:30 - 18:45 On-Demand Library
W13 - CARs beyond T cells: A focus on next generation CAR-NK cells
This session is available in our on-demand library throughout the whole congress
W13-1 CAR NK cells as an "off the shelf" immunotherapy -
Speaker: Ulrike Köhl, DE

W13-2 CARs and ADCC to make off-the-shelf NK cells specific against -

hematologic malignancies
Speaker: Jeffrey Miller, US

W13-3 Target NKG2D ligands on tumor cells -

Speaker: Antonio Pérez-Martínez, ES

Educational
08:30 - 18:45 On-Demand Library
E11 - Management of early complications in an ambulatory/outpatient setting
This session is available in our on-demand library throughout the whole congress
E11-1 Early infectious complications -
Speaker: Jan Styczynski, PL

23 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

E11-2 Non-infective complications: GVHD and organ toxicity -

Speaker: Gerhard Hildebrandt, US

E11-3 The Hospital Clínic experience -

Speaker: Francesc Fernández-Avilés, ES

Quality Management
08:30 - 18:45 On-Demand Library
QM5 - Quality Management Oral Abstracts
This session is available in our on-demand library throughout the whole congress
QM5-1 COMPLIANCE AND COST EFFICACY FOR CELLULAR 08:30 - 08:30
THERAPIES, CAN THESE TWO GO HAND IN HAND?
Speaker: Janik Adriaansen, US

QM5-2 HOW TO MAINTAIN A CONTINUOUS TRAINING PROGRAM FOR 08:30 - 08:30

NURSES IN TIMES OF PANDEMIC
Speaker: Sheila Saco, ES

QM5-3 THE RTN TRANSPLANT POLICY AND ACTIVITY DURING 08:30 - 08:30
COVID-19 PANDEMIC
Speaker: Antonio Bruno, IT

QM5-4 THE DISASTER PLAN ADJUSTMENT TO THE COVID-19 08:30 - 08:30

PANDEMIC AT AORN CARDARELLI TRANSPLANT PROGRAM
IN NAPLES, ITALY
Speaker: Lucia Ammirati, IT

Nurses Group
08:30 - 18:45 On-Demand Library
NG22 - Quality processes in JACIE
This session is available in our on-demand library throughout the whole congress
NG22-1 Quality indicators for nurses -
Speaker: Louise McNamara, GB

NG22-2 JACIE: What's new? -

Speaker: Kim Orchard, GB

NG22-3 What is the nurse role as JACIE Inspector? -

Speaker: Eugenia Trigoso Arjona, ES

Working Party Session

08:30 - 18:45 On-Demand Library
CMWP - Chronic Malignancies Working Party Session
This session is available in our on-demand library throughout the whole congress
CMWP-1 Scientific activity of the CMWP 08:30 - 08:30
Speaker: Ibrahim Yakoub-Agha, FR

CMWP-3 Who and when in the course of disease to transplant? - 08:30 - 08:30
Myelofibrosis
Speaker: Donal McLornan, GB

24 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

CMWP-4 Is Chronic Myeloid Leukaemia still an indication for allo-HCT? 08:30 - 08:30
Speaker: Yves Chalandon, CH

CMWP-5 Is Chronic Lymphocytic Leukemia still an indication for allo- 08:30 - 08:30
HCT?
Speaker: Peter Dreger, DE

Oral Session
08:30 - 18:45 On-Demand Library
OS06 - Oral session 6: Experimental Transplantation, Minimal Residual Disease, Immune Reconstitution and C
This session is available in our on-demand library throughout the whole congress
OS6-1 COMPARATIVE ANALYSIS OF IMMUNE RECONSTITUTION IN 08:30 - 08:30
HSCT PATIENTS WITH PT-CY OR ATG REVEALS DISTINCT T
CELL IMMUNE RECONSTITUTION PATTERNS
Speaker: Saskia Leserer, DE

OS6-2 MINIMAL RESIDUAL DISEASE AND CHIMERISM ANALYSIS 08:30 - 08:30

USING CIRCULATING CELL-FREE DNA AFTER ALLOGENEIC
HEMATOPOIETIC CELL TRANSPLANTATION
Speaker: Sandra Pennisi, DE

OS6-3 SEQUENTIAL QUANTIFICATION OF T-CELL RECEPTOR 08:30 - 08:30

EXCISION CIRCLES (TRECS) AND K-DELETING
RECOMBINATION EXCISION CIRCLES (KRECS) IN
ALLOGENEIC HEMATOPOIETIC STEM CELL
TRANSPLANTATION (ALLOHSCT) RECIPIENTS
Speaker: Carlos De Miguel Jiménez, ES

OS6-4 MUTATIONAL CONSEQUENCES OF HEMATOPOIETIC STEM 08:30 - 08:30

CELL TRANSPLANTATION IN HUMANS
Speaker: Mirjam Belderbos, NL

OS6-5 OVER-EXPRESSION OF HIF-1? IN MESENCHYMAL STROMAL 08:30 - 08:30

CELLS INCREASES HUMAN CD34+ CELLS CLONOGENIC
CAPACITY IN VITRO AND ENGRAFTMENT ABILITY IN A
XENOTRANSPLANTATION MODEL
Speaker: Silvia Preciado, ES

OS6-6 ALEMTUZUMAB BASED-CONDITIONING FOR NON-MALIGNANT 08:30 - 08:30

PAEDIATRIC DISEASES DEPLETES DONOR T-CELLS
ALLOWING EXCEPTIONALLY LOW RATES OF GVHD BUT
ALLOWS PERSISTENCE OF RESIDUAL, AUTOLOGOUS, VIRUS-
SPECIFIC T-CELLS
Speaker: Rubiya Nadaf, GB

OS6-7 TCR REPERTOIRE DYNAMICS AFTER HEMATOPOIETIC STEM 08:30 - 08:30

CELL TRANSPLANTATION IN MYELOID MALIGNANCIES
Speaker: Simona Pagliuca, US

OS6-8 DAY +60 WT1 ASSESSMENT ON BONE MARROW MIGHT 08:30 - 08:30
PREDICT RELAPSE AND MORTALITY AFTER ALLOGENEIC
STEM CELL TRANSPLANTATION
Speaker: Patrizia Chiusolo, IT

25 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

Nurses Group
08:30 - 18:45 On-Demand Library
NG20 - How do I become an expert?
This session is available in our on-demand library throughout the whole congress
NG20-1 Conditioning regimen -
Speaker: Nicolas Kint, BE

NG20-2 Immunosuppression -
Speaker: Tiene Bauters, BE

NG20-3 Vaccinations -
Speaker: Bipin Savani, US

Special Session
08:30 - 18:45 On-Demand Library
SS11 - The EBMT for Trainees
This session is available in our on-demand library throughout the whole congress
SS11-1 Being a Trainee in SCT / Cellular Therapy -
Speaker: Nico Gagelmann, DE
Speaker: Claire Horgan, GB
Speaker: Yasmina Serroukh, BE
Speaker: Yuliya Rogacheva, RU
Speaker: Tamar Azikuri, GE

SS11-2 Overview of allogeneic SCT for the trainee: ‘Things I wish I’d -
known'
Speaker: Helene Schoemans, BE

SS11-3 Establishing a career in SCT/cellular therapy -

Speaker: Jordan Gauthier, US

SS11-4 Complications for trainees 1: How to manage acute GVHD -

Speaker: Zinaida Peric, HR

SS11-5 Complications for trainees 2: How to manage VOD -

Speaker: Ivan Moiseev, RU

Joint Session
08:30 - 18:45 On-Demand Library
JS05 - Joint session WBMT: COVID-19 Vaccination in HSCT
This session is available in our on-demand library throughout the whole congress
JS5-2 COVID-19 vaccination in HSCT 08:30 - 08:30
Speaker: Per Ljungman, SE

JS5-3 Global access to COVID-19 vaccines 08:30 - 08:30

Speaker: Susan Brown, US

26 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

Data Management
08:30 - 18:45 On-Demand Library
DM08 - Education session 8
This session is available in our on-demand library throughout the whole congress
DM8-1 Infectious complications -
Speaker: Malgorzata Mikulska, IT

Joint Session
08:30 - 18:45 On-Demand Library
JS04 - Joint session LABMT
This session is available in our on-demand library throughout the whole congress
JS4-1 Transplant rates, Trends: WBMT/LABMT 2018 survey -
Speaker: Oscar González-Ramella, MX

JS4-2 Financing of HSCT in Latin America -

Speaker: Gregorio Jaimovich, AR

JS4-3 Selection, management and follow up of related donors: -

Overview
Speaker: Nina Worel, AT

JS4-4 Selection, management and follow up of related donors: -

Development of an LABMT consensus
Speaker: Gonzalo Ferini, AR

JS4-5 Haploidentical transplants in Latin America: Experience from -

Argentina/GATMO-TC in acute lymphoblastic leukemia
Speaker: Ana Basquiera, AR

JS4-6 Haploidentical transplants in Latin America: Experience from -

Brazil/SBTMO in aplastic anemia
Speaker: Carmem Bonfim, BR

Nurses Group
08:30 - 18:45 On-Demand Library
NG16 - Cellular therapy update
This session is available in our on-demand library throughout the whole congress
NG16-1 Update: What’s new? -
Speaker: Rose Ellard, GB

NG16-2 Spotlight on the Lymphoma Patient Experience -

Speaker: Lorna Warwick, CA

Oral Session
08:30 - 18:45 On-Demand Library
OS08 - Oral session 8: Graft versus Host Disease I
This session is available in our on-demand library throughout the whole congress
OS8-1 GVHD PROPHYLAXIS WITH POST TRANSPLANTATION 08:30 - 08:30
CYCLOPHOSPHAMIDE (PTCY) VERSUS CYCLOSPORINE A /
METHOTREXATE POST ALLOGENEIC TRANSPLANTATION

27 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

(HSCT) FROM MATCHED SIBLINGS FOR AML: FROM THE

ALWP/EBMT
Speaker: Arnon Nagler, IL

OS8-2 BELUMOSUDIL FOR CHRONIC GRAFT-VERSUS-HOST DISEASE 08:30 - 08:30

(CGVHD) AFTER 2 OR MORE PRIOR LINES OF THERAPY: THE
ROCKSTAR STUDY (KD025-213)
Speaker: Corey Cutler, US

OS8-3 A PERSONALIZED ORGAN-BASED APPROACH TO THE 08:30 - 08:30

TREATMENT OF CHRONIC GRAFT-VERSUS-HOST DISEASE
Speaker: Hanaa A. Fatoum, SA

OS8-4 RUXOLITINIB (RUX) VS BEST AVAILABLE THERAPY (BAT) IN 08:30 - 08:30

PATIENTS WITH STEROID-REFRACTORY ACUTE GRAFT-VS-
HOST DISEASE (SR-AGVHD): 6-MONTH FOLLOW-UP FROM
THE RANDOMIZED, PHASE 3 REACH2 STUDY
Speaker: Mohamad Mohty, FR

OS8-5 IMPACT OF CHRONIC GVHD SEVERITY AND STEROID 08:30 - 08:30

RESPONSE ON THE QUALITY OF LIFE IN PATIENTS
FOLLOWING ALLOGENEIC STEM CELL TRANSPLANTATION:
FINDINGS FROM A REAL-WORLD STUDY
Speaker: Sylvie Lachance, CA

OS8-6 SUCCESSFUL AND SAFE TREATMENT OF INTESTINAL GVHD 08:30 - 08:30

WITH POOLED-DONOR FULL ECOSYSTEM MICROBIOTA
BIOTHERAPEUTIC: RESULTS FROM A 29 PATIENT-COHORT
OF A COMPASSIONATE USE/EXPANDED ACCESS TREATMENT
PROGRAM
Speaker: Florent Malard, FR

OS8-7 REDUCED ACUTE GRAFT-VERSUS HOST DISEASE INCIDENCE 08:30 - 08:30

IN PATIENTS RECEIVING ANTI-T LYMPHOCYTE GLOBULIN IN
COMPARISON TO ANTI-THYMOCYTE GLOBULIN FOR THE
PROPHYLAXIS OF GRAFT-VERSUS-HOST DISEASE AFTER
ALLO-HSCT
Speaker: Marie T Rubio, FR

OS8-8 PATIENT-REPORTED OUTCOMES IN ACUTE GRAFT-VS-HOST 08:30 - 08:30

DISEASE: QUALITY-OF-LIFE FINDINGS FROM A REAL-WORLD
STUDY
Speaker: Nada Hamad, AU

Special Session
08:30 - 18:45 On-Demand Library
SS07 - Young Ambassadors Session
This session is available in our on-demand library throughout the whole congress
SS7-1 How build up a career in: Academia -
Speaker: Didier Blaise, FR

SS7-2 How build up a career in: In Pharmaceutical Industry -

Speaker: Dan Tovar, FR

28 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

SS7-3 How build up a career in: In Public domains -

Speaker: Eva Hilgenfeld, DE

SS7-4 What to avoid when writing a paper -

Speaker: Jakob Passweg, CH

SS7-5 How to write a successful grant -

Speaker: Robert Zeiser, DE

SS7-6 Introduction to medical statistics -

Speaker: Simona Iacobelli, IT

SS7-7 Social media in stem cell transplantation and cellular therapy -

Speaker: Navneet Majhail, US

Educational
08:30 - 18:45 On-Demand Library
E13 - Allogeneic transplantation from alternative donors
This session is available in our on-demand library throughout the whole congress
E13-1 Haploidentical vs unrelated in AML -
Speaker: Didier Blaise, FR

E13-2 Haploidentical vs unrelated in ALL -

Speaker: Arnon Nagler, IL

E13-3 Haploidentical vs cord Blood in acute leukaemia -

Speaker: Frederic Baron, BE

Special Session
08:30 - 18:45 On-Demand Library
SS08 - Social Media Session: Do's and don'ts of the interaction in the social media for the HSCT and cell thera
community
This session is available in our on-demand library throughout the whole congress
SS8-1 Social media beyond twitter for the HSCT and cell therapy -
community
Speaker: Navneet Majhail, US

SS8-2 Do's and don'ts of interaction in social media: Nurse's -

perspective

SS8-3 Do’s and don'ts of interaction in social media: How social -

media can improve patient outcomes - The patient's perspective
Speaker: Gillian Adams, GB

Educational
08:30 - 18:45 On-Demand Library
E10 - HSCT in paediatric non-malignant indications
This session is available in our on-demand library throughout the whole congress
E10-1 Haplo-identical SCT in hemoglobinopathy: Taking pole -
position?

29 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

Speaker: Josu de la Fuente, GB

E10-2 Mismatched family donors in inherited immune disorders: A -

new perspective
Speaker: Mary A. Slatter, GB

E10-3 HSCT for inherited bone marrow failure syndromes -

Speaker: Cristina Díaz de Heredia, ES

E10-4 Cord blood HSCT for non-malignant diseases in children -

Speaker: Vanderson Rocha, BR

Educational
08:30 - 18:45 On-Demand Library
E12 - Steroid-resistant/refractory GVHD
This session is available in our on-demand library throughout the whole congress
E12-1 GVHD - what’s in a name? -
Speaker: Helene Schoemans, BE

E12-2 Treatment of SR/R acute GVHD -

Speaker: Olaf Penack, DE

E12-3 Treatment of SR/R chronic GVHD -

Speaker: Zinaida Peric, HR

E12-4 New technologies in the approach to GVHD -

Speaker: Amin Turki, DE

Workshop
08:30 - 18:45 On-Demand Library
W10 - Controversies in T-cell NHL
This session is available in our on-demand library throughout the whole congress
W10-1 Are we improving first-line therapy in TCL? 08:30 - 08:30
Speaker: Eva Domingo Domenech, ES

W10-3 Insights in CAR-T therapy for T cell Lymphomas 08:30 - 08:30

Speaker: Helen Heslop, US

Workshop
08:30 - 18:45 On-Demand Library
W11 - Key organ manifestations of chronic GVHD
This session is available in our on-demand library throughout the whole congress
W11-1 Pulmonary chronic GVHD -
Speaker: Hildegard Greinix, AT

W11-2 Ocular cGVHD diagnostics - Practical approach -

Speaker: Igor Petricek, HR

W11-3 Gastrointestinal manifestations of chronic GVHD -

Speaker: Daniel Wolff, DE

30 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

How do I … ?
08:30 - 18:45 On-Demand Library
HDI6 - How Do I... manage toxicity in immunosuppressed patients?
This session is available in our on-demand library throughout the whole congress
HDI6-1 Transplant associated TMA -
Speaker: Sergio Giralt, US

HDI6-2 Infectious complication -

Speaker: Jan Styczynski, PL

Workshop
08:30 - 18:45 On-Demand Library
W12 - Donor HLA assessment and matching for allogeneic HSCT
This session is available in our on-demand library throughout the whole congress
W12-1 HLA laboratory perspective and recommendations -
Speaker: Pascale Loiseau, FR

W12-2 Clinical perspective and recommendations -

Speaker: Francesca Lorentino, IT

W12-3 Selection of unrelated donors and cord blood units for -

Hematopoietic Cell Transplantation: Guidelines from
NMDP/CIBMTR
Speaker: Stephen Spellman, US

Nurses Group
08:30 - 18:45 On-Demand Library
NG14 - Nurses Education Day 2: Care of the vulnerable immunocompromised patients in critical care setting
This session is available in our on-demand library throughout the whole congress
NG14-1 Patient's experience -
Speaker: Ruth Tweedie, ES

NG14-2 Psychologist's point of view -

Speaker: Anna Lagerdahl, GB

NG14-3 Nurse's perspective -

Speaker: Núria Ballestar, ES

Nurses Group
08:30 - 18:45 On-Demand Library
NG15 - Nurses Education Day 3: Care of the vulnerable immunocompromised patients in critical care setting
This session is available in our on-demand library throughout the whole congress
NG15-1 Managing virtual conversations -
Speaker: Lloyd Allen, GB

NG15-2 Nurse perspective: Virtual long term follow up for BMT patients -
Speaker: Michelle Kenyon, GB

NG15-3 Back to the future: Emphasizing our new practices -

Speaker: Ibrahim Yakoub-Agha, FR

31 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

Nurses Group
08:30 - 18:45 On-Demand Library
NG17 - Care of the nurses
This session is available in our on-demand library throughout the whole congress
NG17-1 Mindfulness -
Speaker: Ana M. Muñoz Cobo, ES

NG17-2 Resilience and self-care -

Speaker: Christian Williams, GB

NG17-3 Tips and tricks for self care -

Speaker: Jane Keep, GB

Nurses Group
08:30 - 18:45 On-Demand Library
NG18 - Non-malignant diseases update
This session is available in our on-demand library throughout the whole congress
NG18-2 Multiple sclerosis 08:30 - 08:30
Speaker: Helen Jessop, GB

NG18-3 Sickle cell disease 08:30 - 08:30

Speaker: Jean-Hugues Dalle, FR

NG18-4 ITP 08:30 - 08:30

Speaker: Maria Luisa Lozano, ES

Nurses Group
08:30 - 18:45 On-Demand Library
NG19 - Disease update
This session is available in our on-demand library throughout the whole congress
NG19-1 Acute leukaemia -
Speaker: Inge Govaerts, BE

NG19-2 Managing lymphoma: What nurses and healthcare -

professionals need to know
Speaker: Erik Aerts, CH

NG19-3 Multiple myeloma -

Speaker: Maaike de Ruijter, NL

NG19-4 CML (ITK management) -

Speaker: Laura Borg, GB

Nurses Group
08:30 - 18:45 On-Demand Library
NG24 - Outreach projects
This session is available in our on-demand library throughout the whole congress
NG24-2 Outreach project India: EBMT MIC pediatric advanced care 08:30 - 08:30
training (EMPACT)
Speaker: Lawrence Faulkner, IT

32 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

NG24-3 Outreach project: LABMT 08:30 - 08:30

Speaker: Sara Saez Carrasco, CO

Nurses Group
08:30 - 18:45 On-Demand Library
NG21 - Clinical trials in a transplant setting
This session is available in our on-demand library throughout the whole congress
NG21-1 Antimicrobal Lock Therapy for Prevention and Treatment of -
Catheter Related Infections in Hematogical Patients
Speaker: Isabel Salcedo, ES

NG21-2 Convalescent plasma clinical trials for COVID-19 -

Speaker: Rocío Layunta, ES

NG21-3 Post transplant relapse -

Speaker: Stephanie Heyes, GB

Special Session
08:30 - 18:45 On-Demand Library
SS10 - The HARMONY Alliance: Accelerating better and faster treatment for patients with blood cancer
This session is available in our on-demand library throughout the whole congress
SS10-1 General Overview of the HARMONY Alliance: Progress, -
Achievements & Results of HARMONY and HARMONY PLUS
projects
Speaker: Jesús Maria Hernández Rivas, ES

SS10-2 Envisioned contribution of the EBMT to the HARMONY Alliance -

Speaker: Guillermo Sanz Santillana, ES
Speaker: Yann Guillevic, CH

SS10-3 EBMT participation in the HARMONY Alliance -

Speaker: Anna Sureda, ES

SS10-4 HARMONY & HARMONY PLUS Research Projects / Outcomes -

definition
Speaker: Lars Bullinger, DE

SS10-5 HARMONY Platform -

Speaker: Ana Heredia Casanoves, ES

Working Party Session

08:30 - 18:45 On-Demand Library
ADWP - Autoimmune Diseases Working Party Session
This session is available in our on-demand library throughout the whole congress
ADWP-1 Welcome and Update from the EBMT registry -
Speaker: Raffaella Greco, IT

ADWP-2 Introducing the session and speakers -

Speaker: Tobias Alexander, DE

33 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

ADWP-3 HSCT for multiple sclerosis: Future directions in patient -

selection and conditioning regimen
Speaker: Riccardo Saccardi, IT

ADWP-4 HSCT for systemic sclerosis: Future directions in patient -

selection and conditioning regimen
Speaker: Dominique Farge, FR

ADWP-5 HSCT for Crohn’s disease: future directions in patient -

selection, mobilization and conditioning regimen
Speaker: Elena Ricart, ES

ADWP-6 HSCT for autoimmune diseases: Current aspects on early and -

late complications
Speaker: Majid Kazmi, GB

ADWP-7 HSCT for autoimmune diseases: Conditioning regimen and -

outcomes from the Russian experience
Speaker: Denis Fedorenko, RU

ADWP-8 Closing remarks -

Speaker: Tobias Alexander, DE

Working Party Session

08:30 - 18:45 On-Demand Library
ALWP - Acute Leukaemia Working Party Session
This session is available in our on-demand library throughout the whole congress
ALWP-1 Introduction 08:30 - 08:30
Speaker: Mohamad Mohty, FR

ALWP-2 CAR-T cells in adult ALL 08:30 - 08:30

Speaker: Arnon Nagler, IL

ALWP-3 Transplant in refractory AML: Comparison of the different 08:30 - 08:30

FLAMSA approaches
Speaker: Mohamad Mohty, FR

ALWP-4 MRD in AML: Where do we stand? 08:30 - 08:30

Speaker: Ali Bazarbachi, LB

Working Party Session

08:30 - 18:45 On-Demand Library
CTIWP - Cellular Therapy and Immunobiology Working Party Session
This session is available in our on-demand library throughout the whole congress
CTIWP-1 CTIWP Activity Report -
Speaker: Christian Chabannon, FR

CTIWP-2 Virus specific T cells post BMT- Broadening to SARS-CoV2 -

Speaker: Catherine Bollard, US

CTIWP-3 Are mesenchymal stromal cells the right arrow in the quiver to -
fight COVID-19?

34 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

Speaker: Rachele Ciccocioppo, IT

Working Party Session

08:30 - 18:45 On-Demand Library
SAAWP - Severe Aplastic Anaemia Working Party Session
This session is available in our on-demand library throughout the whole congress
SAAWP-1 Introduction -
Speaker: Régis Peffault de Latour, FR

SAAWP-2 Registry Report -

Speaker: Antonio Risitano, IT

SAAWP-3 RACE – clinical update -

Speaker: Antonio Risitano, IT

SAAWP-4 RACE – what we learn on the biology of SAA? -

Speaker: Austin Kulakaseraraj, GB

SAAWP-5 Androgens in AA: Myth or reality in 2021? -

Speaker: Simona Pagliuca, US

SAAWP-6 GVHD and relapse free survival (GRFS) after HSCT for AA -
Speaker: Raynier Devillier, FR

Nurses Group
08:30 - 18:45 On-Demand Library
NG23 - Oral session 2: Abstracts session
This session is available in our on-demand library throughout the whole congress
NG23-1 EFFICACY AND SAFETY OF A COLOSTRUM BASED ORAL 08:30 - 08:30
CARE PROTOCOL FOR THE PREVENTION AND TREATMENT
OF ORAL MUCOSITIS IN STEM CELL TRANSPLANT
RECIPIENTS
Speaker: Monica Guberti, IT

NG23-2 PATIENT-TO-NURSE STAFFING RATIO IN HEMATOPOIETIC 08:30 - 08:30

STEM CELL TRANSPLANT AND ADVANCED CELL THERAPY
UNITS IN SPAIN, HIGHLY NEEDED BUT CHALLENGING
Speaker: Julia Ruiz Pato, ES

NG23-3 ROOT CAUSE ANALYSIS TO IDENTIFY AND PREVENT FALL 08:30 - 08:30
CAUSES IN ALLOGENEIC HEMATOPOIETIC STEM CELL
TRANSPLANTATION PATIENTS
Speaker: Franziska Michaela Lohmeyer, IT

NG23-4 MAPPING THE NURSES' COMPETENCIES IN PAEDIATRIC 08:30 - 08:30

ONCO-HAEMATOLOGY AND HAEMATOPOIETIC STEM CELL
TRANSPLANTATION SETTING AND THEIR MAINTENANCE
OVER TIME
Speaker: Alberto Castagna, IT

NG23-5 EFFECTIVENESS OF AN EDUCATIONAL INTERVENTION FOR 08:30 - 08:30

INFLUENZA VACCINATION IN HEMATOPOIETIC STEM CELL

35 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

TRANSPLANT PATIENTS AND THEIR COHABITANTS

Speaker: Maria Teresa Solano Moliner, ES

Nurses Group
08:30 - 18:45 On-Demand Library
NG13 - Nurses Education Day 1: Care of the vulnerable immunocompromised patients in critical care setting
This session is available in our on-demand library throughout the whole congress
NG13-1 SARS-CoV-2 vaccines overview -
Speaker: Almudena Ramírez, ES

NG13-2 Seasonal human coronaviruses vs SARS-CoV-2 in allogeneic -

hematopoietic stem cell transplantation
Speaker: Jose Luis Piñana, ES

NG13-3 COVID-19: The EBMT recommendations for management of -

HCT patients and donors
Speaker: Per Ljungman, SE

Poster Sessions
08:30 - 18:45 ePoster Area
Multiple Myeloma
P149 HIGH-DOSE MELPHALAN AND AUTOLOGOUS STEM CELL 08:30 - 08:30
TRANSPLANTATION IN ELDERLY PATIENTS ? 70 YEARS IS
SAFE AND EFFECTIVE – A RETROSPECTIVE ANALYSIS
Speaker: Udo Holtick, DE

P150 PEGYLATED G-CSF VERSUS G-CSF FOLLOWING HD-CTX FOR 08:30 - 08:30
PBSC MOBILIZATION AND HEMATOPOIETIC RECONSTITUTION
AFTER ASCT IN NEWLY DIAGNOSED MULTIPLE MYELOMA
PATIENTS
Speaker: Meilan Chen, CN

P152 RECOMBINANT HUMAN THROMBOPOIETIN IMPROVED 08:30 - 08:30

PLATELET ENGRAFTMENT AFTER AUTOLOGOUS
HEMATOPOIETIC STEM CELL TRANSPLANTATION IN
PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA
Speaker: Jingli Gu, CN

P151 AUTOLOGOUS STEM CELL TRANSPLANTATION FOR ELDERLY 08:30 - 08:30

MULTIPLE MYELOMA PATIENTS – A SAFETY OPTION
Speaker: Rita Sousa Gomes, PT

P153 CLINICAL IMPLICATIONS OF ?? T CELL RECONSTITUTION 08:30 - 08:30

AFTER AUTOLOGOUS HEMATOPOIETIC STEM CELL
TRANSPLANTATION IN PATIENTS WITH MULTIPLE MYELOMA
Speaker: Carolina Afonso, PT

P155 INDUCTION RESPONSE SEEMS TO BE A PROGNOSTIC 08:30 - 08:30

FACTOR FOR PROGRESSION-FREE SURVIVAL AFTER
AUTOLOGOUS STEM CELL TRANSPLANTATION IN PATIENTS
WITH MUTIPLE MYELOMA
Speaker: Pilar Velarde López de Ayala, ES

36 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

Poster Sessions
08:30 - 18:45 ePoster Area
CAR-based Cellular Therapy – Preclinical
P026 NON-VIRAL SLEEPING BEAUTY TRANSPOSON ENGINEERED 08:30 - 08:30
CD19-CAR-NK CELLS WITH HIGH ANTILEUKEMIC EFFICIENCY
Speaker: Tobias Bexte, DE

Poster Sessions
08:30 - 18:45 ePoster Area
CAR-based Cellular Therapy – Clinical
P016 HEALTH-RELATED QUALITY OF LIFE IN THE CARTITUDE-1 08:30 - 08:30
STUDY OF CILTACABTAGENE AUTOLEUCEL FOR
RELAPSED/REFRACTORY MULTIPLE MYELOMA
Speaker: Thomas Martin, US

P017 MANUFACTURING COMMERCIAL AXICABTAGENE 08:30 - 08:30

CILOLEUCEL (AXI-CEL) FOR EUROPEAN PATIENTS: A 2-YEAR
RETROSPECTIVE ANALYSIS
Speaker: Didier Hallard, NL

P015 RETREATMENT WITH AXICABTAGENE CILOLEUCEL (AXI-CEL) 08:30 - 08:30

IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) INDOLENT
NON-HODGKIN LYMPHOMA (INHL) IN ZUMA-5
Speaker: Julio C. Chavez, US

P019 COST-EFFECTIVENESS OF KTE-X19 CAR T THERAPY 08:30 - 08:30

FOLLOWING BRUTON TYROSINE KINASE INHIBITOR
TREATMENT FOR RELAPSED/REFRACTORY MANTLE CELL
LYMPHOMA IN ENGLAND
Speaker: Martin Brown, GB

P018 EXPANSION DYNAMICS DETECTED BY FLOW CYTOMETRY 08:30 - 08:30

CORRELATES WITH CLINICAL RESPONSE AFTER CAR-T CELL
THERAPY IN THE REAL WORLD SETTING
Speaker: Silvia monsalvo, ES

P020 PATIENT EXPECTATIONS AND PERCEPTIONS OF TREATMENT 08:30 - 08:30

IN CARTITUDE-1: PHASE 1B/2 STUDY OF CILTACABTAGENE
AUTOLEUCEL IN RELAPSED/REFRACTORY MULTIPLE
MYELOMA
Speaker: Adam D Cohen, US

P021 CHARACTERIZATION OF INFECTIONS AFTER CHIMERIC 08:30 - 08:30

ANTIGEN RECEPTOR T-CELL THERAPY IN PATIENTS WITH
LARGE B-CELL LYMPHOMA
Speaker: Pere Barba, ES

P022 CLINICAL APPLICATION OF HAPLOIDENTICAL DONOR- 08:30 - 08:30

DERIVED CD19 CAR-T CELLS MANUFACTURED FROM
MEMORY T CELL (CD45RA-DEPLETED) FRACTION
Speaker: Larisa Shelikhova, RU

P024 ICU RESOURCE UTILIZATION IN PEDIATRIC AND 08:30 - 08:30

ADOLESCENT YOUNG ADULT PATIENTS POST CAR-T

37 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

THERAPY
Speaker: Dristhi Ragoonanan, US

P023 HEMATOLOGIC RESCUE OF CAR T CELL-MEDIATED 08:30 - 08:30

PROLONGED PANCYTOPENIA USING AUTOLOGOUS
PERIPHERAL BLOOD HEMATOPOIETIC STEM CELLS IN A
LYMPHOMA PATIENT
Speaker: Udo Holtick, DE

P025 ZUMA-19: A PHASE 1/2 MULTICENTER STUDY OF LENZILUMAB 08:30 - 08:30

WITH AXICABTAGENE CILOLEUCEL (AXI?CEL) IN PATIENTS
WITH RELAPSED OR REFRACTORY LARGE B CELL
LYMPHOMA (R/R LBCL)
Speaker: Saad J. Kenderian, US

Poster Sessions
08:30 - 18:45 ePoster Area
Acute Leukaemia
P001 MEASURABLE RESIDUAL DISEASE, FLT3-ITD MUTATION AND 08:30 - 08:30
DISEASE STATUS HAVE INDEPENDENT PROGNOSTIC
INFLUENCE ON POST-TRANSPLANT OUTCOMES IN
NPM1-MUTATED ACUTE MYELOID LEUKEMIA
Speaker: Rama Al Hamed, US

P002 ROLE OF ALLO-HSCT AS CONSOLIDATION OF MRD-NEGATIVE 08:30 - 08:30

REMISSION IN R/R B-ALL AFTER TREATMENT WITH
MONOCLONAL ANTIBODIES
Speaker: Inna Markova, RU

P003 AZACYTIDINE AND DONOR LYMPHOCYTE INFUSIONS (DLI) AS 08:30 - 08:30

SALVAGE TREATMENT IN PATIENTS WITH AML AND MDS
RELAPSED AFTER ALLOGENEIC STEM CELL
TRANSPLANTATION: A RETROSPECTIVE SINGLE CENTER
ANALYSIS
Speaker: Semra Aydin, IT

P004 T-CELL-DEPLETE ALLOGENEIC HAEMATOPOIETIC STEM CELL 08:30 - 08:30

TRANSPLANT AFTER REDUCED-INTENSITY CONDITIONING
FOR MYELOID MALIGNANCIES IN THE OVER-65S – A SINGLE
CENTRE EXPERIENCE OF 90 PATIENTS
Speaker: Alexandros Kanellopoulos, GB

P005 POST-REMISSION TREATMENT PATTERNS FOR PATIENTS 08:30 - 08:30

WITH NEWLY DIAGNOSED (ND) ACUTE MYELOID LEUKEMIA
(AML) IN THE CONNECT® MDS/AML DISEASE REGISTRY

P006 ALLOGENEIC STEM CELL TRANSPLANTATION IN FIRST 08:30 - 08:30

COMPLETE REMISSION IS ASSOCIATED WITH SUPERIOR
OUTCOMES IN ACUTE MYELOID LEUKEMIA INDEPENDENT OF
RECIPIENT AGE AND DONOR TYPE
Speaker: Tatiana Tzenou, GR

P007 GILTERITINIB MONOTHERAPY IN RELAPSED OR 08:30 - 08:30

REFRACTORY ACUTE MYELOID LEUKEMIA FLT3+ IN ADULT

38 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

PATIENTS
Speaker: Sergey Bondarenko, RU

P009 ZUMA-4: A PHASE 1/2 MULTICENTER STUDY OF KTE-X19 IN 08:30 - 08:30

PEDIATRIC AND ADOLESCENT PATIENTS WITH
RELAPSED/REFRACTORY B CELL ACUTE LYMPHOBLASTIC
LEUKEMIA (ALL) OR NON-HODGKIN LYMPHOMA (NHL)
Speaker: Alan S. Wayne, US

P008 VENETOCLAX COMBINED WITH AZACITIDINE OR LOW-DOSE 08:30 - 08:30

CYTARABINE FOR RELAPSED ACUTE MYELOID LEUKAEMIA
POST ALLOGENEIC STEM CELL TRANSPLANT
Speaker: Sandra Easdale, GB

P010 LONG-TERM OUTCOME OF ALLOGENEIC STEM CELL 08:30 - 08:30

TRANSPLANTATION IN PATIENTS WITH ACUTE MYELOID
LEUKEMIA – FOCUS ON MORTALITY
Speaker: Anna Lojko-Dankowska, PL

P011 SORAFENIB MAINTENANCE AFTER HEMATOPOIETIC STEM 08:30 - 08:30

CELL TRANSPLANTATION IMPROVES OUTCOME OF FLT3-ITD
POSITIVE ACUTE MYELOID LEUKEMIA
Speaker: Semra Aydin, IT

P012 BASELINE SOMATIC MUTATIONS PREDICT DISEASE FREE 08:30 - 08:30

SURVIVAL AFTER ALLOGENEIC STEM CELL
TRANSPLANTATION IN ACUTE MYELOID LEUKEMIA: A
RETROSPECTIVE MONOCENTRIC REPORT
Speaker: Elisabetta Metafuni, IT

P013 UNMANIPULATED HAPLOIDENTICAL HEMATOPOIETIC STEM 08:30 - 08:30

CELL TRANSPLANTATION IN ADULT PATIENTS WITH ACUTE
MYELOID LEUKEMIA
Speaker: Sergey Bondarenko, RU

P014 SURVIVAL OF PATIENTS WITH ACUTE MYELOID LEUKEMIA, 08:30 - 08:30

TAKEN TO HEMATOPOIETIC STEM CELL TRANSPLANTATION:
EXPERIENCE OF A CENTER IN COLOMBIA
Speaker: Claudia Lucía Sossa Melo, CO

Poster Sessions
08:30 - 18:45 ePoster Area
Data Management
P045 GENDER DISPARITY IN AUTOLOGOUS HSCT; FACT OR MYTH? 08:30 - 08:30
A BSBMTCT REGISTRY STUDY LOOKING INTO POSSIBLE
MALE PREDOMINANCE IN HSCT PARTICULARLY IN MULTIPLE
MYELOMA
Speaker: Ruth Paul, GB

Poster Sessions
08:30 - 18:45 ePoster Area
Nurses Posters – Research

39 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

NP24 ROLE OF NURSING IN THE CARE OF PATIENT’S SKIN WITH 08:30 - 08:30
CUTANEOUS CHRONIC GRAFT-VERSUS-HOST DISEASE
AFTER ALLOGENEIC HAEMOPOIETIC STEM CELL
TRANSPLANTATION: A QUESTIONNAIRE?BASED SURVEY
Speaker: Jacqui Stringer, GB

NP25 INTRAVENTRICULAR INJECTIONS VIA OMMAYA RESERVOIR 08:30 - 08:30

MAY BE PERFORMED BY A TRAINED NURSE AS A PART OF
PEDIATRIC NEUROONCOLOGY TRANSPLANT TEAM EFFORT
Speaker: Lubov Shepeleva, RU

NP26 THE ROLE OF A NURSE IN NUTRITIONAL COUNSELING 08:30 - 08:30

DEVELOPMENT IN HEMATOPOIETIC STEM CELL
TRANSPLANTATION: FROM PRACTICE TO SCIENCE
Speaker: Natalya Rotan, RU

NP27 LONG TERM SURVIVORS AFTER ALLOGENEIC 08:30 - 08:30

HAEMATOPOIETIC STEM CELL TRANSPLANTATION IN
CHILDHOOD AND ADOLESCENCE IN A DEVELOPING
COUNTRY: HOW ARE THEY NOW?
Speaker: Priscila Oliveira da Silva, BR

NP28 EPIDEMIOLOGICAL SCREENING FOR BACTERIAL DRUG 08:30 - 08:30

RESISTANCE IN CANDIDATES FOR ALLO-HSCT AND MEDICAL
EMPLOYEES OF HEMATOLOGICAL DEPARTMENTS
Speaker: Olga Prokofieva, RU

NP29 EARLY CORONAVIRUS WARNING SCORE IN HEMATOLOGY 08:30 - 08:30

DISEASES
Speaker: Silvia Sangüesa Domínguez, ES

Poster Sessions
08:30 - 18:45 ePoster Area
ePoster Area

Poster Sessions
08:30 - 18:45 ePoster Area
Myeloproliferative Neoplasm

Poster Sessions
08:30 - 18:45 ePoster Area
Nurses Posters – Adult
NP01 NURSES’ TRAINING NEEDS FOR ADVANCED THERAPY 08:30 - 08:30
MEDICINAL PRODUCTS EG CAR T: KEY FINDINGS FROM
QUESTIONNAIRE-BASED SURVEY ON BEHALF OF THE
NURSES GROUP OF THE EBMT
Speaker: Michelle Kenyon, GB

NP02 IMPROVEMENT OF ORAL MUCOSITIS IN HEMATOPOIETIC 08:30 - 08:30

STEM CELL TRANSPLANTATION USING POVIDONE-IODINE
MOUTHWASH UNDER DIRECT NURSING SUPERVISION
Speaker: Napassaya Khanthum, TH

40 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

NP03 COMPREHENSIVE GERIATRIC ASSESSMENT TO PREDICT 08:30 - 08:30

OUTCOMES IN OLDER PATIENTS RECEIVED CAR-T CELL
THERAPY
Speaker: Mercedes Montoro-Lorite, ES

NP04 CAR-T - RECOGNITION AND TREATMENT MANAGEMENT OF 08:30 - 08:30

NEUROLOGIC TOXICITIES AND CYTOKINE RELEASE
SYNDROME
Speaker: Naama Nevo, IL

NP05 HOME PLATELET TRANSFUSION IN AUTOLOGOUS STEM- 08:30 - 08:30

CELL TRANSPLANTATION: IMPROVING HOME-CARE
STRATEGIES DURING SARS-COV-2 PANDEMIC
Speaker: Laura Villa Rodríguez, ES

NP06 IMPROVING LONG-TERM QUALITY OF LIFE FOR PATIENTS 08:30 - 08:30

LIVING WITH MULTIPLE MYELOMA: A SERVICE EVALUATION
Speaker: Sarah Henshaw, GB

NP07 AT-HOME HEMATOPOIETIC STEM CELL TRANSPLANTATION 08:30 - 08:30

DURING SARS-CoV-2 PANDEMIC

NP08 THE NURSING SEARCH COORDINATOR (NSC) OF THE ROME 08:30 - 08:30
TRANSPLANT NETWORK (RTN), A JACIE ACCREDITED
METROPOLITAN TRANSPLANT PROGRAM
Speaker: Antonio Bruno, IT

NP10 PREVENTION OF NOSOCOMIAL SARS-COV2 INFECTIONS 08:30 - 08:30

AMONG HEMATOLOGICAL PATIENTS JUST BY FOLLOWING
WELL ESTABLISHED NURSING CARE STANDARDS
Speaker: Isabel Salcedo, ES

NP11 A TALE OF 2 COLLECTIONS: CAR -T ‘V' PBSC. OUR SINGLE 08:30 - 08:30
CENTRE EXPERIENCE
Speaker: Caroline Jupp, GB

NP12 CREATION OF THE FIRST COURSE ON HEMATOPOIETIC STEM 08:30 - 08:30

CELL TRANSPLANTATION (HSCT) NURSING IN LATIN
AMERICAN. ARGENTINE SOCIETY OF HEMATOLOGY
Speaker: Mariela Blanco, AR

NP13 MANAGEMENT OF PATIENTS SUFFERING FROM AN HEMATO- 08:30 - 08:30

ONCOLOGY MALIGNANCY AND THOSE UNDERGOING
HEMATOPOIETIC CELL TRANSPLANTATION DURING THE
COVID-19. HOW DO WE PROTECT THEM?
Speaker: Anna Serrahima - Mackay, ES

NP14 PREVENTION OF ORAL MUCOSITIS WITH CRYOTHERAPY IN 08:30 - 08:30

ADULT PATIENTS UNDERGOING HEMATOPOIETIC STEM CELL
TRANSPLANTATION
Speaker: Bakhtawar Altaf Hussain, PK

NP15 COVID-19 CHALLENGES – TO THE POINT OF CELL DELIVERY - 08:30 - 08:30

THE REALITY
Speaker: Lindsey Ashton, GB

41 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

NP16 TRANSITION FROM PAEDIATRIC TO THE ADULT CLINIC IN 08:30 - 08:30

SICKLE CELL DISEASE: THE ROLE OF THE SPECIALISED
NURSE
Speaker: Marijke Quaghebeur, BE

NP09 EBMT (GEC) & LABMT COLLABORATION PROJECTT. LABMT 08:30 - 08:40
NURSES GROUP 2020 CONTINUING EDUCATION PROGRAM
Speaker: Mariela Blanco, AR

Poster Sessions
08:30 - 18:45 ePoster Area
Statistics
P201 EVALUATION OF MACHINE LEARNING ALGORITHMS 08:30 - 08:30
APPLICABILITY FOR GRAFT FAILURE PREDICTION
Speaker: Evgeny Bakin, RU

P202 WHITE MATTER DEVELOPMENT IN NEONATES WITH 08:30 - 08:30

INFANTILE KRABBE DISEASE
Speaker: Maria Escolar, US

Poster Sessions
08:30 - 18:45 ePoster Area
Nurses Posters – Paediatric
NP17 NURSING INTERVENTIONS TO PREVENT HYPERTENSIVE 08:30 - 08:30
EMERGENCIES IN CHILDREN UNDERGOING HEMATOPOIETIC
STEM CELL TRANSPLANTATION
Speaker: Deepa Karmegam, IN

NP18 NEUROLOGICAL ASSESSMENT IN PAEDIATRIC PATIENTS 08:30 - 08:30

AFTER CAR-T INFUSION
Speaker: Giulia Del Giorno, IT

NP19 THE WORK OF THE REHABILITATION DEPARTMENT WITH 08:30 - 08:30

VOLUNTEERS DURING THE COVID-19 PANDEMIC
Speaker: Rashida Bikulova, RU

NP20 EVALUATION OF THE EFFECTIVENESS OF NASOGASTRIC 08:30 - 08:30

CATHETERIZATION AS A MEASURE OF NUTRITIONAL
SUPPORT IN PEDIATRIC PATIENTS UNDERGOING
ALLOGENEIC HEMATOPOIETIC STEM CELLS
TRANSPLANTATION
Speaker: Eugenia Trigoso Arjona, ES

NP21 NURSING CARE FOR ACUTE LEUKEMIA CHILDREN WITH 08:30 - 08:30
COMPLICATED BCG VACCINATION DURING CHEMOTHERAPY.
DESCRIPTION OF CLINICAL CASES
Speaker: Anton Silov, RU

NP22 INFUSION OF CHIMERIC ANTIGEN RECEPTOR T CELL (CAR-T 08:30 - 08:30

CELL) THERAPY IN PAEDIATRIC PATIENTS RECEIVING: ONE-
CENTER EXPERIENCE
Speaker: Alba Fernandez-Arroyo Garcia, ES

42 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

NP23 IMPLEMENTATION OF THE ADVANCED CELL THERAPY 08:30 - 08:30

PROGRAM:  EXPERIENCE AT LA PAZ UNIVERSITY
HOSPITAL
Speaker: Alba Fernandez-Arroyo Garcia, ES

Poster Sessions
08:30 - 18:45 ePoster Area
Stem Cell Source
P216 THE BLOOD DONATION BEFORE BONE MARROW HARVEST 08:30 - 08:30
HAS NO IMPACT ON EFFICIENCY OF COLLECTION
Speaker: Iwona Mitrus, PL

P217 UNMANIPULATED HAPLOIDENTICAL TRANSPLANTATION FOR 08:30 - 08:30

HIGH RISK ACUTE LEUKEMIA USING MOBILIZED PERIPHERAL
BLOOD STEM CELLS (PBSC) AS SOURCE OF GRAFT: A
SINGLE CENTER EXPERIENCE
Speaker: Vincenzo Federico, IT

Poster Sessions
08:30 - 18:45 ePoster Area
Pharmacology
P195 PRELIMINARY SAFETY AND EFFICACY OF ITOLIZUMAB, A 08:30 - 08:30
NOVEL TARGETED ANTI-CD6 THERAPY, IN NEWLY
DIAGNOSED SEVERE ACUTE GRAFT-VERSUS-HOST DISEASE:
INTERIM RESULTS FROM THE EQUATE STUDY
Speaker: John Koreth, US

P196 EVALUATION OF A LIMITED SAMPLING STRATEGY IN THE 08:30 - 08:30

THERAPEUTIC DRUG MONITORING OF BUSULFAN
Speaker: Bushra Salman, OM

P197 A NOVEL SHORT HALF-LIFE ANTI-HUMAN CD117-AMANITIN 08:30 - 08:30

ADC EXHIBITS DUAL HSCT CONDITIONING AND ANTI-
LEUKEMIA ACTIVITY AND EXTENDS SURVIVAL IN MULTIPLE
PRECLINICAL MODELS OF AML
Speaker: Leanne Lanieri, US

P199 PHARMACOKINETIC ANALYSIS OF BARICITINIB IN PHASE 1-2 08:30 - 08:30

STUDY FOR TREATMENT REFRACTORY CHRONIC GRAFT-
VERSUS-HOST DISEASE
Speaker: Sara M. Zimmerman, US

P198 THE IMPACT OF LETERMOVIR PRESCRIBING ON THE RATE OF 08:30 - 08:30

CYTOMEGALOVIRUS REACTIVATION FOLLOWING
ALLOGENEIC STEM CELL TRANSPLANTATION
Speaker: Siobhan Smith, GB

Poster Sessions
08:30 - 18:45 ePoster Area
Solid Tumours
P200 HIGH DOSE CHEMOTHERAPY AND STEM-CELL TRANSPLANT 08:30 - 08:30

43 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

FOR RELAPSED GERM CELL TUMORS: MULTICENTRIC REAL-

WORLD EXPERIENCE IN ARGENTINA
Speaker: Adriana Vitriu, AR

Poster Sessions
08:30 - 18:45 ePoster Area
Stem Cell Mobilization, Collection and Engineering
P206 INTERIM ANALYSIS OF THE OPTIMOB STUDY: A NON- 08:30 - 08:30
INTERVENTIONAL STUDY ACROSS GERMANY TO EVALUATE
THE MOBILIZATION AND COLLECTION OF HSCS IN POOR
MOBILIZERS AHEAD OF ASCT
Speaker: Katharina Kriegsmann, DE

P207 TRENDS IN AUTOLOGOUS STEM CELL MOBILISATION 08:30 - 08:30

PRACTICES IN MYELOMA PATIENTS IN EBMT CENTRES
BETWEEN 2008 AND 2017
Speaker: James Dillon, IE

P208 THE IMPACT OF THE “NEW NORMAL” ON STEM CELL 08:30 - 08:30
LABORATORY PRACTICES
Speaker: Sanja Mazi?, HR

P210 AN ALGORITHMIC APPROACH TO PRE-EMPTIVE PLERIXAFOR 08:30 - 08:30

USAGE WITH GCSF ALONE FOR MOBILIZATION OF
PERIPHERAL BLOOD STEM CELLS IN MULTIPLE MYELOMA
Speaker: Mohamed Elemary, CA

P209 PLERIXAFOR MOBILIZATION OF HEMATOPOIETIC STEM 08:30 - 08:30

CELLS IN DIALYSIS DEPENDENT PATIENTS IS SAFE AND
FEASIBLE; A SINGLE CENTER ANALYSIS
Speaker: Moussab Damlaj, SA

P211 PROGRAM OF HEMATOPOIETIC STEM CELL MOBILIZATION 08:30 - 08:30

AND COLLECTION FOR CHILDREN OF FIRST YEAR OF LIFE
AND WITH LOW BODY WEIGHT: SINGLE CENTER EXPERIENCE
Speaker: Nara Stepanyan, RU

P212 A RETROSPECTIVE RECORD REVIEW OF MOBILIZATION 08:30 - 08:30

STRATEGIES WITH AND WITHOUT PLERIXAFOR FOR
AUTOLOGOUS STEM CELL TRANSPLANT IN PATIENTS WITH
MULTIPLE MYELOMA
Speaker: Joshua Richter, US

P213 PREDICTION OF THE MOBILIZATION SUCCESS FOR 08:30 - 08:30

AUTOLOGOUS PERIPHERAL BLOOD STEM CELL COLLECTION
IN PATIENTS WITH MALIGNANT HEMATOLOGIC DISEASES
Speaker: Maria Eduarda Couto, PT

P214 DOES USE OF BIOSIMILAR ZARZIO CHANGE PLERIXAFOR 08:30 - 08:30

UTILIZATION DURING STEM CELL MOBILIZATION FOR
AUTOLOGOUS STEM CELL TRANSPLANT?
Speaker: Pilar Velarde López de Ayala, ES

P215 AUTOLOGOUS PERIPHERAL BLOOD STEM CELL BACKUP 08:30 - 08:30

44 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

BEFORE HAEMATOPOETIC STEM CELL TRANSPLANTATION

FOR INTERMEDIATE OSTEOPETROSIS: A SINGLE CENTRE
EXPERIENCE
Speaker: Madeleine Powys, AU

Poster Sessions
08:30 - 18:45 ePoster Area
Non-infectious Late Effects, Quality of Life and Fertility
P177 IMPACT OF AGE IN EARLY AND LATE COMPLICATIONS AFTER 08:30 - 08:30
AN ALLOGENEIC TRANSPLANT IN ELDERLY PATIENTS
Speaker: Magdalena Corona de Lapuerta, ES

P178 OSTEONECROSIS IN PATIENTS UNDERGOING 08:30 - 08:30

HEMATOPOIETIC STEM CELLS TRANSPLANT: A SINGLE-
CENTRE STUDY OF INCIDENCE, RISK FACTORS,
CHARACTERISTICS AND EVOLUTION
Speaker: Giulia Prunotto, IT

P179 SECONDARY MALIGNANCIES AFTER AUTOLOGOUS 08:30 - 08:30

HEMATOPOIETIC STEM CELL TRANSPLANTATION
Speaker: João Gaião Santos, PT

P181 ANXIETY SYMPTOMATOLOGY PROGRESSION IN PATIENTS 08:30 - 08:30

WITH DIAGNOSIS OF MALIGNANT HEMATOLOGICAL
PATHOLOGY WHO ARE CANDIDATES TO RECEIVE INTENSIVE
CHEMOTHERAPY
Speaker: Walter Javier Zambrano Marquez, ES

P180 SECONDARY MALIGNANCIES AFTER ALLOGENEIC HSCT IN 08:30 - 08:30

CHILDREN
Speaker: Yulia Skvortsova, RU

P182 AN UNUSUAL PRESENTATION OF AUTOIMMUNE DISORDERS 08:30 - 08:30

AFTER ALLOGENEIC STEM CELL TRANSPLANTATION –
AMYOPATHIC DERMATOMYSISTIS, PRIMARY BILIARY
CHOLANGITIS AND AUTOIMMUNE HAEMOLYTIC ANAEMIA
Speaker: Pedro de Vasconcelos M, PT

Poster Sessions
08:30 - 18:45 ePoster Area
Non-infectious Early Complications
P169 POST HEMATOPOIETIC PROGENITORS TRANSPLANT 08:30 - 08:30
LYMPHOMA (PTLD) AND REPLICATION OF EPSTEIN-BARR
VIRUS (EBV): A CENTER'S EXPERIENCE
Speaker: Sara Garrido, ES

P171 CLINICAL OUTCOME OF PATIENTS WITH IMMUNE-MEDIATED 08:30 - 08:30

PLATELET REFRACTORINESS UNDERGOING HEMATOPOIETIC
STEM CELL TRANSPLANTATION. SINGLE CENTER
EXPERIENCE

P170 ANALYSIS OF THE GUT MICROBIOME IN PEDIATRIC PATIENTS 08:30 - 08:30

45 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

UNDERGOING ALLOGENEIC HEMATOPOIETIC STEM CELL

TRANSPLANTATION (HSCT) PRESENTING VENO-OCCLUSIVE
DISEASE (VOD/SOS) REVEALS AN IMPAIRED MICROBIAL
ECOSYSTEM
Speaker: Daniele Zama, IT

P172 HEMORRHAGIC CYSTITIS DURING ALLOGENEIC STEM CELL 08:30 - 08:30

TRASPLANTATION: A POSSIBLE ROLE FOR PROSTATIC
HYPERPLASI
Speaker: Eugenio Galli, IT

P173 THROMBOTIC EVENTS IN HEMATOPOIETIC TRANSPLANT 08:30 - 08:30

RECPIENTS: SINGLE CENTER EXPERIENCE
Speaker: Carlota Mayor Bastida, ES

P175 EVALUATION OF INTESTINAL PERMEABILITY IN CANDIDATES 08:30 - 08:30

FOR ALLOHCT AND IN EARLY POST-TRANSPLANT PERIOD BY
SUGAR ABSORBTION TEST: INTERIM ANALYSIS OF THE
SINGLE-CENTER PROSPECTIVE STUDY
Speaker: Grzegorz Basak, PL

P176 ANICTERIC PRESENTATION OF SEVERE HEPATIC VENO- 08:30 - 08:30

OCCLUSIVE DISEASE (VOD) WITH MULTIORGAN
DYSFUNCTION (MOD)- A PEDIATRIC CASE REPORT
Speaker: Zofia Szmit, PL

Poster Sessions
08:30 - 18:45 ePoster Area
New Drugs- and Cell-based Immune Therapies
P160 INJECTION-SITE REACTIONS IN THE RANDOMIZED PHASE 3 08:30 - 08:30
PEGASUS TRIAL OF PEGCETACOPLAN COMPARED WITH
ECULIZUMAB FOR INDIVIDUALS WITH PAROXYSMAL
NOCTURNAL HEMOGLOBINURIA
Speaker: Vivek Sharma, US

P161 CLINICAL BURDEN OF ILLNESS SURVEY RESULTS FOR U.S. 08:30 - 08:30
PATIENTS WITH PAROXYSMAL NOCTURNAL
HEMOGLOBINURIA RECEIVING C5 INHIBITORS
Speaker: David Dingli, US

P162 IN ACUTE HSCT/BMT-TMA THE ACTIVATION OF THE LECTIN 08:30 - 08:30

PATHWAY INDUCES C5B-9 FORMATION ON ENDOTHELIAL
CELLS AND FAVORS MICROVASCULAR THROMBOSIS
Speaker: Miriam Galbusera, IT

P165 MEMORY-LIKE NK CELLS AS TREATMENT FOR PEDIATRIC 08:30 - 08:30

SARCOMA
Speaker: Carla Martín-Cortázar, ES

P163 POST-HEMATOPOIETIC STEM CELL TRANSPLANT 08:30 - 08:30

MAINTENANCE TKI'S IN PHILADELPHIA POSITIVE ALL: KING
HUSSEIN CANCER CENTRE EXPERIENCE

P166 PHASE 3 MULTICENTER, DOUBLE-BLIND, PLACEBO- 08:30 - 08:30

46 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

CONTROLLED TRIAL OF VIRALYM-M (ALVR105) FOR THE

TREATMENT OF VIRUS?ASSOCIATED HAEMORRHAGIC
CYSTITIS AFTER ALLOGENEIC HAEMATOPOIETIC CELL
TRANSPLANT (HCT) (STUDY DESIGN)
Speaker: Anna Thorner, US

P168 CLINICAL PHARMACOLOGY AND POPULATION 08:30 - 08:30

PHARMACOKINETIC/PHARMACODYNAMIC MODELING OF
LECTIN PATHWAY INHIBITION BY NARSOPLIMAB (OMS721)

P167 WORK PRODUCTIVITY LOSS AND QUALITY OF LIFE IN 08:30 - 08:30

PAROXYSMAL NOCTURNAL HEMOGLOBINURIA AMONG
PATIENTS RECEIVING C5 INHIBITORS IN THE UNITED STATES
Speaker: David Dingli, US

Poster Sessions
08:30 - 18:45 ePoster Area
Myelodysplastic Syndromes
P156 THE ROLE OF AGE IN OUTCOMES OF BONE MARROW 08:30 - 08:30
TRANSPLANTATION IN PATIENTS FROM THE LATIN
AMERICAN REGISTRY
Speaker: Fernando Barroso Duarte, BR

P157 PRE-TRANSPLANT FERRITIN PREDICTS NON-RELAPSE 08:30 - 08:30

MORTALITY IN PATIENTS WITH MYELODYSPLASTIC
SYNDROMES UNDERGOING HEMATOPOIETIC STEM CELL
TRANSPLANTATION
Speaker: Isla Johnson, US

P159 SURVIVAL ANALYSIS IN ALLOGENIC HEMATOPOIETIC STEM 08:30 - 08:30

CELL TRANSPLANTATION IN MYELODYSPLASTIC SYNDROME
AND CHRONIC MYELOMONOCYTIC LEUKEMIA. IMPORTANCE
OF THE PREVIOUS SITUATION

P158 SECONDARY AND TREATMENT-RELATED ACUTE MYELOID 08:30 - 08:30

LEUKEMIA: ALLOGENEIC HEMATOPOIETIC CELL
TRANSPLANTATION REMAINS THE BEST AVAILABLE OPTION
Speaker: Ioanna Sakellari, GR

Poster Sessions
08:30 - 18:45 ePoster Area
Cellular Therapies other than CARs
P027 PROLONGED REPEATEDLY ADMINISTERED LOW DOSE 08:30 - 08:30
DONOR LYMPHOCYTE INFUSION FOR PREVENTION OF
RELAPSE AFTER ALLOGENEIC STEM CELL
TRANSPLANTATION FOR PATIENTS WITH HIGH RISK ACUTE
LEUKEMIA
Speaker: Panagiotis Tsirigotis, GR

P028 CD8?-ENHANCED NY-ESO-1-SPECIFIC TCR T CELLS 08:30 - 08:30

(GSK3901961) IN HLA-A*02 PATIENTS WITH NSCLC: MASTER
PROTOCOL SUBSTUDY 1

47 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

Speaker: Mehmet Altan, US

P029 CLINIMACS PLUS® SELECTION AS A RELIABLE AND SAFE 08:30 - 08:30

ALTERNATIVE PROCEDURE FOR CLINIMACS PRODIGY®
TCR?? AND CD19 DEPLETION
Speaker: Katalin Dobos, HU

P031 COMPREHENSIVE ACTIVATION PROFILING OF 08:30 - 08:30

TABELECLEUCEL, AN OFF-THE-SHELF, ALLOGENEIC EBV-
SPECIFIC T-CELL IMMUNOTHERAPY
Speaker: Fiona Ruiz, US

P030 IMPACT OF CRYOPRESERVED PHOTOPHERESIS IN GRAFT 08:30 - 08:30

VERSUS HOST DISEASE FOR NON-MALIGNANT DISORDERS
AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL
TRANSPLANTATION IN PEDIATRIC PATIENTS

P035 BMT CTN 1803: HAPLOIDENTICAL NATURAL KILLER CELLS (K- 08:30 - 08:30
NK002) TO PREVENT POST-TRANSPLANT RELAPSE IN AML
AND MDS (NK-REALM)
Speaker: Sumithira Vasu, US

P034 NEW, LN2-FREE SOLUTION FOR CRYOGENIC TRANSPORT OF 08:30 - 08:30

CELL THERAPIES
Speaker: Julie Meneghel, GB

P032 DONOR LYMPHOCYTE INFUSION AFTER ALLOGENEIC STEM 08:30 - 08:30

CELL TRANSPLANTATION: A RETROSPECTIVE ANALYSIS
Speaker: Virginia Escamilla Gómez, ES

P033 DONOR LYMPHOCYTE INFUSION (DLI). A STRATEGY TO 08:30 - 08:30

PREVENT OR TREAT RELAPSE FOLLOWING ALLOGENIC
STEM CELL TRANPLANTATION. ONE SINGLE CENTER
EXPERIENCE
Speaker: Melissa Karina Torres Ochando, ES

Poster Sessions
08:30 - 18:45 ePoster Area
Minimal Residual Disease, Tolerance, Chimerism and Immune Reconstitution
P143 EMPIRIC GRANULOCYTE-COLONY STIMULATING FACTOR (G- 08:30 - 08:30
CSF) ADVERSELY IMPACTS SURVIVAL AFTER ALLOGENEIC
STEM CELL TRANSPLANTATION (HCT) PERFORMED WITH
THYMOGLOBULIN: A CIBMTR ANALYSIS
Speaker: Nina Orfali, IE

P144 PREDICTIVE MEANING OF MRD CONVERSION ON DAYS +30 08:30 - 08:30

AND +100 IN PATIENTS WITH AML AFTER ALLO-SCT
Speaker: Nicolaus Kröger, DE

P145 IMPACT OF DIFFERENT T CELL DEPLETION PROTOCOLS ON 08:30 - 08:30

IMMUNE RECONSTITUTION FOLLOWING ALLOGENEIC
HEMATOPOIETIC STEM CELL TRANSPLANTATION
Speaker: Amandine Pradier, CH

48 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

P146 MRD VS CHIMERISM: ARE THEIR EFFECTIVENESS 08:30 - 08:30

COMPARABLE TO PREDICT AML RELAPSE?
Speaker: Valérie Dubois, FR

P148 CELLULAR CHIMERISM – DO REPEATED MARROW BIOPSIES 08:30 - 08:30

OPEN A WINDOW FOR RELAPSE INTERVENTION?
Speaker: Jan Morf, GB

Poster Sessions
08:30 - 18:45 ePoster Area
Lymphoma and Chronic Lymphocytic Leukemia
P134 RESULTS WITH ALLOGENEIC STEM CELL TRANSPLANTATION 08:30 - 08:30
IN PATIENTS WITH RELAPSED/REFRACTORY HODGKIN
LYMPHOMA TREATED WITH ANTI-PD1: A MULTICENTER
RETROSPECTIVE COHORT STUDY
Speaker: Fernando Warley, AR

P133 18FLUOROMETHYLCHOLINE PET/CT TO PREDICT OUTCOMES 08:30 - 08:30

OF PATIENTS PRE AND POST AUTOLOGOUS STEM CELL
TRANSPLANTATION(ASCT) FOR CNS LYMPHOMA – A NEW
CNS LYMPHOMA IMAGING TOOL
Speaker: Sandra Easdale, GB

P135 THE OUTCOMES OF ALLOGENEIC STEM CELLS 08:30 - 08:30

TRANSPLANTATION FOR RELAPSED/REFRACTORY CHRONIC
LYMPHOCYTIC LEUKEMIA IN THE ERA OF TARGETED
THERAPY: SINGLE CENTER EXPERIENCE
Speaker: Ivan Moiseev, RU

P137 STEM CELL TRANSPLANTATION IN MANTLE CELL 08:30 - 08:30

LYMPHOMA: POST-TRANSPLANT OUTCOMES OF TAIWAN
BLOOD AND MARROW TRANSPLANTATION REGISTRY
Speaker: Yu-Hung Wang, TW

P136 NIVOLUMAB 40 MG THERAPY IN RELAPSED AND 08:30 - 08:30

REFRACTORY CLASSICAL HODGKIN LYMPHOMA: RESULTS
OF A SINGLE CENTER MATCHED CASE-CONTROL STUDY
Speaker: Liudmila Fedorova, RU

P138 AUTOLOGOUS HEMATOPOIETIC CELL TRANSPLANTATION 08:30 - 08:30

FOR HIGH GRADE B-CELL LYMPHOMA WITH MYC AND BCL2
AND/OR BCL6 REARRANGEMENTS. A SINGLE INSTITUTION
EXPERIENCE
Speaker: Joanna Romejko-Jarosinska, PL

P142 SUCCESSFUL TREATMENT OF HEPATOSPLENIC T-CELL 08:30 - 08:30

LYMPHOMA WITH INTENSIFIED MYELOABLATIVE
CONDITIONING REGIMENS FOLLOWED BY UNMANIPULATED
HAPLOIDENTICAL HEMATOPOIETIC STEM CELL
TRANSPLANTATION
Speaker: Yan-Li Zhao, CN

P140 POLA-BR AFTER CAR-T CELL THERAPY FAILURE IN R/R 08:30 - 08:30
DIFFUSE LARGE B-CELL LYMPHOMA

49 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

Speaker: Ivan Moiseev, RU

P141 NODAL PERIPHERAL T-CELL LYMPHOMA – THE ROLE OF 08:30 - 08:30

CONSOLIDATIVE AUTOLOGOUS STEM CELL
TRANSPLANTATION IN COMPLETE OR PARTIAL FIRST
REMISSION: A 10-YEAR LESSON FROM SINGAPORE GENERAL
HOSPITAL
Speaker: Christopher Shwei Wen Tham, SG

P139 AUTOLOGOUS STEM CELL TRANSPLANT IN NON HODGKIN 08:30 - 08:30

LYMPHOMA AT AIIMS: TRENDS IN TOLERABILITY AND LONG
TERM OUTCOMES
Speaker: Sudhir Kumar, IN

Poster Sessions
08:30 - 18:45 ePoster Area
Paediatric Issues
P183 POST-TRANSPLANT CYCLOPHOSPHAMIDE AFTER 08:30 - 08:30
ALLOGENEIC HEMATOPOETIC STEM CELL
TRANSPLANTATION FOR PEDIATRIC HODGKIN LYMPHOMA
Speaker: Andrey Kozlov, RU

P185 RISK FACTORS AND SURVIVAL OF GRAFT FAILURE IN 08:30 - 08:30

PEDIATRIC PATIENTS WITH HEMATOLOGICAL MALIGNANCIES
TREATED WITH ALLOGENEIC HEMATOPOIETIC STEM-CELL
TRANSPLANTATION FROM HAPLOIDENTICAL DONORS USING
EXVIVO T-CELL-DEPLETION
Speaker: Iván López Torija, ES

P184 FREQUENCY AND CAUSES OF DEATH AFTER 08:30 - 08:30

HEMATOPOIETIC STEM CELL TRANSPLANTATION IN
CHILDREN WITH NON-MALIGNANT DISEASES
Speaker: Koray Yalcin, TR

P186 SVEGF-R1 LEVELS ARE ASSOCIATED WITH ENDOTHELIAL 08:30 - 08:30

DYSFUNCTION AFTER PEDIATRIC HEMATOPOIETIC STEM
CELL TRANSPLANTATION
Speaker: Denise Elbæk, DK

P187 LATE ENDOCRINE EFFECTS AFTER HSCT IN CHILDREN WITH 08:30 - 08:30
NONMALIGNANT DISEASES: A SINGLE CENTER COHORT
ANALYSIS
Speaker: Joëll Esmée Bense, NL

P188 PROSPECTIVE MULTICENTER STUDY OF A REDUCED- 08:30 - 08:30

TOXICITY MYELOABLATIVE CONDITIONNING REGIMEN USING
FLUDARABINE AND FULL DOSES OF IV BUSULFAN IN
PEDIATRIC PATIENTS NOT ELIGIBLE FOR MYELOABLATIVE
REGIMENS
Speaker: Fanny Rialland, FR

P189 TCR ALFA/BETA DEPLETION FOR HSCT FROM UNRELATED 08:30 - 08:30
DONOR IN PEDIATRIC PATIENTS
Speaker: Luisa Sisinni, ES

50 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

P190 SARS-COV-2 SEROLOGICAL STATUS OF PEDIATRIC HSCT 08:30 - 08:30

RECIPIENTS: A SINGLE CENTER EXPERIENCE
Speaker: Charlotte Nazon, FR

P191 SAFETY AND PERFORMANCE OF CENTRAL VENOUS 08:30 - 08:30

CATHETERS IN PEDIATRIC LEUKAPHERESIS: A SINGLE
CENTRE EXPERIENCE
Speaker: Sofia Martin-Consuegra, ES

P192 TREOSULFAN – BASED CONDITION REGIMEN FOR STEM CELL 08:30 - 08:30
TRANSPLANTATION IN PATIENTS WITH DIAMOND –
BLACKFAN ANEMIA
Speaker: Svetlana Radygina, RU

P193 ALLO-HSCT IN TREATMENT OF TP53 MUTATION-RELATED 08:30 - 08:30

MDS/AML IN PEDIATRIC PATIENTS – REPORT OF TWO CASES
Speaker: Maksymilian Deregowski, PL

P194 CENTRAL LINE REMOVAL IN ALLOGENIC PEDIATRIC 08:30 - 08:30

HEMATOPOIETIC STEM CELL TRANSPLANT PATIENTS
Speaker: Taylor Fitch, US

Poster Sessions
08:30 - 18:45 ePoster Area
Infectious Complications
P118 COMPARISON BETWEEN PRIMARY PROPHYLAXIS AND PRE- 08:30 - 08:30
EMPTIVE THERAPY FOR CITOMEGALOVIRUS AFTER
HEMATOPOIETIC STEM-CELL TRANSPLANTATION
Speaker: Luisa Giaccone, IT

P119 INCIDENCE OF HEMORRHAGIC CYSTITIS FOLLOWING 08:30 - 08:30

HEMATOPOIETIC STEM CELL TRANSPLANTATION IN
PEDIATRIC PATIENTS BASED ON THE UNDERLYING DISEASE
Speaker: Amir Ali Hamidieh, IR

P120 EPIDEMIOLOGY OF RESISTANT AND REFRACTORY 08:30 - 08:30

CYTOMEGALOVIRUS INFECTION FOLLOWING SOLID ORGAN
OR HAEMATOPOIETIC STEM CELL TRANSPLANT: A
SYSTEMATIC REVIEW
Speaker: Aurore Bergamasco, FR

P122 EPIDEMIOLOGY OF INFECTIOUS COMPLICATIONS IN 08:30 - 08:30

PATIENTS WITH CHRONIC GRAFT-VERSUS-HOST DISEASE
Speaker: Aleksandr Siniaev, RU

P121 ANTIBACTERIAL PROPHYLAXIS IN PATIENTS UNDERGOING 08:30 - 08:30

HEMATOPOIETIC STEM CELL TRANSPLANTATION AND
DEVELOPMENT OF INFECTIONS BY ANTIBIOTIC-RESISTANT
BACTERIA
Speaker: Filippo Maraz, IT

P123 CLINICAL AND MICROBIOLOGICAL IMPACT OF 08:30 - 08:30

DISCONTINUATION OF FLUOROQUINOLONE PROPHYLAXIS IN
PATIENTS UNDERGOING HEMATOPOIETIC STEM CELL

51 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

TRANSPLANTATION: A SINGLE-CENTRE EXPERIENCE

Speaker: Anke Verlinden, BE

P124 IRON CHELATION WITH DEFERASIROX SUPPRESSES THE 08:30 - 08:30

APPEARANCE OF LPI DURING CONDITIONING
CHEMOTHERAPY PRIOR TO ALLOGENEIC STEM CELL
TRANSPLANTATION
Speaker: Sonja Essmann, DE

P125 SARS-COV-2 INFECTION IN A HEMATOPOIETIC STEM CELL 08:30 - 08:30

TRANSPLANT CENTER: A SINGLE CENTER EXPERIENCE IN
MEXICO
Speaker: Luis Manuel Valero-Saldaña, MX

P126 ANTIBIOTIC PROPHYLAXIS AND THE RATE OF BACTEREMIA 08:30 - 08:30

AND CLOSTRIDIUM DIFFICILE INFECTION IN PEDIATRIC STEM
CELL TRANSPLANTATION: A SINGLE CENTER
RETROSPECTIVE STUDY
Speaker: Mohammed Essa, SA

P128 TOCILIZUMAB IN POST HEMATOPOIETIC STEM CELL 08:30 - 08:30

TRANSPLANT COVID-19: A PEDIATRIC CASE REPORT
Speaker: Tahereh Rostami, IR

P127 HUMAN POLYOMA BK VIRUS AS A CAUSE OF HEMORRHAGIC 08:30 - 08:30

CYSTITIS: RETROSPECTIVE COHORT STUDY
Speaker: Nikola Pantic, RS

P132 CMV REACTIVATION AFTER ALLOGENIC HEMATOPOIETIC 08:30 - 08:30

STEM CELL TRANSPLANTATION - SINGLE CENTRE
EXPERIENCE
Speaker: Milena Todorovic Balint, RS

P129 PANDEMIC LESSONS OF COVID 19 IN NORTHEAST OF BRAZIL 08:30 - 08:30

Speaker: Fernando Barroso Duarte, BR

P131 SARS-COOV-2 INFECTION IN AN ADOLESCENT PATIENT 08:30 - 08:30

AFTER HAPLOIDENTICAL STEM CELL TRANSPLANTATION
Speaker: Maurizio Caniglia, IT

P130 CLINICAL CHARACTERISTICS AND OUTCOME OF 08:30 - 08:30

POLYMICROBIAL BLOODSTREAM INFECTIONS IN ALLO-SCT
PATIENTS: A MONOCENTRIC 5 YEARS SURVEY
Speaker: Gabriele Facchin, IT

Poster Sessions
08:30 - 18:45 ePoster Area
Inborn Errors
P114 ALLOGENEIC STEM CELL TRANSPLANTATION IN PATIENTS 08:30 - 08:30
WITH MUCOPOLYSACCHARIDOSIS TYPE I (HURLER) WITH
TREOSULFAN-BASED CONDITIONING
Speaker: Matthias Bleeke, DE

P115 LONG-TERM NEURODEVELOPMENTAL, 08:30 - 08:30

52 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

NEUROPHYSIOLOGICAL, AND NEURORADIOLOGICAL

OUTCOMES OF HEMATOPOIETIC STEM CELL
TRANSPLANTATION FOR TREATMENT OF LATE-INFANTILE
METACHROMATIC LEUKODYSTROPHY
Speaker: Maria Escolar, US

P116 OUTCOME OF HAEMATOPOIETIC CELL TRANSPLANTATION IN 08:30 - 08:30

CHILDREN WITH LYSOSOMAL ACID LIPASE DEFICIENCY: A
STUDY ON BEHALF OF THE EBMT INBORN ERRORS WORKING
PARTY
Speaker: Su Han Lum, GB

Poster Sessions
08:30 - 18:45 ePoster Area
Immunodeficiency Diseases and Macrophages
P111 CLINICAL MANIFESTATION AND MECHANISMS OF GRAFT 08:30 - 08:30
FAILURE IN PRIMARY IMMUNODEFICIENCY PATIENTS AFTER
HEMATOPOIETIC STEM CELL TRANSPLANTATION
Speaker: Aishat Idarmacheva, RU

P112 OUTCOMES OF HAEMATOPOIETIC STEM CELL 08:30 - 08:30

TRANSPLANTATION IN CHILDREN WITH ZETA CHAIN
ASSOCIATED PROTEIN KINASE 70KDA DEFICIENCY
Speaker: Liam Reilly, GB

P113 ALLOGENEIC HEMATOPOIETIC STEM CELL 08:30 - 08:30

TRANSPLANTATION IN A PATIENT WITH CLERICUZIO
SYNDROME (POIKILODERMA WITH NEUTROPENIA)
Speaker: Alexandra Burya, RU

Poster Sessions
08:30 - 18:45 ePoster Area
Stem Cell Donor
P203 HAPLOIDENTICAL VS HLA-MATCHED RELATED DONOR HSCT 08:30 - 08:30
FOR ACUTE LEUKEMIA AND MYELODYSPLASTIC SYNDROME:
A SINGLE-CENTER COMPARISON
Speaker: Alisa Lörsch, DE

P204 CLINICAL OUTCOMES IN ALLOGENIC HEMATOPOIETIC STEM 08:30 - 08:30

CELL TRANSPLANTATION FROM ALTERNATIVE DONORS:
SINGLE CENTER EXPERIENCE WITH 9/10 HLA-MISMATCHED
UNRELATED, DOUBLE UMBILICAL CORD BLOOD AND
HAPLOIDENTICAL DONORS
Speaker: Claudie Roy, CA

P205 HAPLOIDENTICAL STEM CELL TRANSPLANTATION WITH 08:30 - 08:30

POST-TRANSPLANT CYCLOPHOSPHAMIDE FOR PATIENTS
WITH HIGH-RISK HEMATOLOGIC MALIGNANCIES. A SINGLE
CENTER EXPERIENCE IN MEXICO
Speaker: Katheryn Garzón-Velásquez, MX

53 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

Poster Sessions
08:30 - 18:45 ePoster Area
Haemoglobinopathy
P107 THE VALUE OF ROUTINE PRE-TRANSPLANT RADIOLOGICAL 08:30 - 08:30
SCREENING IN PEDIATRIC SICKLE CELL DISEASE PATIENTS:
A SINGLE CENTER EXPERIENCE
Speaker: Mohammed Essa, SA

P108 HOW TO FACILITATE DECISION-MAKING FOR 08:30 - 08:30

HEMATOPOIETIC STEM CELL TRANSPLANTATION IN
PATIENTS WITH HEMOGLOBINOPATHIES - THE
PERSPECTIVES OF HEALTH CARE PROFESSIONALS
Speaker: Hilda Mekelenkamp, NL

P109 ENDOCRINE SEQUELAE IN PEDIATRIC HEMATOPOIETIC STEM 08:30 - 08:30

CELL TRANSPLANT RECIPIENTS WITH SICKLE CELL DISEASE:
A RETROSPECTIVE COHORT ANALYSIS
Speaker: Richelle Waldner, CA

P110 DECISION-MAKING FOR HEMATOPOIETIC STEM CELL 08:30 - 08:30

TRANSPLANTATION IN PEDIATRIC, ADOLESCENT AND
YOUNG ADULT PATIENTS WITH A HEMOGLOBINOPATHY –
SHARED OR NOT?
Speaker: Hilda Mekelenkamp, NL

Poster Sessions
08:30 - 18:45 ePoster Area
Haematopoietic Stem Cells
P078 RESULTS OF SECOND ALLOGENEIC HEMATOPOIETIC STEM 08:30 - 08:30
CELL TRANSPLANTATION IN PATIENTS WITH
HEMATOLOGICAL DISEASES: RETROSPECTIVE ANALYSIS OF
OUR HOSPITAL
Speaker: Elena Paumard Rodríguez, ES

P076 LETERMOVIR PROPHYLAXIS REDUCES THE RISK FOR CMV 08:30 - 08:30
INFECTION AFTER STEM CELL TRANSPLANTATION
Speaker: Katrin Koch, DE

P077 KIR B HAPLOTYPES IN UNRELATED HEMATOPOIETIC STEM 08:30 - 08:30

CELL TRANSPLANTATION, REVISITED
Speaker: Kazimierz Halaburda, PL

P079 THE IMPACT OF AGE ON HEMATOLOGIC RECOVERY AFTER 08:30 - 08:30

ALLOGENEIC TRANSPLANTATION
Speaker: Sabrina Giammarco, IT

P081 OUTCOME OF SECOND ALLOGENIC STEM CELL 08:30 - 08:30

TRANSPLANTATION IN CHILDREN WITH PRIMARY IMMUNE
DEFICIENCIES
Speaker: Zohreh Nademi, GB

P080 HEMATOPOIETIC STEM CELL TRANSPLANTATION IN 08:30 - 08:30

PEDIATRIC ACUTE MYELOID LEUKEMIA WITH ABERRANT CD7
ANTIGEN EXPRESSION

54 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

Speaker: Danilo De Novellis, IT

P082 OUTCOME OF ALLOGENIC STEM CELL TRANSPLANTATION IN 08:30 - 08:30

ELDERLY PATIENTS: A SINGLE CENTER STUDY
Speaker: Eshrak Al-Shaibani, CA

P084 ALLOGENEIC HEMATOPOIETIC STEM CELL 08:30 - 08:30

TRANSPLANTATION IN PATIENTS OLDER THAN 65 YEARS
WITH AML AND MDS: RISK FACTORS FOR OVERALL
SURVIVAL AND DISEASE FREE SURVIVAL
Speaker: Simona Piemontese, IT

P083 ALLOGENEIC HEMATOPOIETIC STEM CELL 08:30 - 08:30

TRANSPLANTATION FOR PATIENTS 60 YEARS OR OLDER. A
SINGLE-INSTITUTION EXPERIENCE
Speaker: Marta Hidalgo Soto, ES

P086 EFFICACY OF MODIFIED FC/ATG PRETREATMENT IN HAPLOID 08:30 - 08:30

AND ALLOGENEIC HEMATOPOIETIC STEM CELL
TRANSPLANTATION FOR SEVERE APLASTIC ANEMIA
Speaker: Ma Liangming, CN

P085 IMPACT OF HUMAN LEUKOCYTE ANTIGEN ALLELE 08:30 - 08:30

POLYMORPHISMS ON THE OUTCOMES OF
TRANSPLANTATION FROM HLA-MATCHED UNRELATED
DONORS
Speaker: Anastasia Beynarovich, RU

P087 AUTOMATED DRY THAWING OF CRYOPRESERVED 08:30 - 08:30

HAEMATOPOIETIC CELLS IS NOT ADVERSELY INFLUENCED
BY CRYOSTORAGE TIME, PATIENT AGE OR GENDER
Speaker: Julie Meneghel, GB

P091 UNMANIPULATED HAPLOIDENTICAL STEM CELL 08:30 - 08:30

TRANSPLANTATION FOR PEDIATRIC PATIENTS WITH ACUTE
LEUKEMIA: AN EXPERIENCE FROM THE LARGEST
CHILDREN'S HOSPITAL IN IRAN
Speaker: Amir Ali Hamidieh, IR

P090 INDICATIONS AND SURVIVAL OF ALLOGENEIC TRANSPLANT 08:30 - 08:30

IN PATIENTS OVER 65 YEARS OLD
Speaker: Magdalena Corona de Lapuerta, ES

P089 LONG-TERM RESULTS OF HEMATOPOIETIC STEM CELL 08:30 - 08:30

TRANSPLANTATION FOR HODGKIN’S AND NON-HODGKIN’S
LYMPHOMA: EXPERIENCE OF A SINGLE CENTER IN
COLOMBIAN NORTHEAST
Speaker: Claudia Lucía Sossa Melo, CO

P093 HAPLOIDENTICAL STEM CELL TRANSPLANTATION IN AML 08:30 - 08:30

WITH T(6;9)(P23; Q34); DEK-NUP214 SHOWS A FAVOURABLE
OUTCOME: SINGLE CENTER EXPERIENCE

P092 ABSENCE OF INFLUENCE OF THE PRE- TRANSPLANT IMMUNE 08:30 - 08:30

STATUS OF RECIPIENTS ON SURVIVALS AND GVHD AFTER
ALLOGENEIC STEM CELL TRANSPLANTATION: A

55 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

RETROSPECTIVE STUDY OF 195 CASES

Speaker: Thierry Guillaume, FR

P097 DEFIBROTIDE AS TREATMENT FOR TRANSPLANT- 08:30 - 08:30

ASSOCIATED MICROANGIOPATHY (TA-TAM) IN PEDIATRIC
PATIENTS: A SINGLE CENTER EXPERIENCE
Speaker: Danilo De Novellis, IT

P096 IMPACT OF COVID 19 PANDEMIC ON HSCT ACTIVITIES: 08:30 - 08:30

REPORT FROM A SINGLE CENTER
Speaker: Sabrina Giammarco, IT

P095 IS HAPLOIDENTICAL HAEMATOPOIETIC STEM CELL 08:30 - 08:30

TRANSPLANTATION (HAPLO SCT) USING POST-
TRANSPLANTATION CYCLOPHOSPHAMIDE (PTCY) FEASIBLE
IN SUB-SAHARAN AFRICA?
Speaker: Justin du Toit, ZA

P099 IMPACT OF CYTOGENETIC AND MOLECULAR RISK AT 08:30 - 08:30

DIAGNOSIS ON TRANSPLANTATION RESULTS IN PATIENTS
WITH SECONDARY ACUTE MYELOID LEUKEMIA
Speaker: Claudia Núñez-Torrón, ES

P098 THE IMPACT OF CRYOPRESERVATION ON HAEMATOPOIETIC 08:30 - 08:30

STEM CELL GRAFTS DURING THE COVID-19 PANDEMIC AT
THE ROYAL MARSDEN HOSPITAL
Speaker: Sandra Easdale, GB

P102 EBV COLITIS POST HEMATOPOIETIC STEM CELL 08:30 - 08:30

TRANSPLANTATION IN PATIENT WITH APLASTIC ANEMIA
Speaker: Lucia Prezioso, IT

P100 BURNOUT SYNDROME IN ONCOLOGY PRACTICE: 08:30 - 08:30

EXPERIENCE OF A LARGE HSCT CENTER
Speaker: Irina Artemeva, RU

P103 MORBIDITY AND MORTALITY OF T- CELL LYMPHOMAS 08:30 - 08:30

UNDERGOING AUTOLOGOUS STEM CELL TRANSPLANTATION
(ASCT)
Speaker: Carolina Lilibeth Moreira-Ponce, MX

P101 FACTORS AFFECTING OUTCOMES IN CHILDREN WITH ACUTE 08:30 - 08:30

LEUKEMIA POST HEMATOPOIETIC STEM CELL
TRANSPLANTATION – A RETROSPECTIVE STUDY FROM A
TERTIARY REFERRAL CENTRE IN INDIA
Speaker: Rumesh Chandar, IN

P104 BRENTUXIMAB VEDOTIN STRATEGIES FOR RELAPSED OR 08:30 - 08:30

REFRACTORY HODGKIN'S LYMPHOMA AND HEMATOPOIETIC
STEM CELL TRANSPLANTATION
Speaker: Katheryn Garzón-Velásquez, MX

P106 EHEALTH AS A TOOL IN HEMATOPOIETIC STEM CELL 08:30 - 08:30

TRANSPLANTATION: A NARRATIVE REVIEW
Speaker: Claudia Lucía Sossa Melo, CO

56 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

P105 STAFF EXPERIENCES AND LEARNING FROM WORKING ON A 08:30 - 08:30

HAEMATOLOGICAL STEM CELL TRANSPLANT WARD DURING
COVID-19
Speaker: Sarah Airdrie, GB

Poster Sessions
08:30 - 18:45 ePoster Area
Graft-versus-Host Disease – Preclinical and Animal Models
P074 THE MAGNITUDE OF INTESTINAL T CELL INFILTRATION 08:30 - 08:30
DETERMINES EPITHELIAL REGENERATION DURING IMMUNE-
MEDIATED TISSUE INJURY
Speaker: Sascha Göttert, DE

P075 ITACITINIB ATTENUATES XENOGENEIC GVHD IN HUMANIZED 08:30 - 08:30

MICE

Poster Sessions
08:30 - 18:45 ePoster Area
Graft-versus-Host Disease – Clinical
P051 EFFECT OF EXTRACORPOREAL PHOTOPHERESIS ON 08:30 - 08:30
ENRICHMENT, SURVIVAL AND CYTOKINE PRODUCTION
CAPACITY OF MONOCYTES FROM CHRONIC GRAFT VERSUS
HOST DISEASE PATIENTS
Speaker: Arun Alfred, GB

P056 REDUCED GVHD WITH TRIPLE PTCY BASED GVHD 08:30 - 08:30
PROPHYLAXIS, AS COMPARED TO TRIPLE ATG BASED
PROPHYLAXIS, IN HLA MATCHED TRANSPLANTS
Speaker: Elisabetta Metafuni, IT

P055 PROLONGED SUPPRESSION OF BUTYRATE PRODUCING 08:30 - 08:30

BACTERIA INDICATES DYSBIOSIS AND IS ASSOCIATED WITH
ACUTE GASTROINTESTINAL GRAFT-VERSUS-HOST DISEASE
AND TRANSPLANT RELATED MORTALITY AFTER
ALLOGENEIC STEM CELL TRANSPLANTATION
Speaker: Elisabeth Meedt, DE

P052 ACUTE AND CHRONIC GRAFT-VERSUS-HOST-DISEASE IMPAIR 08:30 - 08:30

B-CELL RECONSTITUTION IN ALLOGENEIC-TRANSPLANTED
PATIENTS AT DIFFERENT MATURATION STAGES
Speaker: Matthias Alexander Fante, DE

P057 THE SAME FOR LESS: 2.5MG/KG VS. 4.5MG/KG RABBIT ANTI- 08:30 - 08:30
THYMOCYTE GLOBULIN IN PATIENTS UNDERGOING
MATCHED UNRELATED DONOR ALLOGENEIC STEM CELL
TRANSPLANTATION FOR HEMATOLOGICAL MALIGNANCIES
Speaker: Osman Radhwi, CA

P060 A PHASE 2/3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, 08:30 - 08:30

PLACEBO-CONTROLLED STUDY OF ALPHA-1 ANTITRYPSIN
FOR THE PREVENTION OF ACUTE GRAFT VERSUS HOST
DISEASE FOLLOWING HEMATOPOIETIC CELL TRANSPLANT

57 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

P061 CHRONIC AND LATE ACUTE GVHD IN CHILDREN USING THE 08:30 - 08:30
NIH 2014 CONSENSUS CRITERIA
Speaker: Koray Yalcin, TR

P058 COMPARISON OF POST-TRANSPLANTATION 08:30 - 08:30

CYCLOPHOSPHAMIDE VERSUS ANTI-T-LYMPHOCYTE
GLOBULIN AS GVHD PROPHYLAXIS IN ADULT PATIENTS WITH
ACUTE LYMPHOBLASTIC LEUKEMIA UNDERGOING
ALLOGENEIC HEMATOPOIETIC STEM CELL
TRANSPLANTATION IN CR1
Speaker: Maximilian Christopeit, DE

P059 TRIPLE PTCY BASED GVHD PROPHYLAXIS: HLA MATCHED 08:30 - 08:30
VERSUS HLA HAPLOIDENTICAL TRANSPLANTS
Speaker: Eugenio Galli, IT

P063 A PHASE 1/2, OPEN-LABEL, SINGLE-ARM, STUDY OF 08:30 - 08:30

RUXOLITINIB ADDED TO CORTICOSTEROIDS IN PEDIATRIC
PATIENTS WITH ACUTE GRAFT-VS-HOST DISEASE AFTER
ALLOGENEIC STEM CELL TRANSPLANTATION (REACH4)
Speaker: Franco Locatelli, IT

P062 AREA UNDER THE CURVE BASED MYCOPHENOLATE MOFETIL 08:30 - 08:30
DOSAGE REDUCED THE INCIDENCE OF GVHD AFTER
ALLOGENIC HSCT IN PEDIATRIC PATIENTS: ONE FACILITY'S
EIGHT-YEAR EXPERIENCE
Speaker: Antonio Grasso, IT

P064 IBRUTINIB FOR STEROID REFRACTORY CHRONIC GRAFT 08:30 - 08:30

VERSUS HOST DISEASE: DATA AND CLINICAL EXPERIENCE
FROM A SINGLE CENTER
Speaker: Panayotis Kaloyannidis, SA

P065 ROUTINE USE OF THE AMICUS BLUE™ ONLINE ECP SYSTEM IN 08:30 - 08:30
PATIENTS WITH CHRONIC AND ACUTE GRAFT VERSUS HOST
DISEASE
Speaker: Angelo Ostuni, IT

P066 RUXOLITINIB OFF-LABEL USE IN STEROID-REFRACTORY 08:30 - 08:30

CHRONIC GRAFT VERSUS HOST DISEASE: A SINGLE CENTRE
EXPERIENCE IN 36 PATIENTS
Speaker: Maria Teresa Lupo Stanghellini, IT

P067 PHARMACOKINETIC MODELING TO GUIDE DOSE SELECTION 08:30 - 08:30

OF ALPHA-1 ANTITRYPSIN IN A STUDY OF GRAFT VERSUS
HOST DISEASE PREVENTION IN PATIENTS RECEIVING
ALLOGENIC HEMATOPOIETIC CELL TRANSPLANT
Speaker: Henry Hu, US

P068 BASILIXIMAB FOR THE TREATMENT OF PATIENTS WITH 08:30 - 08:30

STEROID REFRACTORY ACUTE GRAFT VERSUS HOST
DISEASE: LITERATURE REVIEW AND POOLED ANALYSIS
Speaker: Xiaodong Mo, CN

P069 FIRST LINE SINGLE-AGENT RUXOLITINIB FOR GRADE II-III 08:30 - 08:30

58 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

ACUTE GRAFT-VERSUS-HOST DISEASE IN PATIENTS WITH

SEVERE INFECTIOUS COMPLICATIONS: CASE SERIES
Speaker: Ivan Moiseev, RU

P070 A PHASE 2 OPEN-LABEL, SINGLE-ARM, MULTICENTER STUDY 08:30 - 08:30

OF RUXOLITINIB ADDED TO CORTICOSTEROIDS IN PEDIATRIC
SUBJECTS WITH MODERATE/SEVERE CHRONIC GVHD AFTER
ALLOGENEIC STEM CELL TRANSPLANTATION (REACH5)
Speaker: Franco Locatelli, IT

P071 PRE-TRANSPLANTATION PLASMA VITAMIN D LEVELS AND 08:30 - 08:30

ACUTE GRAFT-VERSUS-HOST DISEASE AFTER
MYELOABLATIVE ALLOGENEIC HEMATOPOIETIC CELL
TRANSPLANTATION
Speaker: Lars Klingen Gjærde, DK

P072 SEVERE REFRACTORY SKIN GVHD IN CHILDREN: SERIES OF 08:30 - 08:30

CLINICAL CASES

P073 Elevated REG3? predicts refractory aGVHD in Patients Who 08:30 - 08:30
Received Steroids- Ruxolitinib as the First Line Therapy
Speaker: Liping Dou, CN

Poster Sessions
08:30 - 18:45 ePoster Area
Gene Therapy
P050 BETIBEGLOGENE AUTOTEMCEL (BETI-CEL; LENTIGLOBIN 08:30 - 08:30
FOR ?-THALASSEMIA) GENE THERAPY TREATMENT OF A
GREEK PATIENT WITH TRANSFUSION-DEPENDENT ?-
THALASSEMIA (TDT)
Speaker: Evangelia Yannaki, GR

Poster Sessions
08:30 - 18:45 ePoster Area
Experimental Transplantation
P048 INFLUENCE OF POLYMORPHISMS RELATED TO DRUG 08:30 - 08:30
METABOLISM IN ALLOGENEIC BONE MARROW
TRANSPLANTATION
Speaker: Marta Santiago, ES

P049 REDUCED-INTENSITY UNMANIPULATED HAPLOIDENTICAL 08:30 - 08:30

STEM CELL TRANSPLANTATION FOR RELAPSED HIGH-RISK
NEUROBLASTOMA AFTER AUTOLOGOUS STEM CELL
TRANSPLANTATION
Speaker: Tahereh Rostami, IR

Poster Sessions
08:30 - 18:45 ePoster Area
Experimental Stem Cell Transplantation
P046 SYNERGISTIC EFFECT OF ATG PLUS PTCY FOR DUAL T CELL 08:30 - 08:30
MODULATION IN HAPLOIDENTICAL STEM CELL

59 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

TRANSPLANTATION FOR POOR PROGNOSIS ACUTE

LEUKAEMIA
Speaker: Maryam Barkhordar, IR

P047 DAY 0 EASIX SCORE MIGHT PREDICT OVERALL SURVIVAL 08:30 - 08:30
AND TRANSPLANT RELATED MORTALITY AFTER
ALLOGENEIC STEM CELL TRANSPLANTATION: SINGLE
CENTRE EXPERIENCE
Speaker: Elisabetta Metafuni, IT

Poster Sessions
08:30 - 18:45 ePoster Area
Conditioning Regimens
P036 OUTCOMES OF ALLOGENEIC HEMATOPOIETIC CELL 08:30 - 08:30
TRANSPLANTATION IN ELDERLY PATIENTS: IS AGE THE
LIMIT?
Speaker: Sara Fernández-Luis, ES

P037 THE IMPACT OF MELPHALAN DE-ESCALATION ON EFFICACY 08:30 - 08:30

AND SAFETY IN PATIENTS WITH MULTIPLE MYELOMA
UNDERGOING AUTOLOGOUS STEM CELL
TRANSPLANTATION: A SINGLE-CENTER EXPERIENCE
Speaker: Bartosz Malecki, PL

P038 CONDITIONING WITH HIGH DOSE TOTAL BODY IRRADIATION 08:30 - 08:30
AND POST TRANSPLANTATION CYCLOPHOSPHAMIDE IN
EARLY RELAPSED MULTIPLE MYELOMA PATIENTS
RECEIVING ALLOGENEIC STEM CELL TRANSPLANTATION
Speaker: Jaap van Doesum, NL

P039 PREVENTING AKI IN TRANSPLANT FOR PAEDIATRIC ALL 08:30 - 08:30

WITH TBI AND ETOPOSIDE CONDITIONING
Speaker: Jane E Potter, GB

P040 ENHANCED IMMUNOSUPPRESSION IN T-CELL REPLETE 08:30 - 08:30

HAPLOIDENTICAL TRANSPLANTATION WITH POST-
TRANSPLANT CYCLOPHOSPHAMIDE IS ASSOCIATED WITH
FAVORABLE OUTCOMES

P041 LONG-TERM SAFETY AND EFFICACY OF A MYELOABLATIVE 08:30 - 08:30

CONDITIONING REGIMEN OF REDUCED TOXICITY IN
ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION
Speaker: Ioanna Sakellari, GR

P042 TREOSULFAN VS. BUSULFAN-BASED REGIMENS IN 08:30 - 08:30

PEDIATRIC PATIENTS: A 7-YEAR RETROSPECTIVE STUDY
Speaker: Raquel Olivas-Mazón, ES

P044 POST-TRANSPLANT CYCLOPHOSPHAMIDE (PTCY) AS GVHD 08:30 - 08:30

PROPHYLAXIS FOR HEMATOPOIETIC STEM CELL
TRANSPLANTATION FROM MATCHED-RELATED SIBLING
DONORS
Speaker: Gabriella Storti, IT

60 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

P043 IMMUNE RECONSTITUTION AFTER SEQUENTIAL 08:30 - 08:30

CONDITIONING IN ELDERLY, HIGH-RISK AML AND MDS
PATIENTS: A MATCHED-PAIR ANALYSIS AMONG DIFFERENT
DONOR TYPES
Speaker: Alessia Fraccaroli, DE

CME Symposium
08:40 - 10:00 Auditorium 1
IS01 - GMMG Symposium
Chair: Hartmut Goldschmidt, DE
Chair: Christof Scheid, DE
IS1-1 Role of allo-TPX in multiple myeloma 08:40 - 08:51
Speaker: Nicolaus Kröger, DE

IS1-2 Importance of achieving a Minimal Residual Disease Negativity 08:51 - 09:00

in multiple myeloma
Speaker: Stefanie Huhn, DE

IS1-3 Role of induction therapy in treatment of multiple myeloma 09:00 - 09:11

Speaker: Hans Salwender, DE

IS1-4 Therapy and prognosis of high-risk multiple myeloma 09:11 - 09:26

Speaker: Katja Weisel, DE

IS1-5 Therapeutic developments for refractory multiple myeloma 09:26 - 09:42

Speaker: Marc Raab, DE

IS1-6 Q&A 09:42 - 10:00

Patient, Family Donor Day

09:15 - 10:30 Auditorium 6
PFD1 - Patient, Family and Donor Day: Post-transplant care
Chair: Guy Bouguet, FR
Chair: Sarah Hutton, GB
PFD1-1 Welcome 09:15 - 09:30
Speaker: Rafael Duarte, ES
Speaker: Natacha Bolaños, ES

PFD1-2 Introduction to post-transplant care and GvHD 09:30 - 09:35

Speaker: Guy Bouguet, FR
Speaker: Sarah Hutton, GB

PFD1-3 A pathway for Post-Transplant Care 09:35 - 09:50

Speaker: Fiona Dignan, GB

PFD1-4 Chronic GVHD: The daily impact 09:50 - 10:05

Speaker: John Murray, GB

PFD1-5 Patient's experience with chronic GVHD 10:05 - 10:15

Speaker: Sam Williams, GB

PFD1-6 Q&A 10:15 - 10:30

61 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

Breaks
10:00 - 10:30 Auditorium 1
Coffee Break, Poster Viewing, Visit Exhibition

Industry Symposium
10:30 - 12:00 Auditorium 2
IS05 - GVHD: What’s new in 2021? - Sanofi Industry Symposium
Chair: Mohamad Mohty, FR
IS5-1 Welcome & Introduction 10:30 - 10:35
Speaker: Mohamad Mohty, FR

IS5-2 Antithymocyte Globulin for Matched Sibling Donor 10:35 - 10:50

Transplantation: results of A Randomized trial
Speaker: Xiaojun Huang, CN

IS5-3 Combining ATG and post-transplant cyclophosphamide 10:50 - 11:05

Speaker: Andrea Bacigalupo, IT

IS5-4 Optimizing outcome: pre and post-transplant interventions 11:05 - 11:20

Speaker: Mohamad Mohty, FR

IS5-5 Nutritional supplements and stem cell transplantation 11:20 - 11:35

Speaker: Bipin Savani, US

IS5-6 Round table discussion and Closing Remarks 11:35 - 12:00

Industry Symposium
10:30 - 12:00 Auditorium 3
IS06 - Induction to beyond transplant: how do we increase long-term remission in high-risk AML*? - Jazz Phar
Industry Symposium
*High-risk AML defined as newly diagnosed therapy-related AML (t-AML) or AML with myelodysplasia-related changes
Chair: Rafael Duarte, ES
IS6-1 Welcome and introduction 10:30 - 10:32
Speaker: Rafael Duarte, ES

IS6-2 How does induction choice impact outcomes in high-risk AML*? 10:32 - 10:52
Speaker: Martin Börnhauser, DE

IS6-3 Panel discussion 10:52 - 11:07

IS6-4 What does real-world evidence tell us about the impact of 11:07 - 11:22
induction on high-risk AML*?
Speaker: Thomas Cluzeau, FR

IS6-5 Panel discussion 11:22 - 11:37

IS6-6 How we have continued intensive chemotherapy during the 11:37 - 11:57
COVID pandemic
Speaker: Rafael Duarte, ES
Speaker: Thomas Cluzeau, FR
Speaker: Martin Börnhauser, DE

IS6-7 Summary and close 11:57 - 12:00

62 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

Speaker: Rafael Duarte, ES

Industry Symposium
10:30 - 12:00 Auditorium 5
IS07 - Is the gold standard for managing transplant eligible newly-diagnosed multiple myeloma still golden? - J
Industry Symposium
Chair: Philippe Moreau, FR
IS7-1 Introduction 10:30 - 10:35
Speaker: Philippe Moreau, FR

IS7-2 Is there still a role for autologous stem cell transplantation 10:35 - 10:55
(ASCT) in frontline management of patients with MM?
Speaker: Francesca Gay, IT
Speaker: Katja Weisel, DE

IS7-3 Panel discussion with Q&A 10:55 - 11:05

IS7-4 What is the optimal initial therapy for patients with MM receiving 11:05 - 11:20
an ASCT?
Speaker: Philippe Moreau, FR

IS7-5 Panel discussion with Q&A 11:20 - 11:35

IS7-6 What is the role of consolidation and maintenance therapy in 11:35 - 11:45
2021?
Speaker: Jesús San Miguel, ES

IS7-7 Panel discussion with Q&A 11:45 - 12:00

Patient, Family Donor Day

10:45 - 11:45 Auditorium 6
PFD2 - Patient, Family and Donor Day: Post-transplant care 2
Chair: Andrea Linke, DE
Chair: Isabel Salcedo, ES
PFD2-1 Introduction to post-transplant care and sexuality and fertility 10:45 - 10:50
Speaker: Andrea Linke, DE
Speaker: Isabel Salcedo, ES

PFD2-2 Patient's experience on post-transplant 10:50 - 11:00

Speaker: Rosan Boersma, NL

PFD2-3 Pediatric and young adults fertility an HSCT 11:00 - 11:15

Speaker: Mara Andrés Moreno, ES

PFD2-4 The case for Psychosexual Therapy in Stem Cell 11:15 - 11:30
Transplantation
Speaker: Caroline Lovett, GB

PFD2-5 Q&A 11:30 - 11:45

63 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

Breaks
12:00 - 12:30 Auditorium 1
Lunch Break, Poster Viewing, Visit Exhibition

Patient, Family Donor Day

12:00 - 12:35 Auditorium 6
PFD3 - Patient, Family and Donor Day: COVID-19
Chair: Guy Bouguet, FR
Chair: Natacha Bolaños, ES
PFD3-1 Panel discussion 12:00 - 12:35
Speaker: Rafael de la Cámara, ES
Speaker: Dennis Heng Lin, ES
Speaker: Maja Koci?, RS

Industry Symposium
12:30 - 14:00 Auditorium 1
IS08 - Survival in R/R NHL: CAR T as the standard of care - Kite-Gilead Industry Symposium
Chair: Wendy Osborne, GB
IS8-1 Welcome and introduction 12:30 - 12:35
Speaker: Wendy Osborne, GB

IS8-2 Curative intent for R/R DLBCL: What are the current data? 12:35 - 13:10
Speaker: Ran Reshef, US
Speaker: Wendy Osborne, GB

IS8-3 How has the patient pathway evolved in R/R MCL? 13:10 - 13:30
Speaker: Tom van Meerten, NL
Speaker: Max Topp, DE

IS8-4 Patient case interactive discussion 13:30 - 14:00

Industry Symposium
12:30 - 14:00 Auditorium 2
IS09 - Learnings from 2020: Are we providing the best management approach for haematology patients with IM
Industry Symposium
Chair: Cornelia Lass-Flörl, AT
IS9-1 Welcome and introduction 12:30 - 12:35
Speaker: Cornelia Lass-Flörl, AT

IS9-2 The evolving landscape of IMD in the haematology unit: 12:35 - 12:55
emerging risk factors and concerns in the COVID-19 era
Speaker: Amit Patel, GB

IS9-3 Navigating the complexities of the haematology patient and 12:55 - 13:15
understanding the spectrum of antifungal therapeutics
Speaker: Galina Klyasova, RU

IS9-4 Managing invasive mould infections in an increasingly complex 13:15 - 13:35

world: what has changed in 2020?
Speaker: Cornelia Lass-Flörl, AT

IS9-5 Discussion, Q&A and close 13:35 - 14:00

64 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

Industry Symposium
12:30 - 14:00 Auditorium 3
IS10 - Evolution in GvHD treatment: expert perspective on the latest clinical data - Novartis Industry Symposiu
Chair: Helene Schoemans, BE
IS10-1 Welcome and introduction 12:30 - 12:33
Speaker: Helene Schoemans, BE

IS10-2 Current landscape of GvHD management 12:33 - 12:41

Speaker: Helene Schoemans, BE

IS10-3 Novel data and upcoming treatment options in acute and 12:41 - 13:11
chronic GvHD
Speaker: Mohamad Mohty, FR
Speaker: Nada Hamad, AU

IS10-4 Novel data and upcoming treatment options: roundtable panel 13:11 - 13:32
discussion
Speaker: Mohamad Mohty, FR
Speaker: Nada Hamad, AU
Speaker: Dietger Niederwieser, DE
Speaker: Helene Schoemans, BE

IS10-5 Expanding the horizon in GvHD management: panel discussion 13:32 - 13:42
Speaker: Mohamad Mohty, FR
Speaker: Nada Hamad, AU
Speaker: Dietger Niederwieser, DE
Speaker: Helene Schoemans, BE

IS10-6 Live audience Q&A and concluding remarks 13:42 - 14:00

Industry Symposium
12:30 - 14:00 Auditorium 4
IS11 - Optimising the chance of survival for severe hepatic VOD patients: global expert insights - Jazz Pharma
Industry Symposium
Chair: Mohamad Mohty, FR
IS11-1 Welcome and introduction 12:30 - 12:35
Speaker: Mohamad Mohty, FR

IS11-2 Global insight: risk assessment, with panel roundtable 12:35 - 12:50
discussion
Speaker: Paul Richardson, US

IS11-3 Global insight: imaging for signs and symptoms, with panel 12:50 - 13:05
roundtable discussion
Speaker: Rafael Duarte, ES
Speaker: Antonio Colecchia, IT

IS11-4 Global insight: severity grading, with panel roundtable 13:05 - 13:20
discussion
Speaker: Tony Pagliuca, GB
Speaker: Jae-Ho Yoon, KR

IS11-5 Global insight: diagnosis, with panel roundtable discussion 13:20 - 13:35

65 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

Speaker: Mohamad Mohty, FR

IS11-6 Global insight: treatment and outcome, with panel roundtable 13:35 - 13:55
discussion
Speaker: Paul Richardson, US
Speaker: Mohamad Mohty, FR

IS11-7 Summary and close 13:55 - 14:00

Speaker: Mohamad Mohty, FR

Industry Symposium
12:30 - 14:00 Auditorium 5
IS12 - Targeting the immune system in multiple myeloma: CAR T cell therapy and beyond - BMS Industry Symp
Chair: Xavier Leleu, FR
IS12-1 Welcome and introduction - Multiple myeloma: understanding 12:30 - 12:40
the unmet need
Speaker: Xavier Leleu, FR

IS12-2 Addressing the unmet need in multiple myeloma: innovative 12:40 - 13:05
immune treatment strategies
Speaker: Niels van de Donk, NL

IS12-3 A novel approach: targeting BCMA with CAR T cell therapy 13:05 - 13:20
Speaker: Nikhil Munshi, US

IS12-4 The patient and the process: putting CAR T cell therapy into 13:20 - 13:35
practice
Speaker: Xavier Leleu, FR

IS12-5 Live Q&A 13:35 - 14:00

Wellness session
12:45 - 13:05 Auditorium 6
Nutrition and healing: The anti-inflammatory plate

Patient, Family Donor Day

13:30 - 14:30 Auditorium 6
PFD4 - Patient, Family and Donor Day: New developments and donor focus
Chair: Julia Ruiz Pato, ES
Chair: Natacha Bolaños, ES
PFD4-1 Introduction 13:30 - 13:35
Speaker: Julia Ruiz Pato, ES
Speaker: Natacha Bolaños, ES

PFD4-2 Patient's experience with CAR T 13:35 - 13:45

Speaker: Kevin McNulty, GB

PFD4-3 Could CAR T therapy cure cancer patients? 13:45 - 14:00

Speaker: Marie Jose Kersten, NL

PFD4-4 HSCT for autoimmune diseases and novel indications 14:00 - 14:15
Speaker: John Snowden, GB

66 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

PFD4-5 Q&A 14:15 - 14:30

Breaks
14:00 - 14:30 Auditorium 1
Coffee Break, Poster Viewing, Visit Exhibition

Industry Symposium
14:30 - 16:00 Auditorium 1
IS13 - Present and future approaches with CAR T cell therapy in B-cell malignancies - BMS Industry Symposiu
Chair: Paolo Corradini, IT
IS13-1 Welcome and introduction 14:30 - 14:35
Speaker: Paolo Corradini, IT

IS13-2 Current state of CAR T cell therapy in DLBCL 14:35 - 14:55

Speaker: Paolo Corradini, IT

IS13-3 CAR T cell therapy in FL and CLL: achievements and 14:55 - 15:15
perspectives
Speaker: Guillaume Cartron, FR

IS13-4 Implementation of CAR T cell therapy: practical considerations 15:15 - 15:35

and future directions
Speaker: Stephan Mielke, SE

IS13-5 Q&A and discussion 15:35 - 16:00

Industry Symposium
14:30 - 16:00 Auditorium 2
IS14 - Antifungal Therapy in the Era of New Treatments for Haematological Malignancies - Kite-Gilead Industry
Chair: Tony Pagliuca, GB
IS14-1 Welcome, introduction and overview of agenda 14:30 - 14:40
Speaker: Tony Pagliuca, GB

IS14-2 Impact of the new haematological treatment landscape on 14:40 - 15:00

invasive fungal infections
Speaker: Livio Pagano, IT

IS14-3 The challenge of drug-drug interactions and antifungal 15:00 - 15:20

treatment choice
Speaker: Dimitrios Kontoyiannis, US

IS14-4 The role of liposomal amphotericin B in current haematology 15:20 - 15:40

practice
Speaker: Johan Maertens, BE

IS14-5 Q&A/Panel discussion 15:40 - 15:55

Speaker: Tony Pagliuca, GB
Speaker: Livio Pagano, IT
Speaker: Dimitrios Kontoyiannis, US

IS14-6 Conclusions and close 15:55 - 16:00

Speaker: Tony Pagliuca, GB

67 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

Industry Symposium
14:30 - 16:00 Auditorium 3
IS15 - Emerging Evidence on the Role of Complement Pathway in the Pathophysiology of HSCT-TMA - Omeros
Symposium
Chair: Miguel-Angel Perales, US
Chair: Jeffrey Laurence, US
Chair: Alessandro Rambaldi, IT
IS15-1 Introduction 14:30 - 14:33
Speaker: Miguel-Angel Perales, US

IS15-2 From bench to clinics: what evidence do we have about the 14:33 - 14:58
complement pathway’s role in HSCT-TMA
Speaker: Jeffrey Laurence, US

IS15-3 Emerged clinical data (including pivotal trial data review with 14:58 - 15:18
subgroup analysis)
Speaker: Alessandro Rambaldi, IT

IS15-4 Implications to clinical practice (with potential case study) 15:18 - 15:33
Speaker: Miguel-Angel Perales, US

IS15-5 Q&A 15:33 - 16:00

CME Symposium
14:30 - 16:00 Auditorium 4
IS16 - Modernizing the Care of CMV in HCT Recipients: Management Updates and Reducing Risks - CME Symp
Chair: Per Ljungman, SE
IS16-1 Introduction and panel discussion: Current Landscape of CMV 14:30 - 14:40
in HCT

IS16-2 Case Scenario #1 14:40 - 14:45

IS16-3 Risk Stratification 14:45 - 14:57

Speaker: Johan Maertens, BE

IS16-4 Panel discussion: Challenges of Patients at High Risk, and of 14:57 - 15:07
R/R CMV

IS16-5 Best Practices 15:07 - 15:17

Speaker: Rafael Duarte, ES

IS16-6 Case Scenario #2 15:17 - 15:22

IS16-7 Panel discussion: Challenges of CMV in the Intolerant Patient 15:22 - 15:30
and in R/R CMV

IS16-8 New Treatment Paradigms 15:30 - 15:42

Speaker: Catherine Cordonnier, FR

IS16-9 Panel discussion: Potential Effect of New Data and New 15:42 - 15:54
Therapies

IS16-10 Audience Q&A 15:54 - 16:00

68 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

Industry Symposium
14:30 - 16:00 Auditorium 5
IS17 - Challenges in Relapse/Refractory Multiple Myeloma - Sanofi Industry Symposium
Chair: Jesús San Miguel, ES
IS17-1 Lenalidomide-refractory patients: evidence-based 14:30 - 14:50
recommendations
Speaker: Francesca Gay, IT

IS17-2 What is the value of MRD negativity in relapsed/refractory 14:50 - 15:10

patients?
Speaker: Mohamad Mohty, FR

IS17-3 Frail patients with Relapsed/Refractory Multiple Myeloma and 15:10 - 15:30
health-related quality of life
Speaker: María Victoria Mateos, ES

IS17-4 Q&A and round table discussion 15:30 - 16:00

Patient, Family Donor Day

14:45 - 15:40 Auditorium 6
PFD5 - Patient, Family and Donor Day: New developments and donor focus 2
Chair: Lola Manterola, ES
Chair: Gillian Adams, GB
PFD5-1 Introduction to speakers 14:45 - 14:50
Speaker: Lola Manterola, ES
Speaker: Gillian Adams, GB

PFD5-2 Donor Registry: “A lifesaver”. General and spanish situation 14:50 - 15:05
Speaker: Juliana Villa, ES

PFD5-3 Live dialogue: Pediatric transplantation: How does it work? 15:05 - 15:30
Speaker: Antonio Pérez-Martínez, ES
Speaker: Daniel Guerrero, ES

PFD5-4 Q&A 15:30 - 15:40

Breaks
16:00 - 16:30 Auditorium 1
Coffee Break, Poster Viewing, Visit Exhibition

Special Session
16:00 - 17:30 Auditorium 6
SS01 - Interactive debate on patient engagement in transplantation and cell therapy
Chair: Helene Schoemans, BE
Chair: Guy Bouguet, FR
SS1-1 The patient's engagement experience 16:00 - 16:10
Speaker: Chris Lewis, GB

SS1-2 Why consider patient engagement in research 16:10 - 16:25

Speaker: Sabina De Geest, CH

SS1-3 Integrating patients in research projects – Practical 16:25 - 16:40

69 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

considerations
Speaker: Linda Burns, US

SS1-4 Using Patient Reported Outcomes in the clinic – Practical 16:40 - 16:55
considerations
Speaker: Sarah Liptrott, IT

SS1-5 Panel discussion - Interactive debate 16:55 - 17:15

SS1-6 Closing comments 17:15 - 17:25

Speaker: Pavel Jindra, CZ
Speaker: Guy Bouguet, FR

Industry Symposium
16:30 - 18:00 Auditorium 1
IS18 - Cell therapy & survival: An interactive focus on the future - Kite-Gilead Industry Symposium
Chair: Mohamad Mohty, FR
IS18-1 Welcome and introduction 16:30 - 16:32
Speaker: Mohamad Mohty, FR

IS18-2 What are the ongoing challenges for cell therapy? 16:32 - 16:40
Speaker: Jim Kochenderfer, US

IS18-3 Does T-cell fitness change during the treatment journey? 16:40 - 16:48
Speaker: Chiara Bonini, IT

IS18-4 How can we optimise safety? 16:48 - 16:56

Speaker: Irit Avivi, IL

IS18-5 How can we improve efficacy? 16:56 - 17:04

Speaker: David Miklos, US

IS18-6 When does survival translate into ‘cure’? 17:04 - 17:12

Speaker: Sarit Assouline, CA

IS18-7 What will the future of cell therapy look like? 17:12 - 17:20
Speaker: Mohamad Mohty, FR

IS18-8 Live Q&A 17:20 - 18:00

Industry Symposium
16:30 - 18:00 Auditorium 2
IS19 - What is the New Evidence in the Era of CMV Prophylaxis? - MSD Industry Symposium
Chair: Rafael de la Cámara, ES
IS19-1 Welcome, and Opening Remarks 16:30 - 16:35
Speaker: Rafael de la Cámara, ES

IS19-2 Do Cellular Immunity and Viral Load Kinetics Predict Clinical 16:35 - 16:55
Outcomes of CMV Infection after HSCT?
Speaker: Miguel-Angel Perales, US

IS19-3 Real World Evidence of CMV prophylaxis: a focus on CMV blips 16:55 - 17:15
and treatment duration

70 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

Speaker: Catherine Cordonnier, FR

IS19-4 Is CMV prophylaxis cost-effective? 17:15 - 17:35

Speaker: Corrado Girmenia, IT

IS19-5 Closing remarks 17:35 - 17:40

Speaker: Rafael de la Cámara, ES

IS19-6 Live Q&A and Closing remarks 17:40 - 18:00

Industry Symposium
16:30 - 17:15 Auditorium 3
IS20 - New maintenance strategies in AML - BMS Industry Symposium
Chair: Nicolaus Kröger, DE
IS20-1 Welcome and introduction 16:30 - 16:35
Speaker: Nicolaus Kröger, DE

IS20-2 Clinical challenges in the management of AML patients in 16:35 - 16:50

complete remission
Speaker: Norbert Vey, FR

IS20-3 Evolving treatment approaches to prolong complete remission 16:50 - 17:05

in AML
Speaker: Farhad Ravandi, US

IS20-4 Panel discussion and Closing remarks 17:05 - 17:15

Industry Symposium
16:30 - 18:00 Auditorium 4
IS21 - The nurse: essential at every step of hepatic VOD management - Jazz Pharmaceuticals Industry Sympos
Chair: Michelle Kenyon, GB
IS21-1 Welcome and introduction 16:30 - 16:35
Speaker: Michelle Kenyon, GB

IS21-2 The essential role of the nurse in hepatic VOD management 16:35 - 16:55
Speaker: Michelle Kenyon, GB

IS21-3 Theory in practice: the MDT perspective 16:55 - 17:25

Speaker: Eleni Tholouli, GB
Speaker: Marie Waller, GB

IS21-4 The reality of hepatic VOD 17:25 - 17:45

Speaker: Zofia Szmit, PL

IS21-5 Empowering nurses through hepatic VOD education 17:45 - 17:55

Speaker: Michelle Kenyon, GB
Speaker: Julia Ruiz Pato, ES

IS21-6 Summary and close 17:55 - 18:00

Speaker: Michelle Kenyon, GB

71 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

Industry Symposium
16:30 - 18:00 Auditorium 5
IS22 - Calibrating the intensity of GvHD therapy to allow clinical tolerance – a role for ECP Immunomodulation
Mallinckrodt Industry Symposium
Chair: Jane Apperley, GB
IS22-1 Introduction 16:30 - 16:35
Speaker: Jane Apperley, GB

IS22-2 Evaluation of societal burden of chronic GvHD 16:35 - 17:00

Speaker: Jonas Mattsson, CA

IS22-3 The Challenges of Implementing the NIH Consensus Criteria for 17:00 - 17:25
Clinical Trials in chronic GvHD
Speaker: Corey Cutler, US

IS22-4 How to reduce therapy-related toxicity in GvHD 17:25 - 17:50

Speaker: Daniel Couriel, US

IS22-5 Q&A session 17:50 - 18:00

Wellness session
17:30 - 18:00 Auditorium 6
Therapeutic Origami session

General
18:00 - 19:15 Auditorium 1
GS1 - Opening Ceremony
GS1-1 Welcome and introduction 18:00 - 18:05
Speaker: Nicolaus Kröger, DE

GS1-2 Welcome and introduction to the conference 18:05 - 18:10

Speaker: Rafael Duarte, ES

GS1-3 Welcome from the Nurses Group 18:10 - 18:14

Speaker: John Murray, GB

GS1-4 EBMT Patient Advocacy Committee: Welcome note 18:14 - 18:18

Speaker: Natacha Bolaños, ES

GS1-5 Honorary Member Awards 2020 and Clinical Achievement 18:18 - 18:48
Award 2021
Speaker: Andrea Bacigalupo, IT
Speaker: Dietger Niederwieser, DE
Speaker: Alejandro Madrigal, GB
Speaker: Ernst Holler, DE
Speaker: Manuel Abecasis, PT

GS1-6 Introduction of the Keynote speaker 18:48 - 18:50

Speaker: Rafael Duarte, ES

GS1-7 Keynote lecture - Management of the COVID-19 pandemic: The 18:50 - 19:15
perspective from Madrid-IFEMA Field Hospital
Speaker: Antonio Zapatero, ES

72 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

Monday, 15. March 2021

Educational
09:15 - 10:30 Auditorium 1
E01 - Long-term management of alloHSCT recipients
Chair: Patrice Chevallier, FR
Chair: María del Mar Perera Álvarez, ES
E1-1 Survivorship care plans 09:15 - 09:30
Speaker: Navneet Majhail, US

E1-2 Secondary malignancies 09:30 - 09:45

Speaker: Christian Koenecke, DE

E1-3 Practical management of long-term organ complications 09:45 - 10:00

Speaker: Mutlu Arat, TR

E1-4 Q&A 10:00 - 10:30

How do I … ?
09:15 - 10:30 Auditorium 2
HDI1 - How do I... manage AML patients in first remission? - Supported through an unrestricted educational gr
Chair: Jordi Esteve, ES
HDI1-1 Transplant eligible patient 09:15 - 09:40
Speaker: Christoph Schmid, DE

HDI1-2 Transplant ineligible patients 09:40 - 10:05

Speaker: Arnold Ganser, DE

HDI1-3 Q&A 10:05 - 10:30

Nurses Group
09:15 - 10:30 Auditorium 3
NG01 - Nurses Group Opening Session
NG01-1 Welcome and overview 09:15 - 09:25
Speaker: John Murray, GB

NG01-2 Presentation of the 13th Distinguished Merit Award and 09:25 - 09:30
awardee acceptance speech
Speaker: John Murray, GB

NG01-3 Nurses in the response to healthcare challenges 09:30 - 10:00

Speaker: Adelaida Zabalegui, ES

NG01-4 Artificial Intelligence in healthcare 10:00 - 10:30

Speaker: Sharukh Hashmi, US

Cell therapy
09:15 - 10:30 Auditorium 4
CTD1 - Cell Therapy Day: Novelties in Donor Management
Chair: Kristina Hölig, DE

73 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

CTD1-1 Use of plerixafor in donors 09:15 - 09:35

Speaker: Nina Worel, AT

CTD1-2 Microbiota and hematopoietic stem cells 09:35 - 09:55

Speaker: Florent Malard, FR

CTD1-3 Role of Donor Clonal Hematopoiesis in Allogeneic 09:55 - 10:10

Hematopoietic Stem-Cell Transplantation
Speaker: Mareike Frick, DE

CTD1-4 Q&A 10:10 - 10:30

Transplant and Search Coordinators Day

09:15 - 10:30 Auditorium 5
TSCD1 - Transplant and Search Coordinators Day: New HLA Typing Techniques and how they changed the wa
transplant
Chair: Joannis Mytilineos, DE
Chair: Eric Spierings, NL
TSCD1-1 Introduction and overview 09:15 - 09:30
Speaker: Eric Spierings, NL

TSCD1-2 Debate: Do we still need Verification Typing (VT) of the donor? -

TSCD1-3 No, rely on initial high resolution typing 09:30 - 09:50

Speaker: Martin Bornhäuser, DE

TSCD1-4 Yes, safety first 09:50 - 10:10

Speaker: Rachel Pawson, GB

TSCD1-5 Panel discussion 10:10 - 10:30

Industrial Theatre
09:15 - 18:00 IT
Industry Theatre sessions

Industrial Theatre
09:15 - 18:00 IT
IT3 - Amicus Blue in Children and Adolescents with GVHD - Fresenius Kabi Industry Theatre session
This session is available throughout the whole congress
Chair: Volker Witt, AT

Industrial Theatre
09:15 - 18:00 IT
IT1 - Kite as innovators in CAR T-cell therapy manufacturing and delivery - Kite-Gilead Industry Theatre sessio
This session is available throughout the whole congress
Chair: Dick Sundh, AU

74 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

Industrial Theatre
09:15 - 18:00 IT
IT2 - Developing the Future of CAR-T Cell Therapy Today - Novartis Industry Theatre session
This session is available throughout the whole congress
Chair: Amir Hefni, GB
Chair: David Kuzan, US
Chair: Carolin Barth, CH

Oral Session
09:15 - 18:00 On-Demand Library
OS04 - Oral session 4: Cellular Therapy, Gene Therapy and New Drugs I
This session is available in our on-demand library throughout the whole congress
OS4-1 INTERIM RESULTS OF BETIBEGLOGENE AUTOTEMCEL GENE 09:15 - 09:25
THERAPY IN PEDIATRIC PATIENTS WITH TRANSFUSION-
DEPENDENT ?-THALASSEMIA (TDT) TREATED IN THE PHASE 3
NORTHSTAR-2 (HGB-207) AND NORTHSTAR-3 (HGB-212)
STUDIES
Speaker: Isabelle Thuret, FR

OS4-2 NARSOPLIMAB (OMS721), A MASP-2 INHIBITOR, FOR THE 09:25 - 09:35

TREATMENT OF ADULT HEMATOPOIETIC STEM CELL
TRANSPLANT-ASSOCIATED THROMBOTIC
MICROANGIOPATHY (HSCT-TMA): SUBGROUP ANALYSES
Speaker: Alessandro Rambaldi, IT

OS4-3 CRISPR-BASED REPLACEMENT OF THE ENDOGENOUS T- 09:35 - 09:45

CELL REPERTOIRE WITH NOVEL, HIGH-AVIDITY, NATURAL T
CELL RECEPTORS TO WT1 FOR THE TREATMENT OF ACUTE
MYELOID LEUKEMIA
Speaker: Eliana Ruggiero, IT

OS4-4 CLINICAL TRIAL UPDATE: EX-VIVO AUTOLOGOUS STEM CELL 09:45 - 09:55
GENE THERAPY IN MPSIIIA
Speaker: Jane Louise Kinsella, GB

OS4-5 EXOGENOUS M-CSF PROTECTS FROM LETHAL A. FUMIGATUS 09:55 - 10:05

PULMONARY INFECTION EARLY AFTER HEMATOPOIETIC
STEM CELL TRANSPLANTATION
Speaker: Dalia Sheta, DE

OS4-6 REAL-WORLD EFFECTIVENESS AND SAFETY OF 10:05 - 10:15

BLINATUMOMAB IN EUROPE: 3-YEAR RESULTS IN RELAPSED
OR REFRACTORY PHILADELPHIA CHROMOSOME-NEGATIVE
BCP-ALL PATIENTS INCLUDING THOSE WITH LATE FIRST
RELAPSE
Speaker: Alessandro Rambaldi, IT

OS4-7 GENERATION OF HSPC-DERIVED CD16A-ENGINEERED NK 10:15 - 10:25

CELLS WITH ADVANCED ANTIBODY-DEPENDENT CELLULAR
CYTOTOXICITY
Speaker: Paulien van Hauten, NL

OS4-8 IMPROVEMENTS IN FATIGUE AND PHYSICAL FUNCTION 10:25 - 10:35

EVALUATED THROUGH CHANGES IN CLINICAL OUTCOMES IN

75 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

PAROXYSMAL NOCTURNAL HEMOGLOBINURIA: POST-HOC

ANALYSES FROM THE PEGASUS STUDY

Educational
09:15 - 18:00 On-Demand Library
E08 - New challenges in infectious complications
This session is available in our on-demand library throughout the whole congress
E8-1 T-cell therapy for infections in SCT patients: An experimental -
treatment or a real choice for the practice?
Speaker: Patrizia Comoli, IT

E8-2 Infectious complications with new drugs in Hematology -

Speaker: Georg Maschmeyer, DE

E8-3 The blood virome of HSCT Recipients: Much more than viremia -
by CMV, EBV, HH6V and adenovirus
Speaker: Marie-Celine Zanella, CH

Data Management
09:15 - 18:00 On-Demand Library
DM09 - Education session 9
This session is available in our on-demand library throughout the whole congress
DM9-1 Follow up forms - How to get a chronological overview of the -
patient history and follow up
Speaker: Elena Ferrer Martínez del Peral, ES

Working Party Session

09:15 - 18:00 On-Demand Library
IDWP - Infectious Diseases Working Party Session
This session is available in our on-demand library throughout the whole congress
IDWP-1 IDWP update -
Speaker: Rafael de la Cámara, ES

IDWP-2 Current scientific proposals of IDWP -

Speaker: Dina Averbuch, IL

IDWP-3 CMV T-cell immunity monitoring: is it time to incorporate it in -

clinical practices?
Speaker: Roy Chemaly, US

IDWP-4 What is new in the field of Gram-negative infections in SCT -

patients?
Speaker: Dina Averbuch, IL

IDWP-5 Seasonal human coronaviruses vs SARS-CoV-2 in allogeneic -

hematopoietic stem cell transplantation
Speaker: Jose Luis Piñana, ES

IDWP-6 Hepatitis C and hepatitis E in SCT -

Speaker: Malgorzata Mikulska, IT

76 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

IDWP-7 Central nervous system (CNS) complications following HSCT -

Speaker: Martin Schmidt-Hieber, DE

Data Management
09:15 - 18:00 On-Demand Library
DM06 - Education session 6
This session is available in our on-demand library throughout the whole congress
DM6-1 Response in Multiple Myeloma -
Speaker: Meral Beksac, TR

Data Management
09:15 - 18:00 On-Demand Library
DM05 - Education session 5
This session is available in our on-demand library throughout the whole congress
DM5-1 Hematopoietic Cell Transplantation-Comorbidity Index ‘Sorror -
Score’
Speaker: Bronwen Shaw, US

On Demand Library
09:15 - 18:00 On-Demand Library
On Demand Library

Working Party Session

09:15 - 18:00 On-Demand Library
ALWP - Acute Leukaemia Working Party Session
This session is available in our on-demand library throughout the whole congress
ALWP-1 Introduction 09:15 - 09:15
Speaker: Mohamad Mohty, FR

ALWP-2 CAR-T cells in adult ALL 09:15 - 09:15

Speaker: Arnon Nagler, IL

ALWP-3 Transplant in refractory AML: Comparison of the different 09:15 - 09:15

FLAMSA approaches
Speaker: Mohamad Mohty, FR

ALWP-4 MRD in AML: Where do we stand? 09:15 - 09:15

Speaker: Ali Bazarbachi, LB

Educational
09:15 - 18:00 On-Demand Library
E13 - Allogeneic transplantation from alternative donors
This session is available in our on-demand library throughout the whole congress
E13-1 Haploidentical vs unrelated in AML -
Speaker: Didier Blaise, FR

E13-2 Haploidentical vs unrelated in ALL -

Speaker: Arnon Nagler, IL

77 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

E13-3 Haploidentical vs cord Blood in acute leukaemia -

Speaker: Frederic Baron, BE

Working Party Session

09:15 - 18:00 On-Demand Library
ADWP - Autoimmune Diseases Working Party Session
This session is available in our on-demand library throughout the whole congress
ADWP-1 Welcome and Update from the EBMT registry -
Speaker: Raffaella Greco, IT

ADWP-2 Introducing the session and speakers -

Speaker: Tobias Alexander, DE

ADWP-3 HSCT for multiple sclerosis: Future directions in patient -

selection and conditioning regimen
Speaker: Riccardo Saccardi, IT

ADWP-4 HSCT for systemic sclerosis: Future directions in patient -

selection and conditioning regimen
Speaker: Dominique Farge, FR

ADWP-5 HSCT for Crohn’s disease: future directions in patient -

selection, mobilization and conditioning regimen
Speaker: Elena Ricart, ES

ADWP-6 HSCT for autoimmune diseases: Current aspects on early and -

late complications
Speaker: Majid Kazmi, GB

ADWP-7 HSCT for autoimmune diseases: Conditioning regimen and -

outcomes from the Russian experience
Speaker: Denis Fedorenko, RU

ADWP-8 Closing remarks -

Speaker: Tobias Alexander, DE

Nurses Group
09:15 - 18:00 On-Demand Library
NG16 - Cellular therapy update
This session is available in our on-demand library throughout the whole congress
NG16-1 Update: What’s new? -
Speaker: Rose Ellard, GB

NG16-2 Spotlight on the Lymphoma Patient Experience -

Speaker: Lorna Warwick, CA

Nurses Group
09:15 - 18:00 On-Demand Library
NG19 - Disease update
This session is available in our on-demand library throughout the whole congress

78 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

NG19-1 Acute leukaemia -

Speaker: Inge Govaerts, BE

NG19-2 Managing lymphoma: What nurses and healthcare -

professionals need to know
Speaker: Erik Aerts, CH

NG19-3 Multiple myeloma -

Speaker: Maaike de Ruijter, NL

NG19-4 CML (ITK management) -

Speaker: Laura Borg, GB

Oral Session
09:15 - 18:00 On-Demand Library
OS19 - Oral session 19: Lymphoma and Chronic Lymphocytic Leukemia
This session is available in our on-demand library throughout the whole congress
OS19-1 INTERIM ANALYSIS (IA) OF ZUMA-12: A PHASE 2 STUDY OF 09:15 - 09:15
AXICABTAGENE CILOLEUCEL (AXI-CEL) AS FIRST-LINE
THERAPY IN PATIENTS WITH HIGH-RISK LARGE B-CELL
LYMPHOMA (LBCL)
Speaker: Catherine Thieblemont, FR

OS19-2 LONG-TERM SURVIVAL AND GRADUAL RECOVERY OF B 09:15 - 09:15

CELLS IN PATIENTS WITH REFRACTORY LARGE B CELL
LYMPHOMA (LBCL) TREATED WITH AXICABTAGENE
CILOLEUCEL (AXI-CEL)
Speaker: Caron A. Jacobson, US

OS19-3 PRIMARY ANALYSIS OF ZUMA-5: A PHASE 2 STUDY OF 09:15 - 09:15

AXICABTAGENE CILOLEUCEL (AXI-CEL) IN PATIENTS WITH
RELAPSED/REFRACTORY (R/R) INDOLENT NON-HODGKIN
LYMPHOMA (INHL)
Speaker: Caron A. Jacobson, US

OS19-4 ONE-YEAR FOLLOW-UP OF ZUMA-2, THE MULTICENTER, 09:15 - 09:15

REGISTRATIONAL STUDY OF KTE-X19 IN PATIENTS WITH
RELAPSED/REFRACTORY (R/R) MANTLE CELL LYMPHOMA
(MCL)
Speaker: Michael L. Wang, US

OS19-5 VALIDATION OF GWAS-IDENTIFIED VARIANTS FOR CHRONIC 09:15 - 09:15

LYMPHOCYTIC LEUKEMIA: A STUDY IN THE CONTEXT OF THE
CRUCIAL CONSORTIUM
Speaker: Antonio José Cabrera-Serrano, ES

OS19-6 EVALUATION OF AUTOLOGOUS AND ALLOGENEIC 09:15 - 09:15

HEMATOPOIETIC CELL TRANSPLANTATION (HCT) IN
PATIENTS WITH HIGH-RISK ANAPLASTIC LARGE CELL
LYMPHOMA (ALCL)
Speaker: Natalie L. Smith, US

OS19-7 ECONOMIC ASPECTS OF STEM CELL TRANSPLANTATION BY 09:15 - 09:15

PATIENTS WITH RELAPSED DIFFUSE B-CELL LYMPHOMA

79 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

(DLBCL) IN A GERMAN TERTIARY HOSPITAL

Speaker: Bernhard Alexander Mörtl, DE

OS19-8 LONG TERM OUTCOMES OF ALLOGENEIC 09:15 - 09:15

TRANSPLANTATION IN LYMPHOMA: A SINGLE CENTRE
EXPERIENCE
Speaker: Alexander Glover, GB

Oral Session
09:15 - 18:00 On-Demand Library
OS07 - Oral session 7: Stem Cell Source and Donors
This session is available in our on-demand library throughout the whole congress
OS7-1 FUNCTIONAL MISMATCHING FOR HLA-DP REDUCES RELAPSE 09:15 - 09:25
RISK AFTER UNRELATED HEMATOPOIETIC CELL
TRANSPLANTATION: A STUDY FROM THE CELLULAR
THERAPY AND IMMUNOBIOLOGY WORKING PARTY OF THE
EBMT
Speaker: Annalisa Ruggeri, ES

OS7-2 POST-TRANSPLANT CYCLOPHOSPHAMIDE IN ONE-ANTIGEN 09:25 - 09:35

MISMATCHED UNRELATED DONOR TRANSPLANTATION
VERSUS HAPLOIDENTICAL TRANSPLANTATION: A
RETROSPECTIVE STUDY ON BEHALF OF THE ACUTE
LEUKEMIA WORKING PARTY OF THE EBMT
Speaker: Giorgia Battipaglia, IT

OS7-3 HLA EVOLUTIONARY DIVERGENCE (HED) INFLUENCES 09:35 - 09:45

OUTCOMES OF ALLOGENEIC HSCT FROM UNRELATED
DONOR (UD) IN PEDIATRIC PATIENTS AND YOUNG ADULTS
AFFECTED BY MALIGNANT DISORDERS
Speaker: Pietro Merli, IT

OS7-4 MANAGEMENT OF DONOR-SPECIFIC ANTIBODIES IN 09:45 - 09:55

HAPLOIDENTICAL TRANSPLANT: MULTICENTER EXPERIENCE
FROM THE MADRID GROUP OF HEMATOPOIETIC
TRANSPLANT
Speaker: Rebeca Bailén, ES

OS7-5 LONG TERM OUTCOMES AFTER INTRABONE UNRELATED 09:55 - 10:05

UMBILICAL CORD BLOOD TRANSPLANT IN PATIENTS WITH
HEMATOLOGICAL MALIGNANCIES: A EUROCORD, CTIWP-
EBMT ANALYSIS
Speaker: Jacopo Peccatori, IT

OS7-6 INFERIOR CLINICAL OUTCOMES IN RECIPIENTS OF 10:05 - 10:15

CRYOPRESERVED GRAFTS FOLLOWING REDUCED INTENSITY
ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION: A
SINGLE CENTER REPORT
Speaker: Andriyana Bankova, US

OS7-8 CLINICAL RESULTS OF PERIPHERAL BLOOD STEM CELL 10:15 - 10:25

TRANSPLANTATION WITH CRYOPRESERVED GRAFTS
DURING THE COVID19 PANDEMIC

80 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

Speaker: Maximilian Christopeit, DE

Oral Session
09:15 - 18:00 On-Demand Library
OS09 - Oral session 9: Graft versus Host Disease II
This session is available in our on-demand library throughout the whole congress
OS9-1 GLUCAGON-LIKE-PEPTIDE-2 (GLP-2) ANALOGUE 09:15 - 09:15
TEDUGLUTIDE FOR GRAFT-VERSUS-HOST DISEASE IN
HUMANS
Speaker: Robert Zeiser, DE

OS9-2 RUXOLITINIB VS BEST AVAILABLE THERAPY IN PATIENTS 09:15 - 09:15

WITH STEROID-REFRACTORY/DEPENDENT CHRONIC GRAFT-
VS-HOST DISEASE (CGVHD): SUBGROUP ANALYSES OF
OVERALL RESPONSE RATE IN THE PHASE 3 REACH3 TRIAL
Speaker: Franco Locatelli, IT

OS9-3 DISCONTINUATION OF SYSTEMIC IMMUNOSUPPRESSIVE 09:15 - 09:15

THERAPY: NEW GOAL OF CHRONIC GVHD TREATMENT?
Speaker: Ivan Moiseev, RU

OS9-4 A PHASE 2, PROSPECTIVE, RANDOMISED, OPEN-LABEL 09:15 - 09:15

STUDY OF DEFIBROTIDE FOR THE PREVENTION OF ACUTE
GRAFT-VERSUS-HOST DISEASE (AGVHD) AFTER
ALLOGENEIC HAEMATOPOIETIC CELL TRANSPLANTATION
(HCT)
Speaker: Michelle Hudspeth, US

OS9-5 THE IMPACT OF GVHD ON OUTCOMES AFTER ADULT SINGLE 09:15 - 09:15
CORD BLOOD TRANSPLANTATION IN EUROPEAN AND
JAPANESE POPULATIONS: THE EUROCORD/ALWP EBMT AND
JSHCT/JDCHCT COLLABORATIVE STUDY
Speaker: Junya Kanda, JP

OS9-6 EARLY RECONSTITUTION OF CD6+ T CELLS AFTER 09:15 - 09:15

HEMATOPOIETIC CELL TRANSPLANTATION IDENTIFIES A
SUITABLE TARGET FOR ACUTE GRAFT-VERSUS-HOST
DISEASE TREATMENT USING ANTI-CD6 MONOCLONAL
ANTIBODY ITOLIZUMAB
Speaker: Benedetta Rambaldi, US

OS9-7 MICROBIAL-DERIVED METABOLITES INDUCE EPITHELIAL 09:15 - 09:15

RECOVERY VIA THE STING PATHWAY IN MICE AND MEN AND
PROTECT FROM GRAFT-VERSUS-HOST DISEASE
Speaker: Erik Thiele Orberg, DE

OS9-8 ASSOCIATION OF GENE POLYMORPHISMS IN 09:15 - 09:15

CYCLOPHOSPHAMIDE METABOLISM PATHWAY WITH
COMPLICATIONS AFTER HAPLOIDENTICAL HEMATOPOIETIC
STEM CELL TRANSPLANTATION
Speaker: Paula Muñiz, ES

81 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

Oral Session
09:15 - 18:00 On-Demand Library
OS02 - Oral session 2: CARs I
This session is available in our on-demand library throughout the whole congress
OS2-1 CARTITUDE-1: PHASE 1B/2 STUDY OF CILTACABTAGENE 09:15 - 09:25
AUTOLEUCEL, A B-CELL MATURATION ANTIGEN–DIRECTED
CHIMERIC ANTIGEN RECEPTOR T CELL THERAPY, IN
RELAPSED/REFRACTORY MULTIPLE MYELOMA
Speaker: Deepu Madduri, US

OS2-2 PROPHYLACTIC CORTICOSTEROID USE WITH 09:25 - 09:35

AXICABTAGENE CILOLEUCEL (AXI-CEL) IN PATIENTS WITH
RELAPSED/REFRACTORY LARGE B CELL LYMPHOMA (R/R
LBCL)
Speaker: Olalekan O. Oluwole, US

OS2-3 MATCHING-ADJUSTED INDIRECT COMPARISON (MAIC) OF 09:35 - 09:45

LISOCABTAGENE MARALEUCEL (LISO-CEL) VERSUS
AXICABTAGENE CILOLEUCEL (AXI-CEL) AND
TISAGENLECLEUCEL IN RELAPSED/REFRACTORY LARGE B-
CELL LYMPHOMA
Speaker: David Maloney, US

OS2-4 STRATEGIES TO INCREASE CAR T-CELL SAFETY AND TO 09:45 - 09:55

PREVENT EPITOPE MASKING IN CAR+ B-CELL LEUKEMIA
BLASTS
Speaker: Concetta Quintarelli, IT

OS2-5 CONTRIBUTION OF AGE AND THE HCT-CI TO PREDICT CRS 09:55 - 10:05
AND ICANS SEVERITY IN NHL PATIENTS RECEIVING CD19
CAR T-CELL THERAPY
Speaker: Jordan Gauthier, US

OS2-6 OUTCOMES OF TREATMENT WITH THE CHIMERIC ANTIGEN 10:05 - 10:15

RECEPTOR (CAR) T CELL THERAPY LISOCABTAGENE
MARALEUCEL (LISO-CEL) IN THE NONUNIVERSITY SETTING:
INITIAL RESULTS FROM THE OUTREACH STUDY
Speaker: John E. Godwin, US

OS2-7 BUILDING OF THE G0-CAR-T INITIATIVE TO PROMOTE USE OF 10:15 - 10:25

DATA COLLECTED FROM PATIENTS TREATED WITH CAR-T
CELLS AT EU OR EBMT AFFILIATED PROGRAMS
Speaker: Christian Chabannon, FR

OS2-8 ENGINEERED CAR.CD123 NK CELLS AS AN INNOVATIVE “OFF 10:25 - 10:35

THE SHELF” STRATEGY TO TREAT CD123POS CHILDHOOD
ACUTE MYELOID LEUKAEMIA
Speaker: Simona Caruso, IT

Oral Session
09:15 - 18:00 On-Demand Library
OS13 - Oral session 13: Transplant Complications I
This session is available in our on-demand library throughout the whole congress

82 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

OS13-1 FINAL PRIMARY RESULTS FROM THE DEFIFRANCE REGISTRY 09:15 - 09:15
STUDY: EFFECTIVENESS AND SAFETY OF DEFIBROTIDE FOR
TREATMENT OF HEPATIC VENO-OCCLUSIVE
DISEASE/SINUSOIDAL OBSTRUCTION SYNDROME AFTER
HAEMATOPOIETIC CELL TRANSPLANTATION
Speaker: Mohamad Mohty, FR

OS13-2 ASSOCIATION OF PRE-EXISTING COMORBIDITIES WITH 09:15 - 09:15

OUTCOME OF ALLOGENEIC STEM CELL TRANSPLANTATION.
A RETROSPECTIVE ANALYSIS FROM THE EBMT
Speaker: Olaf Penack, DE

OS13-3 DEFIBROTIDE PROPHYLAXIS FOR VENO-OCCLUSIVE 09:15 - 09:15

DISEASE/SINUSOIDAL OBSTRUCTION SYNDROME (VOD/SOS)
AFTER HAEMATOPOIETIC CELL TRANSPLANTATION (HCT):
ANALYSIS OF A MULTICENTRE, MULTINATIONAL,
PROSPECTIVE, OBSERVATIONAL REGISTRY STUDY (EBMT
PASS)
Speaker: Mohamad Mohty, FR

OS13-4 EBMT PASS: OUTCOMES OF DEFIBROTIDE-TREATED 09:15 - 09:15

PATIENTS WITH ANICTERIC/ICTERIC VENO-OCCLUSIVE
DISEASE/SINUSOIDAL OBSTRUCTION SYNDROME (VOD/SOS)
AFTER HAEMATOPOIETIC CELL TRANSPLANTATION (HCT)
Speaker: Mohamad Mohty, FR

OS13-5 EASIX SCORE PREDICTS OVERALL SURVIVAL, NON-RELAPSE 09:15 - 09:15

MORTALITY AND THE RISK OF INTENSIVE CARE UNIT
ADMISSION AT PRE-TRANSPLANT EVALUATION
Speaker: Marta Peña Domingo, ES

OS13-6 THE INCIDENCE OF SEVERE ORAL MUCOSITIS AND TASTE 09:15 - 09:15
DISTURBANCE IN PATIENTS UNDERGOING DIFFERENT
CONDITIONING REGIMENS IN HEMATOPOIETIC STEM CELL
TRANSPLANTATION
Speaker: Midori Nakagaki, AU

OS13-7 IMPACT OF SIROLIMUS/TACROLIMUS-BASED GRAFT-VERSUS- 09:15 - 09:15

HOST-DISEASE PROPHYLAXIS ON THE DEVELOPMENT OF
EARLY AND LATE TRANSPLANT-ASSOCIATED THROMBOTIC
MICROANGIOPATHY
Speaker: Aldo A Acosta-Medina, US

OS13-8 RISK FACTORS FOR SINUSOIDAL OBSTRUCTION SYNDROME 09:15 - 09:15

OF THE LIVER AFTER ALLOGENEIC HEMATOPOIETIC STEM
CELL TRANSPLANTATION IN CHILDHOOD
Speaker: Bernd Gruhn, DE

Oral Session
09:15 - 18:00 On-Demand Library
OS14 - Oral session 14: Transplant Complications II
This session is available in our on-demand library throughout the whole congress
OS14-1 PREGNANCY AND PREGNANCY OUTCOMES AFTER 09:15 - 09:15

83 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

HEMATOPOIETIC STEM CELL TRANSPLANTATION DURING

CHILDHOOD: A CROSS-SECTIONAL SURVEY OF THE EBMT
PEDIATRIC WP
Speaker: Tamara Diesch, CH

OS14-2 ONE THOUSAND VOICES ADDRESS PATIENT ENGAGEMENT IN 09:15 - 09:15

HEMATOPOIETIC STEM CELL TRANSPLANTATION AND CELL
THERAPY: RESULTS OF A SURVEY FROM THE EBMT
Speaker: Helene Schoemans, BE

OS14-3 CHRONIC KIDNEY DISEASE TEN YEARS AFTER PEDIATRIC 09:15 - 09:15
ALLOGENEIC HEMATOPOIETIC STEM CELL
TRANSPLANTATION
Speaker: Gertjan Lugthart, NL

OS14-4 NEUROLOGIC COMPLICATIONS AFTER ALLOGENEIC STEM 09:15 - 09:15

CELL TRANSPLANTATION: ANALYSIS OF RISK FACTORS. A
SINGLE CENTER STUDY OVER 20 YEARS OF FOLLOW-UP

OS14-5 AN UPDATED SYSTEMATIC REVIEW OF STUDIES ON 09:15 - 09:15

DEFIBROTIDE PROPHYLAXIS FOR VENO?OCCLUSIVE
DISEASE/SINUSOIDAL OBSTRUCTION SYNDROME (VOD/SOS)
Speaker: Selim Corbacioglu, DE

OS14-6 PROGNOSTIC BIOMARKER SIGNATURE FOR HEPATIC VENO- 09:15 - 09:15

OCCLUSIVE DISEASE/SINUSOIDAL OBSTRUCTION SYNDROME
(VOD/SOS) IN RECIPIENTS OF MYELOABLATIVE (MA)
ALLOGENEIC HAEMATOPOIETIC CELL TRANSPLANTATION
(HCT)
Speaker: Santosh Putta, US

OS14-7 OUTCOME AFTER ADMISSION TO INTENSIVE CARE UNIT (ICU) 09:15 - 09:15
IN HEMATOPOIETIC TRANSPLANT RECIPIENTS: SINGLE
CENTRE EXPERIENCE
Speaker: Isabel Iturrate, ES

OS14-8 DISTRIBUTION AND IMPACT OF ACUTE KIDNEY INJURY IN AT- 09:15 - 09:15
HOME ALLOGENEIC BONE MARROW TRANSPLANTATION
MODELS
Speaker: Marta Garcia-Recio, ES

Oral Session
09:15 - 18:00 On-Demand Library
OS15 - Oral session 15: Conditioning Regimens
This session is available in our on-demand library throughout the whole congress
OS15-1 BENDAMUSTINE-BASED CONDITIONING PRIOR TO 09:15 - 09:25
AUTOLOGOUS HEMATOPOIETIC CELL TRANSPLANT
IMPROVES OUTCOMES IN PATIENTS WITH ELAPSED-
REFRACTORY NON-HODGKIN LYMPHOMA
Speaker: Sylvie Lachance, CA

OS15-2 MICROBIOTA INJURY IS CONDITIONING REGIMEN- 09:25 - 09:35

DEPENDENT IN ALLOGENEIC HEMATOPOIETIC CELL
TRANSPLANTATION RECIPIENTS

84 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

Speaker: Roni Shouval, US

OS15-3 THE IMPACT OF PULMONARY FUNCTION IN PATIENTS 09:35 - 09:45

UNDERGOING AUTOLOGOUS STEM CELL TRANSPLANTATION
Speaker: Jesus Duque-Afonso, DE

OS15-4 HIGH INCIDENCE OF GVHD WITH TBF CONDITIONING IN 09:45 - 09:55

HEMATOLOGIC MALIGNANCIES: A SINGLE CENTER
EXPERIENCE
Speaker: Khalid Halahleh, JO

OS15-5 THIOTEPA BUSULFAN AND FLUDARABINE (TBF) PATIENTS 09:55 - 10:05

WITH ACUTE MYELOID LEUKEMIA IN COMPLETE REMISSION
:A RETROSPECTIVE ANALYSIS ON 221 PATIENTS AND 369
CONTROLS
Speaker: Federica Sora, IT

OS15-6 IMPACT OF THE ADDITION OF ANTITHYMOCYTE GLOBULIN TO 10:05 - 10:15

POST-TRANSPLANT CYCLOPHOSPHAMIDE IN
HAPLOIDENTICAL TRANSPLANTATION WITH PERIPHERAL
BLOOD COMPARED TO POST-TRANSPLANT
CYCLOPHOSPHAMIDE ALONE
Speaker: Giorgia Battipaglia, IT

OS15-7 HEMATOPOIETIC CELL TRANSPLANTATION COMORBIDITY 10:15 - 10:25

INDEX (HCT-CI) AND OUTCOME AFTER NON-MYELOABLATIVE
ALLOGENEIC STEM CELL TRANSPLANTATION IN ACUTE
MYELOID LEUKEMIA (AML) PATIENTS OLDER THAN 60 YEARS
Speaker: Donata Backhaus, DE

OS15-8 SEQUENTIAL FLAMSA-BU VERSUS FLUBU2 IN PATIENTS WITH 10:25 - 10:35

ACTIVE RELAPSED OR REFRACTORY ACUTE MYELOID
LEUKEMIA: A STUDY FROM THE ACUTE LEUKEMIA WORKING
PARTY OF THE EBMT
Speaker: Eduardo Rodríguez-Arbolí, ES

Oral Session
09:15 - 18:00 On-Demand Library
OS16 - Oral session 16: Acute Leukemia I
This session is available in our on-demand library throughout the whole congress
OS16-1 IMPACT OF CO-OCCURRING CYTOGENETIC ABNORMALITIES 09:15 - 09:25
ON TRANSPLANT OUTCOME OF TP53 MUTANT ACUTE
MYELOID LEUKAEMIA: REPORT FROM THE ALWP OF THE
EBMT
Speaker: Justin Loke, GB

OS16-2 IMPACT OF CYTOGENETIC CLASSIFICATION IN ALLO-HCT IN 09:25 - 09:35

PATIENTS WITH ACUTE MYELOID LEUKEMIA SECONDARY TO
MYELODYSPLASTIC SYNDROME: A JOIN STUDY BY THE
ALWP AND THE CMWP
Speaker: Eolia Brissot, FR

OS16-3 THE IMPACT OF CYTOGENETIC RISK ON OUTCOME OF NON-T 09:35 - 09:45

CELL DEPLETED HAPLOIDENTICAL STEM CELL

85 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

TRANSPLANTATION IN RELAPSED/REFRACTORY AML: A

STUDY FROM THE ALWP / EBMT
Speaker: Arnon Nagler, IL

OS16-4 NON-T DEPLETED HAPLOIDENTICAL STEM CELL 09:45 - 09:55

TRANSPLANTATION IN AML PATIENTS ACHIEVING FIRST
COMPLETE REMISSION AFTER ONE VS TWO INDUCTION
COURSES: A STUDY FROM THE ALWP/EBMT
Speaker: Arnon Nagler, IL

OS16-5 PREVALENCE AND OUTCOME OF CNS RELAPSE AFTER 09:55 - 10:05

ALLOGENEIC HEMATOPOIETIC STEM CELL
TRANSPLANTATION IN PATIENTS SUFFERING FROM AML AND
ALL. A STUDY FROM THE ALWP-EBMT
Speaker: Sabine Blum, CH

OS16-6 IMPACT OF ALLOGENIC TRANSPLANTATION IN THE 10:05 - 10:15

TREATMENT OF SECONDARY ACUTE MYELOID LEUKEMIAS.
COMPARISON BETWEEN MYELOABLATIVE VS REDUCE
INTENSITY CONDITIONINGS
Speaker: Claudia Núñez-Torrón, ES

OS16-7 THE DISEASE BURDEN PRIOR TO ALLOGENEIC 10:15 - 10:25

HEMATOPOIETIC STEM CELL TRANSPLANT IS MORE
RELEVANT IN PATIENTS WITH DE NOVO LEUKEMIA COMPARE
TO PATIENTS WITH SECONDARY LEUKEMIA
Speaker: Claudia Núñez-Torrón, ES

OS16-8 PROGNOSIS OF PATIENTS WITH ACUTE LYMPHOBLASTIC 10:25 - 10:35

LEUKEMIA RELAPSING AFTER AN ALLOGENEIC STEM CELL
TRANSPLANTATION. STUDY OF 132 PATIENTS
Speaker: Christelle Ferra Coll, ES

Oral Session
09:15 - 18:00 On-Demand Library
OS17 - Oral session 17: Acute Leukemia II
This session is available in our on-demand library throughout the whole congress
OS17-1 TRENDS AND PREDICTIVE FACTORS FOR OUTCOME OF 09:15 - 09:15
RELAPSED PHILADELPHIA POSITIVE ACUTE LYMPHOBLASTIC
LEUKEMIA AFTER ALLOGENEIC HEMATOPOIETIC CELL
TRANSPLANTION: IMPROVEMENT OF SURVIVAL IN RECENT
YEARS
Speaker: Ali Bazarbachi, LB

OS17-2 HOST IMMUNE GENETIC VARIATIONS INFLUENCE THE RISK 09:15 - 09:15
OF DEVELOPING ACUTE MYELOID LEUKAEMIA: RESULTS
FROM THE NUCLEAR CONSORTIUM
Speaker: José Sánchez Maldonado, ES

OS17-3 COMPARISON OF HAPLOIDENTICAL PERIPHERAL BLOOD 09:15 - 09:15

CELL TRANSPLANTATION USING POST-TRANSPLANT
CYCLOPHOSPHAMIDE WITH DOUBLE CORD BLOOD
TRANSPLANTATION IN ADULTS WITH ACUTE LEUKEMIA

86 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

Speaker: Annalisa Ruggeri, ES

OS17-4 REAL-LIFE EXPERIENCE OF SORAFENIB MAINTENANCE 09:15 - 09:15

AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL
TRANSPLANTATION FOR FLT3-ITD AML REVEALS HIGH
RATES OF TOXICITY-RELATED TREATMENT INTERRUPTION
Speaker: Sarah Morin, CH

OS17-5 VENETOCLAX COMBINED WITH HYPOMETHYLATING AGENT 09:15 - 09:15

(HMA) IS SAFE AND EFFECTIVE MAY BE A GOOD BRIDGE TO
TRANSPLANT IN HIGH-RISK ACUTE MYELOID LEUKEMIA
Speaker: Vincenzo Federico, IT

OS17-6 TKI MAINTENANCE AFTER STEM-CELL TRANSPLANTATION 09:15 - 09:15

FOR FLT3-ITD POSITIVE ACUTE MYELOID LEUKEMIA: A
SYSTEMATIC REVIEW AND META-ANALYSIS
Speaker: Nico Gagelmann, DE

OS17-7 STEM CELL TRANSPLANTATION FROM A HAPLOIDENTICAL 09:15 - 09:15

DONOR FOR PEDIATRIC PATIENTS WITH ACUTE
MYELOGENOUS LEUKEMIA: A RETROSPECTIVE NATIONWIDE
STUDY
Speaker: Charlotte Nazon, FR

OS17-8 COMPREHENSIVE GERIATRIC ASSESSMENT, ALLOGENEIC 09:15 - 09:15

HSCT AND SURVIVAL IN AML PATIENTS 65-75 YEARS OLD
Speaker: Gabriele Magliano, IT

Oral Session
09:15 - 18:00 On-Demand Library
OS18 - Oral session 18: Myeloproliferative Neoplasms and Myelodysplastic Syndromes
This session is available in our on-demand library throughout the whole congress
OS18-1 GENOMIC CONFIGURATION OF TP53 MUTATIONS IN PATIENTS 09:15 - 09:15
WITH MYELOID NEOPLASIA
Speaker: Carmelo Gurnari, US

OS18-2 RETROSPECTIVE ANALYSIS EVALUATING THE EFFECT OF 09:15 - 09:15

AGE ON OUTCOMES AFTER ALLOGENEIC HEMATOPOIETIC
CELL TRANSPLANTATION IN CHRONIC MYELOMONOCYTIC
LEUKEMIA. A STUDY OF THE EBMT-CMWP
Speaker: Alicia Rovó, CH

OS18-3 CHANGE IN IPSS-R BETWEEN DIAGNOSIS AND TRANSPLANT 09:15 - 09:15

AND TRANSPLANT OUTCOME IN PATIENTS WITH MDS. A
RETROSPECTIVE ANALYSIS FROM THE CHRONIC
MALIGNANCIES WORKING PARTY
Speaker: Christof Scheid, DE

OS18-4 ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION IN 09:15 - 09:15

PATIENTS WITH THERAPY-RELATED MYELOID NEOPLASM
AFTER BREAST CANCER TREATMENT: A STUDY OF THE
CHRONIC MALIGNANCIES WORKING PARTY OF THE EBMT
Speaker: Mitja Nabergoj, CH

87 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

OS18-5 IMPACT OF PRIOR JAK-INHIBITOR THERAPY WITH 09:15 - 09:15

RUXOLITINIB ON OUTCOME AFTER ALLOGENEIC STEM CELL
TRANSPLANTATION FOR MYELOFIBROSIS. A LARGE EBMT-
CMWP STUDY
Speaker: Nicolaus Kröger, DE

OS18-6 ADDITIONAL CHROMOSOMAL ABERRATIONS IN CML 09:15 - 09:15

PATIENTS UNDERGOING ALLOGENEIC HEMATOPOIETIC STEM
CELL TRANSPLANTATION
Speaker: Elena Morozova, RU

OS18-7 DONOR AGE, CD34 CELL DOSE AND NON-BLAST CRISIS ARE 09:15 - 09:15
PROGNOSTIC FACTORS FOR OUTCOME AFTER STEM CELL
TRANSPLANTATION IN PATIENTS WITH ADVANCE PHASE CML
Speaker: Christian Niederwieser, DE

OS18-8 OUTCOMES OF ALLOGENEIC HEMATOPOIETIC STEM CELL 09:15 - 09:15

TRANSPLANTATION IN PATIENTS WITH MYELOFIBROSIS
TREATED WITH RUXOLITINIB IN THE PRE-TRANSPLANT
PERIOD
Speaker: Anna Czyz, PL

Special Session
09:15 - 18:00 On-Demand Library
SS08 - Social Media Session: Do's and don'ts of the interaction in the social media for the HSCT and cell thera
community
This session is available in our on-demand library throughout the whole congress
SS8-1 Social media beyond twitter for the HSCT and cell therapy -
community
Speaker: Navneet Majhail, US

SS8-2 Do's and don'ts of interaction in social media: Nurse's -

perspective

SS8-3 Do’s and don'ts of interaction in social media: How social -

media can improve patient outcomes - The patient's perspective
Speaker: Gillian Adams, GB

Special Session
09:15 - 18:00 On-Demand Library
SS07 - Young Ambassadors Session
This session is available in our on-demand library throughout the whole congress
SS7-1 How build up a career in: Academia -
Speaker: Didier Blaise, FR

SS7-2 How build up a career in: In Pharmaceutical Industry -

Speaker: Dan Tovar, FR

SS7-3 How build up a career in: In Public domains -

Speaker: Eva Hilgenfeld, DE

SS7-4 What to avoid when writing a paper -

88 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

Speaker: Jakob Passweg, CH

SS7-5 How to write a successful grant -

Speaker: Robert Zeiser, DE

SS7-6 Introduction to medical statistics -

Speaker: Simona Iacobelli, IT

SS7-7 Social media in stem cell transplantation and cellular therapy -

Speaker: Navneet Majhail, US

Nurses Group
09:15 - 18:00 On-Demand Library
NG20 - How do I become an expert?
This session is available in our on-demand library throughout the whole congress
NG20-1 Conditioning regimen -
Speaker: Nicolas Kint, BE

NG20-2 Immunosuppression -
Speaker: Tiene Bauters, BE

NG20-3 Vaccinations -
Speaker: Bipin Savani, US

Nurses Group
09:15 - 18:00 On-Demand Library
NG18 - Non-malignant diseases update
This session is available in our on-demand library throughout the whole congress
NG18-2 Multiple sclerosis 09:15 - 09:15
Speaker: Helen Jessop, GB

NG18-3 Sickle cell disease 09:15 - 09:15

Speaker: Jean-Hugues Dalle, FR

NG18-4 ITP 09:15 - 09:15

Speaker: Maria Luisa Lozano, ES

Nurses Group
09:15 - 18:00 On-Demand Library
NG14 - Nurses Education Day 2: Care of the vulnerable immunocompromised patients in critical care setting
This session is available in our on-demand library throughout the whole congress
NG14-1 Patient's experience -
Speaker: Ruth Tweedie, ES

NG14-2 Psychologist's point of view -

Speaker: Anna Lagerdahl, GB

NG14-3 Nurse's perspective -

Speaker: Núria Ballestar, ES

89 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

Nurses Group
09:15 - 18:00 On-Demand Library
NG24 - Outreach projects
This session is available in our on-demand library throughout the whole congress
NG24-2 Outreach project India: EBMT MIC pediatric advanced care 09:15 - 09:15
training (EMPACT)
Speaker: Lawrence Faulkner, IT

NG24-3 Outreach project: LABMT 09:15 - 09:15

Speaker: Sara Saez Carrasco, CO

Nurses Group
09:15 - 18:00 On-Demand Library
NG22 - Quality processes in JACIE
This session is available in our on-demand library throughout the whole congress
NG22-1 Quality indicators for nurses -
Speaker: Louise McNamara, GB

NG22-2 JACIE: What's new? -

Speaker: Kim Orchard, GB

NG22-3 What is the nurse role as JACIE Inspector? -

Speaker: Eugenia Trigoso Arjona, ES

Educational
09:15 - 18:00 On-Demand Library
E11 - Management of early complications in an ambulatory/outpatient setting
This session is available in our on-demand library throughout the whole congress
E11-1 Early infectious complications -
Speaker: Jan Styczynski, PL

E11-2 Non-infective complications: GVHD and organ toxicity -

Speaker: Gerhard Hildebrandt, US

E11-3 The Hospital Clínic experience -

Speaker: Francesc Fernández-Avilés, ES

Educational
09:15 - 18:00 On-Demand Library
E12 - Steroid-resistant/refractory GVHD
This session is available in our on-demand library throughout the whole congress
E12-1 GVHD - what’s in a name? -
Speaker: Helene Schoemans, BE

E12-2 Treatment of SR/R acute GVHD -

Speaker: Olaf Penack, DE

E12-3 Treatment of SR/R chronic GVHD -

Speaker: Zinaida Peric, HR

90 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

E12-4 New technologies in the approach to GVHD -

Speaker: Amin Turki, DE

Workshop
09:15 - 18:00 On-Demand Library
W10 - Controversies in T-cell NHL
This session is available in our on-demand library throughout the whole congress
W10-1 Are we improving first-line therapy in TCL? 09:15 - 09:15
Speaker: Eva Domingo Domenech, ES

W10-3 Insights in CAR-T therapy for T cell Lymphomas 09:15 - 09:15

Speaker: Helen Heslop, US

Workshop
09:15 - 18:00 On-Demand Library
W12 - Donor HLA assessment and matching for allogeneic HSCT
This session is available in our on-demand library throughout the whole congress
W12-1 HLA laboratory perspective and recommendations -
Speaker: Pascale Loiseau, FR

W12-2 Clinical perspective and recommendations -

Speaker: Francesca Lorentino, IT

W12-3 Selection of unrelated donors and cord blood units for -

Hematopoietic Cell Transplantation: Guidelines from
NMDP/CIBMTR
Speaker: Stephen Spellman, US

Workshop
09:15 - 18:00 On-Demand Library
W11 - Key organ manifestations of chronic GVHD
This session is available in our on-demand library throughout the whole congress
W11-1 Pulmonary chronic GVHD -
Speaker: Hildegard Greinix, AT

W11-2 Ocular cGVHD diagnostics - Practical approach -

Speaker: Igor Petricek, HR

W11-3 Gastrointestinal manifestations of chronic GVHD -

Speaker: Daniel Wolff, DE

Working Party Session

09:15 - 18:00 On-Demand Library
CMWP - Chronic Malignancies Working Party Session
This session is available in our on-demand library throughout the whole congress
CMWP-1 Scientific activity of the CMWP 09:15 - 09:15
Speaker: Ibrahim Yakoub-Agha, FR

CMWP-3 Who and when in the course of disease to transplant? - 09:15 - 09:15

91 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

Myelofibrosis
Speaker: Donal McLornan, GB

CMWP-4 Is Chronic Myeloid Leukaemia still an indication for allo-HCT? 09:15 - 09:15
Speaker: Yves Chalandon, CH

CMWP-5 Is Chronic Lymphocytic Leukemia still an indication for allo- 09:15 - 09:15
HCT?
Speaker: Peter Dreger, DE

Lab Technicians Day

09:15 - 18:00 On-Demand Library
LT1 - Lab Technicians Day: Specialized cell processing
This session is available in our on-demand library throughout the whole congress
LT1-1 Bone marrow processing: Techniques and results -
Speaker: Boris Calmels, FR

LT1-2 Technical aspects and performance TCRab/CD19 depletion -

Speaker: Kasper Westinga, NL

LT1-3 Donor selection and GMP-compliant manufacturing of virus- -

specific T-cells
Speaker: Britta Eiz-Vesper, DE

Joint Session
09:15 - 18:00 On-Demand Library
JS05 - Joint session WBMT: COVID-19 Vaccination in HSCT
This session is available in our on-demand library throughout the whole congress
JS5-2 COVID-19 vaccination in HSCT 09:15 - 09:15
Speaker: Per Ljungman, SE

JS5-3 Global access to COVID-19 vaccines 09:15 - 09:15

Speaker: Susan Brown, US

How do I … ?
09:15 - 18:00 On-Demand Library
HDI6 - How Do I... manage toxicity in immunosuppressed patients?
This session is available in our on-demand library throughout the whole congress
HDI6-1 Transplant associated TMA -
Speaker: Sergio Giralt, US

HDI6-2 Infectious complication -

Speaker: Jan Styczynski, PL

Data Management
09:15 - 18:00 On-Demand Library
DM08 - Education session 8
This session is available in our on-demand library throughout the whole congress
DM8-1 Infectious complications -

92 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

Speaker: Malgorzata Mikulska, IT

Joint Session
09:15 - 18:00 On-Demand Library
JS04 - Joint session LABMT
This session is available in our on-demand library throughout the whole congress
JS4-1 Transplant rates, Trends: WBMT/LABMT 2018 survey -
Speaker: Oscar González-Ramella, MX

JS4-2 Financing of HSCT in Latin America -

Speaker: Gregorio Jaimovich, AR

JS4-3 Selection, management and follow up of related donors: -

Overview
Speaker: Nina Worel, AT

JS4-4 Selection, management and follow up of related donors: -

Development of an LABMT consensus
Speaker: Gonzalo Ferini, AR

JS4-5 Haploidentical transplants in Latin America: Experience from -

Argentina/GATMO-TC in acute lymphoblastic leukemia
Speaker: Ana Basquiera, AR

JS4-6 Haploidentical transplants in Latin America: Experience from -

Brazil/SBTMO in aplastic anemia
Speaker: Carmem Bonfim, BR

Special Session
09:15 - 18:00 On-Demand Library
SS10 - The HARMONY Alliance: Accelerating better and faster treatment for patients with blood cancer
This session is available in our on-demand library throughout the whole congress
SS10-1 General Overview of the HARMONY Alliance: Progress, -
Achievements & Results of HARMONY and HARMONY PLUS
projects
Speaker: Jesús Maria Hernández Rivas, ES

SS10-2 Envisioned contribution of the EBMT to the HARMONY Alliance -

Speaker: Guillermo Sanz Santillana, ES
Speaker: Yann Guillevic, CH

SS10-3 EBMT participation in the HARMONY Alliance -

Speaker: Anna Sureda, ES

SS10-4 HARMONY & HARMONY PLUS Research Projects / Outcomes -

definition
Speaker: Lars Bullinger, DE

SS10-5 HARMONY Platform -

Speaker: Ana Heredia Casanoves, ES

93 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

Oral Session
09:15 - 18:00 On-Demand Library
OS01 - Oral session 1: Hematopoietic Stem Cells, Mobilization and Engineering
This session is available in our on-demand library throughout the whole congress
OS1-1 MGTA-145, IN COMBINATION WITH PLERIXAFOR IN A PHASE 1 09:15 - 09:15
CLINICAL STUDY, MOBILIZES LARGE NUMBERS OF
HEMATOPOIETIC STEM CELLS AND A GRAFT WITH POTENT
IMMUNOSUPPRESSIVE PROPERTIES
Speaker: Kevin Goncalves, US

OS1-2 EFFICACY AND SAFETY OF PEGFILGRASTIM FOR CD34+ CELL 09:15 - 09:15
MOBILIZATION IN HEALTHY VOLUNTEERS
Speaker: Hideki Goto, JP

OS1-3 THE IMPACT OF PLATELET RECOVERY ON SURVIVAL IN 09:15 - 09:15

CHILDREN UNDERGOING HEMATOPOIETIC STEM CELL
TRANSPLANTATION
Speaker: Rumesh Chandar, IN

OS1-4 THE IMPACT OF CD3 AND CD34 CELL DOSE ON GRAFT 09:15 - 09:15
REJECTION AND GRAFT VERSUS HOST DISEASE IN
CHILDREN UNDERGOING UNRELATED PERIPHERAL BLOOD
STEM CELL TRANSPLANTATION
Speaker: Satish Meena, IN

OS1-5 OUTCOME AND IMMUNE RECONSTITUTION AFTER 09:15 - 09:15

TCR??/CD19 CELL DEPLETED HEMATOPOIETIC STEM CELL
TRANSPLANTATION FROM HAPLOIDENTICAL RELATED
DONOR IN ADULT LEUKEMIA – A SINGLE CENTRE
EXPERIENCE
Speaker: Lucia Prezioso, IT

OS1-6 THE PREVALENCE OF ANTI-HLA ANTIBODIES IN THE FIRST 09:15 - 09:15

100 HAPLOIDENTICAL HEMATOPOIETIC STEM CELL
TRANSPLANTATION IN PEDIATRIC PATIENTS: A SINGLE-
CENTER EXPERIENCE
Speaker: Muhammad Ameen, SA

OS1-7 POST-TRANSPLANT OUTCOMES OF CHILDREN WITH 09:15 - 09:15

PRIMARY HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS
TREATED WITH EMAPALUMAB
Speaker: Michael Jordan, US

OS1-8 WHITE MATTER DEVELOPMENT IN NEONATES WITH 09:15 - 09:15

INFANTILE KRABBE DISEASE
Speaker: Maria Escolar, US

Oral Session
09:15 - 18:00 On-Demand Library
OS06 - Oral session 6: Experimental Transplantation, Minimal Residual Disease, Immune Reconstitution and C
This session is available in our on-demand library throughout the whole congress
OS6-1 COMPARATIVE ANALYSIS OF IMMUNE RECONSTITUTION IN 09:15 - 09:15
HSCT PATIENTS WITH PT-CY OR ATG REVEALS DISTINCT T

94 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

CELL IMMUNE RECONSTITUTION PATTERNS

Speaker: Saskia Leserer, DE

OS6-2 MINIMAL RESIDUAL DISEASE AND CHIMERISM ANALYSIS 09:15 - 09:15

USING CIRCULATING CELL-FREE DNA AFTER ALLOGENEIC
HEMATOPOIETIC CELL TRANSPLANTATION
Speaker: Sandra Pennisi, DE

OS6-3 SEQUENTIAL QUANTIFICATION OF T-CELL RECEPTOR 09:15 - 09:15

EXCISION CIRCLES (TRECS) AND K-DELETING
RECOMBINATION EXCISION CIRCLES (KRECS) IN
ALLOGENEIC HEMATOPOIETIC STEM CELL
TRANSPLANTATION (ALLOHSCT) RECIPIENTS
Speaker: Carlos De Miguel Jiménez, ES

OS6-4 MUTATIONAL CONSEQUENCES OF HEMATOPOIETIC STEM 09:15 - 09:15

CELL TRANSPLANTATION IN HUMANS
Speaker: Mirjam Belderbos, NL

OS6-5 OVER-EXPRESSION OF HIF-1? IN MESENCHYMAL STROMAL 09:15 - 09:15

CELLS INCREASES HUMAN CD34+ CELLS CLONOGENIC
CAPACITY IN VITRO AND ENGRAFTMENT ABILITY IN A
XENOTRANSPLANTATION MODEL
Speaker: Silvia Preciado, ES

OS6-6 ALEMTUZUMAB BASED-CONDITIONING FOR NON-MALIGNANT 09:15 - 09:15

PAEDIATRIC DISEASES DEPLETES DONOR T-CELLS
ALLOWING EXCEPTIONALLY LOW RATES OF GVHD BUT
ALLOWS PERSISTENCE OF RESIDUAL, AUTOLOGOUS, VIRUS-
SPECIFIC T-CELLS
Speaker: Rubiya Nadaf, GB

OS6-7 TCR REPERTOIRE DYNAMICS AFTER HEMATOPOIETIC STEM 09:15 - 09:15

CELL TRANSPLANTATION IN MYELOID MALIGNANCIES
Speaker: Simona Pagliuca, US

OS6-8 DAY +60 WT1 ASSESSMENT ON BONE MARROW MIGHT 09:15 - 09:15
PREDICT RELAPSE AND MORTALITY AFTER ALLOGENEIC
STEM CELL TRANSPLANTATION
Speaker: Patrizia Chiusolo, IT

Oral Session
09:15 - 18:00 On-Demand Library
OS08 - Oral session 8: Graft versus Host Disease I
This session is available in our on-demand library throughout the whole congress
OS8-1 GVHD PROPHYLAXIS WITH POST TRANSPLANTATION 09:15 - 09:15
CYCLOPHOSPHAMIDE (PTCY) VERSUS CYCLOSPORINE A /
METHOTREXATE POST ALLOGENEIC TRANSPLANTATION
(HSCT) FROM MATCHED SIBLINGS FOR AML: FROM THE
ALWP/EBMT
Speaker: Arnon Nagler, IL

OS8-2 BELUMOSUDIL FOR CHRONIC GRAFT-VERSUS-HOST DISEASE 09:15 - 09:15

(CGVHD) AFTER 2 OR MORE PRIOR LINES OF THERAPY: THE

95 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

ROCKSTAR STUDY (KD025-213)

Speaker: Corey Cutler, US

OS8-3 A PERSONALIZED ORGAN-BASED APPROACH TO THE 09:15 - 09:15

TREATMENT OF CHRONIC GRAFT-VERSUS-HOST DISEASE
Speaker: Hanaa A. Fatoum, SA

OS8-4 RUXOLITINIB (RUX) VS BEST AVAILABLE THERAPY (BAT) IN 09:15 - 09:15

PATIENTS WITH STEROID-REFRACTORY ACUTE GRAFT-VS-
HOST DISEASE (SR-AGVHD): 6-MONTH FOLLOW-UP FROM
THE RANDOMIZED, PHASE 3 REACH2 STUDY
Speaker: Mohamad Mohty, FR

OS8-5 IMPACT OF CHRONIC GVHD SEVERITY AND STEROID 09:15 - 09:15

RESPONSE ON THE QUALITY OF LIFE IN PATIENTS
FOLLOWING ALLOGENEIC STEM CELL TRANSPLANTATION:
FINDINGS FROM A REAL-WORLD STUDY
Speaker: Sylvie Lachance, CA

OS8-6 SUCCESSFUL AND SAFE TREATMENT OF INTESTINAL GVHD 09:15 - 09:15

WITH POOLED-DONOR FULL ECOSYSTEM MICROBIOTA
BIOTHERAPEUTIC: RESULTS FROM A 29 PATIENT-COHORT
OF A COMPASSIONATE USE/EXPANDED ACCESS TREATMENT
PROGRAM
Speaker: Florent Malard, FR

OS8-7 REDUCED ACUTE GRAFT-VERSUS HOST DISEASE INCIDENCE 09:15 - 09:15

IN PATIENTS RECEIVING ANTI-T LYMPHOCYTE GLOBULIN IN
COMPARISON TO ANTI-THYMOCYTE GLOBULIN FOR THE
PROPHYLAXIS OF GRAFT-VERSUS-HOST DISEASE AFTER
ALLO-HSCT
Speaker: Marie T Rubio, FR

OS8-8 PATIENT-REPORTED OUTCOMES IN ACUTE GRAFT-VS-HOST 09:15 - 09:15

DISEASE: QUALITY-OF-LIFE FINDINGS FROM A REAL-WORLD
STUDY
Speaker: Nada Hamad, AU

Special Session
09:15 - 18:00 On-Demand Library
SS11 - The EBMT for Trainees
This session is available in our on-demand library throughout the whole congress
SS11-1 Being a Trainee in SCT / Cellular Therapy -
Speaker: Nico Gagelmann, DE
Speaker: Claire Horgan, GB
Speaker: Yasmina Serroukh, BE
Speaker: Yuliya Rogacheva, RU
Speaker: Tamar Azikuri, GE

SS11-2 Overview of allogeneic SCT for the trainee: ‘Things I wish I’d -
known'
Speaker: Helene Schoemans, BE

SS11-3 Establishing a career in SCT/cellular therapy -

96 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

Speaker: Jordan Gauthier, US

SS11-4 Complications for trainees 1: How to manage acute GVHD -

Speaker: Zinaida Peric, HR

SS11-5 Complications for trainees 2: How to manage VOD -

Speaker: Ivan Moiseev, RU

Oral Session
09:15 - 18:00 On-Demand Library
OS21 - Oral session 21: Multiple Myeloma
This session is available in our on-demand library throughout the whole congress
OS21-1 MICROENVIRONMENT IMMUNE RECONSTITUTION PATTERNS 09:15 - 09:15
CORRELATE WITH OUTCOMES AFTER AUTOLOGOUS
TRANSPLANT IN MULTIPLE MYELOMA
Speaker: Harsh Parmar, US

OS21-2 AUTOLOGOUS HEMATOPOIETIC CELL TRANSPLANTATION 09:15 - 09:15

FOR RELAPSED MULTIPLE MYELOMA PERFORMED WITH
STEM CELLS RE-MOBILISED FOLLOWING A PRIOR AUTO-HCT
– A RETROSPECTIVE STUDY ON BEHALF OF EBMT CMWP
Speaker: Joanna Drozd-Soko?owska, PL

OS21-3 ISATUXIMAB PLUS CARFILZOMIB AND DEXAMETHASONE 09:15 - 09:15

VERSUS CARFILZOMIB AND DEXAMETHASONE IN RELAPSED
MULTIPLE MYELOMA PATIENTS WHO PREVIOUSLY
UNDERWENT TRANSPLANTATION: IKEMA SUBGROUP
ANALYSIS
Speaker: Mohamad Mohty, FR

OS21-4 AUTOLOGOUS-ALLOGENEIC VS AUTOLOGOUS TANDEM 09:15 - 09:15

STEM CELL TRANSPLANTATION AND MAINTENANCE WITH
THALIDOMIDE FOR PATIENTS WITH MULTIPLE MYELOMA
(MM) AND AGE <60 YEARS: A PROSPECTIVE PHASE II-
STUDY
Speaker: Nicolaus Kröger, DE

OS21-5 ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION 09:15 - 09:15

FOLLOWED BY BORTEZOMIB IN MULTIPLE MYELOMA: FINAL
RESULTS OF A PROSPECTIVE TRIAL HIGHLIGHTING A
STRONG PROGNOSTIC ROLE OF MEASURABLE RESIDUAL
DISEASE
Speaker: Jean Roy, CA

OS21-6 ACCEPTABLE TOXICITY AND GOOD HEMATOLOGICAL AND 09:15 - 09:15

RENAL RESPONSES AFTER AUTOLOGOUS HEMATOPOIETIC
STEM CELL TRANSPLANTATION IN MYELOMA PATIENTS WITH
RENAL INSUFFICIENCY: A PROSPECTIVE SFGM-TC STUDY
Speaker: laurent Garderet, FR

OS21-7 COAST (OP-501): FIRST IN MAN PHASE I MULTICENTER STUDY 09:15 - 09:15
EVALUATING OPD5 AS A MYELOABLATIVE CONDITIONING
REGIMEN IN RELAPSED REFRACTORY MULTIPLE MYELOMA
(RRMM)

97 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

Speaker: Sergio Giralt, US

OS21-8 CHARACTERISTICS AND TREATMENT PATTERNS OF TRIPLE- 09:15 - 09:15

CLASS-EXPOSED PATIENTS WITH RELAPSED/REFRACTORY
MULTIPLE MYELOMA WHO PARTICIPATED IN CLINICAL
TRIALS OF DARATUMUMAB
Speaker: Katja Weisel, DE

Oral Session
09:15 - 18:00 On-Demand Library
OS05 - Oral session 5: Cellular Therapy, Gene Therapy and New Drugs II
This session is available in our on-demand library throughout the whole congress
OS5-1 HEMATOPOIETIC STEM CELL GENE THERAPY FOR 09:15 - 09:25
MUCOPOLYSACCHARIDOSIS TYPE I, HURLER (MPS-IH):
BIOLOGICAL EFFICACY AND PRELIMINARY EVIDENCE OF
EARLY CLINICAL RESPONSE
Speaker: Maria Ester Bernardo, IT

OS5-2 OVERALL SURVIVAL BY BEST OVERALL RESPONSE WITH 09:25 - 09:35

TABELECLEUCEL IN PATIENTS WITH EPSTEIN-BARR VIRUS-
DRIVEN POST-TRANSPLANT LYMPHOPROLIFERATIVE
DISEASE AFTER ALLOGENEIC HEMATOPOIETIC CELL
TRANSPLANT
Speaker: Susan Prockop, US

OS5-3 RESOLUTION OF SERIOUS VASO-OCCLUSIVE PAIN CRISES: 09:35 - 09:45

RESULTS FROM THE ONGOING PHASE 1/2 HGB-206 GROUP C
STUDY OF LENTIGLOBIN FOR SICKLE CELL DISEASE (SCD)
GENE THERAPY
Speaker: Markus Mapara, US

OS5-4 DURABLE CLINICAL OUTCOMES FOLLOWING 09:45 - 09:55

BETIBEGLOGENE AUTOTEMCEL (BETI-CEL) GENE THERAPY
WITH UP TO 6 YEARS OF FOLLOW-UP IN PATIENTS WITH
TRANSFUSION-DEPENDENT ?-THALASSEMIA (TDT)
Speaker: Franco Locatelli, IT

OS5-5 OPEN LABEL DOSE ESCALATION TRIAL OF AB-205 (E-CEL® 09:55 - 10:05
CELLS) IN ADULTS WITH SYSTEMIC LYMPHOMA
UNDERGOING HIGH-DOSE THERAPY AND AUTOLOGOUS
HEMATOPOIETIC CELL TRANSPLANTATION (HDT-AHCT)
Speaker: Carolyn Mulroney, US

OS5-6 IMMUNOTHERAPY IN ACUTE LEUKEMIA: A GITMO (GRUPPO 10:05 - 10:15

ITALIANO TRAPIANTO MIDOLLO OSSEO) SURVEY ON
EFFICACY AND TOXICITY OF DONOR LYMPHOCYTE
INFUSIONS AFTER ALLOGENEIC STEM CELL
TRANSPLANTATION
Speaker: Francesca Patriarca, IT

OS5-7 MONITORING PATIENT SARS-COV-2-T-CELL IMMUNE 10:15 - 10:25

RESPONSES AND GENERATING SARS-COV-2-SPECIFIC T
CELLS FROM CONVALESCENT DONORS; IMPLICATIONS FOR
THE IDENTIFICATION OF HIGH-RISK PATIENTS AND

98 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

TREATMENT WITH T-CELL IMMUNOTHERAPY

Speaker: Anastasia Papadopoulou, GR

OS5-8 NORMALISED LYSOSOMAL ACID LIPASE ACTIVITY CAN BE 10:25 - 10:35

ACHIEVED IN WOLMAN FIBROBLASTS VIA BOTH DIRECT
TRANSDUCTION AND CROSS-CORRECTION MECHANISMS
USING A LENTIVIRAL-MEDIATED GENE THERAPY APPROACH
Speaker: Jane E Potter, GB

Paed4-2 EARLY SAFETY AND EFFICACY RESULTS WITH A SINGLE 10:35 - 10:45
DOSE OF AUTOLOGOUS CRISPR-CAS9-MODIFIED CD34+
HEMATOPOIETIC STEM AND PROGENITOR CELLS IN
TRANSFUSION-DEPENDENT ?-THALASSEMIA AND SICKLE
CELL DISEASE
Speaker: Selim Corbacioglu, DE

Educational
09:15 - 18:00 On-Demand Library
E09 - Allogeneic HSCT in MDS and MPN
This session is available in our on-demand library throughout the whole congress
E9-1 Definition of graft failure/relapse after allo-HCT in myelofibrosis -
Speaker: Donal McLornan, GB

E9-2 Allogeneic HSCT in patients with therapy-related MDS/AML -

Speaker: Marie Robin, FR

E9-3 The role of maintenance therapy after allogeneic HSCT in MDS -

Speaker: Francesco Onida, IT

Nurses Group
09:15 - 18:00 On-Demand Library
NG17 - Care of the nurses
This session is available in our on-demand library throughout the whole congress
NG17-1 Mindfulness -
Speaker: Ana M. Muñoz Cobo, ES

NG17-2 Resilience and self-care -

Speaker: Christian Williams, GB

NG17-3 Tips and tricks for self care -

Speaker: Jane Keep, GB

Nurses Group
09:15 - 18:00 On-Demand Library
NG21 - Clinical trials in a transplant setting
This session is available in our on-demand library throughout the whole congress
NG21-1 Antimicrobal Lock Therapy for Prevention and Treatment of -
Catheter Related Infections in Hematogical Patients
Speaker: Isabel Salcedo, ES

99 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

NG21-2 Convalescent plasma clinical trials for COVID-19 -

Speaker: Rocío Layunta, ES

NG21-3 Post transplant relapse -

Speaker: Stephanie Heyes, GB

Nurses Group
09:15 - 18:00 On-Demand Library
NG13 - Nurses Education Day 1: Care of the vulnerable immunocompromised patients in critical care setting
This session is available in our on-demand library throughout the whole congress
NG13-1 SARS-CoV-2 vaccines overview -
Speaker: Almudena Ramírez, ES

NG13-2 Seasonal human coronaviruses vs SARS-CoV-2 in allogeneic -

hematopoietic stem cell transplantation
Speaker: Jose Luis Piñana, ES

NG13-3 COVID-19: The EBMT recommendations for management of -

HCT patients and donors
Speaker: Per Ljungman, SE

Nurses Group
09:15 - 18:00 On-Demand Library
NG15 - Nurses Education Day 3: Care of the vulnerable immunocompromised patients in critical care setting
This session is available in our on-demand library throughout the whole congress
NG15-1 Managing virtual conversations -
Speaker: Lloyd Allen, GB

NG15-2 Nurse perspective: Virtual long term follow up for BMT patients -
Speaker: Michelle Kenyon, GB

NG15-3 Back to the future: Emphasizing our new practices -

Speaker: Ibrahim Yakoub-Agha, FR

Nurses Group
09:15 - 18:00 On-Demand Library
NG23 - Oral session 2: Abstracts session
This session is available in our on-demand library throughout the whole congress
NG23-1 EFFICACY AND SAFETY OF A COLOSTRUM BASED ORAL 09:15 - 09:15
CARE PROTOCOL FOR THE PREVENTION AND TREATMENT
OF ORAL MUCOSITIS IN STEM CELL TRANSPLANT
RECIPIENTS
Speaker: Monica Guberti, IT

NG23-2 PATIENT-TO-NURSE STAFFING RATIO IN HEMATOPOIETIC 09:15 - 09:15

STEM CELL TRANSPLANT AND ADVANCED CELL THERAPY
UNITS IN SPAIN, HIGHLY NEEDED BUT CHALLENGING
Speaker: Julia Ruiz Pato, ES

NG23-3 ROOT CAUSE ANALYSIS TO IDENTIFY AND PREVENT FALL 09:15 - 09:15

100 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

CAUSES IN ALLOGENEIC HEMATOPOIETIC STEM CELL

TRANSPLANTATION PATIENTS
Speaker: Franziska Michaela Lohmeyer, IT

NG23-4 MAPPING THE NURSES' COMPETENCIES IN PAEDIATRIC 09:15 - 09:15

ONCO-HAEMATOLOGY AND HAEMATOPOIETIC STEM CELL
TRANSPLANTATION SETTING AND THEIR MAINTENANCE
OVER TIME
Speaker: Alberto Castagna, IT

NG23-5 EFFECTIVENESS OF AN EDUCATIONAL INTERVENTION FOR 09:15 - 09:15

INFLUENZA VACCINATION IN HEMATOPOIETIC STEM CELL
TRANSPLANT PATIENTS AND THEIR COHABITANTS
Speaker: Maria Teresa Solano Moliner, ES

Quality Management
09:15 - 18:00 On-Demand Library
QM5 - Quality Management Oral Abstracts
This session is available in our on-demand library throughout the whole congress
QM5-1 COMPLIANCE AND COST EFFICACY FOR CELLULAR 09:15 - 09:15
THERAPIES, CAN THESE TWO GO HAND IN HAND?
Speaker: Janik Adriaansen, US

QM5-2 HOW TO MAINTAIN A CONTINUOUS TRAINING PROGRAM FOR 09:15 - 09:15

NURSES IN TIMES OF PANDEMIC
Speaker: Sheila Saco, ES

QM5-3 THE RTN TRANSPLANT POLICY AND ACTIVITY DURING 09:15 - 09:15
COVID-19 PANDEMIC
Speaker: Antonio Bruno, IT

QM5-4 THE DISASTER PLAN ADJUSTMENT TO THE COVID-19 09:15 - 09:15

PANDEMIC AT AORN CARDARELLI TRANSPLANT PROGRAM
IN NAPLES, ITALY
Speaker: Lucia Ammirati, IT

Educational
09:15 - 18:00 On-Demand Library
E10 - HSCT in paediatric non-malignant indications
This session is available in our on-demand library throughout the whole congress
E10-1 Haplo-identical SCT in hemoglobinopathy: Taking pole -
position?
Speaker: Josu de la Fuente, GB

E10-2 Mismatched family donors in inherited immune disorders: A -

new perspective
Speaker: Mary A. Slatter, GB

E10-3 HSCT for inherited bone marrow failure syndromes -

Speaker: Cristina Díaz de Heredia, ES

E10-4 Cord blood HSCT for non-malignant diseases in children -

101 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

Speaker: Vanderson Rocha, BR

Oral Session
09:15 - 18:00 On-Demand Library
OS10 - Oral session 10: COVID-19
This session is available in our on-demand library throughout the whole congress
OS10-1 A PHASE I DOSE-ESCALATION SINGLE CENTER STUDY TO 09:15 - 09:25
EVALUATE THE SAFETY OF ALLOGENIC MEMORY T CELLS
CONTAINING SARS-COV-2 SPECIFIC LYMPHOCYTES AS
ADOPTIVE THERAPY IN COVID19
Speaker: Antonio Pérez-Martínez, ES

OS10-2 THE IMPACT OF COVID-19 ON UNRELATED AND DONOR CORD 09:25 - 09:35
PROVISION TO UK TRANSPLANT CENTRES DURING THE 1ST
WAVE OF THE PANDEMIC: UK ALIGNED REGISTRY STUDY
Speaker: Angharad Pryce, GB

OS10-3 IMPACT OF SARS-COV-2 ON DELIVERY OF CAR T CELL 09:35 - 09:45

THERAPY IN EUROPE: A SURVEY FROM THE CELLULAR
THERAPY AND IMMUNOBIOLOGY WORKING PARTY OF THE
EBMT
Speaker: Sara Ghorashian, GB

OS10-4 OUTCOME OF COVID 19 IN ALLOGENEIC STEM CELLS 09:45 - 09:55

TRANSPLANT PATIENTS: THE SINGLE CENTER EXPERIENCE
FROM A SEVERELY AFFECTED AREA (BERGAMO)
Speaker: Maria Caterina Mico', IT

OS10-5 ALLOGENEIC STEM CELL TRANSPLANTATION IN ACUTE 09:55 - 10:05

LEUKEMIA PATIENTS AFTER COVID-19 INFECTION
Speaker: Maximilian Christopeit, DE

OS10-6 INFLUENCE OF THE SARS-COV-2 PANDEMIC ON BONE 10:05 - 10:15

MARROW TRANSPLANTATION CENTERS AND THE
PROTOCOLS ADOPTED IN BRAZIL BETWEEN MAY AND JUNE
2020
Speaker: Fernando Barroso Duarte, BR

OS10-7 CRYOPRESERVATION OF ALLOGENEIC HEMATOPOIETIC 10:15 - 10:25

PROGENITOR CELLS IN THE CURRENT SARS-Cov-2
PANDEMIC: EXPERIENCE OF A SINGLE CENTRE
Speaker: Dolores Moreno, ES

OS10-8 IMPACT OF COVID-19 PANDEMIC ON RELEASE OF FRENCH 10:25 - 10:35

CORD BLOOD UNITS. ON BEHALF THE AGENCY OF
BIOMEDICINE, EUROCORD AND THE SFGM-TC
Speaker: Hanadi Rafii - El Ayoubi, FR

Oral Session
09:15 - 18:00 On-Demand Library
OS11 - Oral session 11: Infectious Diseases I
This session is available in our on-demand library throughout the whole congress

102 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

OS11-1 POLYMORPHISMS WITHIN THE TNFSF4 AND MAPKAPK2 LOCI 09:15 - 09:25
INFLUENCE THE RISK OF INVASIVE ASPERGILLOSIS: A TWO-
STAGE CASE CONTROL STUDY IN THE CONTEXT OF THE
ASPBIOMICS CONSORTIUM
Speaker: Ana Moniz-Díez, ES

OS11-2 THE ASSOCIATION BETWEEN CYTOMEGALOVIRUS AND 09:25 - 09:35

INVASIVE FUNGAL INFECTIONS IN ALLOGENEIC
HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS: A
SYSTEMATIC REVIEW AND META-ANALYSIS
Speaker: Nipat Chuleerarux, TH

OS11-3 IMMUNE RECONSTITUTION DURING CMV PROPHILAXIS BY 09:35 - 09:45

LETERMOVIR: A SINGLE CENTER EXPERIENCE
Speaker: Ilaria Cutini, IT

OS11-4 LETERMOVIR PROPHYLAXIS FOR CYTOMEGALOVIRUS 09:45 - 09:55

REACTIVATION IN ALLOGENEIC STEM CELL
TRANSPLANTATION: A MULTICENTER ITALIAN REAL-WORLD
EXPERIENCE
Speaker: Massimo Martino, IT

OS11-5 PREVENTION OF INVASIVE FUNGAL INFECTION IN HAPLO 09:55 - 10:05

TRANSPLANTATION WITH POST-TRANSPLANTATION
CYCLOPHOSPHAMIDE. UNIVERSAL FLUCONAZOLE
PROPHYLAXIS AND A MOULD DIAGNOSTIC-DIRECTED
APPROACH. RESULTS IN 112 PATIENTS
Speaker: Amado Karduss -Urueta, CO

OS11-6 PATTERN OF FUNGAL INFECTIONS DURING THE INITIAL 100 10:05 - 10:15
DAYS IN CHILDREN UNDERGOING HEMATOPOIETIC STEM
CELL TRANSPLANTATION FROM A TERTIARY REFERRAL
CENTER IN INDIA
Speaker: Harika Varla, IN

OS11-7 THE MANAGEMENT OF CLOSTRIDIOIDES DIFFICILE 10:15 - 10:25

INFECTIONS IN PATIENTS AFTER ALLOGENEIC
HEMATOPOIETIC CELL TRANSPLANTATION: THE RESULTS OF
THE INFECTIOUS DISEASES WORKING PARTY EBMT SURVEY
Speaker: Agnieszka Piekarska, PL

OS11-8 CLINICAL DIAGNOSTIC AND THERAPEUTIC STRATIFICATION 10:25 - 10:35

OF INVASIVE FUNGAL DISEASE IN ADULT PATIENTS WITH
HEMATOLOGY MALIGNANCIES: A REAL-WORLD
OBSERVATIONAL STUDY
Speaker: Sizhou Feng, CN

Oral Session
09:15 - 18:00 On-Demand Library
OS12 - Oral session 12: Infectious Diseases II
This session is available in our on-demand library throughout the whole congress
OS12-1 NOCARDIOSIS FOLLOWING HEMATOPOIETIC CELL 09:15 - 09:15
TRANSPLANTATION: 20 YEARS' EXPERIENCE. THE

103 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

INTERNATIONAL STUDY OF INFECTIOUS DISEASES WORKING

PARTY OF EBMT AND FRANCO-BELGIAN NOCARDIA STUDY
GROUP
Speaker: Dina Averbuch, IL

OS12-2 COLONIZATION-GUIDED PROTOCOL FOR EMPIRICAL 09:15 - 09:15

ANTIBIOTIC THERAPY IN ALLO-HSCT RECIPIENTS: FIRST
RESULTS OF A SINGLE CENTER PROSPECTIVE STUDY
Speaker: Marina Popova, RU

OS12-3 COLONIZATION BY MULTIDRUG-RESISTANT GRAM-NEGATIVE 09:15 - 09:15

BACTERIA IN EARLY PHASE OF HEMATOPOIETIC STEM CELL
TRANSPLANTATION
Speaker: Yuliya Rogacheva, RU

OS12-4 FAVOURABLE OUTCOME AND NO INCREASED RISK OF GVHD 09:15 - 09:15

IN PATIENTS DEVELOPING C.DIFFICILE INFECTION AFTER
HEMATOPOIETIC STEM CELL TRANSPLANTS
Speaker: Chiara Rosignoli, IT

OS12-5 CLINICAL IMPACT OF DE-ESCALATION/DISCONTINUATION OF 09:15 - 09:15

ANTIBIOTICS PRIOR TO NEUTROPHIL RECOVERY IN
PATIENTS UNDERGOING HEMATOPOIETIC STEM CELL
TRANSPLANTATION: A SINGLE-CENTRE EXPERIENCE
Speaker: Anke Verlinden, BE

OS12-6 COLONIZATION WITH MULTIDRUG-RESISTANT BACTERIA AND 09:15 - 09:15

DISEASE RISK INDEX ARE TWO INDEPENDENT FACTORS
THAT AFFECT THE SURVIVAL OF PATIENTS AFTER
ALLOGENEIC HAEMATOPOIETIC STEM CELL
TRANSPLANTATION
Speaker: Anna Czyz, PL

OS12-7 IMPACT OF FLUOROQUINOLONE PROPHYLAXIS IN 09:15 - 09:15

ALLOGENEIC HEMATOPOIETIC STEM CELL
TRANSPLANTATION; SINGLE CENTER EXPERIENCE
Speaker: Eshrak Al-Shaibani, CA

OS12-8 STRONG INFLAMMATORY CYTOKINE RESPONSE AFTER 09:15 - 09:15

HAPLOIDENTICAL HEMATOPOIETIC STEM CELL
TRANSPLANTATION WITH POST-TRANSPLANT
CYCLOPHOSPHAMIDE RELATES TO HUMAN HERPESVIRUS 6
REACTIVATION
Speaker: Kenichiro Takeda, JP

Oral Session
09:15 - 18:00 On-Demand Library
OS20 - Oral session 20: Aplastic Anemia, Autoimmune Disorders, and others
This session is available in our on-demand library throughout the whole congress
OS20-1 HLA EVOLUTIONARY DIVERGENCE INFLUENCES 09:15 - 09:25
CHARACTERISTICS AND OUTCOMES OF PATIENTS WITH
APLASTIC ANEMIA AND PAROXYSMAL NOCTURNAL
HEMOGLOBINURIA

104 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

Speaker: Simona Pagliuca, US

OS20-2 OUTCOME OF NON-MYELOABLATIVE AUTOLOGOUS 09:25 - 09:35

HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR
MULTIPLE SCLEROSIS: A SINGLE CENTER SUMMARY OF 511
PATIENTS
Speaker: Richard K Burt, US

OS20-3 EARLY MORBIDITY OF AUTOLOGOUS HAEMATOPOIETIC 09:35 - 09:45

STEM CELL TRANSPLANTATION IN MULTIPLE SCLEROSIS- A
REAL WORLD EXPERIENCE
Speaker: Varun Mehra, GB

OS20-4 THE GENOMIC LANDSCAPE OF MYELOID NEOPLASMS 09:45 - 09:55

ARISING FROM APLASTIC ANEMIA AND PAROXYSMAL
NOCTURNAL HEMOGLOBINURIA
Speaker: Carmelo Gurnari, US

OS20-5 HIGH-DOSE IMMUNOSUPPRESSIVE THERAPY WITH 09:55 - 10:05

AUTOLOGOUS HEMATOPOIETIC STEM CELL
TRANSPLANTATION (AHSCT) IN MULTIPLE SCLEROSIS:
CHANGING APPROACHES IN SINGLE-CENTER EXPERIENCES
Speaker: Alexey Polushin, RU

OS20-6 HLA MUTATIONS IN PAROXYSMAL NOCTURNAL 10:05 - 10:15

HEMOGLOBINURIA: A POSSIBLE ALTERNATIVE MECHANISM
OF IMMUNE ESCAPE
Speaker: Carmelo Gurnari, US

OS20-7 HEMATOPOIETIC STEM CELL TRANSPLANT AS TREATMENT 10:15 - 10:25

OF REFRACTORY MYASTHENIA GRAVIS
Speaker: Claudia Lucía Sossa Melo, CO

OS20-8 IMPACT OF AHSCT ON FERTILITY IN MULTIPLE SCLEROSIS 10:25 - 10:35

PATIENTS
Speaker: Alice Mariottini, IT

Industry Symposium
09:15 - 18:00 On-Demand Library
IS38 - CMV management in high-risk patients - Biotest Industry Symposium
This session is available in our on-demand library throughout the whole congress
Chair: Fabio Ciceri, IT
IS38-1 A scoring system to define patients at high risk for CMV -
Speaker: Ibrahim Yakoub-Agha, FR

IS38-2 How to manage CMV high-risk patients -

Speaker: Michele Malagola, IT

IS38-3 The immunological benefits of CMV-specific immunoglobulins -

Speaker: Javier Carbone, ES

105 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

Lab Technicians Day

09:15 - 18:00 On-Demand Library
LT2 - Lab Technicians Day: Cell product testing, validation and characterization
This session is available in our on-demand library throughout the whole congress
LT2-1 Quality control assessment of ATMP phenotype and -
functionality using flow cytometry
Speaker: Willemijn Hobo, NL

LT2-2 Flow cytometry-based CD34 enumeration -

Speaker: Harry Dolstra, NL

LT2-3 Flow cytometric in-process and quality control for CAR T cell -
manufacturing
Speaker: Ulrike Köhl, DE

Data Management
09:15 - 18:00 On-Demand Library
DM07 - Education session 7
This session is available in our on-demand library throughout the whole congress
DM7-1 Minimal residual disease (MRD) -
Speaker: Johannes Schetelig, DE

Workshop
09:15 - 18:00 On-Demand Library
W13 - CARs beyond T cells: A focus on next generation CAR-NK cells
This session is available in our on-demand library throughout the whole congress
W13-1 CAR NK cells as an "off the shelf" immunotherapy -
Speaker: Ulrike Köhl, DE

W13-2 CARs and ADCC to make off-the-shelf NK cells specific against -

hematologic malignancies
Speaker: Jeffrey Miller, US

W13-3 Target NKG2D ligands on tumor cells -

Speaker: Antonio Pérez-Martínez, ES

Workshop
09:15 - 18:00 On-Demand Library
W14 - In the absence of a matched-sibling, who's the best alternative allogeneic donor?
This session is available in our on-demand library throughout the whole congress
W14-1 A matched unrelated donor -
Speaker: Bronwen Shaw, US

W14-2 A haploidentical donor -

Speaker: Mi Kwon, ES

W14-3 When to choose cord blood -

Speaker: Filippo Milano, US

W14-4 Do we have to challenge our current donor hierarchy for -

106 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

patients with hemoglobinopathies?

Speaker: Selim Corbacioglu, DE

Working Party Session

09:15 - 18:00 On-Demand Library
CTIWP - Cellular Therapy and Immunobiology Working Party Session
This session is available in our on-demand library throughout the whole congress
CTIWP-1 CTIWP Activity Report -
Speaker: Christian Chabannon, FR

CTIWP-2 Virus specific T cells post BMT- Broadening to SARS-CoV2 -

Speaker: Catherine Bollard, US

CTIWP-3 Are mesenchymal stromal cells the right arrow in the quiver to -
fight COVID-19?
Speaker: Rachele Ciccocioppo, IT

Working Party Session

09:15 - 18:00 On-Demand Library
SAAWP - Severe Aplastic Anaemia Working Party Session
This session is available in our on-demand library throughout the whole congress
SAAWP-1 Introduction -
Speaker: Régis Peffault de Latour, FR

SAAWP-2 Registry Report -

Speaker: Antonio Risitano, IT

SAAWP-3 RACE – clinical update -

Speaker: Antonio Risitano, IT

SAAWP-4 RACE – what we learn on the biology of SAA? -

Speaker: Austin Kulakaseraraj, GB

SAAWP-5 Androgens in AA: Myth or reality in 2021? -

Speaker: Simona Pagliuca, US

SAAWP-6 GVHD and relapse free survival (GRFS) after HSCT for AA -
Speaker: Raynier Devillier, FR

Special Session
09:15 - 18:00 On-Demand Library
SS09 - How to get published
This session is available in our on-demand library throughout the whole congress
SS9-1 BMT: Official journal of the EBMT -
Speaker: Hillard Lazarus, US

SS9-2 How to get published -

Speaker: Mohamad Mohty, FR

107 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

Oral Session
09:15 - 18:00 On-Demand Library
OS03 - Oral session 3: CARs II
This session is available in our on-demand library throughout the whole congress
OS3-1 CD19 CAR T THERAPY IN CHILDREN WITH R/R ALL: ADAPTIVE 09:15 - 09:15
SPLIT DOSING IMPROVES SAFETY AND MAINTAINS EFFICACY
OF THE APPROACH
Speaker: Olga Molostova, RU

OS3-2 CYTOKINE RELEASE SYNDROME IN PATIENTS WITH 09:15 - 09:15

RELAPSED/REFRACTORY MULTIPLE MYELOMA TREATED
WITH CILTACABTAGENE AUTOLEUCEL IN THE PHASE 1B/2
CARTITUDE-1 STUDY
Speaker: Andrzej Jakubowiak, US

OS3-3 PHARMACOLOGY AND EFFICACY OF KTE-X19 BY PRIOR 09:15 - 09:15

BRUTON TYROSINE KINASE INHIBITOR EXPOSURE OR
MANTLE CELL LYMPHOMA (MCL) MORPHOLOGY IN PATIENTS
WITH RELAPSED/REFRACTORY MCL IN ZUMA-2
Speaker: Michael L. Wang, US

OS3-4 REAL WORLD OF EXPERIENCE AXICABTAGENE CILOLEUCEL 09:15 - 09:15

FOR THE TREATMENT OF RELAPSED OR REFRACTORY
LARGE B-CELL LYMPHOMA IN SPAIN
Speaker: Mi Kwon, ES

OS3-5 HUMORAL RESPONSE TO PNEUMOCOCCAL ANTIGENS 09:15 - 09:15

DECLINES AFTER CD19-TARGETED CAR T CELL THERAPY
Speaker: Dasom Lee, US

OS3-6 DECREASED NEUROPROTECTIVE ANALYTES ON DAY OF 09:15 - 09:15

INFUSION OF CHIMERIC ANTIGEN RECEPTOR (CAR) T CELLS
ARE ASSOCIATED WITH NEUROTOXICITY
Speaker: Madhavi Lakkaraja, US

OS3-7 COMPARISON OF TWO KINDS OF ANTI-THYMOCYTE 09:15 - 09:15

GLOBULIN ON OUTCOMES OF HAPLOIDENTICAL STEM CELL
TRANSPLANTATION FOR REFRACTORY/RELAPSED AND HIGH-
RISK B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA AFTER CAR-
T THERAPY
Speaker: Zhao-Yanli Zhao, CN

OS3-8 THIRD-GENERATION GD2.CAR T-CELLS INCORPORATING 09:15 - 09:15

CD28.4-1BB COSTIMULATORY DOMAINS FOR TREATMENT OF
GD2+ SARCOMAS
Speaker: Antonio Camera, IT

Poster Sessions
09:15 - 18:00 ePoster Area
Stem Cell Source
P216 THE BLOOD DONATION BEFORE BONE MARROW HARVEST 09:15 - 09:15
HAS NO IMPACT ON EFFICIENCY OF COLLECTION
Speaker: Iwona Mitrus, PL

108 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

P217 UNMANIPULATED HAPLOIDENTICAL TRANSPLANTATION FOR 09:15 - 09:15

HIGH RISK ACUTE LEUKEMIA USING MOBILIZED PERIPHERAL
BLOOD STEM CELLS (PBSC) AS SOURCE OF GRAFT: A
SINGLE CENTER EXPERIENCE
Speaker: Vincenzo Federico, IT

Poster Sessions
09:15 - 18:00 ePoster Area
Cellular Therapies other than CARs
P027 PROLONGED REPEATEDLY ADMINISTERED LOW DOSE 09:15 - 09:15
DONOR LYMPHOCYTE INFUSION FOR PREVENTION OF
RELAPSE AFTER ALLOGENEIC STEM CELL
TRANSPLANTATION FOR PATIENTS WITH HIGH RISK ACUTE
LEUKEMIA
Speaker: Panagiotis Tsirigotis, GR

P028 CD8?-ENHANCED NY-ESO-1-SPECIFIC TCR T CELLS 09:15 - 09:15

(GSK3901961) IN HLA-A*02 PATIENTS WITH NSCLC: MASTER
PROTOCOL SUBSTUDY 1
Speaker: Mehmet Altan, US

P029 CLINIMACS PLUS® SELECTION AS A RELIABLE AND SAFE 09:15 - 09:15

ALTERNATIVE PROCEDURE FOR CLINIMACS PRODIGY®
TCR?? AND CD19 DEPLETION
Speaker: Katalin Dobos, HU

P031 COMPREHENSIVE ACTIVATION PROFILING OF 09:15 - 09:15

TABELECLEUCEL, AN OFF-THE-SHELF, ALLOGENEIC EBV-
SPECIFIC T-CELL IMMUNOTHERAPY
Speaker: Fiona Ruiz, US

P030 IMPACT OF CRYOPRESERVED PHOTOPHERESIS IN GRAFT 09:15 - 09:15

VERSUS HOST DISEASE FOR NON-MALIGNANT DISORDERS
AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL
TRANSPLANTATION IN PEDIATRIC PATIENTS

P035 BMT CTN 1803: HAPLOIDENTICAL NATURAL KILLER CELLS (K- 09:15 - 09:15
NK002) TO PREVENT POST-TRANSPLANT RELAPSE IN AML
AND MDS (NK-REALM)
Speaker: Sumithira Vasu, US

P034 NEW, LN2-FREE SOLUTION FOR CRYOGENIC TRANSPORT OF 09:15 - 09:15

CELL THERAPIES
Speaker: Julie Meneghel, GB

P032 DONOR LYMPHOCYTE INFUSION AFTER ALLOGENEIC STEM 09:15 - 09:15

CELL TRANSPLANTATION: A RETROSPECTIVE ANALYSIS
Speaker: Virginia Escamilla Gómez, ES

P033 DONOR LYMPHOCYTE INFUSION (DLI). A STRATEGY TO 09:15 - 09:15

PREVENT OR TREAT RELAPSE FOLLOWING ALLOGENIC
STEM CELL TRANPLANTATION. ONE SINGLE CENTER
EXPERIENCE
Speaker: Melissa Karina Torres Ochando, ES

109 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

Poster Sessions
09:15 - 18:00 ePoster Area
Conditioning Regimens
P036 OUTCOMES OF ALLOGENEIC HEMATOPOIETIC CELL 09:15 - 09:15
TRANSPLANTATION IN ELDERLY PATIENTS: IS AGE THE
LIMIT?
Speaker: Sara Fernández-Luis, ES

P037 THE IMPACT OF MELPHALAN DE-ESCALATION ON EFFICACY 09:15 - 09:15

AND SAFETY IN PATIENTS WITH MULTIPLE MYELOMA
UNDERGOING AUTOLOGOUS STEM CELL
TRANSPLANTATION: A SINGLE-CENTER EXPERIENCE
Speaker: Bartosz Malecki, PL

P038 CONDITIONING WITH HIGH DOSE TOTAL BODY IRRADIATION 09:15 - 09:15
AND POST TRANSPLANTATION CYCLOPHOSPHAMIDE IN
EARLY RELAPSED MULTIPLE MYELOMA PATIENTS
RECEIVING ALLOGENEIC STEM CELL TRANSPLANTATION
Speaker: Jaap van Doesum, NL

P039 PREVENTING AKI IN TRANSPLANT FOR PAEDIATRIC ALL 09:15 - 09:15

WITH TBI AND ETOPOSIDE CONDITIONING
Speaker: Jane E Potter, GB

P040 ENHANCED IMMUNOSUPPRESSION IN T-CELL REPLETE 09:15 - 09:15

HAPLOIDENTICAL TRANSPLANTATION WITH POST-
TRANSPLANT CYCLOPHOSPHAMIDE IS ASSOCIATED WITH
FAVORABLE OUTCOMES

P041 LONG-TERM SAFETY AND EFFICACY OF A MYELOABLATIVE 09:15 - 09:15

CONDITIONING REGIMEN OF REDUCED TOXICITY IN
ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION
Speaker: Ioanna Sakellari, GR

P042 TREOSULFAN VS. BUSULFAN-BASED REGIMENS IN 09:15 - 09:15

PEDIATRIC PATIENTS: A 7-YEAR RETROSPECTIVE STUDY
Speaker: Raquel Olivas-Mazón, ES

P044 POST-TRANSPLANT CYCLOPHOSPHAMIDE (PTCY) AS GVHD 09:15 - 09:15

PROPHYLAXIS FOR HEMATOPOIETIC STEM CELL
TRANSPLANTATION FROM MATCHED-RELATED SIBLING
DONORS
Speaker: Gabriella Storti, IT

P043 IMMUNE RECONSTITUTION AFTER SEQUENTIAL 09:15 - 09:15

CONDITIONING IN ELDERLY, HIGH-RISK AML AND MDS
PATIENTS: A MATCHED-PAIR ANALYSIS AMONG DIFFERENT
DONOR TYPES
Speaker: Alessia Fraccaroli, DE

Poster Sessions
09:15 - 18:00 ePoster Area
Data Management
P045 GENDER DISPARITY IN AUTOLOGOUS HSCT; FACT OR MYTH? 09:15 - 09:15

110 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

A BSBMTCT REGISTRY STUDY LOOKING INTO POSSIBLE

MALE PREDOMINANCE IN HSCT PARTICULARLY IN MULTIPLE
MYELOMA
Speaker: Ruth Paul, GB

Poster Sessions
09:15 - 18:00 ePoster Area
Experimental Transplantation
P048 INFLUENCE OF POLYMORPHISMS RELATED TO DRUG 09:15 - 09:15
METABOLISM IN ALLOGENEIC BONE MARROW
TRANSPLANTATION
Speaker: Marta Santiago, ES

P049 REDUCED-INTENSITY UNMANIPULATED HAPLOIDENTICAL 09:15 - 09:15

STEM CELL TRANSPLANTATION FOR RELAPSED HIGH-RISK
NEUROBLASTOMA AFTER AUTOLOGOUS STEM CELL
TRANSPLANTATION
Speaker: Tahereh Rostami, IR

Poster Sessions
09:15 - 18:00 ePoster Area
Gene Therapy
P050 BETIBEGLOGENE AUTOTEMCEL (BETI-CEL; LENTIGLOBIN 09:15 - 09:15
FOR ?-THALASSEMIA) GENE THERAPY TREATMENT OF A
GREEK PATIENT WITH TRANSFUSION-DEPENDENT ?-
THALASSEMIA (TDT)
Speaker: Evangelia Yannaki, GR

Poster Sessions
09:15 - 18:00 ePoster Area
Graft-versus-Host Disease – Clinical
P051 EFFECT OF EXTRACORPOREAL PHOTOPHERESIS ON 09:15 - 09:15
ENRICHMENT, SURVIVAL AND CYTOKINE PRODUCTION
CAPACITY OF MONOCYTES FROM CHRONIC GRAFT VERSUS
HOST DISEASE PATIENTS
Speaker: Arun Alfred, GB

P056 REDUCED GVHD WITH TRIPLE PTCY BASED GVHD 09:15 - 09:15
PROPHYLAXIS, AS COMPARED TO TRIPLE ATG BASED
PROPHYLAXIS, IN HLA MATCHED TRANSPLANTS
Speaker: Elisabetta Metafuni, IT

P055 PROLONGED SUPPRESSION OF BUTYRATE PRODUCING 09:15 - 09:15

BACTERIA INDICATES DYSBIOSIS AND IS ASSOCIATED WITH
ACUTE GASTROINTESTINAL GRAFT-VERSUS-HOST DISEASE
AND TRANSPLANT RELATED MORTALITY AFTER
ALLOGENEIC STEM CELL TRANSPLANTATION
Speaker: Elisabeth Meedt, DE

P052 ACUTE AND CHRONIC GRAFT-VERSUS-HOST-DISEASE IMPAIR 09:15 - 09:15

B-CELL RECONSTITUTION IN ALLOGENEIC-TRANSPLANTED

111 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

PATIENTS AT DIFFERENT MATURATION STAGES

Speaker: Matthias Alexander Fante, DE

P057 THE SAME FOR LESS: 2.5MG/KG VS. 4.5MG/KG RABBIT ANTI- 09:15 - 09:15
THYMOCYTE GLOBULIN IN PATIENTS UNDERGOING
MATCHED UNRELATED DONOR ALLOGENEIC STEM CELL
TRANSPLANTATION FOR HEMATOLOGICAL MALIGNANCIES
Speaker: Osman Radhwi, CA

P060 A PHASE 2/3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, 09:15 - 09:15

PLACEBO-CONTROLLED STUDY OF ALPHA-1 ANTITRYPSIN
FOR THE PREVENTION OF ACUTE GRAFT VERSUS HOST
DISEASE FOLLOWING HEMATOPOIETIC CELL TRANSPLANT

P061 CHRONIC AND LATE ACUTE GVHD IN CHILDREN USING THE 09:15 - 09:15
NIH 2014 CONSENSUS CRITERIA
Speaker: Koray Yalcin, TR

P058 COMPARISON OF POST-TRANSPLANTATION 09:15 - 09:15

CYCLOPHOSPHAMIDE VERSUS ANTI-T-LYMPHOCYTE
GLOBULIN AS GVHD PROPHYLAXIS IN ADULT PATIENTS WITH
ACUTE LYMPHOBLASTIC LEUKEMIA UNDERGOING
ALLOGENEIC HEMATOPOIETIC STEM CELL
TRANSPLANTATION IN CR1
Speaker: Maximilian Christopeit, DE

P059 TRIPLE PTCY BASED GVHD PROPHYLAXIS: HLA MATCHED 09:15 - 09:15
VERSUS HLA HAPLOIDENTICAL TRANSPLANTS
Speaker: Eugenio Galli, IT

P063 A PHASE 1/2, OPEN-LABEL, SINGLE-ARM, STUDY OF 09:15 - 09:15

RUXOLITINIB ADDED TO CORTICOSTEROIDS IN PEDIATRIC
PATIENTS WITH ACUTE GRAFT-VS-HOST DISEASE AFTER
ALLOGENEIC STEM CELL TRANSPLANTATION (REACH4)
Speaker: Franco Locatelli, IT

P062 AREA UNDER THE CURVE BASED MYCOPHENOLATE MOFETIL 09:15 - 09:15
DOSAGE REDUCED THE INCIDENCE OF GVHD AFTER
ALLOGENIC HSCT IN PEDIATRIC PATIENTS: ONE FACILITY'S
EIGHT-YEAR EXPERIENCE
Speaker: Antonio Grasso, IT

P064 IBRUTINIB FOR STEROID REFRACTORY CHRONIC GRAFT 09:15 - 09:15

VERSUS HOST DISEASE: DATA AND CLINICAL EXPERIENCE
FROM A SINGLE CENTER
Speaker: Panayotis Kaloyannidis, SA

P065 ROUTINE USE OF THE AMICUS BLUE™ ONLINE ECP SYSTEM IN 09:15 - 09:15
PATIENTS WITH CHRONIC AND ACUTE GRAFT VERSUS HOST
DISEASE
Speaker: Angelo Ostuni, IT

P066 RUXOLITINIB OFF-LABEL USE IN STEROID-REFRACTORY 09:15 - 09:15

CHRONIC GRAFT VERSUS HOST DISEASE: A SINGLE CENTRE
EXPERIENCE IN 36 PATIENTS

112 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

Speaker: Maria Teresa Lupo Stanghellini, IT

P067 PHARMACOKINETIC MODELING TO GUIDE DOSE SELECTION 09:15 - 09:15

OF ALPHA-1 ANTITRYPSIN IN A STUDY OF GRAFT VERSUS
HOST DISEASE PREVENTION IN PATIENTS RECEIVING
ALLOGENIC HEMATOPOIETIC CELL TRANSPLANT
Speaker: Henry Hu, US

P068 BASILIXIMAB FOR THE TREATMENT OF PATIENTS WITH 09:15 - 09:15

STEROID REFRACTORY ACUTE GRAFT VERSUS HOST
DISEASE: LITERATURE REVIEW AND POOLED ANALYSIS
Speaker: Xiaodong Mo, CN

P069 FIRST LINE SINGLE-AGENT RUXOLITINIB FOR GRADE II-III 09:15 - 09:15
ACUTE GRAFT-VERSUS-HOST DISEASE IN PATIENTS WITH
SEVERE INFECTIOUS COMPLICATIONS: CASE SERIES
Speaker: Ivan Moiseev, RU

P070 A PHASE 2 OPEN-LABEL, SINGLE-ARM, MULTICENTER STUDY 09:15 - 09:15

OF RUXOLITINIB ADDED TO CORTICOSTEROIDS IN PEDIATRIC
SUBJECTS WITH MODERATE/SEVERE CHRONIC GVHD AFTER
ALLOGENEIC STEM CELL TRANSPLANTATION (REACH5)
Speaker: Franco Locatelli, IT

P071 PRE-TRANSPLANTATION PLASMA VITAMIN D LEVELS AND 09:15 - 09:15

ACUTE GRAFT-VERSUS-HOST DISEASE AFTER
MYELOABLATIVE ALLOGENEIC HEMATOPOIETIC CELL
TRANSPLANTATION
Speaker: Lars Klingen Gjærde, DK

P072 SEVERE REFRACTORY SKIN GVHD IN CHILDREN: SERIES OF 09:15 - 09:15

CLINICAL CASES

P073 Elevated REG3? predicts refractory aGVHD in Patients Who 09:15 - 09:15
Received Steroids- Ruxolitinib as the First Line Therapy
Speaker: Liping Dou, CN

Poster Sessions
09:15 - 18:00 ePoster Area
Graft-versus-Host Disease – Preclinical and Animal Models
P074 THE MAGNITUDE OF INTESTINAL T CELL INFILTRATION 09:15 - 09:15
DETERMINES EPITHELIAL REGENERATION DURING IMMUNE-
MEDIATED TISSUE INJURY
Speaker: Sascha Göttert, DE

P075 ITACITINIB ATTENUATES XENOGENEIC GVHD IN HUMANIZED 09:15 - 09:15

MICE

Poster Sessions
09:15 - 18:00 ePoster Area
Haematopoietic Stem Cells
P078 RESULTS OF SECOND ALLOGENEIC HEMATOPOIETIC STEM 09:15 - 09:15
CELL TRANSPLANTATION IN PATIENTS WITH

113 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

HEMATOLOGICAL DISEASES: RETROSPECTIVE ANALYSIS OF

OUR HOSPITAL
Speaker: Elena Paumard Rodríguez, ES

P076 LETERMOVIR PROPHYLAXIS REDUCES THE RISK FOR CMV 09:15 - 09:15
INFECTION AFTER STEM CELL TRANSPLANTATION
Speaker: Katrin Koch, DE

P077 KIR B HAPLOTYPES IN UNRELATED HEMATOPOIETIC STEM 09:15 - 09:15

CELL TRANSPLANTATION, REVISITED
Speaker: Kazimierz Halaburda, PL

P079 THE IMPACT OF AGE ON HEMATOLOGIC RECOVERY AFTER 09:15 - 09:15

ALLOGENEIC TRANSPLANTATION
Speaker: Sabrina Giammarco, IT

P081 OUTCOME OF SECOND ALLOGENIC STEM CELL 09:15 - 09:15

TRANSPLANTATION IN CHILDREN WITH PRIMARY IMMUNE
DEFICIENCIES
Speaker: Zohreh Nademi, GB

P080 HEMATOPOIETIC STEM CELL TRANSPLANTATION IN 09:15 - 09:15

PEDIATRIC ACUTE MYELOID LEUKEMIA WITH ABERRANT CD7
ANTIGEN EXPRESSION
Speaker: Danilo De Novellis, IT

P082 OUTCOME OF ALLOGENIC STEM CELL TRANSPLANTATION IN 09:15 - 09:15

ELDERLY PATIENTS: A SINGLE CENTER STUDY
Speaker: Eshrak Al-Shaibani, CA

P084 ALLOGENEIC HEMATOPOIETIC STEM CELL 09:15 - 09:15

TRANSPLANTATION IN PATIENTS OLDER THAN 65 YEARS
WITH AML AND MDS: RISK FACTORS FOR OVERALL
SURVIVAL AND DISEASE FREE SURVIVAL
Speaker: Simona Piemontese, IT

P083 ALLOGENEIC HEMATOPOIETIC STEM CELL 09:15 - 09:15

TRANSPLANTATION FOR PATIENTS 60 YEARS OR OLDER. A
SINGLE-INSTITUTION EXPERIENCE
Speaker: Marta Hidalgo Soto, ES

P086 EFFICACY OF MODIFIED FC/ATG PRETREATMENT IN HAPLOID 09:15 - 09:15

AND ALLOGENEIC HEMATOPOIETIC STEM CELL
TRANSPLANTATION FOR SEVERE APLASTIC ANEMIA
Speaker: Ma Liangming, CN

P085 IMPACT OF HUMAN LEUKOCYTE ANTIGEN ALLELE 09:15 - 09:15

POLYMORPHISMS ON THE OUTCOMES OF
TRANSPLANTATION FROM HLA-MATCHED UNRELATED
DONORS
Speaker: Anastasia Beynarovich, RU

P087 AUTOMATED DRY THAWING OF CRYOPRESERVED 09:15 - 09:15

HAEMATOPOIETIC CELLS IS NOT ADVERSELY INFLUENCED
BY CRYOSTORAGE TIME, PATIENT AGE OR GENDER

114 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

Speaker: Julie Meneghel, GB

P091 UNMANIPULATED HAPLOIDENTICAL STEM CELL 09:15 - 09:15

TRANSPLANTATION FOR PEDIATRIC PATIENTS WITH ACUTE
LEUKEMIA: AN EXPERIENCE FROM THE LARGEST
CHILDREN'S HOSPITAL IN IRAN
Speaker: Amir Ali Hamidieh, IR

P090 INDICATIONS AND SURVIVAL OF ALLOGENEIC TRANSPLANT 09:15 - 09:15

IN PATIENTS OVER 65 YEARS OLD
Speaker: Magdalena Corona de Lapuerta, ES

P089 LONG-TERM RESULTS OF HEMATOPOIETIC STEM CELL 09:15 - 09:15

TRANSPLANTATION FOR HODGKIN’S AND NON-HODGKIN’S
LYMPHOMA: EXPERIENCE OF A SINGLE CENTER IN
COLOMBIAN NORTHEAST
Speaker: Claudia Lucía Sossa Melo, CO

P093 HAPLOIDENTICAL STEM CELL TRANSPLANTATION IN AML 09:15 - 09:15

WITH T(6;9)(P23; Q34); DEK-NUP214 SHOWS A FAVOURABLE
OUTCOME: SINGLE CENTER EXPERIENCE

P092 ABSENCE OF INFLUENCE OF THE PRE- TRANSPLANT IMMUNE 09:15 - 09:15

STATUS OF RECIPIENTS ON SURVIVALS AND GVHD AFTER
ALLOGENEIC STEM CELL TRANSPLANTATION: A
RETROSPECTIVE STUDY OF 195 CASES
Speaker: Thierry Guillaume, FR

P097 DEFIBROTIDE AS TREATMENT FOR TRANSPLANT- 09:15 - 09:15

ASSOCIATED MICROANGIOPATHY (TA-TAM) IN PEDIATRIC
PATIENTS: A SINGLE CENTER EXPERIENCE
Speaker: Danilo De Novellis, IT

P096 IMPACT OF COVID 19 PANDEMIC ON HSCT ACTIVITIES: 09:15 - 09:15

REPORT FROM A SINGLE CENTER
Speaker: Sabrina Giammarco, IT

P095 IS HAPLOIDENTICAL HAEMATOPOIETIC STEM CELL 09:15 - 09:15

TRANSPLANTATION (HAPLO SCT) USING POST-
TRANSPLANTATION CYCLOPHOSPHAMIDE (PTCY) FEASIBLE
IN SUB-SAHARAN AFRICA?
Speaker: Justin du Toit, ZA

P099 IMPACT OF CYTOGENETIC AND MOLECULAR RISK AT 09:15 - 09:15

DIAGNOSIS ON TRANSPLANTATION RESULTS IN PATIENTS
WITH SECONDARY ACUTE MYELOID LEUKEMIA
Speaker: Claudia Núñez-Torrón, ES

P098 THE IMPACT OF CRYOPRESERVATION ON HAEMATOPOIETIC 09:15 - 09:15

STEM CELL GRAFTS DURING THE COVID-19 PANDEMIC AT
THE ROYAL MARSDEN HOSPITAL
Speaker: Sandra Easdale, GB

P102 EBV COLITIS POST HEMATOPOIETIC STEM CELL 09:15 - 09:15

TRANSPLANTATION IN PATIENT WITH APLASTIC ANEMIA

115 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

Speaker: Lucia Prezioso, IT

P100 BURNOUT SYNDROME IN ONCOLOGY PRACTICE: 09:15 - 09:15

EXPERIENCE OF A LARGE HSCT CENTER
Speaker: Irina Artemeva, RU

P103 MORBIDITY AND MORTALITY OF T- CELL LYMPHOMAS 09:15 - 09:15

UNDERGOING AUTOLOGOUS STEM CELL TRANSPLANTATION
(ASCT)
Speaker: Carolina Lilibeth Moreira-Ponce, MX

P101 FACTORS AFFECTING OUTCOMES IN CHILDREN WITH ACUTE 09:15 - 09:15

LEUKEMIA POST HEMATOPOIETIC STEM CELL
TRANSPLANTATION – A RETROSPECTIVE STUDY FROM A
TERTIARY REFERRAL CENTRE IN INDIA
Speaker: Rumesh Chandar, IN

P104 BRENTUXIMAB VEDOTIN STRATEGIES FOR RELAPSED OR 09:15 - 09:15

REFRACTORY HODGKIN'S LYMPHOMA AND HEMATOPOIETIC
STEM CELL TRANSPLANTATION
Speaker: Katheryn Garzón-Velásquez, MX

P106 EHEALTH AS A TOOL IN HEMATOPOIETIC STEM CELL 09:15 - 09:15

TRANSPLANTATION: A NARRATIVE REVIEW
Speaker: Claudia Lucía Sossa Melo, CO

P105 STAFF EXPERIENCES AND LEARNING FROM WORKING ON A 09:15 - 09:15

HAEMATOLOGICAL STEM CELL TRANSPLANT WARD DURING
COVID-19
Speaker: Sarah Airdrie, GB

Poster Sessions
09:15 - 18:00 ePoster Area
Haemoglobinopathy
P107 THE VALUE OF ROUTINE PRE-TRANSPLANT RADIOLOGICAL 09:15 - 09:15
SCREENING IN PEDIATRIC SICKLE CELL DISEASE PATIENTS:
A SINGLE CENTER EXPERIENCE
Speaker: Mohammed Essa, SA

P108 HOW TO FACILITATE DECISION-MAKING FOR 09:15 - 09:15

HEMATOPOIETIC STEM CELL TRANSPLANTATION IN
PATIENTS WITH HEMOGLOBINOPATHIES - THE
PERSPECTIVES OF HEALTH CARE PROFESSIONALS
Speaker: Hilda Mekelenkamp, NL

P109 ENDOCRINE SEQUELAE IN PEDIATRIC HEMATOPOIETIC STEM 09:15 - 09:15

CELL TRANSPLANT RECIPIENTS WITH SICKLE CELL DISEASE:
A RETROSPECTIVE COHORT ANALYSIS
Speaker: Richelle Waldner, CA

P110 DECISION-MAKING FOR HEMATOPOIETIC STEM CELL 09:15 - 09:15

TRANSPLANTATION IN PEDIATRIC, ADOLESCENT AND
YOUNG ADULT PATIENTS WITH A HEMOGLOBINOPATHY –
SHARED OR NOT?

116 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

Speaker: Hilda Mekelenkamp, NL

Poster Sessions
09:15 - 18:00 ePoster Area
Immunodeficiency Diseases and Macrophages
P111 CLINICAL MANIFESTATION AND MECHANISMS OF GRAFT 09:15 - 09:15
FAILURE IN PRIMARY IMMUNODEFICIENCY PATIENTS AFTER
HEMATOPOIETIC STEM CELL TRANSPLANTATION
Speaker: Aishat Idarmacheva, RU

P112 OUTCOMES OF HAEMATOPOIETIC STEM CELL 09:15 - 09:15

TRANSPLANTATION IN CHILDREN WITH ZETA CHAIN
ASSOCIATED PROTEIN KINASE 70KDA DEFICIENCY
Speaker: Liam Reilly, GB

P113 ALLOGENEIC HEMATOPOIETIC STEM CELL 09:15 - 09:15

TRANSPLANTATION IN A PATIENT WITH CLERICUZIO
SYNDROME (POIKILODERMA WITH NEUTROPENIA)
Speaker: Alexandra Burya, RU

Poster Sessions
09:15 - 18:00 ePoster Area
Paediatric Issues
P183 POST-TRANSPLANT CYCLOPHOSPHAMIDE AFTER 09:15 - 09:15
ALLOGENEIC HEMATOPOETIC STEM CELL
TRANSPLANTATION FOR PEDIATRIC HODGKIN LYMPHOMA
Speaker: Andrey Kozlov, RU

P185 RISK FACTORS AND SURVIVAL OF GRAFT FAILURE IN 09:15 - 09:15

PEDIATRIC PATIENTS WITH HEMATOLOGICAL MALIGNANCIES
TREATED WITH ALLOGENEIC HEMATOPOIETIC STEM-CELL
TRANSPLANTATION FROM HAPLOIDENTICAL DONORS USING
EXVIVO T-CELL-DEPLETION
Speaker: Iván López Torija, ES

P184 FREQUENCY AND CAUSES OF DEATH AFTER 09:15 - 09:15

HEMATOPOIETIC STEM CELL TRANSPLANTATION IN
CHILDREN WITH NON-MALIGNANT DISEASES
Speaker: Koray Yalcin, TR

P186 SVEGF-R1 LEVELS ARE ASSOCIATED WITH ENDOTHELIAL 09:15 - 09:15

DYSFUNCTION AFTER PEDIATRIC HEMATOPOIETIC STEM
CELL TRANSPLANTATION
Speaker: Denise Elbæk, DK

P187 LATE ENDOCRINE EFFECTS AFTER HSCT IN CHILDREN WITH 09:15 - 09:15
NONMALIGNANT DISEASES: A SINGLE CENTER COHORT
ANALYSIS
Speaker: Joëll Esmée Bense, NL

P188 PROSPECTIVE MULTICENTER STUDY OF A REDUCED- 09:15 - 09:15

TOXICITY MYELOABLATIVE CONDITIONNING REGIMEN USING
FLUDARABINE AND FULL DOSES OF IV BUSULFAN IN

117 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

PEDIATRIC PATIENTS NOT ELIGIBLE FOR MYELOABLATIVE

REGIMENS
Speaker: Fanny Rialland, FR

P189 TCR ALFA/BETA DEPLETION FOR HSCT FROM UNRELATED 09:15 - 09:15
DONOR IN PEDIATRIC PATIENTS
Speaker: Luisa Sisinni, ES

P190 SARS-COV-2 SEROLOGICAL STATUS OF PEDIATRIC HSCT 09:15 - 09:15

RECIPIENTS: A SINGLE CENTER EXPERIENCE
Speaker: Charlotte Nazon, FR

P191 SAFETY AND PERFORMANCE OF CENTRAL VENOUS 09:15 - 09:15

CATHETERS IN PEDIATRIC LEUKAPHERESIS: A SINGLE
CENTRE EXPERIENCE
Speaker: Sofia Martin-Consuegra, ES

P192 TREOSULFAN – BASED CONDITION REGIMEN FOR STEM CELL 09:15 - 09:15
TRANSPLANTATION IN PATIENTS WITH DIAMOND –
BLACKFAN ANEMIA
Speaker: Svetlana Radygina, RU

P193 ALLO-HSCT IN TREATMENT OF TP53 MUTATION-RELATED 09:15 - 09:15

MDS/AML IN PEDIATRIC PATIENTS – REPORT OF TWO CASES
Speaker: Maksymilian Deregowski, PL

P194 CENTRAL LINE REMOVAL IN ALLOGENIC PEDIATRIC 09:15 - 09:15

HEMATOPOIETIC STEM CELL TRANSPLANT PATIENTS
Speaker: Taylor Fitch, US

Poster Sessions
09:15 - 18:00 ePoster Area
Non-infectious Late Effects, Quality of Life and Fertility
P177 IMPACT OF AGE IN EARLY AND LATE COMPLICATIONS AFTER 09:15 - 09:15
AN ALLOGENEIC TRANSPLANT IN ELDERLY PATIENTS
Speaker: Magdalena Corona de Lapuerta, ES

P178 OSTEONECROSIS IN PATIENTS UNDERGOING 09:15 - 09:15

HEMATOPOIETIC STEM CELLS TRANSPLANT: A SINGLE-
CENTRE STUDY OF INCIDENCE, RISK FACTORS,
CHARACTERISTICS AND EVOLUTION
Speaker: Giulia Prunotto, IT

P179 SECONDARY MALIGNANCIES AFTER AUTOLOGOUS 09:15 - 09:15

HEMATOPOIETIC STEM CELL TRANSPLANTATION
Speaker: João Gaião Santos, PT

P181 ANXIETY SYMPTOMATOLOGY PROGRESSION IN PATIENTS 09:15 - 09:15

WITH DIAGNOSIS OF MALIGNANT HEMATOLOGICAL
PATHOLOGY WHO ARE CANDIDATES TO RECEIVE INTENSIVE
CHEMOTHERAPY
Speaker: Walter Javier Zambrano Marquez, ES

P180 SECONDARY MALIGNANCIES AFTER ALLOGENEIC HSCT IN 09:15 - 09:15

118 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

CHILDREN
Speaker: Yulia Skvortsova, RU

P182 AN UNUSUAL PRESENTATION OF AUTOIMMUNE DISORDERS 09:15 - 09:15

AFTER ALLOGENEIC STEM CELL TRANSPLANTATION –
AMYOPATHIC DERMATOMYSISTIS, PRIMARY BILIARY
CHOLANGITIS AND AUTOIMMUNE HAEMOLYTIC ANAEMIA
Speaker: Pedro de Vasconcelos M, PT

Poster Sessions
09:15 - 18:00 ePoster Area
New Drugs- and Cell-based Immune Therapies
P160 INJECTION-SITE REACTIONS IN THE RANDOMIZED PHASE 3 09:15 - 09:15
PEGASUS TRIAL OF PEGCETACOPLAN COMPARED WITH
ECULIZUMAB FOR INDIVIDUALS WITH PAROXYSMAL
NOCTURNAL HEMOGLOBINURIA
Speaker: Vivek Sharma, US

P161 CLINICAL BURDEN OF ILLNESS SURVEY RESULTS FOR U.S. 09:15 - 09:15
PATIENTS WITH PAROXYSMAL NOCTURNAL
HEMOGLOBINURIA RECEIVING C5 INHIBITORS
Speaker: David Dingli, US

P162 IN ACUTE HSCT/BMT-TMA THE ACTIVATION OF THE LECTIN 09:15 - 09:15

PATHWAY INDUCES C5B-9 FORMATION ON ENDOTHELIAL
CELLS AND FAVORS MICROVASCULAR THROMBOSIS
Speaker: Miriam Galbusera, IT

P165 MEMORY-LIKE NK CELLS AS TREATMENT FOR PEDIATRIC 09:15 - 09:15

SARCOMA
Speaker: Carla Martín-Cortázar, ES

P163 POST-HEMATOPOIETIC STEM CELL TRANSPLANT 09:15 - 09:15

MAINTENANCE TKI'S IN PHILADELPHIA POSITIVE ALL: KING
HUSSEIN CANCER CENTRE EXPERIENCE

P166 PHASE 3 MULTICENTER, DOUBLE-BLIND, PLACEBO- 09:15 - 09:15

CONTROLLED TRIAL OF VIRALYM-M (ALVR105) FOR THE
TREATMENT OF VIRUS?ASSOCIATED HAEMORRHAGIC
CYSTITIS AFTER ALLOGENEIC HAEMATOPOIETIC CELL
TRANSPLANT (HCT) (STUDY DESIGN)
Speaker: Anna Thorner, US

P168 CLINICAL PHARMACOLOGY AND POPULATION 09:15 - 09:15

PHARMACOKINETIC/PHARMACODYNAMIC MODELING OF
LECTIN PATHWAY INHIBITION BY NARSOPLIMAB (OMS721)
Speaker: William Pullman, US

P167 WORK PRODUCTIVITY LOSS AND QUALITY OF LIFE IN 09:15 - 09:15

PAROXYSMAL NOCTURNAL HEMOGLOBINURIA AMONG
PATIENTS RECEIVING C5 INHIBITORS IN THE UNITED STATES
Speaker: David Dingli, US

119 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

Poster Sessions
09:15 - 18:00 ePoster Area
Myeloproliferative Neoplasm

Poster Sessions
09:15 - 18:00 ePoster Area
Myelodysplastic Syndromes
P156 THE ROLE OF AGE IN OUTCOMES OF BONE MARROW 09:15 - 09:15
TRANSPLANTATION IN PATIENTS FROM THE LATIN
AMERICAN REGISTRY
Speaker: Fernando Barroso Duarte, BR

P157 PRE-TRANSPLANT FERRITIN PREDICTS NON-RELAPSE 09:15 - 09:15

MORTALITY IN PATIENTS WITH MYELODYSPLASTIC
SYNDROMES UNDERGOING HEMATOPOIETIC STEM CELL
TRANSPLANTATION
Speaker: Isla Johnson, US

P159 SURVIVAL ANALYSIS IN ALLOGENIC HEMATOPOIETIC STEM 09:15 - 09:15

CELL TRANSPLANTATION IN MYELODYSPLASTIC SYNDROME
AND CHRONIC MYELOMONOCYTIC LEUKEMIA. IMPORTANCE
OF THE PREVIOUS SITUATION

P158 SECONDARY AND TREATMENT-RELATED ACUTE MYELOID 09:15 - 09:15

LEUKEMIA: ALLOGENEIC HEMATOPOIETIC CELL
TRANSPLANTATION REMAINS THE BEST AVAILABLE OPTION
Speaker: Ioanna Sakellari, GR

Poster Sessions
09:15 - 18:00 ePoster Area
Minimal Residual Disease, Tolerance, Chimerism and Immune Reconstitution
P143 EMPIRIC GRANULOCYTE-COLONY STIMULATING FACTOR (G- 09:15 - 09:15
CSF) ADVERSELY IMPACTS SURVIVAL AFTER ALLOGENEIC
STEM CELL TRANSPLANTATION (HCT) PERFORMED WITH
THYMOGLOBULIN: A CIBMTR ANALYSIS
Speaker: Nina Orfali, IE

P144 PREDICTIVE MEANING OF MRD CONVERSION ON DAYS +30 09:15 - 09:15

AND +100 IN PATIENTS WITH AML AFTER ALLO-SCT
Speaker: Nicolaus Kröger, DE

P145 IMPACT OF DIFFERENT T CELL DEPLETION PROTOCOLS ON 09:15 - 09:15

IMMUNE RECONSTITUTION FOLLOWING ALLOGENEIC
HEMATOPOIETIC STEM CELL TRANSPLANTATION
Speaker: Amandine Pradier, CH

P146 MRD VS CHIMERISM: ARE THEIR EFFECTIVENESS 09:15 - 09:15

COMPARABLE TO PREDICT AML RELAPSE?
Speaker: Valérie Dubois, FR

P148 CELLULAR CHIMERISM – DO REPEATED MARROW BIOPSIES 09:15 - 09:15

OPEN A WINDOW FOR RELAPSE INTERVENTION?
Speaker: Jan Morf, GB

120 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

Poster Sessions
09:15 - 18:00 ePoster Area
Nurses Posters – Adult
NP01 NURSES’ TRAINING NEEDS FOR ADVANCED THERAPY 09:15 - 09:15
MEDICINAL PRODUCTS EG CAR T: KEY FINDINGS FROM
QUESTIONNAIRE-BASED SURVEY ON BEHALF OF THE
NURSES GROUP OF THE EBMT
Speaker: Michelle Kenyon, GB

NP02 IMPROVEMENT OF ORAL MUCOSITIS IN HEMATOPOIETIC 09:15 - 09:15

STEM CELL TRANSPLANTATION USING POVIDONE-IODINE
MOUTHWASH UNDER DIRECT NURSING SUPERVISION
Speaker: Napassaya Khanthum, TH

NP03 COMPREHENSIVE GERIATRIC ASSESSMENT TO PREDICT 09:15 - 09:15

OUTCOMES IN OLDER PATIENTS RECEIVED CAR-T CELL
THERAPY
Speaker: Mercedes Montoro-Lorite, ES

NP04 CAR-T - RECOGNITION AND TREATMENT MANAGEMENT OF 09:15 - 09:15

NEUROLOGIC TOXICITIES AND CYTOKINE RELEASE
SYNDROME
Speaker: Naama Nevo, IL

NP05 HOME PLATELET TRANSFUSION IN AUTOLOGOUS STEM- 09:15 - 09:15

CELL TRANSPLANTATION: IMPROVING HOME-CARE
STRATEGIES DURING SARS-COV-2 PANDEMIC
Speaker: Laura Villa Rodríguez, ES

NP06 IMPROVING LONG-TERM QUALITY OF LIFE FOR PATIENTS 09:15 - 09:15

LIVING WITH MULTIPLE MYELOMA: A SERVICE EVALUATION
Speaker: Sarah Henshaw, GB

NP07 AT-HOME HEMATOPOIETIC STEM CELL TRANSPLANTATION 09:15 - 09:15

DURING SARS-CoV-2 PANDEMIC

NP08 THE NURSING SEARCH COORDINATOR (NSC) OF THE ROME 09:15 - 09:15
TRANSPLANT NETWORK (RTN), A JACIE ACCREDITED
METROPOLITAN TRANSPLANT PROGRAM
Speaker: Antonio Bruno, IT

NP10 PREVENTION OF NOSOCOMIAL SARS-COV2 INFECTIONS 09:15 - 09:15

AMONG HEMATOLOGICAL PATIENTS JUST BY FOLLOWING
WELL ESTABLISHED NURSING CARE STANDARDS
Speaker: Isabel Salcedo, ES

NP11 A TALE OF 2 COLLECTIONS: CAR -T ‘V' PBSC. OUR SINGLE 09:15 - 09:15
CENTRE EXPERIENCE
Speaker: Caroline Jupp, GB

NP12 CREATION OF THE FIRST COURSE ON HEMATOPOIETIC STEM 09:15 - 09:15

CELL TRANSPLANTATION (HSCT) NURSING IN LATIN
AMERICAN. ARGENTINE SOCIETY OF HEMATOLOGY
Speaker: Mariela Blanco, AR

121 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

NP13 MANAGEMENT OF PATIENTS SUFFERING FROM AN HEMATO- 09:15 - 09:15

ONCOLOGY MALIGNANCY AND THOSE UNDERGOING
HEMATOPOIETIC CELL TRANSPLANTATION DURING THE
COVID-19. HOW DO WE PROTECT THEM?
Speaker: Anna Serrahima - Mackay, ES

NP14 PREVENTION OF ORAL MUCOSITIS WITH CRYOTHERAPY IN 09:15 - 09:15

ADULT PATIENTS UNDERGOING HEMATOPOIETIC STEM CELL
TRANSPLANTATION
Speaker: Bakhtawar Altaf Hussain, PK

NP15 COVID-19 CHALLENGES – TO THE POINT OF CELL DELIVERY - 09:15 - 09:15

THE REALITY
Speaker: Lindsey Ashton, GB

NP16 TRANSITION FROM PAEDIATRIC TO THE ADULT CLINIC IN 09:15 - 09:15

SICKLE CELL DISEASE: THE ROLE OF THE SPECIALISED
NURSE
Speaker: Marijke Quaghebeur, BE

NP09 EBMT (GEC) & LABMT COLLABORATION PROJECTT. LABMT 09:15 - 09:25
NURSES GROUP 2020 CONTINUING EDUCATION PROGRAM
Speaker: Mariela Blanco, AR

Poster Sessions
09:15 - 18:00 ePoster Area
Stem Cell Mobilization, Collection and Engineering
P206 INTERIM ANALYSIS OF THE OPTIMOB STUDY: A NON- 09:15 - 09:15
INTERVENTIONAL STUDY ACROSS GERMANY TO EVALUATE
THE MOBILIZATION AND COLLECTION OF HSCS IN POOR
MOBILIZERS AHEAD OF ASCT
Speaker: Katharina Kriegsmann, DE

P207 TRENDS IN AUTOLOGOUS STEM CELL MOBILISATION 09:15 - 09:15

PRACTICES IN MYELOMA PATIENTS IN EBMT CENTRES
BETWEEN 2008 AND 2017
Speaker: James Dillon, IE

P208 THE IMPACT OF THE “NEW NORMAL” ON STEM CELL 09:15 - 09:15
LABORATORY PRACTICES
Speaker: Sanja Mazi?, HR

P210 AN ALGORITHMIC APPROACH TO PRE-EMPTIVE PLERIXAFOR 09:15 - 09:15

USAGE WITH GCSF ALONE FOR MOBILIZATION OF
PERIPHERAL BLOOD STEM CELLS IN MULTIPLE MYELOMA
Speaker: Mohamed Elemary, CA

P209 PLERIXAFOR MOBILIZATION OF HEMATOPOIETIC STEM 09:15 - 09:15

CELLS IN DIALYSIS DEPENDENT PATIENTS IS SAFE AND
FEASIBLE; A SINGLE CENTER ANALYSIS
Speaker: Moussab Damlaj, SA

P211 PROGRAM OF HEMATOPOIETIC STEM CELL MOBILIZATION 09:15 - 09:15

AND COLLECTION FOR CHILDREN OF FIRST YEAR OF LIFE

122 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

AND WITH LOW BODY WEIGHT: SINGLE CENTER EXPERIENCE

Speaker: Nara Stepanyan, RU

P212 A RETROSPECTIVE RECORD REVIEW OF MOBILIZATION 09:15 - 09:15

STRATEGIES WITH AND WITHOUT PLERIXAFOR FOR
AUTOLOGOUS STEM CELL TRANSPLANT IN PATIENTS WITH
MULTIPLE MYELOMA
Speaker: Joshua Richter, US

P213 PREDICTION OF THE MOBILIZATION SUCCESS FOR 09:15 - 09:15

AUTOLOGOUS PERIPHERAL BLOOD STEM CELL COLLECTION
IN PATIENTS WITH MALIGNANT HEMATOLOGIC DISEASES
Speaker: Maria Eduarda Couto, PT

P214 DOES USE OF BIOSIMILAR ZARZIO CHANGE PLERIXAFOR 09:15 - 09:15

UTILIZATION DURING STEM CELL MOBILIZATION FOR
AUTOLOGOUS STEM CELL TRANSPLANT?
Speaker: Pilar Velarde López de Ayala, ES

P215 AUTOLOGOUS PERIPHERAL BLOOD STEM CELL BACKUP 09:15 - 09:15

BEFORE HAEMATOPOETIC STEM CELL TRANSPLANTATION
FOR INTERMEDIATE OSTEOPETROSIS: A SINGLE CENTRE
EXPERIENCE
Speaker: Madeleine Powys, AU

Poster Sessions
09:15 - 18:00 ePoster Area
Statistics
P201 EVALUATION OF MACHINE LEARNING ALGORITHMS 09:15 - 09:15
APPLICABILITY FOR GRAFT FAILURE PREDICTION
Speaker: Evgeny Bakin, RU

P202 WHITE MATTER DEVELOPMENT IN NEONATES WITH 09:15 - 09:15

INFANTILE KRABBE DISEASE
Speaker: Maria Escolar, US

Poster Sessions
09:15 - 18:00 ePoster Area
Nurses Posters – Paediatric
NP17 NURSING INTERVENTIONS TO PREVENT HYPERTENSIVE 09:15 - 09:15
EMERGENCIES IN CHILDREN UNDERGOING HEMATOPOIETIC
STEM CELL TRANSPLANTATION
Speaker: Deepa Karmegam, IN

NP18 NEUROLOGICAL ASSESSMENT IN PAEDIATRIC PATIENTS 09:15 - 09:15

AFTER CAR-T INFUSION
Speaker: Giulia Del Giorno, IT

NP19 THE WORK OF THE REHABILITATION DEPARTMENT WITH 09:15 - 09:15

VOLUNTEERS DURING THE COVID-19 PANDEMIC
Speaker: Rashida Bikulova, RU

123 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

NP20 EVALUATION OF THE EFFECTIVENESS OF NASOGASTRIC 09:15 - 09:15

CATHETERIZATION AS A MEASURE OF NUTRITIONAL
SUPPORT IN PEDIATRIC PATIENTS UNDERGOING
ALLOGENEIC HEMATOPOIETIC STEM CELLS
TRANSPLANTATION
Speaker: Eugenia Trigoso Arjona, ES

NP21 NURSING CARE FOR ACUTE LEUKEMIA CHILDREN WITH 09:15 - 09:15
COMPLICATED BCG VACCINATION DURING CHEMOTHERAPY.
DESCRIPTION OF CLINICAL CASES
Speaker: Anton Silov, RU

NP22 INFUSION OF CHIMERIC ANTIGEN RECEPTOR T CELL (CAR-T 09:15 - 09:15

CELL) THERAPY IN PAEDIATRIC PATIENTS RECEIVING: ONE-
CENTER EXPERIENCE
Speaker: Alba Fernandez-Arroyo Garcia, ES

NP23 IMPLEMENTATION OF THE ADVANCED CELL THERAPY 09:15 - 09:15

PROGRAM:  EXPERIENCE AT LA PAZ UNIVERSITY
HOSPITAL
Speaker: Alba Fernandez-Arroyo Garcia, ES

Poster Sessions
09:15 - 18:00 ePoster Area
Nurses Posters – Research
NP24 ROLE OF NURSING IN THE CARE OF PATIENT’S SKIN WITH 09:15 - 09:15
CUTANEOUS CHRONIC GRAFT-VERSUS-HOST DISEASE
AFTER ALLOGENEIC HAEMOPOIETIC STEM CELL
TRANSPLANTATION: A QUESTIONNAIRE?BASED SURVEY
Speaker: Jacqui Stringer, GB

NP25 INTRAVENTRICULAR INJECTIONS VIA OMMAYA RESERVOIR 09:15 - 09:15

MAY BE PERFORMED BY A TRAINED NURSE AS A PART OF
PEDIATRIC NEUROONCOLOGY TRANSPLANT TEAM EFFORT
Speaker: Lubov Shepeleva, RU

NP26 THE ROLE OF A NURSE IN NUTRITIONAL COUNSELING 09:15 - 09:15

DEVELOPMENT IN HEMATOPOIETIC STEM CELL
TRANSPLANTATION: FROM PRACTICE TO SCIENCE
Speaker: Natalya Rotan, RU

NP27 LONG TERM SURVIVORS AFTER ALLOGENEIC 09:15 - 09:15

HAEMATOPOIETIC STEM CELL TRANSPLANTATION IN
CHILDHOOD AND ADOLESCENCE IN A DEVELOPING
COUNTRY: HOW ARE THEY NOW?
Speaker: Priscila Oliveira da Silva, BR

NP28 EPIDEMIOLOGICAL SCREENING FOR BACTERIAL DRUG 09:15 - 09:15

RESISTANCE IN CANDIDATES FOR ALLO-HSCT AND MEDICAL
EMPLOYEES OF HEMATOLOGICAL DEPARTMENTS
Speaker: Olga Prokofieva, RU

NP29 EARLY CORONAVIRUS WARNING SCORE IN HEMATOLOGY 09:15 - 09:15

DISEASES

124 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

Speaker: Silvia Sangüesa Domínguez, ES

Poster Sessions
09:15 - 18:00 ePoster Area
Pharmacology
P195 PRELIMINARY SAFETY AND EFFICACY OF ITOLIZUMAB, A 09:15 - 09:15
NOVEL TARGETED ANTI-CD6 THERAPY, IN NEWLY
DIAGNOSED SEVERE ACUTE GRAFT-VERSUS-HOST DISEASE:
INTERIM RESULTS FROM THE EQUATE STUDY
Speaker: John Koreth, US

P196 EVALUATION OF A LIMITED SAMPLING STRATEGY IN THE 09:15 - 09:15

THERAPEUTIC DRUG MONITORING OF BUSULFAN
Speaker: Bushra Salman, OM

P197 A NOVEL SHORT HALF-LIFE ANTI-HUMAN CD117-AMANITIN 09:15 - 09:15

ADC EXHIBITS DUAL HSCT CONDITIONING AND ANTI-
LEUKEMIA ACTIVITY AND EXTENDS SURVIVAL IN MULTIPLE
PRECLINICAL MODELS OF AML
Speaker: Leanne Lanieri, US

P199 PHARMACOKINETIC ANALYSIS OF BARICITINIB IN PHASE 1-2 09:15 - 09:15

STUDY FOR TREATMENT REFRACTORY CHRONIC GRAFT-
VERSUS-HOST DISEASE
Speaker: Sara M. Zimmerman, US

P198 THE IMPACT OF LETERMOVIR PRESCRIBING ON THE RATE OF 09:15 - 09:15

CYTOMEGALOVIRUS REACTIVATION FOLLOWING
ALLOGENEIC STEM CELL TRANSPLANTATION
Speaker: Siobhan Smith, GB

Poster Sessions
09:15 - 18:00 ePoster Area
ePoster Area

Poster Sessions
09:15 - 18:00 ePoster Area
Solid Tumours
P200 HIGH DOSE CHEMOTHERAPY AND STEM-CELL TRANSPLANT 09:15 - 09:15
FOR RELAPSED GERM CELL TUMORS: MULTICENTRIC REAL-
WORLD EXPERIENCE IN ARGENTINA
Speaker: Adriana Vitriu, AR

Poster Sessions
09:15 - 18:00 ePoster Area
Multiple Myeloma
P149 HIGH-DOSE MELPHALAN AND AUTOLOGOUS STEM CELL 09:15 - 09:15
TRANSPLANTATION IN ELDERLY PATIENTS ? 70 YEARS IS
SAFE AND EFFECTIVE – A RETROSPECTIVE ANALYSIS
Speaker: Udo Holtick, DE

125 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

P150 PEGYLATED G-CSF VERSUS G-CSF FOLLOWING HD-CTX FOR 09:15 - 09:15
PBSC MOBILIZATION AND HEMATOPOIETIC RECONSTITUTION
AFTER ASCT IN NEWLY DIAGNOSED MULTIPLE MYELOMA
PATIENTS
Speaker: Meilan Chen, CN

P152 RECOMBINANT HUMAN THROMBOPOIETIN IMPROVED 09:15 - 09:15

PLATELET ENGRAFTMENT AFTER AUTOLOGOUS
HEMATOPOIETIC STEM CELL TRANSPLANTATION IN
PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA
Speaker: Jingli Gu, CN

P151 AUTOLOGOUS STEM CELL TRANSPLANTATION FOR ELDERLY 09:15 - 09:15

MULTIPLE MYELOMA PATIENTS – A SAFETY OPTION
Speaker: Rita Sousa Gomes, PT

P153 CLINICAL IMPLICATIONS OF ?? T CELL RECONSTITUTION 09:15 - 09:15

AFTER AUTOLOGOUS HEMATOPOIETIC STEM CELL
TRANSPLANTATION IN PATIENTS WITH MULTIPLE MYELOMA
Speaker: Carolina Afonso, PT

P155 INDUCTION RESPONSE SEEMS TO BE A PROGNOSTIC 09:15 - 09:15

FACTOR FOR PROGRESSION-FREE SURVIVAL AFTER
AUTOLOGOUS STEM CELL TRANSPLANTATION IN PATIENTS
WITH MUTIPLE MYELOMA
Speaker: Pilar Velarde López de Ayala, ES

Poster Sessions
09:15 - 18:00 ePoster Area
Stem Cell Donor
P203 HAPLOIDENTICAL VS HLA-MATCHED RELATED DONOR HSCT 09:15 - 09:15
FOR ACUTE LEUKEMIA AND MYELODYSPLASTIC SYNDROME:
A SINGLE-CENTER COMPARISON
Speaker: Alisa Lörsch, DE

P204 CLINICAL OUTCOMES IN ALLOGENIC HEMATOPOIETIC STEM 09:15 - 09:15

CELL TRANSPLANTATION FROM ALTERNATIVE DONORS:
SINGLE CENTER EXPERIENCE WITH 9/10 HLA-MISMATCHED
UNRELATED, DOUBLE UMBILICAL CORD BLOOD AND
HAPLOIDENTICAL DONORS
Speaker: Claudie Roy, CA

P205 HAPLOIDENTICAL STEM CELL TRANSPLANTATION WITH 09:15 - 09:15

POST-TRANSPLANT CYCLOPHOSPHAMIDE FOR PATIENTS
WITH HIGH-RISK HEMATOLOGIC MALIGNANCIES. A SINGLE
CENTER EXPERIENCE IN MEXICO
Speaker: Katheryn Garzón-Velásquez, MX

Poster Sessions
09:15 - 18:00 ePoster Area
Non-infectious Early Complications
P169 POST HEMATOPOIETIC PROGENITORS TRANSPLANT 09:15 - 09:15

126 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

LYMPHOMA (PTLD) AND REPLICATION OF EPSTEIN-BARR

VIRUS (EBV): A CENTER'S EXPERIENCE
Speaker: Sara Garrido, ES

P171 CLINICAL OUTCOME OF PATIENTS WITH IMMUNE-MEDIATED 09:15 - 09:15

PLATELET REFRACTORINESS UNDERGOING HEMATOPOIETIC
STEM CELL TRANSPLANTATION. SINGLE CENTER
EXPERIENCE

P170 ANALYSIS OF THE GUT MICROBIOME IN PEDIATRIC PATIENTS 09:15 - 09:15

UNDERGOING ALLOGENEIC HEMATOPOIETIC STEM CELL
TRANSPLANTATION (HSCT) PRESENTING VENO-OCCLUSIVE
DISEASE (VOD/SOS) REVEALS AN IMPAIRED MICROBIAL
ECOSYSTEM
Speaker: Daniele Zama, IT

P172 HEMORRHAGIC CYSTITIS DURING ALLOGENEIC STEM CELL 09:15 - 09:15

TRASPLANTATION: A POSSIBLE ROLE FOR PROSTATIC
HYPERPLASI
Speaker: Eugenio Galli, IT

P173 THROMBOTIC EVENTS IN HEMATOPOIETIC TRANSPLANT 09:15 - 09:15

RECPIENTS: SINGLE CENTER EXPERIENCE
Speaker: Carlota Mayor Bastida, ES

P175 EVALUATION OF INTESTINAL PERMEABILITY IN CANDIDATES 09:15 - 09:15

FOR ALLOHCT AND IN EARLY POST-TRANSPLANT PERIOD BY
SUGAR ABSORBTION TEST: INTERIM ANALYSIS OF THE
SINGLE-CENTER PROSPECTIVE STUDY
Speaker: Grzegorz Basak, PL

P176 ANICTERIC PRESENTATION OF SEVERE HEPATIC VENO- 09:15 - 09:15

OCCLUSIVE DISEASE (VOD) WITH MULTIORGAN
DYSFUNCTION (MOD)- A PEDIATRIC CASE REPORT
Speaker: Zofia Szmit, PL

Poster Sessions
09:15 - 18:00 ePoster Area
Acute Leukaemia
P001 MEASURABLE RESIDUAL DISEASE, FLT3-ITD MUTATION AND 09:15 - 09:15
DISEASE STATUS HAVE INDEPENDENT PROGNOSTIC
INFLUENCE ON POST-TRANSPLANT OUTCOMES IN
NPM1-MUTATED ACUTE MYELOID LEUKEMIA
Speaker: Rama Al Hamed, US

P002 ROLE OF ALLO-HSCT AS CONSOLIDATION OF MRD-NEGATIVE 09:15 - 09:15

REMISSION IN R/R B-ALL AFTER TREATMENT WITH
MONOCLONAL ANTIBODIES
Speaker: Inna Markova, RU

P003 AZACYTIDINE AND DONOR LYMPHOCYTE INFUSIONS (DLI) AS 09:15 - 09:15

SALVAGE TREATMENT IN PATIENTS WITH AML AND MDS
RELAPSED AFTER ALLOGENEIC STEM CELL
TRANSPLANTATION: A RETROSPECTIVE SINGLE CENTER

127 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

ANALYSIS
Speaker: Semra Aydin, IT

P004 T-CELL-DEPLETE ALLOGENEIC HAEMATOPOIETIC STEM CELL 09:15 - 09:15

TRANSPLANT AFTER REDUCED-INTENSITY CONDITIONING
FOR MYELOID MALIGNANCIES IN THE OVER-65S – A SINGLE
CENTRE EXPERIENCE OF 90 PATIENTS
Speaker: Alexandros Kanellopoulos, GB

P005 POST-REMISSION TREATMENT PATTERNS FOR PATIENTS 09:15 - 09:15

WITH NEWLY DIAGNOSED (ND) ACUTE MYELOID LEUKEMIA
(AML) IN THE CONNECT® MDS/AML DISEASE REGISTRY

P006 ALLOGENEIC STEM CELL TRANSPLANTATION IN FIRST 09:15 - 09:15

COMPLETE REMISSION IS ASSOCIATED WITH SUPERIOR
OUTCOMES IN ACUTE MYELOID LEUKEMIA INDEPENDENT OF
RECIPIENT AGE AND DONOR TYPE
Speaker: Tatiana Tzenou, GR

P007 GILTERITINIB MONOTHERAPY IN RELAPSED OR 09:15 - 09:15

REFRACTORY ACUTE MYELOID LEUKEMIA FLT3+ IN ADULT
PATIENTS
Speaker: Sergey Bondarenko, RU

P009 ZUMA-4: A PHASE 1/2 MULTICENTER STUDY OF KTE-X19 IN 09:15 - 09:15

PEDIATRIC AND ADOLESCENT PATIENTS WITH
RELAPSED/REFRACTORY B CELL ACUTE LYMPHOBLASTIC
LEUKEMIA (ALL) OR NON-HODGKIN LYMPHOMA (NHL)
Speaker: Alan S. Wayne, US

P008 VENETOCLAX COMBINED WITH AZACITIDINE OR LOW-DOSE 09:15 - 09:15

CYTARABINE FOR RELAPSED ACUTE MYELOID LEUKAEMIA
POST ALLOGENEIC STEM CELL TRANSPLANT
Speaker: Sandra Easdale, GB

P010 LONG-TERM OUTCOME OF ALLOGENEIC STEM CELL 09:15 - 09:15

TRANSPLANTATION IN PATIENTS WITH ACUTE MYELOID
LEUKEMIA – FOCUS ON MORTALITY
Speaker: Anna Lojko-Dankowska, PL

P011 SORAFENIB MAINTENANCE AFTER HEMATOPOIETIC STEM 09:15 - 09:15

CELL TRANSPLANTATION IMPROVES OUTCOME OF FLT3-ITD
POSITIVE ACUTE MYELOID LEUKEMIA
Speaker: Semra Aydin, IT

P012 BASELINE SOMATIC MUTATIONS PREDICT DISEASE FREE 09:15 - 09:15

SURVIVAL AFTER ALLOGENEIC STEM CELL
TRANSPLANTATION IN ACUTE MYELOID LEUKEMIA: A
RETROSPECTIVE MONOCENTRIC REPORT
Speaker: Elisabetta Metafuni, IT

P013 UNMANIPULATED HAPLOIDENTICAL HEMATOPOIETIC STEM 09:15 - 09:15

CELL TRANSPLANTATION IN ADULT PATIENTS WITH ACUTE
MYELOID LEUKEMIA
Speaker: Sergey Bondarenko, RU

128 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

P014 SURVIVAL OF PATIENTS WITH ACUTE MYELOID LEUKEMIA, 09:15 - 09:15

TAKEN TO HEMATOPOIETIC STEM CELL TRANSPLANTATION:
EXPERIENCE OF A CENTER IN COLOMBIA
Speaker: Claudia Lucía Sossa Melo, CO

Poster Sessions
09:15 - 18:00 ePoster Area
Graft-versus-Host Disease – Clinical
P051 EFFECT OF EXTRACORPOREAL PHOTOPHERESIS ON 09:15 - 09:15
ENRICHMENT, SURVIVAL AND CYTOKINE PRODUCTION
CAPACITY OF MONOCYTES FROM CHRONIC GRAFT VERSUS
HOST DISEASE PATIENTS
Speaker: Arun Alfred, GB

P056 REDUCED GVHD WITH TRIPLE PTCY BASED GVHD 09:15 - 09:15
PROPHYLAXIS, AS COMPARED TO TRIPLE ATG BASED
PROPHYLAXIS, IN HLA MATCHED TRANSPLANTS
Speaker: Elisabetta Metafuni, IT

P055 PROLONGED SUPPRESSION OF BUTYRATE PRODUCING 09:15 - 09:15

BACTERIA INDICATES DYSBIOSIS AND IS ASSOCIATED WITH
ACUTE GASTROINTESTINAL GRAFT-VERSUS-HOST DISEASE
AND TRANSPLANT RELATED MORTALITY AFTER
ALLOGENEIC STEM CELL TRANSPLANTATION
Speaker: Elisabeth Meedt, DE

P052 ACUTE AND CHRONIC GRAFT-VERSUS-HOST-DISEASE IMPAIR 09:15 - 09:15

B-CELL RECONSTITUTION IN ALLOGENEIC-TRANSPLANTED
PATIENTS AT DIFFERENT MATURATION STAGES
Speaker: Matthias Alexander Fante, DE

P057 THE SAME FOR LESS: 2.5MG/KG VS. 4.5MG/KG RABBIT ANTI- 09:15 - 09:15
THYMOCYTE GLOBULIN IN PATIENTS UNDERGOING
MATCHED UNRELATED DONOR ALLOGENEIC STEM CELL
TRANSPLANTATION FOR HEMATOLOGICAL MALIGNANCIES
Speaker: Osman Radhwi, CA

P060 A PHASE 2/3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, 09:15 - 09:15

PLACEBO-CONTROLLED STUDY OF ALPHA-1 ANTITRYPSIN
FOR THE PREVENTION OF ACUTE GRAFT VERSUS HOST
DISEASE FOLLOWING HEMATOPOIETIC CELL TRANSPLANT

P061 CHRONIC AND LATE ACUTE GVHD IN CHILDREN USING THE 09:15 - 09:15
NIH 2014 CONSENSUS CRITERIA
Speaker: Koray Yalcin, TR

P058 COMPARISON OF POST-TRANSPLANTATION 09:15 - 09:15

CYCLOPHOSPHAMIDE VERSUS ANTI-T-LYMPHOCYTE
GLOBULIN AS GVHD PROPHYLAXIS IN ADULT PATIENTS WITH
ACUTE LYMPHOBLASTIC LEUKEMIA UNDERGOING
ALLOGENEIC HEMATOPOIETIC STEM CELL
TRANSPLANTATION IN CR1
Speaker: Maximilian Christopeit, DE

129 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

P059 TRIPLE PTCY BASED GVHD PROPHYLAXIS: HLA MATCHED 09:15 - 09:15
VERSUS HLA HAPLOIDENTICAL TRANSPLANTS
Speaker: Eugenio Galli, IT

P063 A PHASE 1/2, OPEN-LABEL, SINGLE-ARM, STUDY OF 09:15 - 09:15

RUXOLITINIB ADDED TO CORTICOSTEROIDS IN PEDIATRIC
PATIENTS WITH ACUTE GRAFT-VS-HOST DISEASE AFTER
ALLOGENEIC STEM CELL TRANSPLANTATION (REACH4)
Speaker: Franco Locatelli, IT

P062 AREA UNDER THE CURVE BASED MYCOPHENOLATE MOFETIL 09:15 - 09:15
DOSAGE REDUCED THE INCIDENCE OF GVHD AFTER
ALLOGENIC HSCT IN PEDIATRIC PATIENTS: ONE FACILITY'S
EIGHT-YEAR EXPERIENCE
Speaker: Antonio Grasso, IT

P064 IBRUTINIB FOR STEROID REFRACTORY CHRONIC GRAFT 09:15 - 09:15

VERSUS HOST DISEASE: DATA AND CLINICAL EXPERIENCE
FROM A SINGLE CENTER
Speaker: Panayotis Kaloyannidis, SA

P065 ROUTINE USE OF THE AMICUS BLUE™ ONLINE ECP SYSTEM IN 09:15 - 09:15
PATIENTS WITH CHRONIC AND ACUTE GRAFT VERSUS HOST
DISEASE
Speaker: Angelo Ostuni, IT

P066 RUXOLITINIB OFF-LABEL USE IN STEROID-REFRACTORY 09:15 - 09:15

CHRONIC GRAFT VERSUS HOST DISEASE: A SINGLE CENTRE
EXPERIENCE IN 36 PATIENTS
Speaker: Maria Teresa Lupo Stanghellini, IT

P067 PHARMACOKINETIC MODELING TO GUIDE DOSE SELECTION 09:15 - 09:15

OF ALPHA-1 ANTITRYPSIN IN A STUDY OF GRAFT VERSUS
HOST DISEASE PREVENTION IN PATIENTS RECEIVING
ALLOGENIC HEMATOPOIETIC CELL TRANSPLANT
Speaker: Henry Hu, US

P068 BASILIXIMAB FOR THE TREATMENT OF PATIENTS WITH 09:15 - 09:15

STEROID REFRACTORY ACUTE GRAFT VERSUS HOST
DISEASE: LITERATURE REVIEW AND POOLED ANALYSIS
Speaker: Xiaodong Mo, CN

P069 FIRST LINE SINGLE-AGENT RUXOLITINIB FOR GRADE II-III 09:15 - 09:15
ACUTE GRAFT-VERSUS-HOST DISEASE IN PATIENTS WITH
SEVERE INFECTIOUS COMPLICATIONS: CASE SERIES
Speaker: Ivan Moiseev, RU

P070 A PHASE 2 OPEN-LABEL, SINGLE-ARM, MULTICENTER STUDY 09:15 - 09:15

OF RUXOLITINIB ADDED TO CORTICOSTEROIDS IN PEDIATRIC
SUBJECTS WITH MODERATE/SEVERE CHRONIC GVHD AFTER
ALLOGENEIC STEM CELL TRANSPLANTATION (REACH5)
Speaker: Franco Locatelli, IT

P071 PRE-TRANSPLANTATION PLASMA VITAMIN D LEVELS AND 09:15 - 09:15

ACUTE GRAFT-VERSUS-HOST DISEASE AFTER

130 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

MYELOABLATIVE ALLOGENEIC HEMATOPOIETIC CELL

TRANSPLANTATION
Speaker: Lars Klingen Gjærde, DK

P072 SEVERE REFRACTORY SKIN GVHD IN CHILDREN: SERIES OF 09:15 - 09:15

CLINICAL CASES

P073 Elevated REG3? predicts refractory aGVHD in Patients Who 09:15 - 09:15
Received Steroids- Ruxolitinib as the First Line Therapy
Speaker: Liping Dou, CN

Poster Sessions
09:15 - 18:00 ePoster Area
Lymphoma and Chronic Lymphocytic Leukemia
P134 RESULTS WITH ALLOGENEIC STEM CELL TRANSPLANTATION 09:15 - 09:15
IN PATIENTS WITH RELAPSED/REFRACTORY HODGKIN
LYMPHOMA TREATED WITH ANTI-PD1: A MULTICENTER
RETROSPECTIVE COHORT STUDY
Speaker: Fernando Warley, AR

P133 18FLUOROMETHYLCHOLINE PET/CT TO PREDICT OUTCOMES 09:15 - 09:15

OF PATIENTS PRE AND POST AUTOLOGOUS STEM CELL
TRANSPLANTATION(ASCT) FOR CNS LYMPHOMA – A NEW
CNS LYMPHOMA IMAGING TOOL
Speaker: Sandra Easdale, GB

P135 THE OUTCOMES OF ALLOGENEIC STEM CELLS 09:15 - 09:15

TRANSPLANTATION FOR RELAPSED/REFRACTORY CHRONIC
LYMPHOCYTIC LEUKEMIA IN THE ERA OF TARGETED
THERAPY: SINGLE CENTER EXPERIENCE
Speaker: Ivan Moiseev, RU

P137 STEM CELL TRANSPLANTATION IN MANTLE CELL 09:15 - 09:15

LYMPHOMA: POST-TRANSPLANT OUTCOMES OF TAIWAN
BLOOD AND MARROW TRANSPLANTATION REGISTRY
Speaker: Yu-Hung Wang, TW

P136 NIVOLUMAB 40 MG THERAPY IN RELAPSED AND 09:15 - 09:15

REFRACTORY CLASSICAL HODGKIN LYMPHOMA: RESULTS
OF A SINGLE CENTER MATCHED CASE-CONTROL STUDY
Speaker: Liudmila Fedorova, RU

P138 AUTOLOGOUS HEMATOPOIETIC CELL TRANSPLANTATION 09:15 - 09:15

FOR HIGH GRADE B-CELL LYMPHOMA WITH MYC AND BCL2
AND/OR BCL6 REARRANGEMENTS. A SINGLE INSTITUTION
EXPERIENCE
Speaker: Joanna Romejko-Jarosinska, PL

P142 SUCCESSFUL TREATMENT OF HEPATOSPLENIC T-CELL 09:15 - 09:15

LYMPHOMA WITH INTENSIFIED MYELOABLATIVE
CONDITIONING REGIMENS FOLLOWED BY UNMANIPULATED
HAPLOIDENTICAL HEMATOPOIETIC STEM CELL
TRANSPLANTATION
Speaker: Yan-Li Zhao, CN

131 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

P140 POLA-BR AFTER CAR-T CELL THERAPY FAILURE IN R/R 09:15 - 09:15
DIFFUSE LARGE B-CELL LYMPHOMA
Speaker: Ivan Moiseev, RU

P141 NODAL PERIPHERAL T-CELL LYMPHOMA – THE ROLE OF 09:15 - 09:15

CONSOLIDATIVE AUTOLOGOUS STEM CELL
TRANSPLANTATION IN COMPLETE OR PARTIAL FIRST
REMISSION: A 10-YEAR LESSON FROM SINGAPORE GENERAL
HOSPITAL
Speaker: Christopher Shwei Wen Tham, SG

P139 AUTOLOGOUS STEM CELL TRANSPLANT IN NON HODGKIN 09:15 - 09:15

LYMPHOMA AT AIIMS: TRENDS IN TOLERABILITY AND LONG
TERM OUTCOMES
Speaker: Sudhir Kumar, IN

Poster Sessions
09:15 - 18:00 ePoster Area
Infectious Complications
P118 COMPARISON BETWEEN PRIMARY PROPHYLAXIS AND PRE- 09:15 - 09:15
EMPTIVE THERAPY FOR CITOMEGALOVIRUS AFTER
HEMATOPOIETIC STEM-CELL TRANSPLANTATION
Speaker: Luisa Giaccone, IT

P119 INCIDENCE OF HEMORRHAGIC CYSTITIS FOLLOWING 09:15 - 09:15

HEMATOPOIETIC STEM CELL TRANSPLANTATION IN
PEDIATRIC PATIENTS BASED ON THE UNDERLYING DISEASE
Speaker: Amir Ali Hamidieh, IR

P120 EPIDEMIOLOGY OF RESISTANT AND REFRACTORY 09:15 - 09:15

CYTOMEGALOVIRUS INFECTION FOLLOWING SOLID ORGAN
OR HAEMATOPOIETIC STEM CELL TRANSPLANT: A
SYSTEMATIC REVIEW
Speaker: Aurore Bergamasco, FR

P122 EPIDEMIOLOGY OF INFECTIOUS COMPLICATIONS IN 09:15 - 09:15

PATIENTS WITH CHRONIC GRAFT-VERSUS-HOST DISEASE
Speaker: Aleksandr Siniaev, RU

P121 ANTIBACTERIAL PROPHYLAXIS IN PATIENTS UNDERGOING 09:15 - 09:15

HEMATOPOIETIC STEM CELL TRANSPLANTATION AND
DEVELOPMENT OF INFECTIONS BY ANTIBIOTIC-RESISTANT
BACTERIA
Speaker: Filippo Maraz, IT

P123 CLINICAL AND MICROBIOLOGICAL IMPACT OF 09:15 - 09:15

DISCONTINUATION OF FLUOROQUINOLONE PROPHYLAXIS IN
PATIENTS UNDERGOING HEMATOPOIETIC STEM CELL
TRANSPLANTATION: A SINGLE-CENTRE EXPERIENCE
Speaker: Anke Verlinden, BE

P124 IRON CHELATION WITH DEFERASIROX SUPPRESSES THE 09:15 - 09:15

APPEARANCE OF LPI DURING CONDITIONING
CHEMOTHERAPY PRIOR TO ALLOGENEIC STEM CELL

132 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

TRANSPLANTATION
Speaker: Sonja Essmann, DE

P125 SARS-COV-2 INFECTION IN A HEMATOPOIETIC STEM CELL 09:15 - 09:15

TRANSPLANT CENTER: A SINGLE CENTER EXPERIENCE IN
MEXICO
Speaker: Luis Manuel Valero-Saldaña, MX

P126 ANTIBIOTIC PROPHYLAXIS AND THE RATE OF BACTEREMIA 09:15 - 09:15

AND CLOSTRIDIUM DIFFICILE INFECTION IN PEDIATRIC STEM
CELL TRANSPLANTATION: A SINGLE CENTER
RETROSPECTIVE STUDY
Speaker: Mohammed Essa, SA

P128 TOCILIZUMAB IN POST HEMATOPOIETIC STEM CELL 09:15 - 09:15

TRANSPLANT COVID-19: A PEDIATRIC CASE REPORT
Speaker: Tahereh Rostami, IR

P127 HUMAN POLYOMA BK VIRUS AS A CAUSE OF HEMORRHAGIC 09:15 - 09:15

CYSTITIS: RETROSPECTIVE COHORT STUDY
Speaker: Nikola Pantic, RS

P132 CMV REACTIVATION AFTER ALLOGENIC HEMATOPOIETIC 09:15 - 09:15

STEM CELL TRANSPLANTATION - SINGLE CENTRE
EXPERIENCE
Speaker: Milena Todorovic Balint, RS

P129 PANDEMIC LESSONS OF COVID 19 IN NORTHEAST OF BRAZIL 09:15 - 09:15

Speaker: Fernando Barroso Duarte, BR

P131 SARS-COOV-2 INFECTION IN AN ADOLESCENT PATIENT 09:15 - 09:15

AFTER HAPLOIDENTICAL STEM CELL TRANSPLANTATION
Speaker: Maurizio Caniglia, IT

P130 CLINICAL CHARACTERISTICS AND OUTCOME OF 09:15 - 09:15

POLYMICROBIAL BLOODSTREAM INFECTIONS IN ALLO-SCT
PATIENTS: A MONOCENTRIC 5 YEARS SURVEY
Speaker: Gabriele Facchin, IT

Poster Sessions
09:15 - 18:00 ePoster Area
Inborn Errors
P114 ALLOGENEIC STEM CELL TRANSPLANTATION IN PATIENTS 09:15 - 09:15
WITH MUCOPOLYSACCHARIDOSIS TYPE I (HURLER) WITH
TREOSULFAN-BASED CONDITIONING
Speaker: Matthias Bleeke, DE

P115 LONG-TERM NEURODEVELOPMENTAL, 09:15 - 09:15

NEUROPHYSIOLOGICAL, AND NEURORADIOLOGICAL
OUTCOMES OF HEMATOPOIETIC STEM CELL
TRANSPLANTATION FOR TREATMENT OF LATE-INFANTILE
METACHROMATIC LEUKODYSTROPHY
Speaker: Maria Escolar, US

133 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

P116 OUTCOME OF HAEMATOPOIETIC CELL TRANSPLANTATION IN 09:15 - 09:15

CHILDREN WITH LYSOSOMAL ACID LIPASE DEFICIENCY: A
STUDY ON BEHALF OF THE EBMT INBORN ERRORS WORKING
PARTY
Speaker: Su Han Lum, GB

Poster Sessions
09:15 - 18:00 ePoster Area
Experimental Stem Cell Transplantation
P046 SYNERGISTIC EFFECT OF ATG PLUS PTCY FOR DUAL T CELL 09:15 - 09:15
MODULATION IN HAPLOIDENTICAL STEM CELL
TRANSPLANTATION FOR POOR PROGNOSIS ACUTE
LEUKAEMIA
Speaker: Maryam Barkhordar, IR

P047 DAY 0 EASIX SCORE MIGHT PREDICT OVERALL SURVIVAL 09:15 - 09:15
AND TRANSPLANT RELATED MORTALITY AFTER
ALLOGENEIC STEM CELL TRANSPLANTATION: SINGLE
CENTRE EXPERIENCE
Speaker: Elisabetta Metafuni, IT

Poster Sessions
09:15 - 18:00 ePoster Area
CAR-based Cellular Therapy – Clinical
P016 HEALTH-RELATED QUALITY OF LIFE IN THE CARTITUDE-1 09:15 - 09:15
STUDY OF CILTACABTAGENE AUTOLEUCEL FOR
RELAPSED/REFRACTORY MULTIPLE MYELOMA
Speaker: Thomas Martin, US

P017 MANUFACTURING COMMERCIAL AXICABTAGENE 09:15 - 09:15

CILOLEUCEL (AXI-CEL) FOR EUROPEAN PATIENTS: A 2-YEAR
RETROSPECTIVE ANALYSIS
Speaker: Didier Hallard, NL

P015 RETREATMENT WITH AXICABTAGENE CILOLEUCEL (AXI-CEL) 09:15 - 09:15

IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) INDOLENT
NON-HODGKIN LYMPHOMA (INHL) IN ZUMA-5
Speaker: Julio C. Chavez, US

P019 COST-EFFECTIVENESS OF KTE-X19 CAR T THERAPY 09:15 - 09:15

FOLLOWING BRUTON TYROSINE KINASE INHIBITOR
TREATMENT FOR RELAPSED/REFRACTORY MANTLE CELL
LYMPHOMA IN ENGLAND
Speaker: Martin Brown, GB

P018 EXPANSION DYNAMICS DETECTED BY FLOW CYTOMETRY 09:15 - 09:15

CORRELATES WITH CLINICAL RESPONSE AFTER CAR-T CELL
THERAPY IN THE REAL WORLD SETTING
Speaker: Silvia monsalvo, ES

P020 PATIENT EXPECTATIONS AND PERCEPTIONS OF TREATMENT 09:15 - 09:15

IN CARTITUDE-1: PHASE 1B/2 STUDY OF CILTACABTAGENE

134 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

AUTOLEUCEL IN RELAPSED/REFRACTORY MULTIPLE

MYELOMA
Speaker: Adam D Cohen, US

P021 CHARACTERIZATION OF INFECTIONS AFTER CHIMERIC 09:15 - 09:15

ANTIGEN RECEPTOR T-CELL THERAPY IN PATIENTS WITH
LARGE B-CELL LYMPHOMA
Speaker: Pere Barba, ES

P022 CLINICAL APPLICATION OF HAPLOIDENTICAL DONOR- 09:15 - 09:15

DERIVED CD19 CAR-T CELLS MANUFACTURED FROM
MEMORY T CELL (CD45RA-DEPLETED) FRACTION
Speaker: Larisa Shelikhova, RU

P024 ICU RESOURCE UTILIZATION IN PEDIATRIC AND 09:15 - 09:15

ADOLESCENT YOUNG ADULT PATIENTS POST CAR-T
THERAPY
Speaker: Dristhi Ragoonanan, US

P023 HEMATOLOGIC RESCUE OF CAR T CELL-MEDIATED 09:15 - 09:15

PROLONGED PANCYTOPENIA USING AUTOLOGOUS
PERIPHERAL BLOOD HEMATOPOIETIC STEM CELLS IN A
LYMPHOMA PATIENT
Speaker: Udo Holtick, DE

P025 ZUMA-19: A PHASE 1/2 MULTICENTER STUDY OF LENZILUMAB 09:15 - 09:15

WITH AXICABTAGENE CILOLEUCEL (AXI?CEL) IN PATIENTS
WITH RELAPSED OR REFRACTORY LARGE B CELL
LYMPHOMA (R/R LBCL)
Speaker: Saad J. Kenderian, US

Poster Sessions
09:15 - 18:00 ePoster Area
CAR-based Cellular Therapy – Preclinical
P026 NON-VIRAL SLEEPING BEAUTY TRANSPOSON ENGINEERED 09:15 - 09:15
CD19-CAR-NK CELLS WITH HIGH ANTILEUKEMIC EFFICIENCY
Speaker: Tobias Bexte, DE

Psy Day
09:35 - 10:30 Auditorium 6
Psy1 - Workshop 1: Survivorship Program
Chair: Alexandra Carpentier, ES
Chair: Frank Schulz-Kindermann, DE
Psy1-1 Introduction 09:35 - 09:41
Speaker: Anna Barata, US

Psy1-2 Cognitive outcomes on CAR T-cell therapy recipients 09:41 - 09:56

Speaker: Anna Barata, US

Psy1-3 Quality of life in childhood cancer survivors and their famílies 09:56 - 10:14
after end of acute treatment
Speaker: Corinna Bergelt, DE

135 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

Psy1-4 Q&A 10:14 - 10:30

Breaks
10:30 - 11:00 Auditorium 1
Coffee Break, Poster Viewing, Visit Exhibition

Wellness session
10:30 - 10:45 Auditorium 1
Meditation Session

Plenary Session
11:00 - 12:15 Auditorium 1
P1 - Landscape for CLL management in 2021
Chair: Peter Dreger, DE
Chair: José García-Marco, ES
P1-1 Dissecting CLL at a single-cell level - Implications for therapy 11:00 - 11:20
and outcome
Speaker: Catherine Wu, US

P1-2 The broadening landscape of targets and therapeutic options 11:20 - 11:40
for CLL
Speaker: Michael Hallek, DE

P1-3 HSCT and cellular therapy for CLL in 2021 11:40 - 12:00
Speaker: John Gribben, GB

P1-4 Q&A 12:00 - 12:15

Educational
11:00 - 12:15 Auditorium 2
E02 - Plasma cell dyscrasias
Chair: Ramón García Sanz, ES
Chair: Meral Beksac, TR
E2-1 Autologous HSCT in patients with light chain amyloidosis 11:00 - 11:20
Speaker: Stefan Schönland, DE

E2-2 Novel immunotherapies in Multiple Myeloma: Bispecific 11:20 - 11:40

antibodies and Anti-body Drug
Speaker: Hermann Einsele, DE

E2-3 CAR-T cells in patients with multiple myeloma 11:40 - 12:00

Speaker: Nikhil Munshi, US

E2-4 Q&A 12:00 - 12:15

Nurses Group
11:00 - 12:15 Auditorium 3
NG02 - How do I... Understand blood counts?
Chair: Julia Ruiz Pato, ES
Chair: Almudena Pérez, ES

136 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

NG02-1 Liver function test 11:00 - 11:15

Speaker: Ignacio Gómez-Centurión, ES

NG02-2 Renal function test 11:15 - 11:30

Speaker: Iván López Torija, ES

NG02-3 Full blood counts 11:30 - 11:45

Speaker: Maria Esther Martínez Muñoz, ES

NG02-4 Cross matching 11:45 - 12:00

Speaker: Josune Zubicaray Salegui, ES

NG02-5 Q&A 12:00 - 12:15

Transplant and Search Coordinators Day

11:00 - 12:15 Auditorium 5
TSCD2 - Transplant and Search Coordinators Day: Cold cases - Stem cells to go?
Chair: Salmah Ahmed, GB
Chair: Anna Sureda, ES
TSCD2-1 Preemptive cryopreservation of stem cells - DKMS perspective 11:00 - 11:20
Speaker: Deborah Buk, DE

TSCD2-2 Preemptive cryopreservation of stem cells - NMDP perspective 11:20 - 11:40

Speaker: Steven Devine, US

TSCD2-3 The use of banked products - Clinical perspective 11:40 - 12:00

Speaker: Annoek Broers, NL

TSCD2-4 Q&A 12:00 - 12:15

Psy Day
11:00 - 12:15 Auditorium 6
Psy2 - Workshops 2: Donors, the transplant team and COVID-19
Chair: Philip Alexander, GB
Psy2-1 Family donors, who cares? 11:00 - 11:20
Speaker: Suzanna van Walraven, NL

Psy2-2 Supporting HCT care team: end of life issues 11:20 - 11:40
Speaker: Alice Polomeni, FR

Psy2-3 The psychological impact and management of patients, carers 11:40 - 12:00
and staff during the COVID-19 pandemic: Lessons learnt
Speaker: Troy Chase, GB

Psy2-4 Q&A 12:00 - 12:15

Cell therapy
11:15 - 12:15 Auditorium 4
CTD2 - Cell Therapy Day: Apheresis
Chair: Halvard Bönig, DE
Chair: Etienne Baudoux, FR

137 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

CTD2-1 Apheresis in low weight children 11:15 - 11:32

Speaker: Christian Chabannon, FR

CTD2-2 Apheresis collections for hematopoietic cellular therapy 11:32 - 11:54

manufacturing: Not all are created equal
Speaker: Miquel Lozano, ES

CTD2-3 Q&A 11:54 - 12:15

Breaks
12:15 - 13:00 Auditorium 1
Lunch Break, Poster Viewing, Visit Exhibition

Industry Symposium
13:00 - 14:00 Auditorium 1
IS23 - CAR-T Cell Therapy in the Current and Emerging Treatment Landscape - Novartis Industry Symposium
Chair: Ulrich Jäger, AT
IS23-1 Introductions and Opening Remarks 13:00 - 13:03
Speaker: Ulrich Jäger, AT

IS23-2 Lessons Learned in CAR-T Cell Therapy for DLBCL: Navigating 13:03 - 13:23
Between Clinical Trials and the Real World
Speaker: Ulrich Jäger, AT
Speaker: Amit Patel, GB

IS23-3 A Clinician’s Guide to Treatment Sequence and Patient Referral 13:23 - 13:33
for CAR-T Cell Therapy in DLBCL
Speaker: Catherine Thieblemont, FR

IS23-4 Leading into New Landscapes: What’s Next for the Treatment 13:33 - 13:43
of r/r FL and 2nd-Line DLBCL
Speaker: Martin Dreyling, DE

IS23-5 Live Q&A and Closing Remarks 13:43 - 14:00

Industry Symposium
13:00 - 14:00 Auditorium 2
IS24 - Current Developments in Allogeneic Haematopoietic Stem Cell Transplantation: Recent data on treosulf
Industry Symposium
Chair: Arnon Nagler, IL
Chair: Franco Locatelli, IT
IS24-1 Welcome and Introduction 13:00 - 13:05
Speaker: Arnon Nagler, IL

IS24-2 Experience in Haploidentical Stem Cell Transplantation Using 13:05 - 13:20

Trecondi®
Speaker: Fabio Ciceri, IT

IS24-3 Trecondi® for Reduced Toxicity Conditioning in Malignant 13:20 - 13:35

Neoplastic Diseases
Speaker: Friedrich Stölzel, DE

138 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

IS24-4 Trecondi® – The Product of Choice for Myeloablative 13:35 - 13:50

Conditioning in Non-Malignant Disesases
Speaker: Selim Corbacioglu, DE

IS24-5 Wrap-Up 13:50 - 13:55

Speaker: Franco Locatelli, IT

IS24-6 Q&A 13:55 - 14:00

Industry Symposium
13:00 - 14:00 Auditorium 3
IS25 - Nurse Symposium: Therakos ECP Immunomodulation – Getting the most out of your service - Therakos
Industry Symposium
Chair: Michelle Kenyon, GB
IS25-1 Introduction 13:00 - 13:05
Speaker: Michelle Kenyon, GB

IS25-2 Overcoming the challenges of ECP service delivery 2020 13:05 - 13:20
Speaker: James Griffin, GB

IS25-3 The Patient pathway 13:20 - 13:35

Speaker: John Murray, GB

IS25-4 2020 challenges – an Operator’s perspective 13:35 - 13:50

Speaker: Alba Pons Cornado, NO

IS25-5 Q&A session 13:50 - 14:00

Statistics
13:00 - 13:45 Auditorium 4
Stat1 - Statistics Workshop
Chair: Hein Putter, NL
Stat1-1 Different method to analyse time-dependent covariates: The 13:00 - 13:45
example of GVL
Speaker: Avichai Shimoni, IL
Speaker: Ariane Boumendil, FR

Transplant and Search Coordinators Day

13:00 - 14:00 Auditorium 5
TSCD3 - Transplant and Search Coordinators Day: Donor Attrition and Backup Strategies
Chair: Annette Rasche, DE
Chair: Christian Chabannon, FR
TSCD3-1 Ethics of donation and donor attrition at the search stage 13:00 - 13:15
Speaker: Bernice Elger, CH

TSCD3-2 ***URGENT: DONOR CANCELLATION*** 13:15 - 13:30

Speaker: Juliana Villa, ES

TSCD3-3 Back-up strategy along graft request 13:30 - 13:45

Speaker: Irina Evseeva, GB

139 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

TSCD3-4 Q&A 13:45 - 14:00

Psy Day
13:00 - 14:00 Auditorium 6
Psy3 - How do I
Chair: Elena Valero, ES
Chair: Alice Polomeni, FR
Psy3-1 How do I... screen patients along the HCT continuum 13:00 - 13:15
Speaker: Alex King, GB

Psy3-2 How do I... address the psycho-oncologists well-being 13:15 - 13:30

Speaker: Frank Schulz-Kindermann, DE

Psy3-3 How do I... conduct e-health studies: Integrating educational 13:30 - 13:45
and psychosocial aspects
Speaker: Christian Ochoa, ES

Psy3-4 Q&A 13:45 - 14:00

Industry Symposium
13:00 - 14:00 MTE rooms
IS26 - Personalized Approach for Managing CMV Reactivation in HSCT Patients: Interactive patient case prese
Industry Meet the Expert Lunch 1 - Room MTE1
Chair: Per Ljungman, SE

Industry Symposium
13:00 - 14:00 MTE rooms
IS30 - Leukemia - 2nd ALLO SCT - Riemser Meet the Expert Lunch - Room MTE5
Chair: Jürgen Finke, DE

Industry Symposium
13:00 - 14:00 MTE rooms
Industry Meet the Expert lunch sessions

Industry Symposium
13:00 - 14:00 MTE rooms
IS27 - Exploring the latest data on severe hepatic VOD and current challenges in HCT* - Jazz Pharmaceuticals
the Expert Lunch - Room MTE2
*This session is intended for physicians only
Chair: Tony Pagliuca, GB
IS27-1 Welcome and introduction 13:00 - 13:01
Speaker: Tony Pagliuca, GB

IS27-2 Data update: severe hepatic VOD 13:01 - 13:14

Speaker: Tony Pagliuca, GB

IS27-3 Discussion: current challenges in hepatic VOD and HCT 13:14 - 13:59

IS27-4 Summary and close 13:59 - 14:00

Speaker: Tony Pagliuca, GB

140 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

Industry Symposium
13:00 - 13:45 MTE rooms
IS29 - Gene therapy for hemoglobinopathies* - Bluebird Bio Industry Meet the Expert Lunch - Room MTE4
*This session is only for HCP
Chair: Franco Locatelli, IT

Breaks
14:00 - 14:30 Auditorium 1
Coffee Break, Poster Viewing, Visit Exhibition

General
14:30 - 16:00 Auditorium 1
GS2 - Presidential Symposium
GS2-1 Van Bekkum Award - Introduction 14:30 - 14:33
Speaker: Nicolaus Kröger, DE

GS2-2 POST-TRANSPLANTATION CYCLOPHOSPHAMIDE VERSUS 14:33 - 14:48

ANTITHYMOCYTE GLOBULIN AFTER RIC REGIMEN ALLO-HCT:
FIRST ANALYSIS OF A PROSPECTIVE RANDOMIZED
MULTICENTER TRIAL IN RECIPIENTS OF 10/10 MATCHED
DONORS
Speaker: Eolia Brissot, FR

GS2-3 Basic Science Award - Introduction 14:48 - 14:51

Speaker: Rafael Duarte, ES

GS2-4 HOST INTESTINAL TISSUE RESIDENT MACROPHAGES 14:51 - 15:06

PROTECT AGAINST MURINE INTESTINAL ACUTE GRAFT-
VERSUS-HOST DISEASE
Speaker: Duc-Dung Le, DE

GS2-5 MARIBAVIR VERSUS INVESTIGATOR-ASSIGNED THERAPY 15:06 - 15:15

(IAT) FOR THE TREATMENT OF TRANSPLANT RECIPIENTS
WITH REFRACTORY/RESISTANT (R/R) CYTOMEGALOVIRUS
INFECTION: EFFICACY DATA FROM A RANDOMIZED PHASE 3
OPEN-LABEL STUDY
Speaker: Rafael Duarte, ES

GS2-6 CALCINEURIN INHIBITOR-FREE GRAFT-VERSUS-HOST 15:15 - 15:24

DISEASE (GVHD) PROPHYLAXIS IN HEMATOPOIETIC CELL
TRANSPLANTATION (HCT) WITH MYELOABLATIVE
CONDITIONING REGIMENS (MAC) AND HLA-MATCHED
DONORS: RESULTS OF THE BMT CTN 1301
Speaker: Leo Luznik, US

GS2-7 RESULTS OF A PHASE III RANDOMIZED, MULTICENTER STUDY 15:24 - 15:33

COMPARING OMIDUBICEL WITH STANDARD UMBILICAL CORD
BLOOD TRANSPLANTATION (UCBT) IN PATIENTS WITH HIGH-
RISK HEMATOLOGIC MALIGNANCIES FOLLOWING
MYELOABLATION
Speaker: Guillermo F. Sanz, ES

GS2-8 ELIVALDOGENE AUTOTEMCEL (ELI-CEL; LENTI-D) GENE 15:33 - 15:42

THERAPY FOR CEREBRAL ADRENOLEUKODYSTROPHY:

141 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

UPDATED RESULTS FROM THE PHASE 2/3 STUDY AND

SAFETY OUTCOMES REPORT FROM THE PHASE 3 STUDY
Speaker: Jörn-Sven Kühl, DE

GS2-9 A PROGNOSTIC SCORE INCLUDING MUTATION PROFILE AND 15:42 - 15:51

CLINICAL FEATURES FOR CMML UNDERGOING STEM CELL
TRANSPLANTATION
Speaker: Nico Gagelmann, DE

GS2-10 IMMUNE ESCAPE DRIVEN BY SOMATIC MUTATIONS IN CLASS 15:51 - 16:00

I/ II HLA ALLELES IN AML RELAPSING AFTER ALLOGENEIC
HSCT: A PIECE OF THE PUZZLE
Speaker: Simona Pagliuca, US

Nurses Group
14:30 - 16:00 Auditorium 3
NG03 - Relapse management
Chair: Marijke Quaghebeur, BE
Chair: Carina Paixao, PT
NG03-1 Decision-making: Ethical and multidisciplinary team issues 14:30 - 14:51
Speaker: Hilda Mekelenkamp, NL

NG03-2 Treatment options after relapse in lymphoma 14:51 - 15:10

Speaker: Daan Dierickx, BE

NG03-3 Psychological aspects 15:10 - 15:30

Speaker: Laura Díaz Sayas, ES

NG03-4 Q&A 15:30 - 16:00

Cell therapy
14:30 - 16:00 Auditorium 4
CTD3 - Cell Therapy Day: How to manage cell collection and processing during COVID 19
Chair: Per Ljungman, SE
Chair: Annalisa Ruggeri, ES
CTD3-1 Should we have a backup donor always? 14:30 - 14:50
Speaker: Catherine Faucher, FR

CTD3-2 Cryopreservation in case of unrelated donor 14:50 - 15:10

Speaker: Jesus Fernandez, ES

CTD3-3 Cryopreservation in case of related donor 15:10 - 15:25

Speaker: Boris Calmels, FR

CTD3-4 Role of Sars-Cov2 testing for donors in the workup 15:25 - 15:40
Speaker: Rafael de la Cámara, ES

CTD3-5 Q&A 15:40 - 16:00

142 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

Transplant and Search Coordinators Day

14:30 - 16:00 Auditorium 5
TSCD4 - Transplant and Search Coordinators Day: Family Donations
Chair: Nina Worel, AT
Chair: Suzanna van Walraven, NL
TSCD4-1 Children as donors – Psychological aspects 14:30 - 14:50
Speaker: Galen Switzer, US

TSCD4-2 International Family Donation – How Registries can help 14:50 - 15:10
Speaker: Paul Johnson, GB

TSCD4-3 Follow up on related donors – the Swiss solution 15:10 - 15:30

Speaker: Grazia Nicoloso, CH

TSCD4-4 Q&A 15:30 - 15:45

Psy Day
14:30 - 15:10 Auditorium 6
Psy4 - Abstract Session
Psy4-1 A CROSS-SECTIONAL STUDY OF THE PSYCHOSOCIAL ISSUES 14:30 - 14:40
EXPERIENCED BY PATIENTS WITH LYMPHOMA TREATED
WITH STEM CELL TRANSPLANT
Speaker: Natalie Dren, CA

Psy4-2 THE EBMT PSY DAY HAS INSPIRED THE DEVELOPMENT OF A 14:40 - 14:55
UK PSY DAY
Speaker: Henrietta Saunders, GB

Psy4-3 PATIENT-CAREGIVER ADAPTATION TO HCT – THE ROLE OF 14:55 - 15:05

THE EFFICACY BELIEFS AND RECEIVED SUPPORT
Speaker: Malgorzata Sobczyk-Kruszelnicka, PL

Psy4-4 Conclusions and remarks 15:05 - 15:10

Speaker: Anna Barata, US

Breaks
16:00 - 16:30 Auditorium 1
Coffee Break, Poster Viewing, Visit Exhibition

Special Session
16:30 - 18:00 Auditorium 1
SS02 - COVID 1: Immunotherapy in COVID-19: a year's worth of experience
Chair: Christian Chabannon, FR
Chair: Malgorzata Mikulska, IT
SS2-1 Humoral immunotherapy with convalescent plasma 16:30 - 16:48
Speaker: Liise-Anne Pirofski, US

SS2-2 Adoptive cellular therapy with SARS?CoV2?memory T cells 16:48 - 17:06

Speaker: Antonio Pérez-Martínez, ES

SS2-3 Immunomodulatory therapy with MSC 17:06 - 17:24

Speaker: Rafael Duarte, ES

143 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

SS2-4 SARS-CoV-2 Vaccination 17:24 - 17:42

Speaker: Steve Pergam, US

SS2-5 Q&A 17:42 - 18:00

Joint Session
16:30 - 17:30 Auditorium 2
JS01 - Joint session KSBMT: Role of ATG in MUD and HLA identical sibling transplantation: Korean and Europ
experience
Chair: Nicolaus Kröger, DE
Chair: Hoon Kook, KR
JS1-1 European Experience and recommendation 16:30 - 16:50
Speaker: Francesca Bonifazi, IT

JS1-2 Korean Experience and recommendation: Role of ATG in HLA- 16:50 - 17:10
identical sibling transplantation
Speaker: Byung-Sik Cho, KR

JS1-3 Q&A 17:10 - 17:30

How do I … ?
16:30 - 17:45 Auditorium 3
HDI2 - How Do I... manage the evolving role of the haematology nurse – lifelong learning with new horizons? -
Session - Supported through an unrestricted educational grant by Janssen
Chair: Michelle Kenyon, GB
HDI2-1 Introduction 16:30 - 16:35
Speaker: Michelle Kenyon, GB

HDI2-2 The Role of the Clinical Nurse Specialist 16:35 - 16:50

Speaker: Emma Whitham, GB

HDI2-3 A typical day as an Advanced Nurse Practitioner in the out- 16:50 - 17:05
patient clinic
Speaker: Theo Nering Bögel, NL

HDI2-4 Educating with new therapies 17:05 - 17:20

Speaker: Maaike de Ruijter, NL

HDI2-5 Q&A and session close 17:20 - 17:45

Joint Session
16:30 - 18:00 Auditorium 5
JS02 - Joint session ASTCT/CIBMTR/APBMT: Transplantation and Cell Therapy During Pandemics
Chair: Nicolaus Kröger, DE
Chair: Stella Davies, US
Chair: Marcie Riches, US
Chair: Alok Srivastav, IN
JS2-1 US Experience: Pandemics and Transplantation/Cell therapy 16:30 - 16:48
Speaker: Alpana Waghmare, US

JS2-2 The CIBMTR COVID Experience: Challenges for research and 16:48 - 17:06

144 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

how COVID has changed transplant practice

Speaker: Marcie Riches, US

JS2-3 The IDWP-EBMT COVID 19 Experience 17:06 - 17:24

Speaker: Rafael de la Cámara, ES

JS2-4 Asian-Pacific Experience: Allo-HSCT and CAR-T cell treatment 17:24 - 17:42
during COVID 19 pandemic
Speaker: Yongxian Hu, CN

Q&A 17:42 - 18:00

Special Session
16:30 - 18:00 Auditorium 6
SS03 - Global Committee Session: The present place of CAR T-cells in the context of stem cell transplantation
the world
Chair: Norbert-Claude Gorin, FR
SS3-1 Introduction and welcome 16:30 - 16:32
Speaker: Norbert-Claude Gorin, FR

SS3-2 CAR T-cells and autologous stem cell transplantation: A 16:32 - 16:46
chinese vision
Speaker: He Huang, CN

SS3-3 CAR T cells and allogeneic stem cell transplantation: a vision 16:46 - 17:00
from Israel
Speaker: Arnon Nagler, IL

SS3-4 CAR T-cells and stem cell transplantation: A japanese vision 17:00 - 17:14
Speaker: Shinichiro Okamoto, JP

SS3-5 A new target: CAR T-cells anti IL1 RAP for the treatment of 17:14 - 17:28
AML?
Speaker: Christophe Ferrand, FR

SS3-6 CAR T-cells and stem cell transplantation in Latin America 17:28 - 17:42
Speaker: Renato Luis Guerino Cunha, BR

SS3-7 Summing up and conclusion 17:42 - 17:44

SS3-8 Q&A 17:44 - 18:00

Cell therapy
16:40 - 18:00 Auditorium 4
CTD4 - Cell Therapy Day: Point of care manufacturing for Immune Effector Cells based medicinal products
Chair: Ulrike Köhl, DE
Chair: Stephan Mielke, SE
CTD4-1 Donor derived CD19 CAR-T cell therapy of relapsed B-ALL post- 16:40 - 17:02
allotransplant
Speaker: Marcelo Pasquini, US

CTD4-2 TGFb-resistant NK cells for Cancer 17:02 - 17:20

Speaker: Catherine Bollard, US

145 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

CTD4-3 Immunotherapies in Haplo HCT with PTCy 17:20 - 17:35

Speaker: Nicole Santoro, IT

CTD4-4 Q&A 17:35 - 18:00

Meet the Expert

18:00 - 19:00 MTE rooms
Meet the Expert sessions
MTE-1 Allogeneic CAR T cells: Progress and challenges - Room MTE1 18:00 - 18:00
Speaker: Reuben Benjamin, GB

MTE-2 Current role of HSCT in Acute Promyelocytic Leukemia - Room 18:00 - 18:00
MTE2
Speaker: Pau Montesinos, ES

MTE-3 Improving results of HSCT in adult ALL - Room MTE3 18:00 - 18:00
Speaker: Josep M. Ribera, ES

MTE-4 How to diagnose and manage TA-TMA in 2021 - Room MTE4 18:00 - 18:00
Speaker: Vincent Ho, US

MTE-5 The role of allogeneic HSCT in CLL in 2021 - Room MTE5 18:00 - 18:00
Speaker: Peter Dreger, DE

Abstract Awards
18:10 - 19:10 Auditorium 2
AA1 - EBMT Talks: Live with best abstracts
Chair: Nicolaus Kröger, DE
Chair: Rafael Duarte, ES
VAN BEKKUM AWARD - POST-TRANSPLANTATION 18:10 - 18:10
CYCLOPHOSPHAMIDE VERSUS ANTITHYMOCYTE GLOBULIN
AFTER RIC REGIMEN ALLO-HCT: FIRST ANALYSIS OF A
PROSPECTIVE RANDOMIZED MULTICENTER TRIAL IN
RECIPIENTS OF 10/10 MATCHED DONORS
Speaker: Eolia Brissot, FR

JON J. VAN ROOD AWARD - METABOLIC REPROGRAMMING 18:10 - 18:10

OF DONOR T CELLS ENHANCES GRAFT-VERSUS-LEUKEMIA
EFFECTS IN MICE AND HUMANS
Read Abstract
Speaker: Franziska Uhl, DE

BASIC SCIENCE AWARD - HOST INTESTINAL TISSUE 18:10 - 18:10

RESIDENT MACROPHAGES PROTECT AGAINST MURINE
INTESTINAL ACUTE GRAFT-VERSUS-HOST DISEASE
Speaker: Duc-Dung Le, DE

JIAN JIAN LUAN AWARD - STANDARD-OF-CARE CAR-T CELL 18:10 - 18:10

THERAPY FOR LARGE B-CELL LYMPHOMA: REAL WORLD
DATA GERMANY
Speaker: Wolfgang Andreas Bethge, DE

146 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

PRESIDENTIAL ABSTRACT - MARIBAVIR VERSUS 18:10 - 18:10

INVESTIGATOR-ASSIGNED THERAPY (IAT) FOR THE
TREATMENT OF TRANSPLANT RECIPIENTS WITH
REFRACTORY/RESISTANT (R/R) CYTOMEGALOVIRUS
INFECTION: EFFICACY DATA FROM A RANDOMIZED PHASE 3
OPEN-LABEL STUDY
Speaker: Rafael Duarte, ES

PRESIDENTIAL ABSTRACT - RESULTS OF A PHASE III 18:10 - 18:10

RANDOMIZED, MULTICENTER STUDY COMPARING
OMIDUBICEL WITH STANDARD UMBILICAL CORD BLOOD
TRANSPLANTATION (UCBT) IN PATIENTS WITH HIGH-RISK
HEMATOLOGIC MALIGNANCIES FOLLOWING
MYELOABLATION
Speaker: Guillermo F. Sanz, ES

PRESIDENTIAL ABSTRACT - ELIVALDOGENE AUTOTEMCEL 18:10 - 18:10

(ELI-CEL; LENTI-D) GENE THERAPY FOR CEREBRAL
ADRENOLEUKODYSTROPHY: UPDATED RESULTS FROM THE
PHASE 2/3 STUDY AND SAFETY OUTCOMES REPORT FROM
THE PHASE 3 STUDY
Speaker: Jörn-Sven Kühl, DE

PRESIDENTIAL ABSTRACT - A PROGNOSTIC SCORE 18:10 - 18:10

INCLUDING MUTATION PROFILE AND CLINICAL FEATURES
FOR CMML UNDERGOING STEM CELL TRANSPLANTATION
Speaker: Nico Gagelmann, DE

PRESIDENTIAL ABSTRACT - IMMUNE ESCAPE DRIVEN BY 18:10 - 18:10

SOMATIC MUTATIONS IN CLASS I/ II HLA ALLELES IN AML
RELAPSING AFTER ALLOGENEIC HSCT: A PIECE OF THE
PUZZLE
Speaker: Simona Pagliuca, US

147 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

Tuesday, 16. March 2021

Quality Management
08:00 - 09:00 MTE rooms
QM MTE - Quality Management Meet the Expert sessions (pre-registration required)
QM MTE-1 Risk & Change Management - Room MTE1 -
Speaker: Olga López Villar, ES
Speaker: Dieter Klarmann, DE

QM MTE-2 Audits & Document Development and Control - Room MTE2 -

Speaker: Julie Dolva, NO
Speaker: Renza Monteleone, IT

QM MTE-3 Adverse events & CAPA - Room MTE3 -

Speaker: Anne Emmett, GB

QM MTE-4 Maintaining the QM program and QM plan - Room MTE4 -

Speaker: Phuong Huynh, BE
Speaker: Nick van Sinderen, NL

QM MTE-5 Outcome analysis and benchmarking & Validation and -

verification - Room MTE5
Speaker: Mara Magri, IT
Speaker: Kim Orchard, GB

QM MTE-6 Personnel, Training and Competency - Room MTE6 -

Speaker: Sarah Holtby, GB

Educational
09:15 - 10:30 Auditorium 1
E03 - What's new in the pathophysiology and treatment of patient complications?
Chair: Francesca Bonifazi, IT
Chair: Gustavo Kusminsky, AR
E3-1 Updates on early transplant complications - VOD/SOS and TMA 09:15 - 09:30
Speaker: Vincent Ho, US

E3-2 Regulation of GVHD by promoting tissue tolerance 09:30 - 09:45

Speaker: Pavan Reddy, US

E3-3 Chronic GVHD 09:45 - 10:00

Speaker: José Antonio Pérez-Simón, ES

E3-4 Q&A 10:00 - 10:30

Educational
09:15 - 10:30 Auditorium 2
E04 - Doubts and evidences in the treatment of Relapsed/Refractory Lymphoid Malignancies
Chair: Bertram Glass, DE
Chair: Dolores Caballero, ES
E4-1 The case of follicular lymphoma 09:15 - 09:30
Speaker: Silvia Montoto, GB

148 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

E4-2 How to sequence cell-based therapies in Mantle Cell Lymphoma 09:30 - 09:45
Speaker: Mehdi Hamadani, US

E4-3 The case of Hodgkin's lymphoma 09:45 - 10:00

Speaker: Paolo Corradini, IT

E4-4 Q&A 10:00 - 10:30

Paediatric Day
09:15 - 10:30 Auditorium 4
Paed1 - Paediatric Diseases Working Party Session
Chair: Selim Corbacioglu, DE
Chair: Anita Lawitschka, AT
Paed1-1 CMV-associated thymus dysfunction independently increase 09:15 - 09:30
the risk of chronic GVHD
Speaker: Katrine Kielsen, DK

Paed1-2 Specific CAR-T targets in Pediatric AML 09:30 - 09:45

Speaker: Tobias Feuchtinger, DE

Paed1-3 Is there a role for CNS boost with transplant in ALL? 09:45 - 10:00
Speaker: Anna Marie Ewins, GB

Paed1-4 NIH Consensus Project 2020: Therapy of established cGvHD 10:00 - 10:15
Speaker: Hildegard Greinix, AT

Paed1-5 Q&A 10:15 - 10:30

Pharmacists Day
09:15 - 10:30 Auditorium 5
Pharm1 - Pharmacotherapy in SCT
Chair: Maria Estela Moreno Martínez, ES
Chair: Claudia Langebrake, DE
Pharm1-1 Current evidence for TDM in HSCT: An overview 09:15 - 09:35
Speaker: Vera Domingos, PT

Pharm1-2 Treosulfan-containing regimens for patients with malignant and 09:35 - 09:55
non-malignant disorders
Speaker: Krzysztof Kalwak, PL

Pharm1-3 Individualized treatment in pediatric stem cell transplantation: 09:55 - 10:15

therapeutic drug monitoring and pharmacogenetics
Speaker: Eileen van der Stoep, NL

Pharm1-4 Q&A 10:15 - 10:30

Special Session
09:15 - 10:30 Auditorium 6
SS04 - EBMT Benchmarking - A key quality improvement tool
Chair: Carlos Solano, ES
Chair: Eoin McGrath, ES

149 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

SS4-1 Project update 09:15 - 09:30

Speaker: John Snowden, GB

SS4-2 Methodological aspects of EBMT benchmarking 09:30 - 09:45

Speaker: Hein Putter, NL

SS4-3 Results so far 09:45 - 10:00

Speaker: Riccardo Saccardi, IT

SS4-4 Next steps - Gaining confidence 10:00 - 10:15

Speaker: Kim Orchard, GB

SS4-5 Round table: Will benchmarking replace the need for 10:15 - 10:30
accreditation?

Industrial Theatre
09:15 - 17:30 IT
IT2 - Developing the Future of CAR-T Cell Therapy Today - Novartis Industry Theatre session
This session is available throughout the whole congress
Chair: Amir Hefni, GB
Chair: David Kuzan, US
Chair: Carolin Barth, CH

Industrial Theatre
09:15 - 17:30 IT
IT1 - Kite as innovators in CAR T-cell therapy manufacturing and delivery - Kite-Gilead Industry Theatre sessio
This session is available throughout the whole congress
Chair: Dick Sundh, AU

Industrial Theatre
09:15 - 17:30 IT
IT3 - Amicus Blue in Children and Adolescents with GVHD - Fresenius Kabi Industry Theatre session
This session is available throughout the whole congress
Chair: Volker Witt, AT

Industrial Theatre
09:15 - 17:30 IT
Industry Theatre sessions

Data Management
09:15 - 17:30 On-Demand Library
DM05 - Education session 5
This session is available in our on-demand library throughout the whole congress
DM5-1 Hematopoietic Cell Transplantation-Comorbidity Index ‘Sorror -
Score’
Speaker: Bronwen Shaw, US

150 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

Workshop
09:15 - 17:30 On-Demand Library
W13 - CARs beyond T cells: A focus on next generation CAR-NK cells
This session is available in our on-demand library throughout the whole congress
W13-1 CAR NK cells as an "off the shelf" immunotherapy -
Speaker: Ulrike Köhl, DE

W13-2 CARs and ADCC to make off-the-shelf NK cells specific against -

hematologic malignancies
Speaker: Jeffrey Miller, US

W13-3 Target NKG2D ligands on tumor cells -

Speaker: Antonio Pérez-Martínez, ES

Workshop
09:15 - 17:30 On-Demand Library
W10 - Controversies in T-cell NHL
This session is available in our on-demand library throughout the whole congress
W10-1 Are we improving first-line therapy in TCL? 09:15 - 09:15
Speaker: Eva Domingo Domenech, ES

W10-3 Insights in CAR-T therapy for T cell Lymphomas 09:15 - 09:15

Speaker: Helen Heslop, US

Educational
09:15 - 17:30 On-Demand Library
E08 - New challenges in infectious complications
This session is available in our on-demand library throughout the whole congress
E8-1 T-cell therapy for infections in SCT patients: An experimental -
treatment or a real choice for the practice?
Speaker: Patrizia Comoli, IT

E8-2 Infectious complications with new drugs in Hematology -

Speaker: Georg Maschmeyer, DE

E8-3 The blood virome of HSCT Recipients: Much more than viremia -
by CMV, EBV, HH6V and adenovirus
Speaker: Marie-Celine Zanella, CH

Special Session
09:15 - 17:30 On-Demand Library
SS10 - The HARMONY Alliance: Accelerating better and faster treatment for patients with blood cancer
This session is available in our on-demand library throughout the whole congress
SS10-1 General Overview of the HARMONY Alliance: Progress, -
Achievements & Results of HARMONY and HARMONY PLUS
projects
Speaker: Jesús Maria Hernández Rivas, ES

SS10-2 Envisioned contribution of the EBMT to the HARMONY Alliance -

Speaker: Guillermo Sanz Santillana, ES

151 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

Speaker: Yann Guillevic, CH

SS10-3 EBMT participation in the HARMONY Alliance -

Speaker: Anna Sureda, ES

SS10-4 HARMONY & HARMONY PLUS Research Projects / Outcomes -

definition
Speaker: Lars Bullinger, DE

SS10-5 HARMONY Platform -

Speaker: Ana Heredia Casanoves, ES

On Demand Library
09:15 - 17:30 On-Demand Library
On Demand Library

Nurses Group
09:15 - 17:30 On-Demand Library
NG23 - Oral session 2: Abstracts session
This session is available in our on-demand library throughout the whole congress
NG23-1 EFFICACY AND SAFETY OF A COLOSTRUM BASED ORAL 09:15 - 09:15
CARE PROTOCOL FOR THE PREVENTION AND TREATMENT
OF ORAL MUCOSITIS IN STEM CELL TRANSPLANT
RECIPIENTS
Speaker: Monica Guberti, IT

NG23-2 PATIENT-TO-NURSE STAFFING RATIO IN HEMATOPOIETIC 09:15 - 09:15

STEM CELL TRANSPLANT AND ADVANCED CELL THERAPY
UNITS IN SPAIN, HIGHLY NEEDED BUT CHALLENGING
Speaker: Julia Ruiz Pato, ES

NG23-3 ROOT CAUSE ANALYSIS TO IDENTIFY AND PREVENT FALL 09:15 - 09:15
CAUSES IN ALLOGENEIC HEMATOPOIETIC STEM CELL
TRANSPLANTATION PATIENTS
Speaker: Franziska Michaela Lohmeyer, IT

NG23-4 MAPPING THE NURSES' COMPETENCIES IN PAEDIATRIC 09:15 - 09:15

ONCO-HAEMATOLOGY AND HAEMATOPOIETIC STEM CELL
TRANSPLANTATION SETTING AND THEIR MAINTENANCE
OVER TIME
Speaker: Alberto Castagna, IT

NG23-5 EFFECTIVENESS OF AN EDUCATIONAL INTERVENTION FOR 09:15 - 09:15

INFLUENZA VACCINATION IN HEMATOPOIETIC STEM CELL
TRANSPLANT PATIENTS AND THEIR COHABITANTS
Speaker: Maria Teresa Solano Moliner, ES

Oral Session
09:15 - 17:30 On-Demand Library
OS06 - Oral session 6: Experimental Transplantation, Minimal Residual Disease, Immune Reconstitution and C
This session is available in our on-demand library throughout the whole congress
OS6-1 COMPARATIVE ANALYSIS OF IMMUNE RECONSTITUTION IN 09:15 - 09:15

152 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

HSCT PATIENTS WITH PT-CY OR ATG REVEALS DISTINCT T

CELL IMMUNE RECONSTITUTION PATTERNS
Speaker: Saskia Leserer, DE

OS6-2 MINIMAL RESIDUAL DISEASE AND CHIMERISM ANALYSIS 09:15 - 09:15

USING CIRCULATING CELL-FREE DNA AFTER ALLOGENEIC
HEMATOPOIETIC CELL TRANSPLANTATION
Speaker: Sandra Pennisi, DE

OS6-3 SEQUENTIAL QUANTIFICATION OF T-CELL RECEPTOR 09:15 - 09:15

EXCISION CIRCLES (TRECS) AND K-DELETING
RECOMBINATION EXCISION CIRCLES (KRECS) IN
ALLOGENEIC HEMATOPOIETIC STEM CELL
TRANSPLANTATION (ALLOHSCT) RECIPIENTS
Speaker: Carlos De Miguel Jiménez, ES

OS6-4 MUTATIONAL CONSEQUENCES OF HEMATOPOIETIC STEM 09:15 - 09:15

CELL TRANSPLANTATION IN HUMANS
Speaker: Mirjam Belderbos, NL

OS6-5 OVER-EXPRESSION OF HIF-1? IN MESENCHYMAL STROMAL 09:15 - 09:15

CELLS INCREASES HUMAN CD34+ CELLS CLONOGENIC
CAPACITY IN VITRO AND ENGRAFTMENT ABILITY IN A
XENOTRANSPLANTATION MODEL
Speaker: Silvia Preciado, ES

OS6-6 ALEMTUZUMAB BASED-CONDITIONING FOR NON-MALIGNANT 09:15 - 09:15

PAEDIATRIC DISEASES DEPLETES DONOR T-CELLS
ALLOWING EXCEPTIONALLY LOW RATES OF GVHD BUT
ALLOWS PERSISTENCE OF RESIDUAL, AUTOLOGOUS, VIRUS-
SPECIFIC T-CELLS
Speaker: Rubiya Nadaf, GB

OS6-7 TCR REPERTOIRE DYNAMICS AFTER HEMATOPOIETIC STEM 09:15 - 09:15

CELL TRANSPLANTATION IN MYELOID MALIGNANCIES
Speaker: Simona Pagliuca, US

OS6-8 DAY +60 WT1 ASSESSMENT ON BONE MARROW MIGHT 09:15 - 09:15
PREDICT RELAPSE AND MORTALITY AFTER ALLOGENEIC
STEM CELL TRANSPLANTATION
Speaker: Patrizia Chiusolo, IT

Oral Session
09:15 - 17:30 On-Demand Library
OS11 - Oral session 11: Infectious Diseases I
This session is available in our on-demand library throughout the whole congress
OS11-1 POLYMORPHISMS WITHIN THE TNFSF4 AND MAPKAPK2 LOCI 09:15 - 09:25
INFLUENCE THE RISK OF INVASIVE ASPERGILLOSIS: A TWO-
STAGE CASE CONTROL STUDY IN THE CONTEXT OF THE
ASPBIOMICS CONSORTIUM
Speaker: Ana Moniz-Díez, ES

OS11-2 THE ASSOCIATION BETWEEN CYTOMEGALOVIRUS AND 09:25 - 09:35

INVASIVE FUNGAL INFECTIONS IN ALLOGENEIC

153 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS: A

SYSTEMATIC REVIEW AND META-ANALYSIS
Speaker: Nipat Chuleerarux, TH

OS11-3 IMMUNE RECONSTITUTION DURING CMV PROPHILAXIS BY 09:35 - 09:45

LETERMOVIR: A SINGLE CENTER EXPERIENCE
Speaker: Ilaria Cutini, IT

OS11-4 LETERMOVIR PROPHYLAXIS FOR CYTOMEGALOVIRUS 09:45 - 09:55

REACTIVATION IN ALLOGENEIC STEM CELL
TRANSPLANTATION: A MULTICENTER ITALIAN REAL-WORLD
EXPERIENCE
Speaker: Massimo Martino, IT

OS11-5 PREVENTION OF INVASIVE FUNGAL INFECTION IN HAPLO 09:55 - 10:05

TRANSPLANTATION WITH POST-TRANSPLANTATION
CYCLOPHOSPHAMIDE. UNIVERSAL FLUCONAZOLE
PROPHYLAXIS AND A MOULD DIAGNOSTIC-DIRECTED
APPROACH. RESULTS IN 112 PATIENTS
Speaker: Amado Karduss -Urueta, CO

OS11-6 PATTERN OF FUNGAL INFECTIONS DURING THE INITIAL 100 10:05 - 10:15
DAYS IN CHILDREN UNDERGOING HEMATOPOIETIC STEM
CELL TRANSPLANTATION FROM A TERTIARY REFERRAL
CENTER IN INDIA
Speaker: Harika Varla, IN

OS11-7 THE MANAGEMENT OF CLOSTRIDIOIDES DIFFICILE 10:15 - 10:25

INFECTIONS IN PATIENTS AFTER ALLOGENEIC
HEMATOPOIETIC CELL TRANSPLANTATION: THE RESULTS OF
THE INFECTIOUS DISEASES WORKING PARTY EBMT SURVEY
Speaker: Agnieszka Piekarska, PL

OS11-8 CLINICAL DIAGNOSTIC AND THERAPEUTIC STRATIFICATION 10:25 - 10:35

OF INVASIVE FUNGAL DISEASE IN ADULT PATIENTS WITH
HEMATOLOGY MALIGNANCIES: A REAL-WORLD
OBSERVATIONAL STUDY
Speaker: Sizhou Feng, CN

Oral Session
09:15 - 17:30 On-Demand Library
OS12 - Oral session 12: Infectious Diseases II
This session is available in our on-demand library throughout the whole congress
OS12-1 NOCARDIOSIS FOLLOWING HEMATOPOIETIC CELL 09:15 - 09:15
TRANSPLANTATION: 20 YEARS' EXPERIENCE. THE
INTERNATIONAL STUDY OF INFECTIOUS DISEASES WORKING
PARTY OF EBMT AND FRANCO-BELGIAN NOCARDIA STUDY
GROUP
Speaker: Dina Averbuch, IL

OS12-2 COLONIZATION-GUIDED PROTOCOL FOR EMPIRICAL 09:15 - 09:15

ANTIBIOTIC THERAPY IN ALLO-HSCT RECIPIENTS: FIRST
RESULTS OF A SINGLE CENTER PROSPECTIVE STUDY

154 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

Speaker: Marina Popova, RU

OS12-3 COLONIZATION BY MULTIDRUG-RESISTANT GRAM-NEGATIVE 09:15 - 09:15

BACTERIA IN EARLY PHASE OF HEMATOPOIETIC STEM CELL
TRANSPLANTATION
Speaker: Yuliya Rogacheva, RU

OS12-4 FAVOURABLE OUTCOME AND NO INCREASED RISK OF GVHD 09:15 - 09:15

IN PATIENTS DEVELOPING C.DIFFICILE INFECTION AFTER
HEMATOPOIETIC STEM CELL TRANSPLANTS
Speaker: Chiara Rosignoli, IT

OS12-5 CLINICAL IMPACT OF DE-ESCALATION/DISCONTINUATION OF 09:15 - 09:15

ANTIBIOTICS PRIOR TO NEUTROPHIL RECOVERY IN
PATIENTS UNDERGOING HEMATOPOIETIC STEM CELL
TRANSPLANTATION: A SINGLE-CENTRE EXPERIENCE
Speaker: Anke Verlinden, BE

OS12-6 COLONIZATION WITH MULTIDRUG-RESISTANT BACTERIA AND 09:15 - 09:15

DISEASE RISK INDEX ARE TWO INDEPENDENT FACTORS
THAT AFFECT THE SURVIVAL OF PATIENTS AFTER
ALLOGENEIC HAEMATOPOIETIC STEM CELL
TRANSPLANTATION
Speaker: Anna Czyz, PL

OS12-7 IMPACT OF FLUOROQUINOLONE PROPHYLAXIS IN 09:15 - 09:15

ALLOGENEIC HEMATOPOIETIC STEM CELL
TRANSPLANTATION; SINGLE CENTER EXPERIENCE
Speaker: Eshrak Al-Shaibani, CA

OS12-8 STRONG INFLAMMATORY CYTOKINE RESPONSE AFTER 09:15 - 09:15

HAPLOIDENTICAL HEMATOPOIETIC STEM CELL
TRANSPLANTATION WITH POST-TRANSPLANT
CYCLOPHOSPHAMIDE RELATES TO HUMAN HERPESVIRUS 6
REACTIVATION
Speaker: Kenichiro Takeda, JP

Oral Session
09:15 - 17:30 On-Demand Library
OS13 - Oral session 13: Transplant Complications I
This session is available in our on-demand library throughout the whole congress
OS13-1 FINAL PRIMARY RESULTS FROM THE DEFIFRANCE REGISTRY 09:15 - 09:15
STUDY: EFFECTIVENESS AND SAFETY OF DEFIBROTIDE FOR
TREATMENT OF HEPATIC VENO-OCCLUSIVE
DISEASE/SINUSOIDAL OBSTRUCTION SYNDROME AFTER
HAEMATOPOIETIC CELL TRANSPLANTATION
Speaker: Mohamad Mohty, FR

OS13-2 ASSOCIATION OF PRE-EXISTING COMORBIDITIES WITH 09:15 - 09:15

OUTCOME OF ALLOGENEIC STEM CELL TRANSPLANTATION.
A RETROSPECTIVE ANALYSIS FROM THE EBMT
Speaker: Olaf Penack, DE

OS13-3 DEFIBROTIDE PROPHYLAXIS FOR VENO-OCCLUSIVE 09:15 - 09:15

155 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

DISEASE/SINUSOIDAL OBSTRUCTION SYNDROME (VOD/SOS)

AFTER HAEMATOPOIETIC CELL TRANSPLANTATION (HCT):
ANALYSIS OF A MULTICENTRE, MULTINATIONAL,
PROSPECTIVE, OBSERVATIONAL REGISTRY STUDY (EBMT
PASS)
Speaker: Mohamad Mohty, FR

OS13-4 EBMT PASS: OUTCOMES OF DEFIBROTIDE-TREATED 09:15 - 09:15

PATIENTS WITH ANICTERIC/ICTERIC VENO-OCCLUSIVE
DISEASE/SINUSOIDAL OBSTRUCTION SYNDROME (VOD/SOS)
AFTER HAEMATOPOIETIC CELL TRANSPLANTATION (HCT)
Speaker: Mohamad Mohty, FR

OS13-5 EASIX SCORE PREDICTS OVERALL SURVIVAL, NON-RELAPSE 09:15 - 09:15

MORTALITY AND THE RISK OF INTENSIVE CARE UNIT
ADMISSION AT PRE-TRANSPLANT EVALUATION
Speaker: Marta Peña Domingo, ES

OS13-6 THE INCIDENCE OF SEVERE ORAL MUCOSITIS AND TASTE 09:15 - 09:15
DISTURBANCE IN PATIENTS UNDERGOING DIFFERENT
CONDITIONING REGIMENS IN HEMATOPOIETIC STEM CELL
TRANSPLANTATION
Speaker: Midori Nakagaki, AU

OS13-7 IMPACT OF SIROLIMUS/TACROLIMUS-BASED GRAFT-VERSUS- 09:15 - 09:15

HOST-DISEASE PROPHYLAXIS ON THE DEVELOPMENT OF
EARLY AND LATE TRANSPLANT-ASSOCIATED THROMBOTIC
MICROANGIOPATHY
Speaker: Aldo A Acosta-Medina, US

OS13-8 RISK FACTORS FOR SINUSOIDAL OBSTRUCTION SYNDROME 09:15 - 09:15

OF THE LIVER AFTER ALLOGENEIC HEMATOPOIETIC STEM
CELL TRANSPLANTATION IN CHILDHOOD
Speaker: Bernd Gruhn, DE

Oral Session
09:15 - 17:30 On-Demand Library
OS14 - Oral session 14: Transplant Complications II
This session is available in our on-demand library throughout the whole congress
OS14-1 PREGNANCY AND PREGNANCY OUTCOMES AFTER 09:15 - 09:15
HEMATOPOIETIC STEM CELL TRANSPLANTATION DURING
CHILDHOOD: A CROSS-SECTIONAL SURVEY OF THE EBMT
PEDIATRIC WP
Speaker: Tamara Diesch, CH

OS14-2 ONE THOUSAND VOICES ADDRESS PATIENT ENGAGEMENT IN 09:15 - 09:15

HEMATOPOIETIC STEM CELL TRANSPLANTATION AND CELL
THERAPY: RESULTS OF A SURVEY FROM THE EBMT
Speaker: Helene Schoemans, BE

OS14-3 CHRONIC KIDNEY DISEASE TEN YEARS AFTER PEDIATRIC 09:15 - 09:15
ALLOGENEIC HEMATOPOIETIC STEM CELL
TRANSPLANTATION

156 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

Speaker: Gertjan Lugthart, NL

OS14-4 NEUROLOGIC COMPLICATIONS AFTER ALLOGENEIC STEM 09:15 - 09:15

CELL TRANSPLANTATION: ANALYSIS OF RISK FACTORS. A
SINGLE CENTER STUDY OVER 20 YEARS OF FOLLOW-UP

OS14-5 AN UPDATED SYSTEMATIC REVIEW OF STUDIES ON 09:15 - 09:15

DEFIBROTIDE PROPHYLAXIS FOR VENO?OCCLUSIVE
DISEASE/SINUSOIDAL OBSTRUCTION SYNDROME (VOD/SOS)
Speaker: Selim Corbacioglu, DE

OS14-6 PROGNOSTIC BIOMARKER SIGNATURE FOR HEPATIC VENO- 09:15 - 09:15

OCCLUSIVE DISEASE/SINUSOIDAL OBSTRUCTION SYNDROME
(VOD/SOS) IN RECIPIENTS OF MYELOABLATIVE (MA)
ALLOGENEIC HAEMATOPOIETIC CELL TRANSPLANTATION
(HCT)
Speaker: Santosh Putta, US

OS14-7 OUTCOME AFTER ADMISSION TO INTENSIVE CARE UNIT (ICU) 09:15 - 09:15
IN HEMATOPOIETIC TRANSPLANT RECIPIENTS: SINGLE
CENTRE EXPERIENCE
Speaker: Isabel Iturrate, ES

OS14-8 DISTRIBUTION AND IMPACT OF ACUTE KIDNEY INJURY IN AT- 09:15 - 09:15
HOME ALLOGENEIC BONE MARROW TRANSPLANTATION
MODELS
Speaker: Marta Garcia-Recio, ES

Oral Session
09:15 - 17:30 On-Demand Library
OS15 - Oral session 15: Conditioning Regimens
This session is available in our on-demand library throughout the whole congress
OS15-1 BENDAMUSTINE-BASED CONDITIONING PRIOR TO 09:15 - 09:25
AUTOLOGOUS HEMATOPOIETIC CELL TRANSPLANT
IMPROVES OUTCOMES IN PATIENTS WITH ELAPSED-
REFRACTORY NON-HODGKIN LYMPHOMA
Speaker: Sylvie Lachance, CA

OS15-2 MICROBIOTA INJURY IS CONDITIONING REGIMEN- 09:25 - 09:35

DEPENDENT IN ALLOGENEIC HEMATOPOIETIC CELL
TRANSPLANTATION RECIPIENTS
Speaker: Roni Shouval, US

OS15-3 THE IMPACT OF PULMONARY FUNCTION IN PATIENTS 09:35 - 09:45

UNDERGOING AUTOLOGOUS STEM CELL TRANSPLANTATION
Speaker: Jesus Duque-Afonso, DE

OS15-4 HIGH INCIDENCE OF GVHD WITH TBF CONDITIONING IN 09:45 - 09:55

HEMATOLOGIC MALIGNANCIES: A SINGLE CENTER
EXPERIENCE
Speaker: Khalid Halahleh, JO

OS15-5 THIOTEPA BUSULFAN AND FLUDARABINE (TBF) PATIENTS 09:55 - 10:05

WITH ACUTE MYELOID LEUKEMIA IN COMPLETE REMISSION

157 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

:A RETROSPECTIVE ANALYSIS ON 221 PATIENTS AND 369

CONTROLS
Speaker: Federica Sora, IT

OS15-6 IMPACT OF THE ADDITION OF ANTITHYMOCYTE GLOBULIN TO 10:05 - 10:15

POST-TRANSPLANT CYCLOPHOSPHAMIDE IN
HAPLOIDENTICAL TRANSPLANTATION WITH PERIPHERAL
BLOOD COMPARED TO POST-TRANSPLANT
CYCLOPHOSPHAMIDE ALONE
Speaker: Giorgia Battipaglia, IT

OS15-7 HEMATOPOIETIC CELL TRANSPLANTATION COMORBIDITY 10:15 - 10:25

INDEX (HCT-CI) AND OUTCOME AFTER NON-MYELOABLATIVE
ALLOGENEIC STEM CELL TRANSPLANTATION IN ACUTE
MYELOID LEUKEMIA (AML) PATIENTS OLDER THAN 60 YEARS
Speaker: Donata Backhaus, DE

OS15-8 SEQUENTIAL FLAMSA-BU VERSUS FLUBU2 IN PATIENTS WITH 10:25 - 10:35

ACTIVE RELAPSED OR REFRACTORY ACUTE MYELOID
LEUKEMIA: A STUDY FROM THE ACUTE LEUKEMIA WORKING
PARTY OF THE EBMT
Speaker: Eduardo Rodríguez-Arbolí, ES

Oral Session
09:15 - 17:30 On-Demand Library
OS16 - Oral session 16: Acute Leukemia I
This session is available in our on-demand library throughout the whole congress
OS16-1 IMPACT OF CO-OCCURRING CYTOGENETIC ABNORMALITIES 09:15 - 09:25
ON TRANSPLANT OUTCOME OF TP53 MUTANT ACUTE
MYELOID LEUKAEMIA: REPORT FROM THE ALWP OF THE
EBMT
Speaker: Justin Loke, GB

OS16-2 IMPACT OF CYTOGENETIC CLASSIFICATION IN ALLO-HCT IN 09:25 - 09:35

PATIENTS WITH ACUTE MYELOID LEUKEMIA SECONDARY TO
MYELODYSPLASTIC SYNDROME: A JOIN STUDY BY THE
ALWP AND THE CMWP
Speaker: Eolia Brissot, FR

OS16-3 THE IMPACT OF CYTOGENETIC RISK ON OUTCOME OF NON-T 09:35 - 09:45

CELL DEPLETED HAPLOIDENTICAL STEM CELL
TRANSPLANTATION IN RELAPSED/REFRACTORY AML: A
STUDY FROM THE ALWP / EBMT
Speaker: Arnon Nagler, IL

OS16-4 NON-T DEPLETED HAPLOIDENTICAL STEM CELL 09:45 - 09:55

TRANSPLANTATION IN AML PATIENTS ACHIEVING FIRST
COMPLETE REMISSION AFTER ONE VS TWO INDUCTION
COURSES: A STUDY FROM THE ALWP/EBMT
Speaker: Arnon Nagler, IL

OS16-5 PREVALENCE AND OUTCOME OF CNS RELAPSE AFTER 09:55 - 10:05

ALLOGENEIC HEMATOPOIETIC STEM CELL

158 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

TRANSPLANTATION IN PATIENTS SUFFERING FROM AML AND

ALL. A STUDY FROM THE ALWP-EBMT
Speaker: Sabine Blum, CH

OS16-6 IMPACT OF ALLOGENIC TRANSPLANTATION IN THE 10:05 - 10:15

TREATMENT OF SECONDARY ACUTE MYELOID LEUKEMIAS.
COMPARISON BETWEEN MYELOABLATIVE VS REDUCE
INTENSITY CONDITIONINGS
Speaker: Claudia Núñez-Torrón, ES

OS16-7 THE DISEASE BURDEN PRIOR TO ALLOGENEIC 10:15 - 10:25

HEMATOPOIETIC STEM CELL TRANSPLANT IS MORE
RELEVANT IN PATIENTS WITH DE NOVO LEUKEMIA COMPARE
TO PATIENTS WITH SECONDARY LEUKEMIA
Speaker: Claudia Núñez-Torrón, ES

OS16-8 PROGNOSIS OF PATIENTS WITH ACUTE LYMPHOBLASTIC 10:25 - 10:35

LEUKEMIA RELAPSING AFTER AN ALLOGENEIC STEM CELL
TRANSPLANTATION. STUDY OF 132 PATIENTS
Speaker: Christelle Ferra Coll, ES

Oral Session
09:15 - 17:30 On-Demand Library
OS17 - Oral session 17: Acute Leukemia II
This session is available in our on-demand library throughout the whole congress
OS17-1 TRENDS AND PREDICTIVE FACTORS FOR OUTCOME OF 09:15 - 09:15
RELAPSED PHILADELPHIA POSITIVE ACUTE LYMPHOBLASTIC
LEUKEMIA AFTER ALLOGENEIC HEMATOPOIETIC CELL
TRANSPLANTION: IMPROVEMENT OF SURVIVAL IN RECENT
YEARS
Speaker: Ali Bazarbachi, LB

OS17-2 HOST IMMUNE GENETIC VARIATIONS INFLUENCE THE RISK 09:15 - 09:15
OF DEVELOPING ACUTE MYELOID LEUKAEMIA: RESULTS
FROM THE NUCLEAR CONSORTIUM
Speaker: José Sánchez Maldonado, ES

OS17-3 COMPARISON OF HAPLOIDENTICAL PERIPHERAL BLOOD 09:15 - 09:15

CELL TRANSPLANTATION USING POST-TRANSPLANT
CYCLOPHOSPHAMIDE WITH DOUBLE CORD BLOOD
TRANSPLANTATION IN ADULTS WITH ACUTE LEUKEMIA
Speaker: Annalisa Ruggeri, ES

OS17-4 REAL-LIFE EXPERIENCE OF SORAFENIB MAINTENANCE 09:15 - 09:15

AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL
TRANSPLANTATION FOR FLT3-ITD AML REVEALS HIGH
RATES OF TOXICITY-RELATED TREATMENT INTERRUPTION
Speaker: Sarah Morin, CH

OS17-5 VENETOCLAX COMBINED WITH HYPOMETHYLATING AGENT 09:15 - 09:15

(HMA) IS SAFE AND EFFECTIVE MAY BE A GOOD BRIDGE TO
TRANSPLANT IN HIGH-RISK ACUTE MYELOID LEUKEMIA
Speaker: Vincenzo Federico, IT

159 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

OS17-6 TKI MAINTENANCE AFTER STEM-CELL TRANSPLANTATION 09:15 - 09:15

FOR FLT3-ITD POSITIVE ACUTE MYELOID LEUKEMIA: A
SYSTEMATIC REVIEW AND META-ANALYSIS
Speaker: Nico Gagelmann, DE

OS17-7 STEM CELL TRANSPLANTATION FROM A HAPLOIDENTICAL 09:15 - 09:15

DONOR FOR PEDIATRIC PATIENTS WITH ACUTE
MYELOGENOUS LEUKEMIA: A RETROSPECTIVE NATIONWIDE
STUDY
Speaker: Charlotte Nazon, FR

OS17-8 COMPREHENSIVE GERIATRIC ASSESSMENT, ALLOGENEIC 09:15 - 09:15

HSCT AND SURVIVAL IN AML PATIENTS 65-75 YEARS OLD
Speaker: Gabriele Magliano, IT

Oral Session
09:15 - 17:30 On-Demand Library
OS18 - Oral session 18: Myeloproliferative Neoplasms and Myelodysplastic Syndromes
This session is available in our on-demand library throughout the whole congress
OS18-1 GENOMIC CONFIGURATION OF TP53 MUTATIONS IN PATIENTS 09:15 - 09:15
WITH MYELOID NEOPLASIA
Speaker: Carmelo Gurnari, US

OS18-2 RETROSPECTIVE ANALYSIS EVALUATING THE EFFECT OF 09:15 - 09:15

AGE ON OUTCOMES AFTER ALLOGENEIC HEMATOPOIETIC
CELL TRANSPLANTATION IN CHRONIC MYELOMONOCYTIC
LEUKEMIA. A STUDY OF THE EBMT-CMWP
Speaker: Alicia Rovó, CH

OS18-3 CHANGE IN IPSS-R BETWEEN DIAGNOSIS AND TRANSPLANT 09:15 - 09:15

AND TRANSPLANT OUTCOME IN PATIENTS WITH MDS. A
RETROSPECTIVE ANALYSIS FROM THE CHRONIC
MALIGNANCIES WORKING PARTY
Speaker: Christof Scheid, DE

OS18-4 ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION IN 09:15 - 09:15

PATIENTS WITH THERAPY-RELATED MYELOID NEOPLASM
AFTER BREAST CANCER TREATMENT: A STUDY OF THE
CHRONIC MALIGNANCIES WORKING PARTY OF THE EBMT
Speaker: Mitja Nabergoj, CH

OS18-5 IMPACT OF PRIOR JAK-INHIBITOR THERAPY WITH 09:15 - 09:15

RUXOLITINIB ON OUTCOME AFTER ALLOGENEIC STEM CELL
TRANSPLANTATION FOR MYELOFIBROSIS. A LARGE EBMT-
CMWP STUDY
Speaker: Nicolaus Kröger, DE

OS18-6 ADDITIONAL CHROMOSOMAL ABERRATIONS IN CML 09:15 - 09:15

PATIENTS UNDERGOING ALLOGENEIC HEMATOPOIETIC STEM
CELL TRANSPLANTATION
Speaker: Elena Morozova, RU

OS18-7 DONOR AGE, CD34 CELL DOSE AND NON-BLAST CRISIS ARE 09:15 - 09:15
PROGNOSTIC FACTORS FOR OUTCOME AFTER STEM CELL

160 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

TRANSPLANTATION IN PATIENTS WITH ADVANCE PHASE CML

Speaker: Christian Niederwieser, DE

OS18-8 OUTCOMES OF ALLOGENEIC HEMATOPOIETIC STEM CELL 09:15 - 09:15

TRANSPLANTATION IN PATIENTS WITH MYELOFIBROSIS
TREATED WITH RUXOLITINIB IN THE PRE-TRANSPLANT
PERIOD
Speaker: Anna Czyz, PL

Oral Session
09:15 - 17:30 On-Demand Library
OS19 - Oral session 19: Lymphoma and Chronic Lymphocytic Leukemia
This session is available in our on-demand library throughout the whole congress
OS19-1 INTERIM ANALYSIS (IA) OF ZUMA-12: A PHASE 2 STUDY OF 09:15 - 09:15
AXICABTAGENE CILOLEUCEL (AXI-CEL) AS FIRST-LINE
THERAPY IN PATIENTS WITH HIGH-RISK LARGE B-CELL
LYMPHOMA (LBCL)
Speaker: Catherine Thieblemont, FR

OS19-2 LONG-TERM SURVIVAL AND GRADUAL RECOVERY OF B 09:15 - 09:15

CELLS IN PATIENTS WITH REFRACTORY LARGE B CELL
LYMPHOMA (LBCL) TREATED WITH AXICABTAGENE
CILOLEUCEL (AXI-CEL)
Speaker: Caron A. Jacobson, US

OS19-3 PRIMARY ANALYSIS OF ZUMA-5: A PHASE 2 STUDY OF 09:15 - 09:15

AXICABTAGENE CILOLEUCEL (AXI-CEL) IN PATIENTS WITH
RELAPSED/REFRACTORY (R/R) INDOLENT NON-HODGKIN
LYMPHOMA (INHL)
Speaker: Caron A. Jacobson, US

OS19-4 ONE-YEAR FOLLOW-UP OF ZUMA-2, THE MULTICENTER, 09:15 - 09:15

REGISTRATIONAL STUDY OF KTE-X19 IN PATIENTS WITH
RELAPSED/REFRACTORY (R/R) MANTLE CELL LYMPHOMA
(MCL)
Speaker: Michael L. Wang, US

OS19-5 VALIDATION OF GWAS-IDENTIFIED VARIANTS FOR CHRONIC 09:15 - 09:15

LYMPHOCYTIC LEUKEMIA: A STUDY IN THE CONTEXT OF THE
CRUCIAL CONSORTIUM
Speaker: Antonio José Cabrera-Serrano, ES

OS19-6 EVALUATION OF AUTOLOGOUS AND ALLOGENEIC 09:15 - 09:15

HEMATOPOIETIC CELL TRANSPLANTATION (HCT) IN
PATIENTS WITH HIGH-RISK ANAPLASTIC LARGE CELL
LYMPHOMA (ALCL)
Speaker: Natalie L. Smith, US

OS19-7 ECONOMIC ASPECTS OF STEM CELL TRANSPLANTATION BY 09:15 - 09:15

PATIENTS WITH RELAPSED DIFFUSE B-CELL LYMPHOMA
(DLBCL) IN A GERMAN TERTIARY HOSPITAL
Speaker: Bernhard Alexander Mörtl, DE

OS19-8 LONG TERM OUTCOMES OF ALLOGENEIC 09:15 - 09:15

161 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

TRANSPLANTATION IN LYMPHOMA: A SINGLE CENTRE

EXPERIENCE
Speaker: Alexander Glover, GB

Oral Session
09:15 - 17:30 On-Demand Library
OS20 - Oral session 20: Aplastic Anemia, Autoimmune Disorders, and others
This session is available in our on-demand library throughout the whole congress
OS20-1 HLA EVOLUTIONARY DIVERGENCE INFLUENCES 09:15 - 09:25
CHARACTERISTICS AND OUTCOMES OF PATIENTS WITH
APLASTIC ANEMIA AND PAROXYSMAL NOCTURNAL
HEMOGLOBINURIA
Speaker: Simona Pagliuca, US

OS20-2 OUTCOME OF NON-MYELOABLATIVE AUTOLOGOUS 09:25 - 09:35

HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR
MULTIPLE SCLEROSIS: A SINGLE CENTER SUMMARY OF 511
PATIENTS
Speaker: Richard K Burt, US

OS20-3 EARLY MORBIDITY OF AUTOLOGOUS HAEMATOPOIETIC 09:35 - 09:45

STEM CELL TRANSPLANTATION IN MULTIPLE SCLEROSIS- A
REAL WORLD EXPERIENCE
Speaker: Varun Mehra, GB

OS20-4 THE GENOMIC LANDSCAPE OF MYELOID NEOPLASMS 09:45 - 09:55

ARISING FROM APLASTIC ANEMIA AND PAROXYSMAL
NOCTURNAL HEMOGLOBINURIA
Speaker: Carmelo Gurnari, US

OS20-5 HIGH-DOSE IMMUNOSUPPRESSIVE THERAPY WITH 09:55 - 10:05

AUTOLOGOUS HEMATOPOIETIC STEM CELL
TRANSPLANTATION (AHSCT) IN MULTIPLE SCLEROSIS:
CHANGING APPROACHES IN SINGLE-CENTER EXPERIENCES
Speaker: Alexey Polushin, RU

OS20-6 HLA MUTATIONS IN PAROXYSMAL NOCTURNAL 10:05 - 10:15

HEMOGLOBINURIA: A POSSIBLE ALTERNATIVE MECHANISM
OF IMMUNE ESCAPE
Speaker: Carmelo Gurnari, US

OS20-7 HEMATOPOIETIC STEM CELL TRANSPLANT AS TREATMENT 10:15 - 10:25

OF REFRACTORY MYASTHENIA GRAVIS
Speaker: Claudia Lucía Sossa Melo, CO

OS20-8 IMPACT OF AHSCT ON FERTILITY IN MULTIPLE SCLEROSIS 10:25 - 10:35

PATIENTS
Speaker: Alice Mariottini, IT

162 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

Educational
09:15 - 17:30 On-Demand Library
E13 - Allogeneic transplantation from alternative donors
This session is available in our on-demand library throughout the whole congress
E13-1 Haploidentical vs unrelated in AML -
Speaker: Didier Blaise, FR

E13-2 Haploidentical vs unrelated in ALL -

Speaker: Arnon Nagler, IL

E13-3 Haploidentical vs cord Blood in acute leukaemia -

Speaker: Frederic Baron, BE

Nurses Group
09:15 - 17:30 On-Demand Library
NG16 - Cellular therapy update
This session is available in our on-demand library throughout the whole congress
NG16-1 Update: What’s new? -
Speaker: Rose Ellard, GB

NG16-2 Spotlight on the Lymphoma Patient Experience -

Speaker: Lorna Warwick, CA

Nurses Group
09:15 - 17:30 On-Demand Library
NG20 - How do I become an expert?
This session is available in our on-demand library throughout the whole congress
NG20-1 Conditioning regimen -
Speaker: Nicolas Kint, BE

NG20-2 Immunosuppression -
Speaker: Tiene Bauters, BE

NG20-3 Vaccinations -
Speaker: Bipin Savani, US

Nurses Group
09:15 - 17:30 On-Demand Library
NG13 - Nurses Education Day 1: Care of the vulnerable immunocompromised patients in critical care setting
This session is available in our on-demand library throughout the whole congress
NG13-1 SARS-CoV-2 vaccines overview -
Speaker: Almudena Ramírez, ES

NG13-2 Seasonal human coronaviruses vs SARS-CoV-2 in allogeneic -

hematopoietic stem cell transplantation
Speaker: Jose Luis Piñana, ES

NG13-3 COVID-19: The EBMT recommendations for management of -

HCT patients and donors
Speaker: Per Ljungman, SE

163 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

Nurses Group
09:15 - 17:30 On-Demand Library
NG22 - Quality processes in JACIE
This session is available in our on-demand library throughout the whole congress
NG22-1 Quality indicators for nurses -
Speaker: Louise McNamara, GB

NG22-2 JACIE: What's new? -

Speaker: Kim Orchard, GB

NG22-3 What is the nurse role as JACIE Inspector? -

Speaker: Eugenia Trigoso Arjona, ES

Nurses Group
09:15 - 17:30 On-Demand Library
NG17 - Care of the nurses
This session is available in our on-demand library throughout the whole congress
NG17-1 Mindfulness -
Speaker: Ana M. Muñoz Cobo, ES

NG17-2 Resilience and self-care -

Speaker: Christian Williams, GB

NG17-3 Tips and tricks for self care -

Speaker: Jane Keep, GB

Nurses Group
09:15 - 17:30 On-Demand Library
NG21 - Clinical trials in a transplant setting
This session is available in our on-demand library throughout the whole congress
NG21-1 Antimicrobal Lock Therapy for Prevention and Treatment of -
Catheter Related Infections in Hematogical Patients
Speaker: Isabel Salcedo, ES

NG21-2 Convalescent plasma clinical trials for COVID-19 -

Speaker: Rocío Layunta, ES

NG21-3 Post transplant relapse -

Speaker: Stephanie Heyes, GB

Nurses Group
09:15 - 17:30 On-Demand Library
NG19 - Disease update
This session is available in our on-demand library throughout the whole congress
NG19-1 Acute leukaemia -
Speaker: Inge Govaerts, BE

NG19-2 Managing lymphoma: What nurses and healthcare -

professionals need to know
Speaker: Erik Aerts, CH

164 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

NG19-3 Multiple myeloma -

Speaker: Maaike de Ruijter, NL

NG19-4 CML (ITK management) -

Speaker: Laura Borg, GB

Educational
09:15 - 17:30 On-Demand Library
E09 - Allogeneic HSCT in MDS and MPN
This session is available in our on-demand library throughout the whole congress
E9-1 Definition of graft failure/relapse after allo-HCT in myelofibrosis -
Speaker: Donal McLornan, GB

E9-2 Allogeneic HSCT in patients with therapy-related MDS/AML -

Speaker: Marie Robin, FR

E9-3 The role of maintenance therapy after allogeneic HSCT in MDS -

Speaker: Francesco Onida, IT

Data Management
09:15 - 17:30 On-Demand Library
DM09 - Education session 9
This session is available in our on-demand library throughout the whole congress
DM9-1 Follow up forms - How to get a chronological overview of the -
patient history and follow up
Speaker: Elena Ferrer Martínez del Peral, ES

Working Party Session

09:15 - 17:30 On-Demand Library
SAAWP - Severe Aplastic Anaemia Working Party Session
This session is available in our on-demand library throughout the whole congress
SAAWP-1 Introduction -
Speaker: Régis Peffault de Latour, FR

SAAWP-2 Registry Report -

Speaker: Antonio Risitano, IT

SAAWP-3 RACE – clinical update -

Speaker: Antonio Risitano, IT

SAAWP-4 RACE – what we learn on the biology of SAA? -

Speaker: Austin Kulakaseraraj, GB

SAAWP-5 Androgens in AA: Myth or reality in 2021? -

Speaker: Simona Pagliuca, US

SAAWP-6 GVHD and relapse free survival (GRFS) after HSCT for AA -
Speaker: Raynier Devillier, FR

165 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

Lab Technicians Day

09:15 - 17:30 On-Demand Library
LT1 - Lab Technicians Day: Specialized cell processing
This session is available in our on-demand library throughout the whole congress
LT1-1 Bone marrow processing: Techniques and results -
Speaker: Boris Calmels, FR

LT1-2 Technical aspects and performance TCRab/CD19 depletion -

Speaker: Kasper Westinga, NL

LT1-3 Donor selection and GMP-compliant manufacturing of virus- -

specific T-cells
Speaker: Britta Eiz-Vesper, DE

Working Party Session

09:15 - 17:30 On-Demand Library
ALWP - Acute Leukaemia Working Party Session
This session is available in our on-demand library throughout the whole congress
ALWP-1 Introduction 09:15 - 09:15
Speaker: Mohamad Mohty, FR

ALWP-2 CAR-T cells in adult ALL 09:15 - 09:15

Speaker: Arnon Nagler, IL

ALWP-3 Transplant in refractory AML: Comparison of the different 09:15 - 09:15

FLAMSA approaches
Speaker: Mohamad Mohty, FR

ALWP-4 MRD in AML: Where do we stand? 09:15 - 09:15

Speaker: Ali Bazarbachi, LB

Working Party Session

09:15 - 17:30 On-Demand Library
ADWP - Autoimmune Diseases Working Party Session
This session is available in our on-demand library throughout the whole congress
ADWP-1 Welcome and Update from the EBMT registry -
Speaker: Raffaella Greco, IT

ADWP-2 Introducing the session and speakers -

Speaker: Tobias Alexander, DE

ADWP-3 HSCT for multiple sclerosis: Future directions in patient -

selection and conditioning regimen
Speaker: Riccardo Saccardi, IT

ADWP-4 HSCT for systemic sclerosis: Future directions in patient -

selection and conditioning regimen
Speaker: Dominique Farge, FR

ADWP-5 HSCT for Crohn’s disease: future directions in patient -

selection, mobilization and conditioning regimen

166 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

Speaker: Elena Ricart, ES

ADWP-6 HSCT for autoimmune diseases: Current aspects on early and -

late complications
Speaker: Majid Kazmi, GB

ADWP-7 HSCT for autoimmune diseases: Conditioning regimen and -

outcomes from the Russian experience
Speaker: Denis Fedorenko, RU

ADWP-8 Closing remarks -

Speaker: Tobias Alexander, DE

Nurses Group
09:15 - 17:30 On-Demand Library
NG18 - Non-malignant diseases update
This session is available in our on-demand library throughout the whole congress
NG18-2 Multiple sclerosis 09:15 - 09:15
Speaker: Helen Jessop, GB

NG18-3 Sickle cell disease 09:15 - 09:15

Speaker: Jean-Hugues Dalle, FR

NG18-4 ITP 09:15 - 09:15

Speaker: Maria Luisa Lozano, ES

Nurses Group
09:15 - 17:30 On-Demand Library
NG14 - Nurses Education Day 2: Care of the vulnerable immunocompromised patients in critical care setting
This session is available in our on-demand library throughout the whole congress
NG14-1 Patient's experience -
Speaker: Ruth Tweedie, ES

NG14-2 Psychologist's point of view -

Speaker: Anna Lagerdahl, GB

NG14-3 Nurse's perspective -

Speaker: Núria Ballestar, ES

Nurses Group
09:15 - 17:30 On-Demand Library
NG15 - Nurses Education Day 3: Care of the vulnerable immunocompromised patients in critical care setting
This session is available in our on-demand library throughout the whole congress
NG15-1 Managing virtual conversations -
Speaker: Lloyd Allen, GB

NG15-2 Nurse perspective: Virtual long term follow up for BMT patients -
Speaker: Michelle Kenyon, GB

NG15-3 Back to the future: Emphasizing our new practices -

Speaker: Ibrahim Yakoub-Agha, FR

167 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

Nurses Group
09:15 - 17:30 On-Demand Library
NG24 - Outreach projects
This session is available in our on-demand library throughout the whole congress
NG24-2 Outreach project India: EBMT MIC pediatric advanced care 09:15 - 09:15
training (EMPACT)
Speaker: Lawrence Faulkner, IT

NG24-3 Outreach project: LABMT 09:15 - 09:15

Speaker: Sara Saez Carrasco, CO

Educational
09:15 - 17:30 On-Demand Library
E11 - Management of early complications in an ambulatory/outpatient setting
This session is available in our on-demand library throughout the whole congress
E11-1 Early infectious complications -
Speaker: Jan Styczynski, PL

E11-2 Non-infective complications: GVHD and organ toxicity -

Speaker: Gerhard Hildebrandt, US

E11-3 The Hospital Clínic experience -

Speaker: Francesc Fernández-Avilés, ES

Workshop
09:15 - 17:30 On-Demand Library
W14 - In the absence of a matched-sibling, who's the best alternative allogeneic donor?
This session is available in our on-demand library throughout the whole congress
W14-1 A matched unrelated donor -
Speaker: Bronwen Shaw, US

W14-2 A haploidentical donor -

Speaker: Mi Kwon, ES

W14-3 When to choose cord blood -

Speaker: Filippo Milano, US

W14-4 Do we have to challenge our current donor hierarchy for -

patients with hemoglobinopathies?
Speaker: Selim Corbacioglu, DE

Workshop
09:15 - 17:30 On-Demand Library
W11 - Key organ manifestations of chronic GVHD
This session is available in our on-demand library throughout the whole congress
W11-1 Pulmonary chronic GVHD -
Speaker: Hildegard Greinix, AT

W11-2 Ocular cGVHD diagnostics - Practical approach -

Speaker: Igor Petricek, HR

168 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

W11-3 Gastrointestinal manifestations of chronic GVHD -

Speaker: Daniel Wolff, DE

Data Management
09:15 - 17:30 On-Demand Library
DM07 - Education session 7
This session is available in our on-demand library throughout the whole congress
DM7-1 Minimal residual disease (MRD) -
Speaker: Johannes Schetelig, DE

Data Management
09:15 - 17:30 On-Demand Library
DM08 - Education session 8
This session is available in our on-demand library throughout the whole congress
DM8-1 Infectious complications -
Speaker: Malgorzata Mikulska, IT

Special Session
09:15 - 17:30 On-Demand Library
SS09 - How to get published
This session is available in our on-demand library throughout the whole congress
SS9-1 BMT: Official journal of the EBMT -
Speaker: Hillard Lazarus, US

SS9-2 How to get published -

Speaker: Mohamad Mohty, FR

Special Session
09:15 - 17:30 On-Demand Library
SS11 - The EBMT for Trainees
This session is available in our on-demand library throughout the whole congress
SS11-1 Being a Trainee in SCT / Cellular Therapy -
Speaker: Nico Gagelmann, DE
Speaker: Claire Horgan, GB
Speaker: Yasmina Serroukh, BE
Speaker: Yuliya Rogacheva, RU
Speaker: Tamar Azikuri, GE

SS11-2 Overview of allogeneic SCT for the trainee: ‘Things I wish I’d -
known'
Speaker: Helene Schoemans, BE

SS11-3 Establishing a career in SCT/cellular therapy -

Speaker: Jordan Gauthier, US

SS11-4 Complications for trainees 1: How to manage acute GVHD -

Speaker: Zinaida Peric, HR

SS11-5 Complications for trainees 2: How to manage VOD -

169 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

Speaker: Ivan Moiseev, RU

Special Session
09:15 - 17:30 On-Demand Library
SS07 - Young Ambassadors Session
This session is available in our on-demand library throughout the whole congress
SS7-1 How build up a career in: Academia -
Speaker: Didier Blaise, FR

SS7-2 How build up a career in: In Pharmaceutical Industry -

Speaker: Dan Tovar, FR

SS7-3 How build up a career in: In Public domains -

Speaker: Eva Hilgenfeld, DE

SS7-4 What to avoid when writing a paper -

Speaker: Jakob Passweg, CH

SS7-5 How to write a successful grant -

Speaker: Robert Zeiser, DE

SS7-6 Introduction to medical statistics -

Speaker: Simona Iacobelli, IT

SS7-7 Social media in stem cell transplantation and cellular therapy -

Speaker: Navneet Majhail, US

How do I … ?
09:15 - 17:30 On-Demand Library
HDI6 - How Do I... manage toxicity in immunosuppressed patients?
This session is available in our on-demand library throughout the whole congress
HDI6-1 Transplant associated TMA -
Speaker: Sergio Giralt, US

HDI6-2 Infectious complication -

Speaker: Jan Styczynski, PL

Industry Symposium
09:15 - 17:30 On-Demand Library
IS38 - CMV management in high-risk patients - Biotest Industry Symposium
This session is available in our on-demand library throughout the whole congress
Chair: Fabio Ciceri, IT
IS38-1 A scoring system to define patients at high risk for CMV -
Speaker: Ibrahim Yakoub-Agha, FR

IS38-2 How to manage CMV high-risk patients -

Speaker: Michele Malagola, IT

IS38-3 The immunological benefits of CMV-specific immunoglobulins -

Speaker: Javier Carbone, ES

170 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

Joint Session
09:15 - 17:30 On-Demand Library
JS05 - Joint session WBMT: COVID-19 Vaccination in HSCT
This session is available in our on-demand library throughout the whole congress
JS5-2 COVID-19 vaccination in HSCT 09:15 - 09:15
Speaker: Per Ljungman, SE

JS5-3 Global access to COVID-19 vaccines 09:15 - 09:15

Speaker: Susan Brown, US

Oral Session
09:15 - 17:30 On-Demand Library
OS04 - Oral session 4: Cellular Therapy, Gene Therapy and New Drugs I
This session is available in our on-demand library throughout the whole congress
OS4-1 INTERIM RESULTS OF BETIBEGLOGENE AUTOTEMCEL GENE 09:15 - 09:25
THERAPY IN PEDIATRIC PATIENTS WITH TRANSFUSION-
DEPENDENT ?-THALASSEMIA (TDT) TREATED IN THE PHASE 3
NORTHSTAR-2 (HGB-207) AND NORTHSTAR-3 (HGB-212)
STUDIES
Speaker: Isabelle Thuret, FR

OS4-2 NARSOPLIMAB (OMS721), A MASP-2 INHIBITOR, FOR THE 09:25 - 09:35

TREATMENT OF ADULT HEMATOPOIETIC STEM CELL
TRANSPLANT-ASSOCIATED THROMBOTIC
MICROANGIOPATHY (HSCT-TMA): SUBGROUP ANALYSES
Speaker: Alessandro Rambaldi, IT

OS4-3 CRISPR-BASED REPLACEMENT OF THE ENDOGENOUS T- 09:35 - 09:45

CELL REPERTOIRE WITH NOVEL, HIGH-AVIDITY, NATURAL T
CELL RECEPTORS TO WT1 FOR THE TREATMENT OF ACUTE
MYELOID LEUKEMIA
Speaker: Eliana Ruggiero, IT

OS4-4 CLINICAL TRIAL UPDATE: EX-VIVO AUTOLOGOUS STEM CELL 09:45 - 09:55
GENE THERAPY IN MPSIIIA
Speaker: Jane Louise Kinsella, GB

OS4-5 EXOGENOUS M-CSF PROTECTS FROM LETHAL A. FUMIGATUS 09:55 - 10:05

PULMONARY INFECTION EARLY AFTER HEMATOPOIETIC
STEM CELL TRANSPLANTATION
Speaker: Dalia Sheta, DE

OS4-6 REAL-WORLD EFFECTIVENESS AND SAFETY OF 10:05 - 10:15

BLINATUMOMAB IN EUROPE: 3-YEAR RESULTS IN RELAPSED
OR REFRACTORY PHILADELPHIA CHROMOSOME-NEGATIVE
BCP-ALL PATIENTS INCLUDING THOSE WITH LATE FIRST
RELAPSE
Speaker: Alessandro Rambaldi, IT

OS4-7 GENERATION OF HSPC-DERIVED CD16A-ENGINEERED NK 10:15 - 10:25

CELLS WITH ADVANCED ANTIBODY-DEPENDENT CELLULAR
CYTOTOXICITY
Speaker: Paulien van Hauten, NL

171 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

OS4-8 IMPROVEMENTS IN FATIGUE AND PHYSICAL FUNCTION 10:25 - 10:35

EVALUATED THROUGH CHANGES IN CLINICAL OUTCOMES IN
PAROXYSMAL NOCTURNAL HEMOGLOBINURIA: POST-HOC
ANALYSES FROM THE PEGASUS STUDY

Quality Management
09:15 - 17:30 On-Demand Library
QM5 - Quality Management Oral Abstracts
This session is available in our on-demand library throughout the whole congress
QM5-1 COMPLIANCE AND COST EFFICACY FOR CELLULAR 09:15 - 09:15
THERAPIES, CAN THESE TWO GO HAND IN HAND?
Speaker: Janik Adriaansen, US

QM5-2 HOW TO MAINTAIN A CONTINUOUS TRAINING PROGRAM FOR 09:15 - 09:15

NURSES IN TIMES OF PANDEMIC
Speaker: Sheila Saco, ES

QM5-3 THE RTN TRANSPLANT POLICY AND ACTIVITY DURING 09:15 - 09:15
COVID-19 PANDEMIC
Speaker: Antonio Bruno, IT

QM5-4 THE DISASTER PLAN ADJUSTMENT TO THE COVID-19 09:15 - 09:15

PANDEMIC AT AORN CARDARELLI TRANSPLANT PROGRAM
IN NAPLES, ITALY
Speaker: Lucia Ammirati, IT

Oral Session
09:15 - 17:30 On-Demand Library
OS03 - Oral session 3: CARs II
This session is available in our on-demand library throughout the whole congress
OS3-1 CD19 CAR T THERAPY IN CHILDREN WITH R/R ALL: ADAPTIVE 09:15 - 09:15
SPLIT DOSING IMPROVES SAFETY AND MAINTAINS EFFICACY
OF THE APPROACH
Speaker: Olga Molostova, RU

OS3-2 CYTOKINE RELEASE SYNDROME IN PATIENTS WITH 09:15 - 09:15

RELAPSED/REFRACTORY MULTIPLE MYELOMA TREATED
WITH CILTACABTAGENE AUTOLEUCEL IN THE PHASE 1B/2
CARTITUDE-1 STUDY
Speaker: Andrzej Jakubowiak, US

OS3-3 PHARMACOLOGY AND EFFICACY OF KTE-X19 BY PRIOR 09:15 - 09:15

BRUTON TYROSINE KINASE INHIBITOR EXPOSURE OR
MANTLE CELL LYMPHOMA (MCL) MORPHOLOGY IN PATIENTS
WITH RELAPSED/REFRACTORY MCL IN ZUMA-2
Speaker: Michael L. Wang, US

OS3-4 REAL WORLD OF EXPERIENCE AXICABTAGENE CILOLEUCEL 09:15 - 09:15

FOR THE TREATMENT OF RELAPSED OR REFRACTORY
LARGE B-CELL LYMPHOMA IN SPAIN
Speaker: Mi Kwon, ES

172 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

OS3-5 HUMORAL RESPONSE TO PNEUMOCOCCAL ANTIGENS 09:15 - 09:15

DECLINES AFTER CD19-TARGETED CAR T CELL THERAPY
Speaker: Dasom Lee, US

OS3-6 DECREASED NEUROPROTECTIVE ANALYTES ON DAY OF 09:15 - 09:15

INFUSION OF CHIMERIC ANTIGEN RECEPTOR (CAR) T CELLS
ARE ASSOCIATED WITH NEUROTOXICITY
Speaker: Madhavi Lakkaraja, US

OS3-7 COMPARISON OF TWO KINDS OF ANTI-THYMOCYTE 09:15 - 09:15

GLOBULIN ON OUTCOMES OF HAPLOIDENTICAL STEM CELL
TRANSPLANTATION FOR REFRACTORY/RELAPSED AND HIGH-
RISK B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA AFTER CAR-
T THERAPY
Speaker: Zhao-Yanli Zhao, CN

OS3-8 THIRD-GENERATION GD2.CAR T-CELLS INCORPORATING 09:15 - 09:15

CD28.4-1BB COSTIMULATORY DOMAINS FOR TREATMENT OF
GD2+ SARCOMAS
Speaker: Antonio Camera, IT

Oral Session
09:15 - 17:30 On-Demand Library
OS10 - Oral session 10: COVID-19
This session is available in our on-demand library throughout the whole congress
OS10-1 A PHASE I DOSE-ESCALATION SINGLE CENTER STUDY TO 09:15 - 09:25
EVALUATE THE SAFETY OF ALLOGENIC MEMORY T CELLS
CONTAINING SARS-COV-2 SPECIFIC LYMPHOCYTES AS
ADOPTIVE THERAPY IN COVID19
Speaker: Antonio Pérez-Martínez, ES

OS10-2 THE IMPACT OF COVID-19 ON UNRELATED AND DONOR CORD 09:25 - 09:35
PROVISION TO UK TRANSPLANT CENTRES DURING THE 1ST
WAVE OF THE PANDEMIC: UK ALIGNED REGISTRY STUDY
Speaker: Angharad Pryce, GB

OS10-3 IMPACT OF SARS-COV-2 ON DELIVERY OF CAR T CELL 09:35 - 09:45

THERAPY IN EUROPE: A SURVEY FROM THE CELLULAR
THERAPY AND IMMUNOBIOLOGY WORKING PARTY OF THE
EBMT
Speaker: Sara Ghorashian, GB

OS10-4 OUTCOME OF COVID 19 IN ALLOGENEIC STEM CELLS 09:45 - 09:55

TRANSPLANT PATIENTS: THE SINGLE CENTER EXPERIENCE
FROM A SEVERELY AFFECTED AREA (BERGAMO)
Speaker: Maria Caterina Mico', IT

OS10-5 ALLOGENEIC STEM CELL TRANSPLANTATION IN ACUTE 09:55 - 10:05

LEUKEMIA PATIENTS AFTER COVID-19 INFECTION
Speaker: Maximilian Christopeit, DE

OS10-6 INFLUENCE OF THE SARS-COV-2 PANDEMIC ON BONE 10:05 - 10:15

MARROW TRANSPLANTATION CENTERS AND THE
PROTOCOLS ADOPTED IN BRAZIL BETWEEN MAY AND JUNE

173 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

2020
Speaker: Fernando Barroso Duarte, BR

OS10-7 CRYOPRESERVATION OF ALLOGENEIC HEMATOPOIETIC 10:15 - 10:25

PROGENITOR CELLS IN THE CURRENT SARS-Cov-2
PANDEMIC: EXPERIENCE OF A SINGLE CENTRE
Speaker: Dolores Moreno, ES

OS10-8 IMPACT OF COVID-19 PANDEMIC ON RELEASE OF FRENCH 10:25 - 10:35

CORD BLOOD UNITS. ON BEHALF THE AGENCY OF
BIOMEDICINE, EUROCORD AND THE SFGM-TC
Speaker: Hanadi Rafii - El Ayoubi, FR

Working Party Session

09:15 - 17:30 On-Demand Library
CTIWP - Cellular Therapy and Immunobiology Working Party Session
This session is available in our on-demand library throughout the whole congress
CTIWP-1 CTIWP Activity Report -
Speaker: Christian Chabannon, FR

CTIWP-2 Virus specific T cells post BMT- Broadening to SARS-CoV2 -

Speaker: Catherine Bollard, US

CTIWP-3 Are mesenchymal stromal cells the right arrow in the quiver to -
fight COVID-19?
Speaker: Rachele Ciccocioppo, IT

Oral Session
09:15 - 17:30 On-Demand Library
OS02 - Oral session 2: CARs I
This session is available in our on-demand library throughout the whole congress
OS2-1 CARTITUDE-1: PHASE 1B/2 STUDY OF CILTACABTAGENE 09:15 - 09:25
AUTOLEUCEL, A B-CELL MATURATION ANTIGEN–DIRECTED
CHIMERIC ANTIGEN RECEPTOR T CELL THERAPY, IN
RELAPSED/REFRACTORY MULTIPLE MYELOMA
Speaker: Deepu Madduri, US

OS2-2 PROPHYLACTIC CORTICOSTEROID USE WITH 09:25 - 09:35

AXICABTAGENE CILOLEUCEL (AXI-CEL) IN PATIENTS WITH
RELAPSED/REFRACTORY LARGE B CELL LYMPHOMA (R/R
LBCL)
Speaker: Olalekan O. Oluwole, US

OS2-3 MATCHING-ADJUSTED INDIRECT COMPARISON (MAIC) OF 09:35 - 09:45

LISOCABTAGENE MARALEUCEL (LISO-CEL) VERSUS
AXICABTAGENE CILOLEUCEL (AXI-CEL) AND
TISAGENLECLEUCEL IN RELAPSED/REFRACTORY LARGE B-
CELL LYMPHOMA
Speaker: David Maloney, US

OS2-4 STRATEGIES TO INCREASE CAR T-CELL SAFETY AND TO 09:45 - 09:55

PREVENT EPITOPE MASKING IN CAR+ B-CELL LEUKEMIA

174 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

BLASTS
Speaker: Concetta Quintarelli, IT

OS2-5 CONTRIBUTION OF AGE AND THE HCT-CI TO PREDICT CRS 09:55 - 10:05
AND ICANS SEVERITY IN NHL PATIENTS RECEIVING CD19
CAR T-CELL THERAPY
Speaker: Jordan Gauthier, US

OS2-6 OUTCOMES OF TREATMENT WITH THE CHIMERIC ANTIGEN 10:05 - 10:15

RECEPTOR (CAR) T CELL THERAPY LISOCABTAGENE
MARALEUCEL (LISO-CEL) IN THE NONUNIVERSITY SETTING:
INITIAL RESULTS FROM THE OUTREACH STUDY
Speaker: John E. Godwin, US

OS2-7 BUILDING OF THE G0-CAR-T INITIATIVE TO PROMOTE USE OF 10:15 - 10:25

DATA COLLECTED FROM PATIENTS TREATED WITH CAR-T
CELLS AT EU OR EBMT AFFILIATED PROGRAMS
Speaker: Christian Chabannon, FR

OS2-8 ENGINEERED CAR.CD123 NK CELLS AS AN INNOVATIVE “OFF 10:25 - 10:35

THE SHELF” STRATEGY TO TREAT CD123POS CHILDHOOD
ACUTE MYELOID LEUKAEMIA
Speaker: Simona Caruso, IT

Oral Session
09:15 - 17:30 On-Demand Library
OS09 - Oral session 9: Graft versus Host Disease II
This session is available in our on-demand library throughout the whole congress
OS9-1 GLUCAGON-LIKE-PEPTIDE-2 (GLP-2) ANALOGUE 09:15 - 09:15
TEDUGLUTIDE FOR GRAFT-VERSUS-HOST DISEASE IN
HUMANS
Speaker: Robert Zeiser, DE

OS9-2 RUXOLITINIB VS BEST AVAILABLE THERAPY IN PATIENTS 09:15 - 09:15

WITH STEROID-REFRACTORY/DEPENDENT CHRONIC GRAFT-
VS-HOST DISEASE (CGVHD): SUBGROUP ANALYSES OF
OVERALL RESPONSE RATE IN THE PHASE 3 REACH3 TRIAL
Speaker: Franco Locatelli, IT

OS9-3 DISCONTINUATION OF SYSTEMIC IMMUNOSUPPRESSIVE 09:15 - 09:15

THERAPY: NEW GOAL OF CHRONIC GVHD TREATMENT?
Speaker: Ivan Moiseev, RU

OS9-4 A PHASE 2, PROSPECTIVE, RANDOMISED, OPEN-LABEL 09:15 - 09:15

STUDY OF DEFIBROTIDE FOR THE PREVENTION OF ACUTE
GRAFT-VERSUS-HOST DISEASE (AGVHD) AFTER
ALLOGENEIC HAEMATOPOIETIC CELL TRANSPLANTATION
(HCT)
Speaker: Michelle Hudspeth, US

OS9-5 THE IMPACT OF GVHD ON OUTCOMES AFTER ADULT SINGLE 09:15 - 09:15
CORD BLOOD TRANSPLANTATION IN EUROPEAN AND
JAPANESE POPULATIONS: THE EUROCORD/ALWP EBMT AND
JSHCT/JDCHCT COLLABORATIVE STUDY

175 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

Speaker: Junya Kanda, JP

OS9-6 EARLY RECONSTITUTION OF CD6+ T CELLS AFTER 09:15 - 09:15

HEMATOPOIETIC CELL TRANSPLANTATION IDENTIFIES A
SUITABLE TARGET FOR ACUTE GRAFT-VERSUS-HOST
DISEASE TREATMENT USING ANTI-CD6 MONOCLONAL
ANTIBODY ITOLIZUMAB
Speaker: Benedetta Rambaldi, US

OS9-7 MICROBIAL-DERIVED METABOLITES INDUCE EPITHELIAL 09:15 - 09:15

RECOVERY VIA THE STING PATHWAY IN MICE AND MEN AND
PROTECT FROM GRAFT-VERSUS-HOST DISEASE
Speaker: Erik Thiele Orberg, DE

OS9-8 ASSOCIATION OF GENE POLYMORPHISMS IN 09:15 - 09:15

CYCLOPHOSPHAMIDE METABOLISM PATHWAY WITH
COMPLICATIONS AFTER HAPLOIDENTICAL HEMATOPOIETIC
STEM CELL TRANSPLANTATION
Speaker: Paula Muñiz, ES

Special Session
09:15 - 17:30 On-Demand Library
SS08 - Social Media Session: Do's and don'ts of the interaction in the social media for the HSCT and cell thera
community
This session is available in our on-demand library throughout the whole congress
SS8-1 Social media beyond twitter for the HSCT and cell therapy -
community
Speaker: Navneet Majhail, US

SS8-2 Do's and don'ts of interaction in social media: Nurse's -

perspective

SS8-3 Do’s and don'ts of interaction in social media: How social -

media can improve patient outcomes - The patient's perspective
Speaker: Gillian Adams, GB

Lab Technicians Day

09:15 - 17:30 On-Demand Library
LT2 - Lab Technicians Day: Cell product testing, validation and characterization
This session is available in our on-demand library throughout the whole congress
LT2-1 Quality control assessment of ATMP phenotype and -
functionality using flow cytometry
Speaker: Willemijn Hobo, NL

LT2-2 Flow cytometry-based CD34 enumeration -

Speaker: Harry Dolstra, NL

LT2-3 Flow cytometric in-process and quality control for CAR T cell -
manufacturing
Speaker: Ulrike Köhl, DE

176 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

Educational
09:15 - 17:30 On-Demand Library
E10 - HSCT in paediatric non-malignant indications
This session is available in our on-demand library throughout the whole congress
E10-1 Haplo-identical SCT in hemoglobinopathy: Taking pole -
position?
Speaker: Josu de la Fuente, GB

E10-2 Mismatched family donors in inherited immune disorders: A -

new perspective
Speaker: Mary A. Slatter, GB

E10-3 HSCT for inherited bone marrow failure syndromes -

Speaker: Cristina Díaz de Heredia, ES

E10-4 Cord blood HSCT for non-malignant diseases in children -

Speaker: Vanderson Rocha, BR

Educational
09:15 - 17:30 On-Demand Library
E12 - Steroid-resistant/refractory GVHD
This session is available in our on-demand library throughout the whole congress
E12-1 GVHD - what’s in a name? -
Speaker: Helene Schoemans, BE

E12-2 Treatment of SR/R acute GVHD -

Speaker: Olaf Penack, DE

E12-3 Treatment of SR/R chronic GVHD -

Speaker: Zinaida Peric, HR

E12-4 New technologies in the approach to GVHD -

Speaker: Amin Turki, DE

Data Management
09:15 - 17:30 On-Demand Library
DM06 - Education session 6
This session is available in our on-demand library throughout the whole congress
DM6-1 Response in Multiple Myeloma -
Speaker: Meral Beksac, TR

Workshop
09:15 - 17:30 On-Demand Library
W12 - Donor HLA assessment and matching for allogeneic HSCT
This session is available in our on-demand library throughout the whole congress
W12-1 HLA laboratory perspective and recommendations -
Speaker: Pascale Loiseau, FR

W12-2 Clinical perspective and recommendations -

Speaker: Francesca Lorentino, IT

177 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

W12-3 Selection of unrelated donors and cord blood units for -

Hematopoietic Cell Transplantation: Guidelines from
NMDP/CIBMTR
Speaker: Stephen Spellman, US

Working Party Session

09:15 - 17:30 On-Demand Library
CMWP - Chronic Malignancies Working Party Session
This session is available in our on-demand library throughout the whole congress
CMWP-1 Scientific activity of the CMWP 09:15 - 09:15
Speaker: Ibrahim Yakoub-Agha, FR

CMWP-3 Who and when in the course of disease to transplant? - 09:15 - 09:15
Myelofibrosis
Speaker: Donal McLornan, GB

CMWP-4 Is Chronic Myeloid Leukaemia still an indication for allo-HCT? 09:15 - 09:15
Speaker: Yves Chalandon, CH

CMWP-5 Is Chronic Lymphocytic Leukemia still an indication for allo- 09:15 - 09:15
HCT?
Speaker: Peter Dreger, DE

Working Party Session

09:15 - 17:30 On-Demand Library
IDWP - Infectious Diseases Working Party Session
This session is available in our on-demand library throughout the whole congress
IDWP-1 IDWP update -
Speaker: Rafael de la Cámara, ES

IDWP-2 Current scientific proposals of IDWP -

Speaker: Dina Averbuch, IL

IDWP-3 CMV T-cell immunity monitoring: is it time to incorporate it in -

clinical practices?
Speaker: Roy Chemaly, US

IDWP-4 What is new in the field of Gram-negative infections in SCT -

patients?
Speaker: Dina Averbuch, IL

IDWP-5 Seasonal human coronaviruses vs SARS-CoV-2 in allogeneic -

hematopoietic stem cell transplantation
Speaker: Jose Luis Piñana, ES

IDWP-6 Hepatitis C and hepatitis E in SCT -

Speaker: Malgorzata Mikulska, IT

IDWP-7 Central nervous system (CNS) complications following HSCT -

Speaker: Martin Schmidt-Hieber, DE

178 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

Oral Session
09:15 - 17:30 On-Demand Library
OS21 - Oral session 21: Multiple Myeloma
This session is available in our on-demand library throughout the whole congress
OS21-1 MICROENVIRONMENT IMMUNE RECONSTITUTION PATTERNS 09:15 - 09:15
CORRELATE WITH OUTCOMES AFTER AUTOLOGOUS
TRANSPLANT IN MULTIPLE MYELOMA
Speaker: Harsh Parmar, US

OS21-2 AUTOLOGOUS HEMATOPOIETIC CELL TRANSPLANTATION 09:15 - 09:15

FOR RELAPSED MULTIPLE MYELOMA PERFORMED WITH
STEM CELLS RE-MOBILISED FOLLOWING A PRIOR AUTO-HCT
– A RETROSPECTIVE STUDY ON BEHALF OF EBMT CMWP
Speaker: Joanna Drozd-Soko?owska, PL

OS21-3 ISATUXIMAB PLUS CARFILZOMIB AND DEXAMETHASONE 09:15 - 09:15

VERSUS CARFILZOMIB AND DEXAMETHASONE IN RELAPSED
MULTIPLE MYELOMA PATIENTS WHO PREVIOUSLY
UNDERWENT TRANSPLANTATION: IKEMA SUBGROUP
ANALYSIS
Speaker: Mohamad Mohty, FR

OS21-4 AUTOLOGOUS-ALLOGENEIC VS AUTOLOGOUS TANDEM 09:15 - 09:15

STEM CELL TRANSPLANTATION AND MAINTENANCE WITH
THALIDOMIDE FOR PATIENTS WITH MULTIPLE MYELOMA
(MM) AND AGE <60 YEARS: A PROSPECTIVE PHASE II-
STUDY
Speaker: Nicolaus Kröger, DE

OS21-5 ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION 09:15 - 09:15

FOLLOWED BY BORTEZOMIB IN MULTIPLE MYELOMA: FINAL
RESULTS OF A PROSPECTIVE TRIAL HIGHLIGHTING A
STRONG PROGNOSTIC ROLE OF MEASURABLE RESIDUAL
DISEASE
Speaker: Jean Roy, CA

OS21-6 ACCEPTABLE TOXICITY AND GOOD HEMATOLOGICAL AND 09:15 - 09:15

RENAL RESPONSES AFTER AUTOLOGOUS HEMATOPOIETIC
STEM CELL TRANSPLANTATION IN MYELOMA PATIENTS WITH
RENAL INSUFFICIENCY: A PROSPECTIVE SFGM-TC STUDY
Speaker: laurent Garderet, FR

OS21-7 COAST (OP-501): FIRST IN MAN PHASE I MULTICENTER STUDY 09:15 - 09:15
EVALUATING OPD5 AS A MYELOABLATIVE CONDITIONING
REGIMEN IN RELAPSED REFRACTORY MULTIPLE MYELOMA
(RRMM)
Speaker: Sergio Giralt, US

OS21-8 CHARACTERISTICS AND TREATMENT PATTERNS OF TRIPLE- 09:15 - 09:15

CLASS-EXPOSED PATIENTS WITH RELAPSED/REFRACTORY
MULTIPLE MYELOMA WHO PARTICIPATED IN CLINICAL
TRIALS OF DARATUMUMAB
Speaker: Katja Weisel, DE

179 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

Joint Session
09:15 - 17:30 On-Demand Library
JS04 - Joint session LABMT
This session is available in our on-demand library throughout the whole congress
JS4-1 Transplant rates, Trends: WBMT/LABMT 2018 survey -
Speaker: Oscar González-Ramella, MX

JS4-2 Financing of HSCT in Latin America -

Speaker: Gregorio Jaimovich, AR

JS4-3 Selection, management and follow up of related donors: -

Overview
Speaker: Nina Worel, AT

JS4-4 Selection, management and follow up of related donors: -

Development of an LABMT consensus
Speaker: Gonzalo Ferini, AR

JS4-5 Haploidentical transplants in Latin America: Experience from -

Argentina/GATMO-TC in acute lymphoblastic leukemia
Speaker: Ana Basquiera, AR

JS4-6 Haploidentical transplants in Latin America: Experience from -

Brazil/SBTMO in aplastic anemia
Speaker: Carmem Bonfim, BR

Oral Session
09:15 - 17:30 On-Demand Library
OS01 - Oral session 1: Hematopoietic Stem Cells, Mobilization and Engineering
This session is available in our on-demand library throughout the whole congress
OS1-1 MGTA-145, IN COMBINATION WITH PLERIXAFOR IN A PHASE 1 09:15 - 09:25
CLINICAL STUDY, MOBILIZES LARGE NUMBERS OF
HEMATOPOIETIC STEM CELLS AND A GRAFT WITH POTENT
IMMUNOSUPPRESSIVE PROPERTIES
Speaker: Kevin Goncalves, US

OS1-2 EFFICACY AND SAFETY OF PEGFILGRASTIM FOR CD34+ CELL 09:25 - 09:35
MOBILIZATION IN HEALTHY VOLUNTEERS
Speaker: Hideki Goto, JP

OS1-3 THE IMPACT OF PLATELET RECOVERY ON SURVIVAL IN 09:35 - 09:45

CHILDREN UNDERGOING HEMATOPOIETIC STEM CELL
TRANSPLANTATION
Speaker: Rumesh Chandar, IN

OS1-4 THE IMPACT OF CD3 AND CD34 CELL DOSE ON GRAFT 09:45 - 09:55
REJECTION AND GRAFT VERSUS HOST DISEASE IN
CHILDREN UNDERGOING UNRELATED PERIPHERAL BLOOD
STEM CELL TRANSPLANTATION
Speaker: Satish Meena, IN

OS1-5 OUTCOME AND IMMUNE RECONSTITUTION AFTER 09:55 - 10:05

TCR??/CD19 CELL DEPLETED HEMATOPOIETIC STEM CELL

180 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

TRANSPLANTATION FROM HAPLOIDENTICAL RELATED

DONOR IN ADULT LEUKEMIA – A SINGLE CENTRE
EXPERIENCE
Speaker: Lucia Prezioso, IT

OS1-6 THE PREVALENCE OF ANTI-HLA ANTIBODIES IN THE FIRST 10:05 - 10:15

100 HAPLOIDENTICAL HEMATOPOIETIC STEM CELL
TRANSPLANTATION IN PEDIATRIC PATIENTS: A SINGLE-
CENTER EXPERIENCE
Speaker: Muhammad Ameen, SA

OS1-7 POST-TRANSPLANT OUTCOMES OF CHILDREN WITH 10:15 - 10:25

PRIMARY HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS
TREATED WITH EMAPALUMAB
Speaker: Michael Jordan, US

OS1-8 WHITE MATTER DEVELOPMENT IN NEONATES WITH 10:25 - 10:35

INFANTILE KRABBE DISEASE
Speaker: Maria Escolar, US

Oral Session
09:15 - 17:30 On-Demand Library
OS05 - Oral session 5: Cellular Therapy, Gene Therapy and New Drugs II
This session is available in our on-demand library throughout the whole congress
OS5-1 HEMATOPOIETIC STEM CELL GENE THERAPY FOR 09:15 - 09:25
MUCOPOLYSACCHARIDOSIS TYPE I, HURLER (MPS-IH):
BIOLOGICAL EFFICACY AND PRELIMINARY EVIDENCE OF
EARLY CLINICAL RESPONSE
Speaker: Maria Ester Bernardo, IT

OS5-2 OVERALL SURVIVAL BY BEST OVERALL RESPONSE WITH 09:25 - 09:35

TABELECLEUCEL IN PATIENTS WITH EPSTEIN-BARR VIRUS-
DRIVEN POST-TRANSPLANT LYMPHOPROLIFERATIVE
DISEASE AFTER ALLOGENEIC HEMATOPOIETIC CELL
TRANSPLANT
Speaker: Susan Prockop, US

OS5-3 RESOLUTION OF SERIOUS VASO-OCCLUSIVE PAIN CRISES: 09:35 - 09:45

RESULTS FROM THE ONGOING PHASE 1/2 HGB-206 GROUP C
STUDY OF LENTIGLOBIN FOR SICKLE CELL DISEASE (SCD)
GENE THERAPY
Speaker: Markus Mapara, US

OS5-4 DURABLE CLINICAL OUTCOMES FOLLOWING 09:45 - 09:55

BETIBEGLOGENE AUTOTEMCEL (BETI-CEL) GENE THERAPY
WITH UP TO 6 YEARS OF FOLLOW-UP IN PATIENTS WITH
TRANSFUSION-DEPENDENT ?-THALASSEMIA (TDT)
Speaker: Franco Locatelli, IT

OS5-5 OPEN LABEL DOSE ESCALATION TRIAL OF AB-205 (E-CEL® 09:55 - 10:05
CELLS) IN ADULTS WITH SYSTEMIC LYMPHOMA
UNDERGOING HIGH-DOSE THERAPY AND AUTOLOGOUS
HEMATOPOIETIC CELL TRANSPLANTATION (HDT-AHCT)

181 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

Speaker: Carolyn Mulroney, US

OS5-6 IMMUNOTHERAPY IN ACUTE LEUKEMIA: A GITMO (GRUPPO 10:05 - 10:15

ITALIANO TRAPIANTO MIDOLLO OSSEO) SURVEY ON
EFFICACY AND TOXICITY OF DONOR LYMPHOCYTE
INFUSIONS AFTER ALLOGENEIC STEM CELL
TRANSPLANTATION
Speaker: Francesca Patriarca, IT

OS5-7 MONITORING PATIENT SARS-COV-2-T-CELL IMMUNE 10:15 - 10:25

RESPONSES AND GENERATING SARS-COV-2-SPECIFIC T
CELLS FROM CONVALESCENT DONORS; IMPLICATIONS FOR
THE IDENTIFICATION OF HIGH-RISK PATIENTS AND
TREATMENT WITH T-CELL IMMUNOTHERAPY
Speaker: Anastasia Papadopoulou, GR

OS5-8 NORMALISED LYSOSOMAL ACID LIPASE ACTIVITY CAN BE 10:25 - 10:35

ACHIEVED IN WOLMAN FIBROBLASTS VIA BOTH DIRECT
TRANSDUCTION AND CROSS-CORRECTION MECHANISMS
USING A LENTIVIRAL-MEDIATED GENE THERAPY APPROACH
Speaker: Jane E Potter, GB

Paed4-2 EARLY SAFETY AND EFFICACY RESULTS WITH A SINGLE 10:35 - 10:45
DOSE OF AUTOLOGOUS CRISPR-CAS9-MODIFIED CD34+
HEMATOPOIETIC STEM AND PROGENITOR CELLS IN
TRANSFUSION-DEPENDENT ?-THALASSEMIA AND SICKLE
CELL DISEASE
Speaker: Selim Corbacioglu, DE

Oral Session
09:15 - 17:30 On-Demand Library
OS07 - Oral session 7: Stem Cell Source and Donors
This session is available in our on-demand library throughout the whole congress
OS7-1 FUNCTIONAL MISMATCHING FOR HLA-DP REDUCES RELAPSE 09:15 - 09:25
RISK AFTER UNRELATED HEMATOPOIETIC CELL
TRANSPLANTATION: A STUDY FROM THE CELLULAR
THERAPY AND IMMUNOBIOLOGY WORKING PARTY OF THE
EBMT
Speaker: Annalisa Ruggeri, ES

OS7-2 POST-TRANSPLANT CYCLOPHOSPHAMIDE IN ONE-ANTIGEN 09:25 - 09:35

MISMATCHED UNRELATED DONOR TRANSPLANTATION
VERSUS HAPLOIDENTICAL TRANSPLANTATION: A
RETROSPECTIVE STUDY ON BEHALF OF THE ACUTE
LEUKEMIA WORKING PARTY OF THE EBMT
Speaker: Giorgia Battipaglia, IT

OS7-3 HLA EVOLUTIONARY DIVERGENCE (HED) INFLUENCES 09:35 - 09:45

OUTCOMES OF ALLOGENEIC HSCT FROM UNRELATED
DONOR (UD) IN PEDIATRIC PATIENTS AND YOUNG ADULTS
AFFECTED BY MALIGNANT DISORDERS
Speaker: Pietro Merli, IT

OS7-4 MANAGEMENT OF DONOR-SPECIFIC ANTIBODIES IN 09:45 - 09:55

182 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

HAPLOIDENTICAL TRANSPLANT: MULTICENTER EXPERIENCE

FROM THE MADRID GROUP OF HEMATOPOIETIC
TRANSPLANT
Speaker: Rebeca Bailén, ES

OS7-5 LONG TERM OUTCOMES AFTER INTRABONE UNRELATED 09:55 - 10:05

UMBILICAL CORD BLOOD TRANSPLANT IN PATIENTS WITH
HEMATOLOGICAL MALIGNANCIES: A EUROCORD, CTIWP-
EBMT ANALYSIS
Speaker: Jacopo Peccatori, IT

OS7-6 INFERIOR CLINICAL OUTCOMES IN RECIPIENTS OF 10:05 - 10:15

CRYOPRESERVED GRAFTS FOLLOWING REDUCED INTENSITY
ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION: A
SINGLE CENTER REPORT
Speaker: Andriyana Bankova, US

OS7-8 CLINICAL RESULTS OF PERIPHERAL BLOOD STEM CELL 10:15 - 10:25

TRANSPLANTATION WITH CRYOPRESERVED GRAFTS
DURING THE COVID19 PANDEMIC
Speaker: Maximilian Christopeit, DE

Oral Session
09:15 - 17:30 On-Demand Library
OS08 - Oral session 8: Graft versus Host Disease I
This session is available in our on-demand library throughout the whole congress
OS8-1 GVHD PROPHYLAXIS WITH POST TRANSPLANTATION 09:15 - 09:15
CYCLOPHOSPHAMIDE (PTCY) VERSUS CYCLOSPORINE A /
METHOTREXATE POST ALLOGENEIC TRANSPLANTATION
(HSCT) FROM MATCHED SIBLINGS FOR AML: FROM THE
ALWP/EBMT
Speaker: Arnon Nagler, IL

OS8-2 BELUMOSUDIL FOR CHRONIC GRAFT-VERSUS-HOST DISEASE 09:15 - 09:15

(CGVHD) AFTER 2 OR MORE PRIOR LINES OF THERAPY: THE
ROCKSTAR STUDY (KD025-213)
Speaker: Corey Cutler, US

OS8-3 A PERSONALIZED ORGAN-BASED APPROACH TO THE 09:15 - 09:15

TREATMENT OF CHRONIC GRAFT-VERSUS-HOST DISEASE
Speaker: Hanaa A. Fatoum, SA

OS8-4 RUXOLITINIB (RUX) VS BEST AVAILABLE THERAPY (BAT) IN 09:15 - 09:15

PATIENTS WITH STEROID-REFRACTORY ACUTE GRAFT-VS-
HOST DISEASE (SR-AGVHD): 6-MONTH FOLLOW-UP FROM
THE RANDOMIZED, PHASE 3 REACH2 STUDY
Speaker: Mohamad Mohty, FR

OS8-5 IMPACT OF CHRONIC GVHD SEVERITY AND STEROID 09:15 - 09:15

RESPONSE ON THE QUALITY OF LIFE IN PATIENTS
FOLLOWING ALLOGENEIC STEM CELL TRANSPLANTATION:
FINDINGS FROM A REAL-WORLD STUDY
Speaker: Sylvie Lachance, CA

183 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

OS8-6 SUCCESSFUL AND SAFE TREATMENT OF INTESTINAL GVHD 09:15 - 09:15

WITH POOLED-DONOR FULL ECOSYSTEM MICROBIOTA
BIOTHERAPEUTIC: RESULTS FROM A 29 PATIENT-COHORT
OF A COMPASSIONATE USE/EXPANDED ACCESS TREATMENT
PROGRAM
Speaker: Florent Malard, FR

OS8-7 REDUCED ACUTE GRAFT-VERSUS HOST DISEASE INCIDENCE 09:15 - 09:15

IN PATIENTS RECEIVING ANTI-T LYMPHOCYTE GLOBULIN IN
COMPARISON TO ANTI-THYMOCYTE GLOBULIN FOR THE
PROPHYLAXIS OF GRAFT-VERSUS-HOST DISEASE AFTER
ALLO-HSCT
Speaker: Marie T Rubio, FR

OS8-8 PATIENT-REPORTED OUTCOMES IN ACUTE GRAFT-VS-HOST 09:15 - 09:15

DISEASE: QUALITY-OF-LIFE FINDINGS FROM A REAL-WORLD
STUDY
Speaker: Nada Hamad, AU

Poster Sessions
09:15 - 17:30 ePoster Area
CAR-based Cellular Therapy – Preclinical
P026 NON-VIRAL SLEEPING BEAUTY TRANSPOSON ENGINEERED 09:15 - 09:15
CD19-CAR-NK CELLS WITH HIGH ANTILEUKEMIC EFFICIENCY
Speaker: Tobias Bexte, DE

Poster Sessions
09:15 - 17:30 ePoster Area
Cellular Therapies other than CARs
P027 PROLONGED REPEATEDLY ADMINISTERED LOW DOSE 09:15 - 09:15
DONOR LYMPHOCYTE INFUSION FOR PREVENTION OF
RELAPSE AFTER ALLOGENEIC STEM CELL
TRANSPLANTATION FOR PATIENTS WITH HIGH RISK ACUTE
LEUKEMIA
Speaker: Panagiotis Tsirigotis, GR

P028 CD8?-ENHANCED NY-ESO-1-SPECIFIC TCR T CELLS 09:15 - 09:15

(GSK3901961) IN HLA-A*02 PATIENTS WITH NSCLC: MASTER
PROTOCOL SUBSTUDY 1
Speaker: Mehmet Altan, US

P029 CLINIMACS PLUS® SELECTION AS A RELIABLE AND SAFE 09:15 - 09:15

ALTERNATIVE PROCEDURE FOR CLINIMACS PRODIGY®
TCR?? AND CD19 DEPLETION
Speaker: Katalin Dobos, HU

P031 COMPREHENSIVE ACTIVATION PROFILING OF 09:15 - 09:15

TABELECLEUCEL, AN OFF-THE-SHELF, ALLOGENEIC EBV-
SPECIFIC T-CELL IMMUNOTHERAPY
Speaker: Fiona Ruiz, US

P030 IMPACT OF CRYOPRESERVED PHOTOPHERESIS IN GRAFT 09:15 - 09:15

184 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

VERSUS HOST DISEASE FOR NON-MALIGNANT DISORDERS

AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL
TRANSPLANTATION IN PEDIATRIC PATIENTS

P035 BMT CTN 1803: HAPLOIDENTICAL NATURAL KILLER CELLS (K- 09:15 - 09:15
NK002) TO PREVENT POST-TRANSPLANT RELAPSE IN AML
AND MDS (NK-REALM)
Speaker: Sumithira Vasu, US

P034 NEW, LN2-FREE SOLUTION FOR CRYOGENIC TRANSPORT OF 09:15 - 09:15

CELL THERAPIES
Speaker: Julie Meneghel, GB

P032 DONOR LYMPHOCYTE INFUSION AFTER ALLOGENEIC STEM 09:15 - 09:15

CELL TRANSPLANTATION: A RETROSPECTIVE ANALYSIS
Speaker: Virginia Escamilla Gómez, ES

P033 DONOR LYMPHOCYTE INFUSION (DLI). A STRATEGY TO 09:15 - 09:15

PREVENT OR TREAT RELAPSE FOLLOWING ALLOGENIC
STEM CELL TRANPLANTATION. ONE SINGLE CENTER
EXPERIENCE
Speaker: Melissa Karina Torres Ochando, ES

Poster Sessions
09:15 - 17:30 ePoster Area
Conditioning Regimens
P036 OUTCOMES OF ALLOGENEIC HEMATOPOIETIC CELL 09:15 - 09:15
TRANSPLANTATION IN ELDERLY PATIENTS: IS AGE THE
LIMIT?
Speaker: Sara Fernández-Luis, ES

P037 THE IMPACT OF MELPHALAN DE-ESCALATION ON EFFICACY 09:15 - 09:15

AND SAFETY IN PATIENTS WITH MULTIPLE MYELOMA
UNDERGOING AUTOLOGOUS STEM CELL
TRANSPLANTATION: A SINGLE-CENTER EXPERIENCE
Speaker: Bartosz Malecki, PL

P038 CONDITIONING WITH HIGH DOSE TOTAL BODY IRRADIATION 09:15 - 09:15
AND POST TRANSPLANTATION CYCLOPHOSPHAMIDE IN
EARLY RELAPSED MULTIPLE MYELOMA PATIENTS
RECEIVING ALLOGENEIC STEM CELL TRANSPLANTATION
Speaker: Jaap van Doesum, NL

P039 PREVENTING AKI IN TRANSPLANT FOR PAEDIATRIC ALL 09:15 - 09:15

WITH TBI AND ETOPOSIDE CONDITIONING
Speaker: Jane E Potter, GB

P040 ENHANCED IMMUNOSUPPRESSION IN T-CELL REPLETE 09:15 - 09:15

HAPLOIDENTICAL TRANSPLANTATION WITH POST-
TRANSPLANT CYCLOPHOSPHAMIDE IS ASSOCIATED WITH
FAVORABLE OUTCOMES

P041 LONG-TERM SAFETY AND EFFICACY OF A MYELOABLATIVE 09:15 - 09:15

CONDITIONING REGIMEN OF REDUCED TOXICITY IN

185 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION

Speaker: Ioanna Sakellari, GR

P042 TREOSULFAN VS. BUSULFAN-BASED REGIMENS IN 09:15 - 09:15

PEDIATRIC PATIENTS: A 7-YEAR RETROSPECTIVE STUDY
Speaker: Raquel Olivas-Mazón, ES

P044 POST-TRANSPLANT CYCLOPHOSPHAMIDE (PTCY) AS GVHD 09:15 - 09:15

PROPHYLAXIS FOR HEMATOPOIETIC STEM CELL
TRANSPLANTATION FROM MATCHED-RELATED SIBLING
DONORS
Speaker: Gabriella Storti, IT

P043 IMMUNE RECONSTITUTION AFTER SEQUENTIAL 09:15 - 09:15

CONDITIONING IN ELDERLY, HIGH-RISK AML AND MDS
PATIENTS: A MATCHED-PAIR ANALYSIS AMONG DIFFERENT
DONOR TYPES
Speaker: Alessia Fraccaroli, DE

Poster Sessions
09:15 - 17:30 ePoster Area
Data Management
P045 GENDER DISPARITY IN AUTOLOGOUS HSCT; FACT OR MYTH? 09:15 - 09:15
A BSBMTCT REGISTRY STUDY LOOKING INTO POSSIBLE
MALE PREDOMINANCE IN HSCT PARTICULARLY IN MULTIPLE
MYELOMA
Speaker: Ruth Paul, GB

Poster Sessions
09:15 - 17:30 ePoster Area
Experimental Stem Cell Transplantation
P046 SYNERGISTIC EFFECT OF ATG PLUS PTCY FOR DUAL T CELL 09:15 - 09:15
MODULATION IN HAPLOIDENTICAL STEM CELL
TRANSPLANTATION FOR POOR PROGNOSIS ACUTE
LEUKAEMIA
Speaker: Maryam Barkhordar, IR

P047 DAY 0 EASIX SCORE MIGHT PREDICT OVERALL SURVIVAL 09:15 - 09:15
AND TRANSPLANT RELATED MORTALITY AFTER
ALLOGENEIC STEM CELL TRANSPLANTATION: SINGLE
CENTRE EXPERIENCE
Speaker: Elisabetta Metafuni, IT

Poster Sessions
09:15 - 17:30 ePoster Area
Experimental Transplantation
P048 INFLUENCE OF POLYMORPHISMS RELATED TO DRUG 09:15 - 09:15
METABOLISM IN ALLOGENEIC BONE MARROW
TRANSPLANTATION
Speaker: Marta Santiago, ES

186 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

P049 REDUCED-INTENSITY UNMANIPULATED HAPLOIDENTICAL 09:15 - 09:15

STEM CELL TRANSPLANTATION FOR RELAPSED HIGH-RISK
NEUROBLASTOMA AFTER AUTOLOGOUS STEM CELL
TRANSPLANTATION
Speaker: Tahereh Rostami, IR

Poster Sessions
09:15 - 17:30 ePoster Area
Gene Therapy
P050 BETIBEGLOGENE AUTOTEMCEL (BETI-CEL; LENTIGLOBIN 09:15 - 09:15
FOR ?-THALASSEMIA) GENE THERAPY TREATMENT OF A
GREEK PATIENT WITH TRANSFUSION-DEPENDENT ?-
THALASSEMIA (TDT)
Speaker: Evangelia Yannaki, GR

Poster Sessions
09:15 - 17:30 ePoster Area
Graft-versus-Host Disease – Preclinical and Animal Models
P074 THE MAGNITUDE OF INTESTINAL T CELL INFILTRATION 09:15 - 09:15
DETERMINES EPITHELIAL REGENERATION DURING IMMUNE-
MEDIATED TISSUE INJURY
Speaker: Sascha Göttert, DE

P075 ITACITINIB ATTENUATES XENOGENEIC GVHD IN HUMANIZED 09:15 - 09:15

MICE

Poster Sessions
09:15 - 17:30 ePoster Area
Haematopoietic Stem Cells
P078 RESULTS OF SECOND ALLOGENEIC HEMATOPOIETIC STEM 09:15 - 09:15
CELL TRANSPLANTATION IN PATIENTS WITH
HEMATOLOGICAL DISEASES: RETROSPECTIVE ANALYSIS OF
OUR HOSPITAL
Speaker: Elena Paumard Rodríguez, ES

P076 LETERMOVIR PROPHYLAXIS REDUCES THE RISK FOR CMV 09:15 - 09:15
INFECTION AFTER STEM CELL TRANSPLANTATION
Speaker: Katrin Koch, DE

P077 KIR B HAPLOTYPES IN UNRELATED HEMATOPOIETIC STEM 09:15 - 09:15

CELL TRANSPLANTATION, REVISITED
Speaker: Kazimierz Halaburda, PL

P079 THE IMPACT OF AGE ON HEMATOLOGIC RECOVERY AFTER 09:15 - 09:15

ALLOGENEIC TRANSPLANTATION
Speaker: Sabrina Giammarco, IT

P081 OUTCOME OF SECOND ALLOGENIC STEM CELL 09:15 - 09:15

TRANSPLANTATION IN CHILDREN WITH PRIMARY IMMUNE
DEFICIENCIES
Speaker: Zohreh Nademi, GB

187 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

P080 HEMATOPOIETIC STEM CELL TRANSPLANTATION IN 09:15 - 09:15

PEDIATRIC ACUTE MYELOID LEUKEMIA WITH ABERRANT CD7
ANTIGEN EXPRESSION
Speaker: Danilo De Novellis, IT

P082 OUTCOME OF ALLOGENIC STEM CELL TRANSPLANTATION IN 09:15 - 09:15

ELDERLY PATIENTS: A SINGLE CENTER STUDY
Speaker: Eshrak Al-Shaibani, CA

P084 ALLOGENEIC HEMATOPOIETIC STEM CELL 09:15 - 09:15

TRANSPLANTATION IN PATIENTS OLDER THAN 65 YEARS
WITH AML AND MDS: RISK FACTORS FOR OVERALL
SURVIVAL AND DISEASE FREE SURVIVAL
Speaker: Simona Piemontese, IT

P083 ALLOGENEIC HEMATOPOIETIC STEM CELL 09:15 - 09:15

TRANSPLANTATION FOR PATIENTS 60 YEARS OR OLDER. A
SINGLE-INSTITUTION EXPERIENCE
Speaker: Marta Hidalgo Soto, ES

P086 EFFICACY OF MODIFIED FC/ATG PRETREATMENT IN HAPLOID 09:15 - 09:15

AND ALLOGENEIC HEMATOPOIETIC STEM CELL
TRANSPLANTATION FOR SEVERE APLASTIC ANEMIA
Speaker: Ma Liangming, CN

P085 IMPACT OF HUMAN LEUKOCYTE ANTIGEN ALLELE 09:15 - 09:15

POLYMORPHISMS ON THE OUTCOMES OF
TRANSPLANTATION FROM HLA-MATCHED UNRELATED
DONORS
Speaker: Anastasia Beynarovich, RU

P087 AUTOMATED DRY THAWING OF CRYOPRESERVED 09:15 - 09:15

HAEMATOPOIETIC CELLS IS NOT ADVERSELY INFLUENCED
BY CRYOSTORAGE TIME, PATIENT AGE OR GENDER
Speaker: Julie Meneghel, GB

P091 UNMANIPULATED HAPLOIDENTICAL STEM CELL 09:15 - 09:15

TRANSPLANTATION FOR PEDIATRIC PATIENTS WITH ACUTE
LEUKEMIA: AN EXPERIENCE FROM THE LARGEST
CHILDREN'S HOSPITAL IN IRAN
Speaker: Amir Ali Hamidieh, IR

P090 INDICATIONS AND SURVIVAL OF ALLOGENEIC TRANSPLANT 09:15 - 09:15

IN PATIENTS OVER 65 YEARS OLD
Speaker: Magdalena Corona de Lapuerta, ES

P089 LONG-TERM RESULTS OF HEMATOPOIETIC STEM CELL 09:15 - 09:15

TRANSPLANTATION FOR HODGKIN’S AND NON-HODGKIN’S
LYMPHOMA: EXPERIENCE OF A SINGLE CENTER IN
COLOMBIAN NORTHEAST
Speaker: Claudia Lucía Sossa Melo, CO

P093 HAPLOIDENTICAL STEM CELL TRANSPLANTATION IN AML 09:15 - 09:15

WITH T(6;9)(P23; Q34); DEK-NUP214 SHOWS A FAVOURABLE
OUTCOME: SINGLE CENTER EXPERIENCE

188 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

P092 ABSENCE OF INFLUENCE OF THE PRE- TRANSPLANT IMMUNE 09:15 - 09:15

STATUS OF RECIPIENTS ON SURVIVALS AND GVHD AFTER
ALLOGENEIC STEM CELL TRANSPLANTATION: A
RETROSPECTIVE STUDY OF 195 CASES
Speaker: Thierry Guillaume, FR

P097 DEFIBROTIDE AS TREATMENT FOR TRANSPLANT- 09:15 - 09:15

ASSOCIATED MICROANGIOPATHY (TA-TAM) IN PEDIATRIC
PATIENTS: A SINGLE CENTER EXPERIENCE
Speaker: Danilo De Novellis, IT

P096 IMPACT OF COVID 19 PANDEMIC ON HSCT ACTIVITIES: 09:15 - 09:15

REPORT FROM A SINGLE CENTER
Speaker: Sabrina Giammarco, IT

P095 IS HAPLOIDENTICAL HAEMATOPOIETIC STEM CELL 09:15 - 09:15

TRANSPLANTATION (HAPLO SCT) USING POST-
TRANSPLANTATION CYCLOPHOSPHAMIDE (PTCY) FEASIBLE
IN SUB-SAHARAN AFRICA?
Speaker: Justin du Toit, ZA

P099 IMPACT OF CYTOGENETIC AND MOLECULAR RISK AT 09:15 - 09:15

DIAGNOSIS ON TRANSPLANTATION RESULTS IN PATIENTS
WITH SECONDARY ACUTE MYELOID LEUKEMIA
Speaker: Claudia Núñez-Torrón, ES

P098 THE IMPACT OF CRYOPRESERVATION ON HAEMATOPOIETIC 09:15 - 09:15

STEM CELL GRAFTS DURING THE COVID-19 PANDEMIC AT
THE ROYAL MARSDEN HOSPITAL
Speaker: Sandra Easdale, GB

P102 EBV COLITIS POST HEMATOPOIETIC STEM CELL 09:15 - 09:15

TRANSPLANTATION IN PATIENT WITH APLASTIC ANEMIA
Speaker: Lucia Prezioso, IT

P100 BURNOUT SYNDROME IN ONCOLOGY PRACTICE: 09:15 - 09:15

EXPERIENCE OF A LARGE HSCT CENTER
Speaker: Irina Artemeva, RU

P103 MORBIDITY AND MORTALITY OF T- CELL LYMPHOMAS 09:15 - 09:15

UNDERGOING AUTOLOGOUS STEM CELL TRANSPLANTATION
(ASCT)
Speaker: Carolina Lilibeth Moreira-Ponce, MX

P101 FACTORS AFFECTING OUTCOMES IN CHILDREN WITH ACUTE 09:15 - 09:15

LEUKEMIA POST HEMATOPOIETIC STEM CELL
TRANSPLANTATION – A RETROSPECTIVE STUDY FROM A
TERTIARY REFERRAL CENTRE IN INDIA
Speaker: Rumesh Chandar, IN

P104 BRENTUXIMAB VEDOTIN STRATEGIES FOR RELAPSED OR 09:15 - 09:15

REFRACTORY HODGKIN'S LYMPHOMA AND HEMATOPOIETIC
STEM CELL TRANSPLANTATION
Speaker: Katheryn Garzón-Velásquez, MX

189 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

P106 EHEALTH AS A TOOL IN HEMATOPOIETIC STEM CELL 09:15 - 09:15

TRANSPLANTATION: A NARRATIVE REVIEW
Speaker: Claudia Lucía Sossa Melo, CO

P105 STAFF EXPERIENCES AND LEARNING FROM WORKING ON A 09:15 - 09:15

HAEMATOLOGICAL STEM CELL TRANSPLANT WARD DURING
COVID-19
Speaker: Sarah Airdrie, GB

Poster Sessions
09:15 - 17:30 ePoster Area
Haemoglobinopathy
P107 THE VALUE OF ROUTINE PRE-TRANSPLANT RADIOLOGICAL 09:15 - 09:15
SCREENING IN PEDIATRIC SICKLE CELL DISEASE PATIENTS:
A SINGLE CENTER EXPERIENCE
Speaker: Mohammed Essa, SA

P108 HOW TO FACILITATE DECISION-MAKING FOR 09:15 - 09:15

HEMATOPOIETIC STEM CELL TRANSPLANTATION IN
PATIENTS WITH HEMOGLOBINOPATHIES - THE
PERSPECTIVES OF HEALTH CARE PROFESSIONALS
Speaker: Hilda Mekelenkamp, NL

P109 ENDOCRINE SEQUELAE IN PEDIATRIC HEMATOPOIETIC STEM 09:15 - 09:15

CELL TRANSPLANT RECIPIENTS WITH SICKLE CELL DISEASE:
A RETROSPECTIVE COHORT ANALYSIS
Speaker: Richelle Waldner, CA

P110 DECISION-MAKING FOR HEMATOPOIETIC STEM CELL 09:15 - 09:15

TRANSPLANTATION IN PEDIATRIC, ADOLESCENT AND
YOUNG ADULT PATIENTS WITH A HEMOGLOBINOPATHY –
SHARED OR NOT?
Speaker: Hilda Mekelenkamp, NL

Poster Sessions
09:15 - 17:30 ePoster Area
Immunodeficiency Diseases and Macrophages
P111 CLINICAL MANIFESTATION AND MECHANISMS OF GRAFT 09:15 - 09:15
FAILURE IN PRIMARY IMMUNODEFICIENCY PATIENTS AFTER
HEMATOPOIETIC STEM CELL TRANSPLANTATION
Speaker: Aishat Idarmacheva, RU

P112 OUTCOMES OF HAEMATOPOIETIC STEM CELL 09:15 - 09:15

TRANSPLANTATION IN CHILDREN WITH ZETA CHAIN
ASSOCIATED PROTEIN KINASE 70KDA DEFICIENCY
Speaker: Liam Reilly, GB

P113 ALLOGENEIC HEMATOPOIETIC STEM CELL 09:15 - 09:15

TRANSPLANTATION IN A PATIENT WITH CLERICUZIO
SYNDROME (POIKILODERMA WITH NEUTROPENIA)
Speaker: Alexandra Burya, RU

190 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

Poster Sessions
09:15 - 17:30 ePoster Area
Paediatric Issues
P183 POST-TRANSPLANT CYCLOPHOSPHAMIDE AFTER 09:15 - 09:15
ALLOGENEIC HEMATOPOETIC STEM CELL
TRANSPLANTATION FOR PEDIATRIC HODGKIN LYMPHOMA
Speaker: Andrey Kozlov, RU

P185 RISK FACTORS AND SURVIVAL OF GRAFT FAILURE IN 09:15 - 09:15

PEDIATRIC PATIENTS WITH HEMATOLOGICAL MALIGNANCIES
TREATED WITH ALLOGENEIC HEMATOPOIETIC STEM-CELL
TRANSPLANTATION FROM HAPLOIDENTICAL DONORS USING
EXVIVO T-CELL-DEPLETION
Speaker: Iván López Torija, ES

P184 FREQUENCY AND CAUSES OF DEATH AFTER 09:15 - 09:15

HEMATOPOIETIC STEM CELL TRANSPLANTATION IN
CHILDREN WITH NON-MALIGNANT DISEASES
Speaker: Koray Yalcin, TR

P186 SVEGF-R1 LEVELS ARE ASSOCIATED WITH ENDOTHELIAL 09:15 - 09:15

DYSFUNCTION AFTER PEDIATRIC HEMATOPOIETIC STEM
CELL TRANSPLANTATION
Speaker: Denise Elbæk, DK

P187 LATE ENDOCRINE EFFECTS AFTER HSCT IN CHILDREN WITH 09:15 - 09:15
NONMALIGNANT DISEASES: A SINGLE CENTER COHORT
ANALYSIS
Speaker: Joëll Esmée Bense, NL

P188 PROSPECTIVE MULTICENTER STUDY OF A REDUCED- 09:15 - 09:15

TOXICITY MYELOABLATIVE CONDITIONNING REGIMEN USING
FLUDARABINE AND FULL DOSES OF IV BUSULFAN IN
PEDIATRIC PATIENTS NOT ELIGIBLE FOR MYELOABLATIVE
REGIMENS
Speaker: Fanny Rialland, FR

P189 TCR ALFA/BETA DEPLETION FOR HSCT FROM UNRELATED 09:15 - 09:15
DONOR IN PEDIATRIC PATIENTS
Speaker: Luisa Sisinni, ES

P190 SARS-COV-2 SEROLOGICAL STATUS OF PEDIATRIC HSCT 09:15 - 09:15

RECIPIENTS: A SINGLE CENTER EXPERIENCE
Speaker: Charlotte Nazon, FR

P191 SAFETY AND PERFORMANCE OF CENTRAL VENOUS 09:15 - 09:15

CATHETERS IN PEDIATRIC LEUKAPHERESIS: A SINGLE
CENTRE EXPERIENCE
Speaker: Sofia Martin-Consuegra, ES

P192 TREOSULFAN – BASED CONDITION REGIMEN FOR STEM CELL 09:15 - 09:15
TRANSPLANTATION IN PATIENTS WITH DIAMOND –
BLACKFAN ANEMIA
Speaker: Svetlana Radygina, RU

191 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

P193 ALLO-HSCT IN TREATMENT OF TP53 MUTATION-RELATED 09:15 - 09:15

MDS/AML IN PEDIATRIC PATIENTS – REPORT OF TWO CASES
Speaker: Maksymilian Deregowski, PL

P194 CENTRAL LINE REMOVAL IN ALLOGENIC PEDIATRIC 09:15 - 09:15

HEMATOPOIETIC STEM CELL TRANSPLANT PATIENTS
Speaker: Taylor Fitch, US

Poster Sessions
09:15 - 17:30 ePoster Area
Stem Cell Source
P216 THE BLOOD DONATION BEFORE BONE MARROW HARVEST 09:15 - 09:15
HAS NO IMPACT ON EFFICIENCY OF COLLECTION
Speaker: Iwona Mitrus, PL

P217 UNMANIPULATED HAPLOIDENTICAL TRANSPLANTATION FOR 09:15 - 09:15

HIGH RISK ACUTE LEUKEMIA USING MOBILIZED PERIPHERAL
BLOOD STEM CELLS (PBSC) AS SOURCE OF GRAFT: A
SINGLE CENTER EXPERIENCE
Speaker: Vincenzo Federico, IT

Poster Sessions
09:15 - 17:30 ePoster Area
Non-infectious Early Complications
P169 POST HEMATOPOIETIC PROGENITORS TRANSPLANT 09:15 - 09:15
LYMPHOMA (PTLD) AND REPLICATION OF EPSTEIN-BARR
VIRUS (EBV): A CENTER'S EXPERIENCE
Speaker: Sara Garrido, ES

P171 CLINICAL OUTCOME OF PATIENTS WITH IMMUNE-MEDIATED 09:15 - 09:15

PLATELET REFRACTORINESS UNDERGOING HEMATOPOIETIC
STEM CELL TRANSPLANTATION. SINGLE CENTER
EXPERIENCE

P170 ANALYSIS OF THE GUT MICROBIOME IN PEDIATRIC PATIENTS 09:15 - 09:15

UNDERGOING ALLOGENEIC HEMATOPOIETIC STEM CELL
TRANSPLANTATION (HSCT) PRESENTING VENO-OCCLUSIVE
DISEASE (VOD/SOS) REVEALS AN IMPAIRED MICROBIAL
ECOSYSTEM
Speaker: Daniele Zama, IT

P172 HEMORRHAGIC CYSTITIS DURING ALLOGENEIC STEM CELL 09:15 - 09:15

TRASPLANTATION: A POSSIBLE ROLE FOR PROSTATIC
HYPERPLASI
Speaker: Eugenio Galli, IT

P173 THROMBOTIC EVENTS IN HEMATOPOIETIC TRANSPLANT 09:15 - 09:15

RECPIENTS: SINGLE CENTER EXPERIENCE
Speaker: Carlota Mayor Bastida, ES

P175 EVALUATION OF INTESTINAL PERMEABILITY IN CANDIDATES 09:15 - 09:15

FOR ALLOHCT AND IN EARLY POST-TRANSPLANT PERIOD BY

192 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

SUGAR ABSORBTION TEST: INTERIM ANALYSIS OF THE

SINGLE-CENTER PROSPECTIVE STUDY
Speaker: Grzegorz Basak, PL

P176 ANICTERIC PRESENTATION OF SEVERE HEPATIC VENO- 09:15 - 09:15

OCCLUSIVE DISEASE (VOD) WITH MULTIORGAN
DYSFUNCTION (MOD)- A PEDIATRIC CASE REPORT
Speaker: Zofia Szmit, PL

Poster Sessions
09:15 - 17:30 ePoster Area
Myelodysplastic Syndromes
P156 THE ROLE OF AGE IN OUTCOMES OF BONE MARROW 09:15 - 09:15
TRANSPLANTATION IN PATIENTS FROM THE LATIN
AMERICAN REGISTRY
Speaker: Fernando Barroso Duarte, BR

P157 PRE-TRANSPLANT FERRITIN PREDICTS NON-RELAPSE 09:15 - 09:15

MORTALITY IN PATIENTS WITH MYELODYSPLASTIC
SYNDROMES UNDERGOING HEMATOPOIETIC STEM CELL
TRANSPLANTATION
Speaker: Isla Johnson, US

P159 SURVIVAL ANALYSIS IN ALLOGENIC HEMATOPOIETIC STEM 09:15 - 09:15

CELL TRANSPLANTATION IN MYELODYSPLASTIC SYNDROME
AND CHRONIC MYELOMONOCYTIC LEUKEMIA. IMPORTANCE
OF THE PREVIOUS SITUATION

P158 SECONDARY AND TREATMENT-RELATED ACUTE MYELOID 09:15 - 09:15

LEUKEMIA: ALLOGENEIC HEMATOPOIETIC CELL
TRANSPLANTATION REMAINS THE BEST AVAILABLE OPTION
Speaker: Ioanna Sakellari, GR

Poster Sessions
09:15 - 17:30 ePoster Area
Minimal Residual Disease, Tolerance, Chimerism and Immune Reconstitution
P143 EMPIRIC GRANULOCYTE-COLONY STIMULATING FACTOR (G- 09:15 - 09:15
CSF) ADVERSELY IMPACTS SURVIVAL AFTER ALLOGENEIC
STEM CELL TRANSPLANTATION (HCT) PERFORMED WITH
THYMOGLOBULIN: A CIBMTR ANALYSIS
Speaker: Nina Orfali, IE

P144 PREDICTIVE MEANING OF MRD CONVERSION ON DAYS +30 09:15 - 09:15

AND +100 IN PATIENTS WITH AML AFTER ALLO-SCT
Speaker: Nicolaus Kröger, DE

P145 IMPACT OF DIFFERENT T CELL DEPLETION PROTOCOLS ON 09:15 - 09:15

IMMUNE RECONSTITUTION FOLLOWING ALLOGENEIC
HEMATOPOIETIC STEM CELL TRANSPLANTATION
Speaker: Amandine Pradier, CH

P146 MRD VS CHIMERISM: ARE THEIR EFFECTIVENESS 09:15 - 09:15

193 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

COMPARABLE TO PREDICT AML RELAPSE?

Speaker: Valérie Dubois, FR

P148 CELLULAR CHIMERISM – DO REPEATED MARROW BIOPSIES 09:15 - 09:15

OPEN A WINDOW FOR RELAPSE INTERVENTION?
Speaker: Jan Morf, GB

Poster Sessions
09:15 - 17:30 ePoster Area
Stem Cell Mobilization, Collection and Engineering
P206 INTERIM ANALYSIS OF THE OPTIMOB STUDY: A NON- 09:15 - 09:15
INTERVENTIONAL STUDY ACROSS GERMANY TO EVALUATE
THE MOBILIZATION AND COLLECTION OF HSCS IN POOR
MOBILIZERS AHEAD OF ASCT
Speaker: Katharina Kriegsmann, DE

P207 TRENDS IN AUTOLOGOUS STEM CELL MOBILISATION 09:15 - 09:15

PRACTICES IN MYELOMA PATIENTS IN EBMT CENTRES
BETWEEN 2008 AND 2017
Speaker: James Dillon, IE

P208 THE IMPACT OF THE “NEW NORMAL” ON STEM CELL 09:15 - 09:15
LABORATORY PRACTICES
Speaker: Sanja Mazi?, HR

P210 AN ALGORITHMIC APPROACH TO PRE-EMPTIVE PLERIXAFOR 09:15 - 09:15

USAGE WITH GCSF ALONE FOR MOBILIZATION OF
PERIPHERAL BLOOD STEM CELLS IN MULTIPLE MYELOMA
Speaker: Mohamed Elemary, CA

P209 PLERIXAFOR MOBILIZATION OF HEMATOPOIETIC STEM 09:15 - 09:15

CELLS IN DIALYSIS DEPENDENT PATIENTS IS SAFE AND
FEASIBLE; A SINGLE CENTER ANALYSIS
Speaker: Moussab Damlaj, SA

P211 PROGRAM OF HEMATOPOIETIC STEM CELL MOBILIZATION 09:15 - 09:15

AND COLLECTION FOR CHILDREN OF FIRST YEAR OF LIFE
AND WITH LOW BODY WEIGHT: SINGLE CENTER EXPERIENCE
Speaker: Nara Stepanyan, RU

P212 A RETROSPECTIVE RECORD REVIEW OF MOBILIZATION 09:15 - 09:15

STRATEGIES WITH AND WITHOUT PLERIXAFOR FOR
AUTOLOGOUS STEM CELL TRANSPLANT IN PATIENTS WITH
MULTIPLE MYELOMA
Speaker: Joshua Richter, US

P213 PREDICTION OF THE MOBILIZATION SUCCESS FOR 09:15 - 09:15

AUTOLOGOUS PERIPHERAL BLOOD STEM CELL COLLECTION
IN PATIENTS WITH MALIGNANT HEMATOLOGIC DISEASES
Speaker: Maria Eduarda Couto, PT

P214 DOES USE OF BIOSIMILAR ZARZIO CHANGE PLERIXAFOR 09:15 - 09:15

UTILIZATION DURING STEM CELL MOBILIZATION FOR
AUTOLOGOUS STEM CELL TRANSPLANT?

194 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

Speaker: Pilar Velarde López de Ayala, ES

P215 AUTOLOGOUS PERIPHERAL BLOOD STEM CELL BACKUP 09:15 - 09:15

BEFORE HAEMATOPOETIC STEM CELL TRANSPLANTATION
FOR INTERMEDIATE OSTEOPETROSIS: A SINGLE CENTRE
EXPERIENCE
Speaker: Madeleine Powys, AU

Poster Sessions
09:15 - 17:30 ePoster Area
Nurses Posters – Adult
NP01 NURSES’ TRAINING NEEDS FOR ADVANCED THERAPY 09:15 - 09:15
MEDICINAL PRODUCTS EG CAR T: KEY FINDINGS FROM
QUESTIONNAIRE-BASED SURVEY ON BEHALF OF THE
NURSES GROUP OF THE EBMT
Speaker: Michelle Kenyon, GB

NP02 IMPROVEMENT OF ORAL MUCOSITIS IN HEMATOPOIETIC 09:15 - 09:15

STEM CELL TRANSPLANTATION USING POVIDONE-IODINE
MOUTHWASH UNDER DIRECT NURSING SUPERVISION
Speaker: Napassaya Khanthum, TH

NP03 COMPREHENSIVE GERIATRIC ASSESSMENT TO PREDICT 09:15 - 09:15

OUTCOMES IN OLDER PATIENTS RECEIVED CAR-T CELL
THERAPY
Speaker: Mercedes Montoro-Lorite, ES

NP04 CAR-T - RECOGNITION AND TREATMENT MANAGEMENT OF 09:15 - 09:15

NEUROLOGIC TOXICITIES AND CYTOKINE RELEASE
SYNDROME
Speaker: Naama Nevo, IL

NP05 HOME PLATELET TRANSFUSION IN AUTOLOGOUS STEM- 09:15 - 09:15

CELL TRANSPLANTATION: IMPROVING HOME-CARE
STRATEGIES DURING SARS-COV-2 PANDEMIC
Speaker: Laura Villa Rodríguez, ES

NP06 IMPROVING LONG-TERM QUALITY OF LIFE FOR PATIENTS 09:15 - 09:15

LIVING WITH MULTIPLE MYELOMA: A SERVICE EVALUATION
Speaker: Sarah Henshaw, GB

NP07 AT-HOME HEMATOPOIETIC STEM CELL TRANSPLANTATION 09:15 - 09:15

DURING SARS-CoV-2 PANDEMIC

NP08 THE NURSING SEARCH COORDINATOR (NSC) OF THE ROME 09:15 - 09:15
TRANSPLANT NETWORK (RTN), A JACIE ACCREDITED
METROPOLITAN TRANSPLANT PROGRAM
Speaker: Antonio Bruno, IT

NP10 PREVENTION OF NOSOCOMIAL SARS-COV2 INFECTIONS 09:15 - 09:15

AMONG HEMATOLOGICAL PATIENTS JUST BY FOLLOWING
WELL ESTABLISHED NURSING CARE STANDARDS
Speaker: Isabel Salcedo, ES

195 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

NP11 A TALE OF 2 COLLECTIONS: CAR -T ‘V' PBSC. OUR SINGLE 09:15 - 09:15
CENTRE EXPERIENCE
Speaker: Caroline Jupp, GB

NP12 CREATION OF THE FIRST COURSE ON HEMATOPOIETIC STEM 09:15 - 09:15

CELL TRANSPLANTATION (HSCT) NURSING IN LATIN
AMERICAN. ARGENTINE SOCIETY OF HEMATOLOGY
Speaker: Mariela Blanco, AR

NP13 MANAGEMENT OF PATIENTS SUFFERING FROM AN HEMATO- 09:15 - 09:15

ONCOLOGY MALIGNANCY AND THOSE UNDERGOING
HEMATOPOIETIC CELL TRANSPLANTATION DURING THE
COVID-19. HOW DO WE PROTECT THEM?
Speaker: Anna Serrahima - Mackay, ES

NP14 PREVENTION OF ORAL MUCOSITIS WITH CRYOTHERAPY IN 09:15 - 09:15

ADULT PATIENTS UNDERGOING HEMATOPOIETIC STEM CELL
TRANSPLANTATION
Speaker: Bakhtawar Altaf Hussain, PK

NP15 COVID-19 CHALLENGES – TO THE POINT OF CELL DELIVERY - 09:15 - 09:15

THE REALITY
Speaker: Lindsey Ashton, GB

NP16 TRANSITION FROM PAEDIATRIC TO THE ADULT CLINIC IN 09:15 - 09:15

SICKLE CELL DISEASE: THE ROLE OF THE SPECIALISED
NURSE
Speaker: Marijke Quaghebeur, BE

NP09 EBMT (GEC) & LABMT COLLABORATION PROJECTT. LABMT 09:15 - 09:25
NURSES GROUP 2020 CONTINUING EDUCATION PROGRAM
Speaker: Mariela Blanco, AR

Poster Sessions
09:15 - 17:30 ePoster Area
Stem Cell Donor
P203 HAPLOIDENTICAL VS HLA-MATCHED RELATED DONOR HSCT 09:15 - 09:15
FOR ACUTE LEUKEMIA AND MYELODYSPLASTIC SYNDROME:
A SINGLE-CENTER COMPARISON
Speaker: Alisa Lörsch, DE

P204 CLINICAL OUTCOMES IN ALLOGENIC HEMATOPOIETIC STEM 09:15 - 09:15

CELL TRANSPLANTATION FROM ALTERNATIVE DONORS:
SINGLE CENTER EXPERIENCE WITH 9/10 HLA-MISMATCHED
UNRELATED, DOUBLE UMBILICAL CORD BLOOD AND
HAPLOIDENTICAL DONORS
Speaker: Claudie Roy, CA

P205 HAPLOIDENTICAL STEM CELL TRANSPLANTATION WITH 09:15 - 09:15

POST-TRANSPLANT CYCLOPHOSPHAMIDE FOR PATIENTS
WITH HIGH-RISK HEMATOLOGIC MALIGNANCIES. A SINGLE
CENTER EXPERIENCE IN MEXICO
Speaker: Katheryn Garzón-Velásquez, MX

196 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

Poster Sessions
09:15 - 17:30 ePoster Area
Nurses Posters – Research
NP24 ROLE OF NURSING IN THE CARE OF PATIENT’S SKIN WITH 09:15 - 09:15
CUTANEOUS CHRONIC GRAFT-VERSUS-HOST DISEASE
AFTER ALLOGENEIC HAEMOPOIETIC STEM CELL
TRANSPLANTATION: A QUESTIONNAIRE?BASED SURVEY
Speaker: Jacqui Stringer, GB

NP25 INTRAVENTRICULAR INJECTIONS VIA OMMAYA RESERVOIR 09:15 - 09:15

MAY BE PERFORMED BY A TRAINED NURSE AS A PART OF
PEDIATRIC NEUROONCOLOGY TRANSPLANT TEAM EFFORT
Speaker: Lubov Shepeleva, RU

NP26 THE ROLE OF A NURSE IN NUTRITIONAL COUNSELING 09:15 - 09:15

DEVELOPMENT IN HEMATOPOIETIC STEM CELL
TRANSPLANTATION: FROM PRACTICE TO SCIENCE
Speaker: Natalya Rotan, RU

NP27 LONG TERM SURVIVORS AFTER ALLOGENEIC 09:15 - 09:15

HAEMATOPOIETIC STEM CELL TRANSPLANTATION IN
CHILDHOOD AND ADOLESCENCE IN A DEVELOPING
COUNTRY: HOW ARE THEY NOW?
Speaker: Priscila Oliveira da Silva, BR

NP28 EPIDEMIOLOGICAL SCREENING FOR BACTERIAL DRUG 09:15 - 09:15

RESISTANCE IN CANDIDATES FOR ALLO-HSCT AND MEDICAL
EMPLOYEES OF HEMATOLOGICAL DEPARTMENTS
Speaker: Olga Prokofieva, RU

NP29 EARLY CORONAVIRUS WARNING SCORE IN HEMATOLOGY 09:15 - 09:15

DISEASES
Speaker: Silvia Sangüesa Domínguez, ES

Poster Sessions
09:15 - 17:30 ePoster Area
Pharmacology
P195 PRELIMINARY SAFETY AND EFFICACY OF ITOLIZUMAB, A 09:15 - 09:15
NOVEL TARGETED ANTI-CD6 THERAPY, IN NEWLY
DIAGNOSED SEVERE ACUTE GRAFT-VERSUS-HOST DISEASE:
INTERIM RESULTS FROM THE EQUATE STUDY
Speaker: John Koreth, US

P196 EVALUATION OF A LIMITED SAMPLING STRATEGY IN THE 09:15 - 09:15

THERAPEUTIC DRUG MONITORING OF BUSULFAN
Speaker: Bushra Salman, OM

P197 A NOVEL SHORT HALF-LIFE ANTI-HUMAN CD117-AMANITIN 09:15 - 09:15

ADC EXHIBITS DUAL HSCT CONDITIONING AND ANTI-
LEUKEMIA ACTIVITY AND EXTENDS SURVIVAL IN MULTIPLE
PRECLINICAL MODELS OF AML
Speaker: Leanne Lanieri, US

P199 PHARMACOKINETIC ANALYSIS OF BARICITINIB IN PHASE 1-2 09:15 - 09:15

197 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

STUDY FOR TREATMENT REFRACTORY CHRONIC GRAFT-

VERSUS-HOST DISEASE
Speaker: Sara M. Zimmerman, US

P198 THE IMPACT OF LETERMOVIR PRESCRIBING ON THE RATE OF 09:15 - 09:15

CYTOMEGALOVIRUS REACTIVATION FOLLOWING
ALLOGENEIC STEM CELL TRANSPLANTATION
Speaker: Siobhan Smith, GB

Poster Sessions
09:15 - 17:30 ePoster Area
Solid Tumours
P200 HIGH DOSE CHEMOTHERAPY AND STEM-CELL TRANSPLANT 09:15 - 09:15
FOR RELAPSED GERM CELL TUMORS: MULTICENTRIC REAL-
WORLD EXPERIENCE IN ARGENTINA
Speaker: Adriana Vitriu, AR

Poster Sessions
09:15 - 17:30 ePoster Area
Statistics
P201 EVALUATION OF MACHINE LEARNING ALGORITHMS 09:15 - 09:15
APPLICABILITY FOR GRAFT FAILURE PREDICTION
Speaker: Evgeny Bakin, RU

P202 WHITE MATTER DEVELOPMENT IN NEONATES WITH 09:15 - 09:15

INFANTILE KRABBE DISEASE
Speaker: Maria Escolar, US

Poster Sessions
09:15 - 17:30 ePoster Area
Multiple Myeloma
P149 HIGH-DOSE MELPHALAN AND AUTOLOGOUS STEM CELL 09:15 - 09:15
TRANSPLANTATION IN ELDERLY PATIENTS ? 70 YEARS IS
SAFE AND EFFECTIVE – A RETROSPECTIVE ANALYSIS
Speaker: Udo Holtick, DE

P150 PEGYLATED G-CSF VERSUS G-CSF FOLLOWING HD-CTX FOR 09:15 - 09:15
PBSC MOBILIZATION AND HEMATOPOIETIC RECONSTITUTION
AFTER ASCT IN NEWLY DIAGNOSED MULTIPLE MYELOMA
PATIENTS
Speaker: Meilan Chen, CN

P152 RECOMBINANT HUMAN THROMBOPOIETIN IMPROVED 09:15 - 09:15

PLATELET ENGRAFTMENT AFTER AUTOLOGOUS
HEMATOPOIETIC STEM CELL TRANSPLANTATION IN
PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA
Speaker: Jingli Gu, CN

P151 AUTOLOGOUS STEM CELL TRANSPLANTATION FOR ELDERLY 09:15 - 09:15

MULTIPLE MYELOMA PATIENTS – A SAFETY OPTION
Speaker: Rita Sousa Gomes, PT

198 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

P153 CLINICAL IMPLICATIONS OF ?? T CELL RECONSTITUTION 09:15 - 09:15

AFTER AUTOLOGOUS HEMATOPOIETIC STEM CELL
TRANSPLANTATION IN PATIENTS WITH MULTIPLE MYELOMA
Speaker: Carolina Afonso, PT

P155 INDUCTION RESPONSE SEEMS TO BE A PROGNOSTIC 09:15 - 09:15

FACTOR FOR PROGRESSION-FREE SURVIVAL AFTER
AUTOLOGOUS STEM CELL TRANSPLANTATION IN PATIENTS
WITH MUTIPLE MYELOMA
Speaker: Pilar Velarde López de Ayala, ES

Poster Sessions
09:15 - 17:30 ePoster Area
Nurses Posters – Paediatric
NP17 NURSING INTERVENTIONS TO PREVENT HYPERTENSIVE 09:15 - 09:15
EMERGENCIES IN CHILDREN UNDERGOING HEMATOPOIETIC
STEM CELL TRANSPLANTATION
Speaker: Deepa Karmegam, IN

NP18 NEUROLOGICAL ASSESSMENT IN PAEDIATRIC PATIENTS 09:15 - 09:15

AFTER CAR-T INFUSION
Speaker: Giulia Del Giorno, IT

NP19 THE WORK OF THE REHABILITATION DEPARTMENT WITH 09:15 - 09:15

VOLUNTEERS DURING THE COVID-19 PANDEMIC
Speaker: Rashida Bikulova, RU

NP20 EVALUATION OF THE EFFECTIVENESS OF NASOGASTRIC 09:15 - 09:15

CATHETERIZATION AS A MEASURE OF NUTRITIONAL
SUPPORT IN PEDIATRIC PATIENTS UNDERGOING
ALLOGENEIC HEMATOPOIETIC STEM CELLS
TRANSPLANTATION
Speaker: Eugenia Trigoso Arjona, ES

NP21 NURSING CARE FOR ACUTE LEUKEMIA CHILDREN WITH 09:15 - 09:15
COMPLICATED BCG VACCINATION DURING CHEMOTHERAPY.
DESCRIPTION OF CLINICAL CASES
Speaker: Anton Silov, RU

NP22 INFUSION OF CHIMERIC ANTIGEN RECEPTOR T CELL (CAR-T 09:15 - 09:15

CELL) THERAPY IN PAEDIATRIC PATIENTS RECEIVING: ONE-
CENTER EXPERIENCE
Speaker: Alba Fernandez-Arroyo Garcia, ES

NP23 IMPLEMENTATION OF THE ADVANCED CELL THERAPY 09:15 - 09:15

PROGRAM:  EXPERIENCE AT LA PAZ UNIVERSITY
HOSPITAL
Speaker: Alba Fernandez-Arroyo Garcia, ES

Poster Sessions
09:15 - 17:30 ePoster Area
Non-infectious Late Effects, Quality of Life and Fertility

199 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

P177 IMPACT OF AGE IN EARLY AND LATE COMPLICATIONS AFTER 09:15 - 09:15
AN ALLOGENEIC TRANSPLANT IN ELDERLY PATIENTS
Speaker: Magdalena Corona de Lapuerta, ES

P178 OSTEONECROSIS IN PATIENTS UNDERGOING 09:15 - 09:15

HEMATOPOIETIC STEM CELLS TRANSPLANT: A SINGLE-
CENTRE STUDY OF INCIDENCE, RISK FACTORS,
CHARACTERISTICS AND EVOLUTION
Speaker: Giulia Prunotto, IT

P179 SECONDARY MALIGNANCIES AFTER AUTOLOGOUS 09:15 - 09:15

HEMATOPOIETIC STEM CELL TRANSPLANTATION
Speaker: João Gaião Santos, PT

P181 ANXIETY SYMPTOMATOLOGY PROGRESSION IN PATIENTS 09:15 - 09:15

WITH DIAGNOSIS OF MALIGNANT HEMATOLOGICAL
PATHOLOGY WHO ARE CANDIDATES TO RECEIVE INTENSIVE
CHEMOTHERAPY
Speaker: Walter Javier Zambrano Marquez, ES

P180 SECONDARY MALIGNANCIES AFTER ALLOGENEIC HSCT IN 09:15 - 09:15

CHILDREN
Speaker: Yulia Skvortsova, RU

P182 AN UNUSUAL PRESENTATION OF AUTOIMMUNE DISORDERS 09:15 - 09:15

AFTER ALLOGENEIC STEM CELL TRANSPLANTATION –
AMYOPATHIC DERMATOMYSISTIS, PRIMARY BILIARY
CHOLANGITIS AND AUTOIMMUNE HAEMOLYTIC ANAEMIA
Speaker: Pedro de Vasconcelos M, PT

Poster Sessions
09:15 - 17:30 ePoster Area
New Drugs- and Cell-based Immune Therapies
P160 INJECTION-SITE REACTIONS IN THE RANDOMIZED PHASE 3 09:15 - 09:15
PEGASUS TRIAL OF PEGCETACOPLAN COMPARED WITH
ECULIZUMAB FOR INDIVIDUALS WITH PAROXYSMAL
NOCTURNAL HEMOGLOBINURIA
Speaker: Vivek Sharma, US

P161 CLINICAL BURDEN OF ILLNESS SURVEY RESULTS FOR U.S. 09:15 - 09:15
PATIENTS WITH PAROXYSMAL NOCTURNAL
HEMOGLOBINURIA RECEIVING C5 INHIBITORS
Speaker: David Dingli, US

P162 IN ACUTE HSCT/BMT-TMA THE ACTIVATION OF THE LECTIN 09:15 - 09:15

PATHWAY INDUCES C5B-9 FORMATION ON ENDOTHELIAL
CELLS AND FAVORS MICROVASCULAR THROMBOSIS
Speaker: Miriam Galbusera, IT

P165 MEMORY-LIKE NK CELLS AS TREATMENT FOR PEDIATRIC 09:15 - 09:15

SARCOMA
Speaker: Carla Martín-Cortázar, ES

P163 POST-HEMATOPOIETIC STEM CELL TRANSPLANT 09:15 - 09:15

200 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

MAINTENANCE TKI'S IN PHILADELPHIA POSITIVE ALL: KING

HUSSEIN CANCER CENTRE EXPERIENCE

P166 PHASE 3 MULTICENTER, DOUBLE-BLIND, PLACEBO- 09:15 - 09:15

CONTROLLED TRIAL OF VIRALYM-M (ALVR105) FOR THE
TREATMENT OF VIRUS?ASSOCIATED HAEMORRHAGIC
CYSTITIS AFTER ALLOGENEIC HAEMATOPOIETIC CELL
TRANSPLANT (HCT) (STUDY DESIGN)
Speaker: Anna Thorner, US

P168 CLINICAL PHARMACOLOGY AND POPULATION 09:15 - 09:15

PHARMACOKINETIC/PHARMACODYNAMIC MODELING OF
LECTIN PATHWAY INHIBITION BY NARSOPLIMAB (OMS721)
Speaker: William Pullman, US

P167 WORK PRODUCTIVITY LOSS AND QUALITY OF LIFE IN 09:15 - 09:15

PAROXYSMAL NOCTURNAL HEMOGLOBINURIA AMONG
PATIENTS RECEIVING C5 INHIBITORS IN THE UNITED STATES
Speaker: David Dingli, US

Poster Sessions
09:15 - 17:30 ePoster Area
Myeloproliferative Neoplasm

Poster Sessions
09:15 - 17:30 ePoster Area
ePoster Area

Poster Sessions
09:15 - 17:30 ePoster Area
Acute Leukaemia
P001 MEASURABLE RESIDUAL DISEASE, FLT3-ITD MUTATION AND 09:15 - 09:15
DISEASE STATUS HAVE INDEPENDENT PROGNOSTIC
INFLUENCE ON POST-TRANSPLANT OUTCOMES IN
NPM1-MUTATED ACUTE MYELOID LEUKEMIA
Speaker: Rama Al Hamed, US

P002 ROLE OF ALLO-HSCT AS CONSOLIDATION OF MRD-NEGATIVE 09:15 - 09:15

REMISSION IN R/R B-ALL AFTER TREATMENT WITH
MONOCLONAL ANTIBODIES
Speaker: Inna Markova, RU

P003 AZACYTIDINE AND DONOR LYMPHOCYTE INFUSIONS (DLI) AS 09:15 - 09:15

SALVAGE TREATMENT IN PATIENTS WITH AML AND MDS
RELAPSED AFTER ALLOGENEIC STEM CELL
TRANSPLANTATION: A RETROSPECTIVE SINGLE CENTER
ANALYSIS
Speaker: Semra Aydin, IT

P004 T-CELL-DEPLETE ALLOGENEIC HAEMATOPOIETIC STEM CELL 09:15 - 09:15

TRANSPLANT AFTER REDUCED-INTENSITY CONDITIONING
FOR MYELOID MALIGNANCIES IN THE OVER-65S – A SINGLE
CENTRE EXPERIENCE OF 90 PATIENTS

201 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

Speaker: Alexandros Kanellopoulos, GB

P005 POST-REMISSION TREATMENT PATTERNS FOR PATIENTS 09:15 - 09:15

WITH NEWLY DIAGNOSED (ND) ACUTE MYELOID LEUKEMIA
(AML) IN THE CONNECT® MDS/AML DISEASE REGISTRY

P006 ALLOGENEIC STEM CELL TRANSPLANTATION IN FIRST 09:15 - 09:15

COMPLETE REMISSION IS ASSOCIATED WITH SUPERIOR
OUTCOMES IN ACUTE MYELOID LEUKEMIA INDEPENDENT OF
RECIPIENT AGE AND DONOR TYPE
Speaker: Tatiana Tzenou, GR

P007 GILTERITINIB MONOTHERAPY IN RELAPSED OR 09:15 - 09:15

REFRACTORY ACUTE MYELOID LEUKEMIA FLT3+ IN ADULT
PATIENTS
Speaker: Sergey Bondarenko, RU

P009 ZUMA-4: A PHASE 1/2 MULTICENTER STUDY OF KTE-X19 IN 09:15 - 09:15

PEDIATRIC AND ADOLESCENT PATIENTS WITH
RELAPSED/REFRACTORY B CELL ACUTE LYMPHOBLASTIC
LEUKEMIA (ALL) OR NON-HODGKIN LYMPHOMA (NHL)
Speaker: Alan S. Wayne, US

P008 VENETOCLAX COMBINED WITH AZACITIDINE OR LOW-DOSE 09:15 - 09:15

CYTARABINE FOR RELAPSED ACUTE MYELOID LEUKAEMIA
POST ALLOGENEIC STEM CELL TRANSPLANT
Speaker: Sandra Easdale, GB

P010 LONG-TERM OUTCOME OF ALLOGENEIC STEM CELL 09:15 - 09:15

TRANSPLANTATION IN PATIENTS WITH ACUTE MYELOID
LEUKEMIA – FOCUS ON MORTALITY
Speaker: Anna Lojko-Dankowska, PL

P011 SORAFENIB MAINTENANCE AFTER HEMATOPOIETIC STEM 09:15 - 09:15

CELL TRANSPLANTATION IMPROVES OUTCOME OF FLT3-ITD
POSITIVE ACUTE MYELOID LEUKEMIA
Speaker: Semra Aydin, IT

P012 BASELINE SOMATIC MUTATIONS PREDICT DISEASE FREE 09:15 - 09:15

SURVIVAL AFTER ALLOGENEIC STEM CELL
TRANSPLANTATION IN ACUTE MYELOID LEUKEMIA: A
RETROSPECTIVE MONOCENTRIC REPORT
Speaker: Elisabetta Metafuni, IT

P013 UNMANIPULATED HAPLOIDENTICAL HEMATOPOIETIC STEM 09:15 - 09:15

CELL TRANSPLANTATION IN ADULT PATIENTS WITH ACUTE
MYELOID LEUKEMIA
Speaker: Sergey Bondarenko, RU

P014 SURVIVAL OF PATIENTS WITH ACUTE MYELOID LEUKEMIA, 09:15 - 09:15

TAKEN TO HEMATOPOIETIC STEM CELL TRANSPLANTATION:
EXPERIENCE OF A CENTER IN COLOMBIA
Speaker: Claudia Lucía Sossa Melo, CO

202 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

Poster Sessions
09:15 - 17:30 ePoster Area
Lymphoma and Chronic Lymphocytic Leukemia
P134 RESULTS WITH ALLOGENEIC STEM CELL TRANSPLANTATION 09:15 - 09:15
IN PATIENTS WITH RELAPSED/REFRACTORY HODGKIN
LYMPHOMA TREATED WITH ANTI-PD1: A MULTICENTER
RETROSPECTIVE COHORT STUDY
Speaker: Fernando Warley, AR

P133 18FLUOROMETHYLCHOLINE PET/CT TO PREDICT OUTCOMES 09:15 - 09:15

OF PATIENTS PRE AND POST AUTOLOGOUS STEM CELL
TRANSPLANTATION(ASCT) FOR CNS LYMPHOMA – A NEW
CNS LYMPHOMA IMAGING TOOL
Speaker: Sandra Easdale, GB

P135 THE OUTCOMES OF ALLOGENEIC STEM CELLS 09:15 - 09:15

TRANSPLANTATION FOR RELAPSED/REFRACTORY CHRONIC
LYMPHOCYTIC LEUKEMIA IN THE ERA OF TARGETED
THERAPY: SINGLE CENTER EXPERIENCE
Speaker: Ivan Moiseev, RU

P137 STEM CELL TRANSPLANTATION IN MANTLE CELL 09:15 - 09:15

LYMPHOMA: POST-TRANSPLANT OUTCOMES OF TAIWAN
BLOOD AND MARROW TRANSPLANTATION REGISTRY
Speaker: Yu-Hung Wang, TW

P136 NIVOLUMAB 40 MG THERAPY IN RELAPSED AND 09:15 - 09:15

REFRACTORY CLASSICAL HODGKIN LYMPHOMA: RESULTS
OF A SINGLE CENTER MATCHED CASE-CONTROL STUDY
Speaker: Liudmila Fedorova, RU

P138 AUTOLOGOUS HEMATOPOIETIC CELL TRANSPLANTATION 09:15 - 09:15

FOR HIGH GRADE B-CELL LYMPHOMA WITH MYC AND BCL2
AND/OR BCL6 REARRANGEMENTS. A SINGLE INSTITUTION
EXPERIENCE
Speaker: Joanna Romejko-Jarosinska, PL

P142 SUCCESSFUL TREATMENT OF HEPATOSPLENIC T-CELL 09:15 - 09:15

LYMPHOMA WITH INTENSIFIED MYELOABLATIVE
CONDITIONING REGIMENS FOLLOWED BY UNMANIPULATED
HAPLOIDENTICAL HEMATOPOIETIC STEM CELL
TRANSPLANTATION
Speaker: Yan-Li Zhao, CN

P140 POLA-BR AFTER CAR-T CELL THERAPY FAILURE IN R/R 09:15 - 09:15
DIFFUSE LARGE B-CELL LYMPHOMA
Speaker: Ivan Moiseev, RU

P141 NODAL PERIPHERAL T-CELL LYMPHOMA – THE ROLE OF 09:15 - 09:15

CONSOLIDATIVE AUTOLOGOUS STEM CELL
TRANSPLANTATION IN COMPLETE OR PARTIAL FIRST
REMISSION: A 10-YEAR LESSON FROM SINGAPORE GENERAL
HOSPITAL
Speaker: Christopher Shwei Wen Tham, SG

203 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

P139 AUTOLOGOUS STEM CELL TRANSPLANT IN NON HODGKIN 09:15 - 09:15

LYMPHOMA AT AIIMS: TRENDS IN TOLERABILITY AND LONG
TERM OUTCOMES
Speaker: Sudhir Kumar, IN

Poster Sessions
09:15 - 17:30 ePoster Area
Infectious Complications
P118 COMPARISON BETWEEN PRIMARY PROPHYLAXIS AND PRE- 09:15 - 09:15
EMPTIVE THERAPY FOR CITOMEGALOVIRUS AFTER
HEMATOPOIETIC STEM-CELL TRANSPLANTATION
Speaker: Luisa Giaccone, IT

P119 INCIDENCE OF HEMORRHAGIC CYSTITIS FOLLOWING 09:15 - 09:15

HEMATOPOIETIC STEM CELL TRANSPLANTATION IN
PEDIATRIC PATIENTS BASED ON THE UNDERLYING DISEASE
Speaker: Amir Ali Hamidieh, IR

P120 EPIDEMIOLOGY OF RESISTANT AND REFRACTORY 09:15 - 09:15

CYTOMEGALOVIRUS INFECTION FOLLOWING SOLID ORGAN
OR HAEMATOPOIETIC STEM CELL TRANSPLANT: A
SYSTEMATIC REVIEW
Speaker: Aurore Bergamasco, FR

P122 EPIDEMIOLOGY OF INFECTIOUS COMPLICATIONS IN 09:15 - 09:15

PATIENTS WITH CHRONIC GRAFT-VERSUS-HOST DISEASE
Speaker: Aleksandr Siniaev, RU

P121 ANTIBACTERIAL PROPHYLAXIS IN PATIENTS UNDERGOING 09:15 - 09:15

HEMATOPOIETIC STEM CELL TRANSPLANTATION AND
DEVELOPMENT OF INFECTIONS BY ANTIBIOTIC-RESISTANT
BACTERIA
Speaker: Filippo Maraz, IT

P123 CLINICAL AND MICROBIOLOGICAL IMPACT OF 09:15 - 09:15

DISCONTINUATION OF FLUOROQUINOLONE PROPHYLAXIS IN
PATIENTS UNDERGOING HEMATOPOIETIC STEM CELL
TRANSPLANTATION: A SINGLE-CENTRE EXPERIENCE
Speaker: Anke Verlinden, BE

P124 IRON CHELATION WITH DEFERASIROX SUPPRESSES THE 09:15 - 09:15

APPEARANCE OF LPI DURING CONDITIONING
CHEMOTHERAPY PRIOR TO ALLOGENEIC STEM CELL
TRANSPLANTATION
Speaker: Sonja Essmann, DE

P125 SARS-COV-2 INFECTION IN A HEMATOPOIETIC STEM CELL 09:15 - 09:15

TRANSPLANT CENTER: A SINGLE CENTER EXPERIENCE IN
MEXICO
Speaker: Luis Manuel Valero-Saldaña, MX

P126 ANTIBIOTIC PROPHYLAXIS AND THE RATE OF BACTEREMIA 09:15 - 09:15

AND CLOSTRIDIUM DIFFICILE INFECTION IN PEDIATRIC STEM
CELL TRANSPLANTATION: A SINGLE CENTER

204 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

RETROSPECTIVE STUDY
Speaker: Mohammed Essa, SA

P128 TOCILIZUMAB IN POST HEMATOPOIETIC STEM CELL 09:15 - 09:15

TRANSPLANT COVID-19: A PEDIATRIC CASE REPORT
Speaker: Tahereh Rostami, IR

P127 HUMAN POLYOMA BK VIRUS AS A CAUSE OF HEMORRHAGIC 09:15 - 09:15

CYSTITIS: RETROSPECTIVE COHORT STUDY
Speaker: Nikola Pantic, RS

P132 CMV REACTIVATION AFTER ALLOGENIC HEMATOPOIETIC 09:15 - 09:15

STEM CELL TRANSPLANTATION - SINGLE CENTRE
EXPERIENCE
Speaker: Milena Todorovic Balint, RS

P129 PANDEMIC LESSONS OF COVID 19 IN NORTHEAST OF BRAZIL 09:15 - 09:15

Speaker: Fernando Barroso Duarte, BR

P131 SARS-COOV-2 INFECTION IN AN ADOLESCENT PATIENT 09:15 - 09:15

AFTER HAPLOIDENTICAL STEM CELL TRANSPLANTATION
Speaker: Maurizio Caniglia, IT

P130 CLINICAL CHARACTERISTICS AND OUTCOME OF 09:15 - 09:15

POLYMICROBIAL BLOODSTREAM INFECTIONS IN ALLO-SCT
PATIENTS: A MONOCENTRIC 5 YEARS SURVEY
Speaker: Gabriele Facchin, IT

Poster Sessions
09:15 - 17:30 ePoster Area
Inborn Errors
P114 ALLOGENEIC STEM CELL TRANSPLANTATION IN PATIENTS 09:15 - 09:15
WITH MUCOPOLYSACCHARIDOSIS TYPE I (HURLER) WITH
TREOSULFAN-BASED CONDITIONING
Speaker: Matthias Bleeke, DE

P115 LONG-TERM NEURODEVELOPMENTAL, 09:15 - 09:15

NEUROPHYSIOLOGICAL, AND NEURORADIOLOGICAL
OUTCOMES OF HEMATOPOIETIC STEM CELL
TRANSPLANTATION FOR TREATMENT OF LATE-INFANTILE
METACHROMATIC LEUKODYSTROPHY
Speaker: Maria Escolar, US

P116 OUTCOME OF HAEMATOPOIETIC CELL TRANSPLANTATION IN 09:15 - 09:15

CHILDREN WITH LYSOSOMAL ACID LIPASE DEFICIENCY: A
STUDY ON BEHALF OF THE EBMT INBORN ERRORS WORKING
PARTY
Speaker: Su Han Lum, GB

Poster Sessions
09:15 - 17:30 ePoster Area
CAR-based Cellular Therapy – Clinical

205 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

P016 HEALTH-RELATED QUALITY OF LIFE IN THE CARTITUDE-1 09:15 - 09:15

STUDY OF CILTACABTAGENE AUTOLEUCEL FOR
RELAPSED/REFRACTORY MULTIPLE MYELOMA
Speaker: Thomas Martin, US

P017 MANUFACTURING COMMERCIAL AXICABTAGENE 09:15 - 09:15

CILOLEUCEL (AXI-CEL) FOR EUROPEAN PATIENTS: A 2-YEAR
RETROSPECTIVE ANALYSIS
Speaker: Didier Hallard, NL

P015 RETREATMENT WITH AXICABTAGENE CILOLEUCEL (AXI-CEL) 09:15 - 09:15

IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) INDOLENT
NON-HODGKIN LYMPHOMA (INHL) IN ZUMA-5
Speaker: Julio C. Chavez, US

P019 COST-EFFECTIVENESS OF KTE-X19 CAR T THERAPY 09:15 - 09:15

FOLLOWING BRUTON TYROSINE KINASE INHIBITOR
TREATMENT FOR RELAPSED/REFRACTORY MANTLE CELL
LYMPHOMA IN ENGLAND
Speaker: Martin Brown, GB

P018 EXPANSION DYNAMICS DETECTED BY FLOW CYTOMETRY 09:15 - 09:15

CORRELATES WITH CLINICAL RESPONSE AFTER CAR-T CELL
THERAPY IN THE REAL WORLD SETTING
Speaker: Silvia monsalvo, ES

P020 PATIENT EXPECTATIONS AND PERCEPTIONS OF TREATMENT 09:15 - 09:15

IN CARTITUDE-1: PHASE 1B/2 STUDY OF CILTACABTAGENE
AUTOLEUCEL IN RELAPSED/REFRACTORY MULTIPLE
MYELOMA
Speaker: Adam D Cohen, US

P021 CHARACTERIZATION OF INFECTIONS AFTER CHIMERIC 09:15 - 09:15

ANTIGEN RECEPTOR T-CELL THERAPY IN PATIENTS WITH
LARGE B-CELL LYMPHOMA
Speaker: Pere Barba, ES

P022 CLINICAL APPLICATION OF HAPLOIDENTICAL DONOR- 09:15 - 09:15

DERIVED CD19 CAR-T CELLS MANUFACTURED FROM
MEMORY T CELL (CD45RA-DEPLETED) FRACTION
Speaker: Larisa Shelikhova, RU

P024 ICU RESOURCE UTILIZATION IN PEDIATRIC AND 09:15 - 09:15

ADOLESCENT YOUNG ADULT PATIENTS POST CAR-T
THERAPY
Speaker: Dristhi Ragoonanan, US

P023 HEMATOLOGIC RESCUE OF CAR T CELL-MEDIATED 09:15 - 09:15

PROLONGED PANCYTOPENIA USING AUTOLOGOUS
PERIPHERAL BLOOD HEMATOPOIETIC STEM CELLS IN A
LYMPHOMA PATIENT
Speaker: Udo Holtick, DE

P025 ZUMA-19: A PHASE 1/2 MULTICENTER STUDY OF LENZILUMAB 09:15 - 09:15

WITH AXICABTAGENE CILOLEUCEL (AXI?CEL) IN PATIENTS

206 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

WITH RELAPSED OR REFRACTORY LARGE B CELL

LYMPHOMA (R/R LBCL)
Speaker: Saad J. Kenderian, US

Nurses Group
09:35 - 10:30 Auditorium 3
NG04 - GVHD
Chair: Kathy Goris, BE
Chair: Francisco Xosé Román Losada, ES
NG04-1 Update on treatments: New agents and strategy 09:35 - 09:58
Speaker: Blanca Molina Angulo, ES

NG04-2 Pulmonary GVHD 09:58 - 10:14

Speaker: Saskia Bos, BE

NG04-3 Q&A 10:14 - 10:30

Breaks
10:30 - 11:00 Auditorium 1
Coffee Break, Poster Viewing, Visit Exhibition

Educational
11:00 - 12:15 Auditorium 1
E05 - Maintenance therapies after HSCT in acute leukaemia
Chair: Mohamad Mohty, FR
Chair: Pau Montesinos, ES
E5-1 Novel targeted therapy post-HSCT for ALL 11:00 - 11:15
Speaker: Eolia Brissot, FR

E5-2 Novel targeted therapy post-HSCT for AML/MDS 11:15 - 11:30

Speaker: Gesine Bug, DE

E5-3 T-cell therapies after transplantation 11:30 - 11:45

Speaker: Fred Falkenburg, NL

E5-4 Q&A 11:45 - 12:15

Educational
11:00 - 12:15 Auditorium 2
E06 - CAR-T toxicity and management
Chair: Maria Liz Paciello, ES
Chair: Olaf Penack, DE
E6-1 Cytokine release syndrome 11:00 - 11:15
Speaker: Susana Rives, ES

E6-2 Neurotoxicity 11:15 - 11:30

Speaker: Miguel-Angel Perales, US

E6-3 EBMT recommendations 11:30 - 11:45

Speaker: Patrick Hayden, IE

207 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

E6-4 Q&A 11:45 - 12:15

Paediatric Day
11:00 - 12:15 Auditorium 4
Paed2 - Inborn Errors Working Party Session
Chair: Michael Albert, DE
Chair: Benedicte Neven, FR
Paed2-1 Antibody-based conditioning in SCID and beyond 11:00 - 11:15
Speaker: Agnieszka Czechowicz, US

Paed2-2 Clinical and immunological outcome after HSCT in severe 11:15 - 11:30
combined immune deficiency, a SCETIDE cohort study
Speaker: Arjan Lankester, NL

Paed2-3 A prospective outcome study in profound combined immune 11:30 - 11:45

deficiency
Speaker: Stephan Ehl, DE

Paed2-4 Advances in stem cell therapy in metachromatic 11:45 - 12:00

leukodystrophy
Speaker: Valeria Calbi, IT

Paed2-5 Q&A 12:00 - 12:15

Pharmacists Day
11:00 - 12:15 Auditorium 5
Pharm2 - Supportive care 1
Chair: Nick Duncan, GB
Chair: Agnès Bonnin, FR
Pharm2-1 Drug-drug interactions between antifungals and 11:00 - 11:20
immunosuppressive agents
Speaker: Eline Muilwijk, NL

Pharm2-2 Drug interactions with complementary and alternatives herbs 11:20 - 11:40
and medicines
Speaker: Christoph Ritter, DE

Pharm2-3 New developments in the management of steroid-refractory 11:40 - 12:00

GVHD
Speaker: Raakhee Shah, GB

Pharm2-4 Q&A 12:00 - 12:15

Quality Management
11:00 - 12:15 Auditorium 6
QM1 - Center Session
Chair: Isabel Sánchez-Ortega, ES
QM1-1 Accreditation Process 11:00 - 11:10
Speaker: Carla Sánchez, ES

QM1-2 Basic quality management concepts 11:10 - 11:20

208 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

Speaker: John Fitzgerald, IE

QM1-3 Lessons learned from first-time inspections and re- 11:20 - 11:30
accreditation inspections
Speaker: Carolina Herranz, ES

QM1-4 HSCT QM Book 11:30 - 11:45

Speaker: Joaquim Vives Armengol, ES

QM1-5 Q&A 11:45 - 12:15

Nurses Group
11:25 - 12:15 Auditorium 3
NG05 - Joint session: Teamwork in the CAR T-cells setting
Chair: Sara Marcos Corrales, ES
Chair: John Murray, GB
NG05-1 Training workforce 11:25 - 11:40
Speaker: Ian Hollingsworth, GB

NG05-2 Quality of life in caregivers and patients undergoing CAR T 11:40 - 11:57
therapy
Speaker: Anna Barata, US

NG05-3 Q&A 11:57 - 12:15

Breaks
12:15 - 13:00 Auditorium 1
Lunch Break, Poster Viewing, Visit Exhibition

Wellness session
12:20 - 12:50 Auditorium 1
Therapeutic Origami session

CME Symposium
13:00 - 14:00 Auditorium 1
IS31 - Gene Therapies for Inherited and Rare Diseases in 2021: What Will They Mean for Patients? - CME Symp
Chair: Janet Kwiatkowski, US
IS31-1 What do You Know About Gene Therapy? 13:00 - 13:10
Speaker: Janet Kwiatkowski, US

IS31-2 Overview of Gene Therapy in Different Diseases 13:10 - 13:20

Speaker: Andreas E. Kulozik, DE

IS31-3 Practical Considerations for Gene Therapy 13:20 - 13:30

Speaker: Franco Locatelli, IT

IS31-4 Do Gene Therapies Have the Potential for Cure? 13:30 - 13:50
Speaker: Franco Locatelli, IT
Speaker: Andreas E. Kulozik, DE
Speaker: Janet Kwiatkowski, US

IS31-5 Summary and Audience Q&A 13:50 - 14:00

209 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

Speaker: Janet Kwiatkowski, US

Industry Symposium
13:00 - 14:00 Auditorium 2
IS32 - A look into the future: how will cellular therapies affect our clinical practice in multiple myeloma? - Jans
Symposium
Chair: John Gribben, GB
IS32-1 Introduction and welcome 13:00 - 13:05
Speaker: John Gribben, GB

IS32-2 Cellular therapies in MM – where are we now and where are we 13:05 - 13:20
going?
Speaker: John Gribben, GB

IS32-3 Panel discussion: What do we need to know about cellular 13:20 - 13:58
therapies for our clinical practice?
Speaker: María Victoria Mateos, ES
Speaker: Saad Usmani, US

IS32-4 Close 13:58 - 14:00

Speaker: John Gribben, GB

General
13:00 - 13:50 Auditorium 4
GS3 - General Assembly
Chair: Nicolaus Kröger, DE
GS3-1 President's Report 13:00 - 13:10
Speaker: Nicolaus Kröger, DE

GS3-2 Treasurer's Financial Report 13:10 - 13:20

Speaker: Harry Dolstra, NL

GS3-3 Secretary's Report 13:20 - 13:30

Speaker: John Snowden, GB

GS3-4 2021 Election results 13:30 - 13:35

Speaker: John Snowden, GB

GS3-5 Outgoing Board members 13:35 - 13:45

Speaker: Nicolaus Kröger, DE

GS3-6 Q&A 13:45 - 13:50

Statistics
13:00 - 14:00 Auditorium 5
Stat2 - Statistical Symposium
Chair: Liesbeth de Wreede, NL
Stat2-1 Sensitivity Analysis: E-value based on directly adjusted survival 13:00 - 13:25
probabilities
Speaker: Mei-Jie Zhang, US

210 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

Stat2-2 Working with incomplete data: When one-size-fits-all does not 13:25 - 13:50
fit
Speaker: Nicole Erler, NL

Stat2-3 Q&A 13:50 - 14:00

Quality Management
13:00 - 14:00 Auditorium 6
QM2 - QMS and new activities in SC Program
Chair: Carlos Torrico, ES
QM2-1 Allogeneic SCT in the COVID era 13:00 - 13:15
Speaker: Anna Grassi, IT

QM2-2 Integration of JACIE Quality Management System and 13:15 - 13:30

Qualification for IEC
Speaker: Helena Munro, GB

QM2-3 Investigational Products 13:30 - 13:45

Speaker: Simon Hack, GB

QM2-4 Q&A 13:45 - 14:00

Industry Symposium
13:00 - 14:00 MTE rooms
IS33 - New Agents and New Tools for the Management of CMV in HSCT Patients: Interactive patient case prese
Industry Meet the Expert Lunch 2 - Room MTE1
Chair: Roy Chemaly, US

Industry Symposium
13:00 - 14:00 MTE rooms
IS34 - Early use of ECP in aGvHD - Therakos-Mallinckrodt Industry Meet the Expert Lunch - Room MTE2
Chair: Amin Alousi, US

Industry Symposium
13:00 - 14:00 MTE rooms
IS36 - How do I manage the high-risk ‘difficult-to-treat’ stem cell transplant recipients with CMV infections (inc
refractory/resistant) - Takeda Industry Meet the Expert Lunch - Room MTE4
IS36-1 Identifying the high-risk ‘difficult-to-treat’ HSCT recipient 13:00 - 13:10
Speaker: Per Ljungman, SE

IS36-2 Q&A and discussion 13:10 - 13:25

IS36-3 Managing the high-risk transplant recipient with CMV 13:25 - 13:40
Speaker: Per Ljungman, SE

IS36-4 Q&A and discussion 13:40 - 14:00

Industry Symposium
13:00 - 14:00 MTE rooms
Industry Meet the Expert lunch sessions

211 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

Breaks
14:00 - 14:30 Auditorium 1
Coffee Break, Poster Viewing, Visit Exhibition

Workshop
14:30 - 15:45 Auditorium 1
W01 - Battling acute leukemia relapse after allogeneic HSCT
Chair: Thomas Cluzeau, FR
Chair: David Valcárcel Ferreiras, ES
W1-1 CAR T-cells 14:30 - 14:45
Speaker: Mohamad Mohty, FR

W1-2 Maintenance strategies after allogeneic HSCT 14:45 - 15:00

Speaker: Charles Craddock, GB

W1-3 Second allogeneic HSCT 15:00 - 15:15

Speaker: Bipin Savani, US

W1-4 Q&A 15:15 - 15:45

Workshop
14:30 - 15:45 Auditorium 2
W02 - Immune biology and therapy beyond CAR-T cells
Chair: Harry Dolstra, NL
Chair: José M. Moraleda, ES
W2-1 Engineering hematopoietic stem and progenitor cells for gene 14:30 - 14:45
and immunotherapy
Speaker: Hans-Peter Kiem, US

W2-2 Immunobiology of Mesenchymal Stromal Cells in allo- and auto- 14:45 - 15:00
immune disorders
Speaker: Willem Fibbe, NL

W2-3 Mesenchymal stromal cells for respiratory distress and other 15:00 - 15:15
organ failure
Speaker: Sergio Querol, ES

W2-4 Q&A 15:15 - 15:45

Nurses Group
14:30 - 15:45 Auditorium 3
NG06 - Supportive and palliative care
Chair: Sandra Schoenfeld, CH
Chair: Cristina Canaleta, ES
NG06-1 Meaning centered interventions 14:30 - 14:50
Speaker: Silke Walter, CH
Speaker: Sandra Eckstein, CH

NG06-2 Challenges of decision making - End of life 14:50 - 15:10

Speaker: Jakob Passweg, CH

NG06-3 Early integration 15:10 - 15:30

212 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

Speaker: Richard Towers, GB

NG06-4 Q&A 15:30 - 15:45

Paediatric Day
14:30 - 15:45 Auditorium 4
Paed3 - Paediatric Diseases Oral Session
Paed3-1 TREOSULFAN- VERSUS BUSULFAN-BASED MYELOABLATIVE 14:30 - 14:39
CONDITIONING FOR ALLOGENEIC HEMATOPOIETIC STEM
CELL TRANSPLANTATION IN PEDIATRIC ACUTE
LYMPHOBLASTIC LEUKEMIA. A REPORT FROM THE
INTERNATIONAL ALL-SCTPED FORUM TRIAL
Speaker: Herbert Pichler, AT

Paed3-2 SEROTHERAPY-FREE REGIMEN IMPROVES NON-RELAPSE 14:39 - 14:48

MORTALITY AND EARLY IMMUNE RECOVERY AMONG THE
RECIPIENTS OF ?? T CELL-DEPLETED HAPLOIDENTICAL
GRAFTS: RETROSPECTIVE STUDY IN CHILDHOOD LEUKEMIA
Speaker: Maria Dunaykina, RU

Paed3-3 EXCELLENT TRANSPLANT SURVIVAL FOR CHILDREN WITH 14:48 - 14:57

ADENOSINE DEAMINASE (ADA) DEFICIENCY
Speaker: Elisabetta Ghimenton, GB

Paed3-4 IMPACT OF EARLY LYMPHOCYTE IMMUNE RECONSTITUTION 14:57 - 15:06

ON TRANSPLANT-RELATED MORTALITY AMONG CHILDREN
AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL
TRANSPLANTATION WITH ALPHA-BETA T CELL DEPLETION
Speaker: Svetlana Glushkova, RU

Paed3-5 AZACITIDINE AND PROPHYLACTIC DONOR LYMPHOCYTE 15:06 - 15:15

INFUSION AFTER ALLOGENEIC STEM CELL
TRANSPLANTATION IN PEDIATRIC PATIENTS WITH HIGH RISK
ACUTE MYELOID LEUKEMIA: A RETROSPECTIVE SINGLE-
CENTER COHORT STUDY
Speaker: Natalie Booth, US

Paed3-6 ENTERAL NUTRITION PROMOTES THE RECOVERY OF GUT 15:15 - 15:24

MICROBIOME HOMEOSTASIS AND PROTECTS FROM
BLOODSTREAM INFECTIONS IN CHILDREN RECEIVING
ALLOGENEIC HEMATOPOIETIC STEM CELL
TRANSPLANTATION
Speaker: Daniele Zama, IT

Paed3-7 IN VIVO B-CELL DEPLETION WITH MYELOABLATIVE 15:24 - 15:33

CONDITIONING FOR UMBILICAL CORD BLOOD TRANSPLANT
IN HURLER SYNDROME ABOLISHES IMMUNE MEDIATED
CYTOPENIA AND GRAFT REJECTION
Speaker: Ramya Hanasoge Nataraj, GB

Paed3-8 ALEMTUZUMAB PROTECTS CHILDREN FROM SEVERE ACUTE 15:33 - 15:42

AND FROM CHRONIC GVHD IN PBSC AS WELL AS MARROW
GRAFT RECIPIENTS: A MULTICENTRE RETROSPECTIVE
COHORT ANALYSIS

213 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

Speaker: Su Han Lum, GB

Pharmacists Day
14:30 - 15:45 Auditorium 5
Pharm3 - Supportive care 2
Chair: Vera Domingos, PT
Chair: Vera Pires, PT
Pharm3-1 What's new in antifungals? 14:30 - 14:50
Speaker: Rodrigo Martino, ES

Pharm3-2 Chemotherapy Induced Nausea and Vomiting 14:50 - 15:10

Speaker: Sumantha Gabriel, GB

Pharm3-3 Nutrition strategies in Hematopoietic Stem Cell Transplantation 15:10 - 15:30

Speaker: Hartmut Bertz, DE

Pharm3-4 Q&A 15:30 - 15:45

Quality Management
14:30 - 15:45 Auditorium 6
QM3 - Draft 8th Edition of the STD
Chair: Riccardo Saccardi, IT
QM3-1 Clinical standards 14:30 - 14:42
Speaker: Kim Orchard, GB

QM3-2 Collections Standards 14:42 - 14:54

Speaker: Nina Worel, AT

QM3-3 Processing Standards 14:54 - 15:06

Speaker: Ivan van Riet, BE

QM3-4 Quality Management Standards 15:06 - 15:18

Speaker: Simon Hack, GB

QM3-5 Immune Effector Cells Standards 15:18 - 15:30

Speaker: Riccardo Saccardi, IT

QM3-6 Q&A 15:30 - 15:45

Breaks
15:45 - 16:15 Auditorium 1
Coffee Break, Poster Viewing, Visit Exhibition

Plenary Session
16:15 - 17:30 Auditorium 1
P2 - Artificial Intelligence approaching Hemato-oncology and HSCT
Chair: Rafael Duarte, ES
Chair: Myriam Labopin, FR
P2-1 Basic concepts, applications, and limitations of Machine 16:15 - 16:30
Learning: A primer for hematologists
Speaker: Roni Shouval, US

214 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

P2-2 Artificial Intelligence in Hematology 16:30 - 16:45

Speaker: Grzegorz Basak, PL

P2-3 Artificial Intelligence to support clinical decision making on 16:45 - 17:00

infections in Hematology
Speaker: Carolina García-Vidal, ES

P2-4 The role of technology and Artificial Intelligence in GVHD 17:00 - 17:15
Speaker: Sharukh Hashmi, US

P2-5 Q&A 17:15 - 17:30

Workshop
16:15 - 17:30 Auditorium 2
W03 - Autoimmune diseases
Chair: Raffaella Greco, IT
Chair: Montserrat Rovira, ES
W3-1 Immunological basis of HSCT in autoimmune disorders 16:15 - 16:30
Speaker: Paolo Muraro, GB

W3-2 Stem cells in System Sclerosis: Clinical experience and 16:30 - 16:45
translational relevance
Speaker: Nicoletta Del Papa, IT

W3-3 Autologous HSCT as a treatment for autoimmune disease of the 16:45 - 17:00
nervous system
Speaker: Harry Atkins, CA

W3-4 Q&A 17:00 - 17:30

Nurses Group
16:15 - 17:30 Auditorium 3
NG07 - Infections
Chair: Daphna Hutt, IL
Chair: Marta Pamias, ES
NG07-1 How to find a fungal infection 16:15 - 16:30
Speaker: Toine Mercier, BE

NG07-2 CMV 16:30 - 16:45

Speaker: Patrice Ceballos, FR

NG07-3 Polyoma virus 16:45 - 17:00

Speaker: Marta Canesi, IT

NG07-4 Nursing leadership in antimicrobial stewardship interventions 17:00 - 17:15

Speaker: Franky Buyle, BE

NG07-5 Q&A 17:15 - 17:30

Paediatric Day
16:15 - 17:30 Auditorium 4
Paed4 - Inborn Errors Oral Session

215 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

Paed4-1 T-REPLETE HLA-MATCHED GRAFTS VERSUS T-DEPLETED 16:15 - 16:24

HLA-MISMATCHED GRAFTS IN INBORN ERRORS OF
IMMUNITY: WHERE ARE WE NOW?
Speaker: Su Han Lum, GB

Paed4-2 EARLY SAFETY AND EFFICACY RESULTS WITH A SINGLE 16:24 - 16:33
DOSE OF AUTOLOGOUS CRISPR-CAS9-MODIFIED CD34+
HEMATOPOIETIC STEM AND PROGENITOR CELLS IN
TRANSFUSION-DEPENDENT ?-THALASSEMIA AND SICKLE
CELL DISEASE
Speaker: Selim Corbacioglu, DE

Paed4-3 INTERNATIONAL SURVEY AND RETROSPECTIVE ANALYSIS 16:33 - 16:42

OF 28 PATIENTS WITH IFN-?-RECEPTOR DEFICIENCY
Speaker: Peter Olbrich, ES

Paed4-4 PHENOTYPE REVERSAL, EXCELLENT OVERALL, GVHD-FREE 16:42 - 16:51

AND GRAFT FAILURE-FREE SURVIVAL IN 55 ADOLESCENTS
AND ADULTS WITH INBORN ERRORS OF IMMUNITY
FOLLOWING REDUCED INTENSITY ALLOGENEIC HSCT
Speaker: Thomas A Fox, GB

Paed4-5 ALLOGENEIC HEMATOPOIETIC STEM CELL 16:51 - 17:00

TRANSPLANTATION IN PATIENTS WITH CEREBRAL
ADRENOLEUKODYSTROPHY: OUTCOMES BY DONOR CELL
SOURCE AND MATCH, CONDITIONING REGIMEN, AND STAGE
OF CEREBRAL DISEASE
Speaker: Robert Chiesa, GB

Paed4-6 ALLOGENEIC HSCT FOR ADOLESCENTS AND ADULTS WITH 17:00 - 17:09
INBORN ERRORS OF IMMUNITY: A RETROSPECTIVE STUDY
OF THE INBORN ERRORS WORKING PARTY (IEWP)
Speaker: Michael Albert, DE

Paed4-7 COMBINING ENZYME REPLACEMENT THERAPY AND 17:09 - 17:18

HEMATOPOIETIC STEM CELL TRANSPLANT FOR WOLMAN
DISEASE: A NOVEL TREATMENT PARADIGM FOR OPTIMAL
LONG TERM DISEASE CONTROL
Speaker: Jane E Potter, GB

Paed4-8 FEASIBILITY OF PREMATURE SIROLIMUS CESSATION POST 17:18 - 17:27

NON-MYELOABLATIVE TRANSPLANTATION IN ADULT
PATIENTS WITH SEVERE SICKLE CELL DISEASE
Speaker: Moussab Damlaj, SA

Pharmacists Day
16:15 - 17:30 Auditorium 5
Pharm4 - Pharmaceutical Research in HSCT
Chair: Claudia Langebrake, DE
Chair: Tiene Bauters, BE
Pharm4-1 IRON CHELATION WITH DEFERASIROX INCREASES 16:15 - 16:27
BUSULFAN AUC DURING CONDITIONING CHEMOTHERAPY
PRIOR TO ALLOGENEIC STEM CELL TRANSPLANTATION

216 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

Speaker: Sonja Essmann, DE

Pharm4-2 DOES TREATMENT WITH GLUCOCORTICOIDS INFLUENCE THE 16:27 - 16:39

ESTIMATION OF GLOMERULAR FILTRATION RATE IN ADULTS
AFTER ALLOGENEIC STEM CELL TRANSPLANTATION USING
CYSTATIN C?
Speaker: Claudia Langebrake, DE

Pharm4-3 ORAL LEVETIRACETAM IS ASSOCIATED WITH DECREASED 16:39 - 16:51

SYSTEMIC BUSULFAN EXPOSURE AFTER ORAL DOSING
Speaker: Tareq Artul, IL

Pharm4-4 Pharmaceutical Research in HSCT 16:51 - 17:15

Speaker: Rick Admiraal, NL

Pharm4-5 Discussion 17:15 - 17:30

Quality Management
16:15 - 17:30 Auditorium 6
QM4 - Inspectors Session
Chair: Tuula Rintala, GB
QM4-1 JACIE Activity Report & Update / Volunteers JACIE´s most 16:15 - 16:25
important resource
Speaker: Raquel Espada, ES
Speaker: Anna Pasztor, ES

QM4-2 Inspection team: Roles 16:25 - 16:35

Speaker: Mara Magri, IT
Speaker: Nick van Sinderen, NL

QM4-3 How to prepare the JACIE Inspection Report? 16:35 - 16:45

Speaker: Renza Monteleone, IT
Speaker: Esther Zafra, ES

QM4-4 Most frequent difficulties faced by JACIE Report Assessors 16:45 - 16:55
Speaker: Raquel Espada, ES
Speaker: Carolina Herranz, ES

QM4-5 Post Inspection Phase (Assessing CAPA) and Post 16:55 - 17:05
Accreditation (Interim Audit)
Speaker: Carla Sánchez, ES
Speaker: Richard Olaussen, NO

QM4-6 Transparency in Reporting 17:05 - 17:15

Speaker: Yiskah Simons, SA

QM4-7 Q&A 17:15 - 17:30

Abstract Awards
17:30 - 18:00 Auditorium 1
AA2 - Abstracts Awards
AA2-1 Jian-Jian Luan Award - Introduction 17:30 - 17:31
Speaker: Bertram Glass, DE

217 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

AA2-2 STANDARD-OF-CARE CAR-T CELL THERAPY FOR LARGE B- 17:31 - 17:43

CELL LYMPHOMA: REAL WORLD DATA GERMANY
Speaker: Wolfgang Andreas Bethge, DE

AA2-3 Jon J. van Rood Award - Introduction 17:43 - 17:44

Speaker: Hans-Hochem Kolb, DE

AA2-4 METABOLIC REPROGRAMMING OF DONOR T CELLS 17:44 - 17:56

ENHANCES GRAFT-VERSUS-LEUKEMIA EFFECTS IN MICE
AND HUMANS
Read Abstract
Speaker: Franziska Uhl, DE

AA2-5 Best Young Abstracts 17:56 - 18:00

Speaker: Harry Dolstra, NL

Meet the Expert

17:30 - 18:30 MTE rooms
Meet the Expert sessions
MTE-6 How to modulate the microbiome in HSCT - Room MTE1 17:30 - 17:30
Speaker: Florent Malard, FR

MTE-7 COVID-19 and other vaccines in HSCT recipients - Room MTE2 17:30 - 17:30
Speaker: Simone Cesaro, IT

MTE-8 What changes in conditioning regimens we should implement in 17:30 - 17:30

2021? - Room MTE3
Speaker: Andrea Bacigalupo, IT

MTE-9 Update on biomarkers for GVHD - Room MTE4 17:30 - 17:30

Speaker: Kirk Schultz, CA

MTE-10 Management of EBV-PTLD in 2021 - Room MTE5 17:30 - 17:30

Speaker: Jan Styczynski, PL

218 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

Wednesday, 17. March 2021

Workshop
09:15 - 10:30 Auditorium 1
W04 - The expanding field of cellular therapies in inborn errors of immunity (IEI)
Chair: Arjan Lankester, NL
Chair: Cristina Díaz de Heredia, ES
W4-1 Curative options in X-CGD: HCT or gene therapy 09:15 - 09:31
Speaker: Tayfun Gungor, CH

W4-2 HSCT in monogenic autoimmune disorders 09:31 - 09:55

Speaker: Eleonora Gambineri, IT

W4-3 Challenges of HSCT in adult IEI patients 09:55 - 10:10

Speaker: Emma Morris, GB

W4-4 Advances in gene editing to treat non-SCID IEI 10:10 - 10:25

Speaker: Alessandro Aiuti, IT

W4-5 Q&A 10:25 - 10:30

Workshop
09:15 - 10:30 Auditorium 2
W05 - Transplantation and bone marrow failure in 2021
Chair: Béatrice Drexler, CH
Chair: Lucrecia Yañez, ES
W5-1 Up-front transplantation in aplastic anemia: Where are we? 09:15 - 09:30
Speaker: Jean-Hugues Dalle, FR

W5-2 Haploidentical HSCT and idiopathic aplastic anaemia 09:30 - 09:45

Speaker: Amy DeZern, US

W5-3 Haploidentical HSCT in Fanconi anaemia 09:45 - 10:00

Speaker: Carmem Bonfim, BR

W5-4 Blackfan Diamond anaemia and HSCT 10:00 - 10:15

Speaker: Brigitte Strahm, DE

W5-5 Q&A 10:15 - 10:30

Nurses Group
09:15 - 10:30 Auditorium 3
NG08 - How do I manage... Isolation practices and patient and donors preparation?
Chair: Janet Baker, GB
Chair: Alba Fernández Arroyo, ES
NG08-1 Evidence for Isolation 09:15 - 09:30
Speaker: Iris Agreiter, IE

NG08-2 Evidence against Isolation 09:30 - 09:45

Speaker: Cristina Gallego, ES

219 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

NG08-3 Hematopoietic Transplant patient's preparation 09:45 - 10:00

Speaker: Manuela Salinero, ES

NG08-4 Donor work up 10:00 - 10:15

Speaker: Annika Kisch, SE

NG08-5 Q&A 10:15 - 10:30

How do I … ?
09:15 - 10:30 Auditorium 4
HDI3 - How Do I... Adapt my treatment approach for high risk GvHD patients? - Supported through an unrestric
educational grant by Therakos-Mallinckrodt
Chair: Daniel Wolff, DE
HDI3-1 Role of biomarker 09:15 - 09:40
Speaker: Francis Ayuk, DE

HDI3-2 Role of microbiome 09:40 - 10:05

Speaker: Henrik Sengeløv, DK

HDI3-3 Q&A 10:05 - 10:30

Data Management
09:15 - 10:30 Auditorium 5
DM01 - Education session 1 - Discussion forum: Cellular therapy
Chair: Lucas Stolarczyk, GB
DM1-1 Toxicities after CART: pathology clinical manifestations and 09:15 - 09:35
grading
Speaker: Jürgen Kuball, NL

DM1-2 Toxicities after CART: treatment and prognostic factors 09:35 - 10:00
Speaker: Álvaro Urbano-Ispizua, ES

DM1-3 Discussion forum - Cellular therapy Q&A 10:00 - 10:30

Speaker: Chiara Bonini, IT
Speaker: Lawrence Vermeir, GB
Speaker: Jürgen Kuball, NL
Speaker: Álvaro Urbano-Ispizua, ES

Industrial Theatre
09:15 - 17:30 IT
Industry Theatre sessions

Industrial Theatre
09:15 - 17:30 IT
IT3 - Amicus Blue in Children and Adolescents with GVHD - Fresenius Kabi Industry Theatre session
This session is available throughout the whole congress
Chair: Volker Witt, AT

220 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

Industrial Theatre
09:15 - 17:30 IT
IT2 - Developing the Future of CAR-T Cell Therapy Today - Novartis Industry Theatre session
This session is available throughout the whole congress
Chair: Amir Hefni, GB
Chair: David Kuzan, US
Chair: Carolin Barth, CH

Industrial Theatre
09:15 - 17:30 IT
IT1 - Kite as innovators in CAR T-cell therapy manufacturing and delivery - Kite-Gilead Industry Theatre sessio
This session is available throughout the whole congress
Chair: Dick Sundh, AU

Educational
09:15 - 17:30 On-Demand Library
E13 - Allogeneic transplantation from alternative donors
This session is available in our on-demand library throughout the whole congress
E13-1 Haploidentical vs unrelated in AML -
Speaker: Didier Blaise, FR

E13-2 Haploidentical vs unrelated in ALL -

Speaker: Arnon Nagler, IL

E13-3 Haploidentical vs cord Blood in acute leukaemia -

Speaker: Frederic Baron, BE

Working Party Session

09:15 - 17:30 On-Demand Library
ADWP - Autoimmune Diseases Working Party Session
This session is available in our on-demand library throughout the whole congress
ADWP-1 Welcome and Update from the EBMT registry -
Speaker: Raffaella Greco, IT

ADWP-2 Introducing the session and speakers -

Speaker: Tobias Alexander, DE

ADWP-3 HSCT for multiple sclerosis: Future directions in patient -

selection and conditioning regimen
Speaker: Riccardo Saccardi, IT

ADWP-4 HSCT for systemic sclerosis: Future directions in patient -

selection and conditioning regimen
Speaker: Dominique Farge, FR

ADWP-5 HSCT for Crohn’s disease: future directions in patient -

selection, mobilization and conditioning regimen
Speaker: Elena Ricart, ES

ADWP-6 HSCT for autoimmune diseases: Current aspects on early and -

late complications

221 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

Speaker: Majid Kazmi, GB

ADWP-7 HSCT for autoimmune diseases: Conditioning regimen and -

outcomes from the Russian experience
Speaker: Denis Fedorenko, RU

ADWP-8 Closing remarks -

Speaker: Tobias Alexander, DE

Nurses Group
09:15 - 17:30 On-Demand Library
NG16 - Cellular therapy update
This session is available in our on-demand library throughout the whole congress
NG16-1 Update: What’s new? -
Speaker: Rose Ellard, GB

NG16-2 Spotlight on the Lymphoma Patient Experience -

Speaker: Lorna Warwick, CA

Nurses Group
09:15 - 17:30 On-Demand Library
NG19 - Disease update
This session is available in our on-demand library throughout the whole congress
NG19-1 Acute leukaemia -
Speaker: Inge Govaerts, BE

NG19-2 Managing lymphoma: What nurses and healthcare -

professionals need to know
Speaker: Erik Aerts, CH

NG19-3 Multiple myeloma -

Speaker: Maaike de Ruijter, NL

NG19-4 CML (ITK management) -

Speaker: Laura Borg, GB

Nurses Group
09:15 - 17:30 On-Demand Library
NG13 - Nurses Education Day 1: Care of the vulnerable immunocompromised patients in critical care setting
This session is available in our on-demand library throughout the whole congress
NG13-1 SARS-CoV-2 vaccines overview -
Speaker: Almudena Ramírez, ES

NG13-2 Seasonal human coronaviruses vs SARS-CoV-2 in allogeneic -

hematopoietic stem cell transplantation
Speaker: Jose Luis Piñana, ES

NG13-3 COVID-19: The EBMT recommendations for management of -

HCT patients and donors
Speaker: Per Ljungman, SE

222 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

Nurses Group
09:15 - 17:30 On-Demand Library
NG15 - Nurses Education Day 3: Care of the vulnerable immunocompromised patients in critical care setting
This session is available in our on-demand library throughout the whole congress
NG15-1 Managing virtual conversations -
Speaker: Lloyd Allen, GB

NG15-2 Nurse perspective: Virtual long term follow up for BMT patients -
Speaker: Michelle Kenyon, GB

NG15-3 Back to the future: Emphasizing our new practices -

Speaker: Ibrahim Yakoub-Agha, FR

Nurses Group
09:15 - 17:30 On-Demand Library
NG24 - Outreach projects
This session is available in our on-demand library throughout the whole congress
NG24-2 Outreach project India: EBMT MIC pediatric advanced care 09:15 - 09:15
training (EMPACT)
Speaker: Lawrence Faulkner, IT

NG24-3 Outreach project: LABMT 09:15 - 09:15

Speaker: Sara Saez Carrasco, CO

Educational
09:15 - 17:30 On-Demand Library
E11 - Management of early complications in an ambulatory/outpatient setting
This session is available in our on-demand library throughout the whole congress
E11-1 Early infectious complications -
Speaker: Jan Styczynski, PL

E11-2 Non-infective complications: GVHD and organ toxicity -

Speaker: Gerhard Hildebrandt, US

E11-3 The Hospital Clínic experience -

Speaker: Francesc Fernández-Avilés, ES

Workshop
09:15 - 17:30 On-Demand Library
W10 - Controversies in T-cell NHL
This session is available in our on-demand library throughout the whole congress
W10-1 Are we improving first-line therapy in TCL? 09:15 - 09:15
Speaker: Eva Domingo Domenech, ES

W10-3 Insights in CAR-T therapy for T cell Lymphomas 09:15 - 09:15

Speaker: Helen Heslop, US

223 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

Workshop
09:15 - 17:30 On-Demand Library
W13 - CARs beyond T cells: A focus on next generation CAR-NK cells
This session is available in our on-demand library throughout the whole congress
W13-1 CAR NK cells as an "off the shelf" immunotherapy -
Speaker: Ulrike Köhl, DE

W13-2 CARs and ADCC to make off-the-shelf NK cells specific against -

hematologic malignancies
Speaker: Jeffrey Miller, US

W13-3 Target NKG2D ligands on tumor cells -

Speaker: Antonio Pérez-Martínez, ES

Workshop
09:15 - 17:30 On-Demand Library
W14 - In the absence of a matched-sibling, who's the best alternative allogeneic donor?
This session is available in our on-demand library throughout the whole congress
W14-1 A matched unrelated donor -
Speaker: Bronwen Shaw, US

W14-2 A haploidentical donor -

Speaker: Mi Kwon, ES

W14-3 When to choose cord blood -

Speaker: Filippo Milano, US

W14-4 Do we have to challenge our current donor hierarchy for -

patients with hemoglobinopathies?
Speaker: Selim Corbacioglu, DE

Workshop
09:15 - 17:30 On-Demand Library
W11 - Key organ manifestations of chronic GVHD
This session is available in our on-demand library throughout the whole congress
W11-1 Pulmonary chronic GVHD -
Speaker: Hildegard Greinix, AT

W11-2 Ocular cGVHD diagnostics - Practical approach -

Speaker: Igor Petricek, HR

W11-3 Gastrointestinal manifestations of chronic GVHD -

Speaker: Daniel Wolff, DE

Educational
09:15 - 17:30 On-Demand Library
E09 - Allogeneic HSCT in MDS and MPN
This session is available in our on-demand library throughout the whole congress
E9-1 Definition of graft failure/relapse after allo-HCT in myelofibrosis -
Speaker: Donal McLornan, GB

224 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

E9-2 Allogeneic HSCT in patients with therapy-related MDS/AML -

Speaker: Marie Robin, FR

E9-3 The role of maintenance therapy after allogeneic HSCT in MDS -

Speaker: Francesco Onida, IT

Data Management
09:15 - 17:30 On-Demand Library
DM06 - Education session 6
This session is available in our on-demand library throughout the whole congress
DM6-1 Response in Multiple Myeloma -
Speaker: Meral Beksac, TR

Data Management
09:15 - 17:30 On-Demand Library
DM08 - Education session 8
This session is available in our on-demand library throughout the whole congress
DM8-1 Infectious complications -
Speaker: Malgorzata Mikulska, IT

Special Session
09:15 - 17:30 On-Demand Library
SS09 - How to get published
This session is available in our on-demand library throughout the whole congress
SS9-1 BMT: Official journal of the EBMT -
Speaker: Hillard Lazarus, US

SS9-2 How to get published -

Speaker: Mohamad Mohty, FR

Joint Session
09:15 - 17:30 On-Demand Library
JS04 - Joint session LABMT
This session is available in our on-demand library throughout the whole congress
JS4-1 Transplant rates, Trends: WBMT/LABMT 2018 survey -
Speaker: Oscar González-Ramella, MX

JS4-2 Financing of HSCT in Latin America -

Speaker: Gregorio Jaimovich, AR

JS4-3 Selection, management and follow up of related donors: -

Overview
Speaker: Nina Worel, AT

JS4-4 Selection, management and follow up of related donors: -

Development of an LABMT consensus
Speaker: Gonzalo Ferini, AR

JS4-5 Haploidentical transplants in Latin America: Experience from -

225 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

Argentina/GATMO-TC in acute lymphoblastic leukemia

Speaker: Ana Basquiera, AR

JS4-6 Haploidentical transplants in Latin America: Experience from -

Brazil/SBTMO in aplastic anemia
Speaker: Carmem Bonfim, BR

Nurses Group
09:15 - 17:30 On-Demand Library
NG20 - How do I become an expert?
This session is available in our on-demand library throughout the whole congress
NG20-1 Conditioning regimen -
Speaker: Nicolas Kint, BE

NG20-2 Immunosuppression -
Speaker: Tiene Bauters, BE

NG20-3 Vaccinations -
Speaker: Bipin Savani, US

Special Session
09:15 - 17:30 On-Demand Library
SS11 - The EBMT for Trainees
This session is available in our on-demand library throughout the whole congress
SS11-1 Being a Trainee in SCT / Cellular Therapy -
Speaker: Nico Gagelmann, DE
Speaker: Claire Horgan, GB
Speaker: Yasmina Serroukh, BE
Speaker: Yuliya Rogacheva, RU
Speaker: Tamar Azikuri, GE

SS11-2 Overview of allogeneic SCT for the trainee: ‘Things I wish I’d -
known'
Speaker: Helene Schoemans, BE

SS11-3 Establishing a career in SCT/cellular therapy -

Speaker: Jordan Gauthier, US

SS11-4 Complications for trainees 1: How to manage acute GVHD -

Speaker: Zinaida Peric, HR

SS11-5 Complications for trainees 2: How to manage VOD -

Speaker: Ivan Moiseev, RU

How do I … ?
09:15 - 17:30 On-Demand Library
HDI6 - How Do I... manage toxicity in immunosuppressed patients?
This session is available in our on-demand library throughout the whole congress
HDI6-1 Transplant associated TMA -
Speaker: Sergio Giralt, US

226 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

HDI6-2 Infectious complication -

Speaker: Jan Styczynski, PL

Industry Symposium
09:15 - 17:30 On-Demand Library
IS38 - CMV management in high-risk patients - Biotest Industry Symposium
This session is available in our on-demand library throughout the whole congress
Chair: Fabio Ciceri, IT
IS38-1 A scoring system to define patients at high risk for CMV 09:15 - 09:15
Speaker: Ibrahim Yakoub-Agha, FR

IS38-2 How to manage CMV high-risk patients 09:15 - 09:15

Speaker: Michele Malagola, IT

IS38-3 The immunological benefits of CMV-specific immunoglobulins 09:15 - 09:15

Speaker: Javier Carbone, ES

Special Session
09:15 - 17:30 On-Demand Library
SS07 - Young Ambassadors Session
This session is available in our on-demand library throughout the whole congress
SS7-1 How build up a career in: Academia -
Speaker: Didier Blaise, FR

SS7-2 How build up a career in: In Pharmaceutical Industry -

Speaker: Dan Tovar, FR

SS7-3 How build up a career in: In Public domains -

Speaker: Eva Hilgenfeld, DE

SS7-4 What to avoid when writing a paper -

Speaker: Jakob Passweg, CH

SS7-5 How to write a successful grant -

Speaker: Robert Zeiser, DE

SS7-6 Introduction to medical statistics -

Speaker: Simona Iacobelli, IT

SS7-7 Social media in stem cell transplantation and cellular therapy -

Speaker: Navneet Majhail, US

Oral Session
09:15 - 17:30 On-Demand Library
OS04 - Oral session 4: Cellular Therapy, Gene Therapy and New Drugs I
This session is available in our on-demand library throughout the whole congress
OS4-1 INTERIM RESULTS OF BETIBEGLOGENE AUTOTEMCEL GENE 09:15 - 09:25
THERAPY IN PEDIATRIC PATIENTS WITH TRANSFUSION-
DEPENDENT ?-THALASSEMIA (TDT) TREATED IN THE PHASE 3
NORTHSTAR-2 (HGB-207) AND NORTHSTAR-3 (HGB-212)

227 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

STUDIES
Speaker: Isabelle Thuret, FR

OS4-2 NARSOPLIMAB (OMS721), A MASP-2 INHIBITOR, FOR THE 09:25 - 09:35

TREATMENT OF ADULT HEMATOPOIETIC STEM CELL
TRANSPLANT-ASSOCIATED THROMBOTIC
MICROANGIOPATHY (HSCT-TMA): SUBGROUP ANALYSES
Speaker: Alessandro Rambaldi, IT

OS4-3 CRISPR-BASED REPLACEMENT OF THE ENDOGENOUS T- 09:35 - 09:45

CELL REPERTOIRE WITH NOVEL, HIGH-AVIDITY, NATURAL T
CELL RECEPTORS TO WT1 FOR THE TREATMENT OF ACUTE
MYELOID LEUKEMIA
Speaker: Eliana Ruggiero, IT

OS4-4 CLINICAL TRIAL UPDATE: EX-VIVO AUTOLOGOUS STEM CELL 09:45 - 09:55
GENE THERAPY IN MPSIIIA
Speaker: Jane Louise Kinsella, GB

OS4-5 EXOGENOUS M-CSF PROTECTS FROM LETHAL A. FUMIGATUS 09:55 - 10:05

PULMONARY INFECTION EARLY AFTER HEMATOPOIETIC
STEM CELL TRANSPLANTATION
Speaker: Dalia Sheta, DE

OS4-6 REAL-WORLD EFFECTIVENESS AND SAFETY OF 10:05 - 10:15

BLINATUMOMAB IN EUROPE: 3-YEAR RESULTS IN RELAPSED
OR REFRACTORY PHILADELPHIA CHROMOSOME-NEGATIVE
BCP-ALL PATIENTS INCLUDING THOSE WITH LATE FIRST
RELAPSE
Speaker: Alessandro Rambaldi, IT

OS4-7 GENERATION OF HSPC-DERIVED CD16A-ENGINEERED NK 10:15 - 10:25

CELLS WITH ADVANCED ANTIBODY-DEPENDENT CELLULAR
CYTOTOXICITY
Speaker: Paulien van Hauten, NL

OS4-8 IMPROVEMENTS IN FATIGUE AND PHYSICAL FUNCTION 10:25 - 10:35

EVALUATED THROUGH CHANGES IN CLINICAL OUTCOMES IN
PAROXYSMAL NOCTURNAL HEMOGLOBINURIA: POST-HOC
ANALYSES FROM THE PEGASUS STUDY

Oral Session
09:15 - 17:30 On-Demand Library
OS18 - Oral session 18: Myeloproliferative Neoplasms and Myelodysplastic Syndromes
This session is available in our on-demand library throughout the whole congress
OS18-1 GENOMIC CONFIGURATION OF TP53 MUTATIONS IN PATIENTS 09:15 - 09:15
WITH MYELOID NEOPLASIA
Speaker: Carmelo Gurnari, US

OS18-2 RETROSPECTIVE ANALYSIS EVALUATING THE EFFECT OF 09:15 - 09:15

AGE ON OUTCOMES AFTER ALLOGENEIC HEMATOPOIETIC
CELL TRANSPLANTATION IN CHRONIC MYELOMONOCYTIC
LEUKEMIA. A STUDY OF THE EBMT-CMWP

228 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

Speaker: Alicia Rovó, CH

OS18-3 CHANGE IN IPSS-R BETWEEN DIAGNOSIS AND TRANSPLANT 09:15 - 09:15

AND TRANSPLANT OUTCOME IN PATIENTS WITH MDS. A
RETROSPECTIVE ANALYSIS FROM THE CHRONIC
MALIGNANCIES WORKING PARTY
Speaker: Christof Scheid, DE

OS18-4 ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION IN 09:15 - 09:15

PATIENTS WITH THERAPY-RELATED MYELOID NEOPLASM
AFTER BREAST CANCER TREATMENT: A STUDY OF THE
CHRONIC MALIGNANCIES WORKING PARTY OF THE EBMT
Speaker: Mitja Nabergoj, CH

OS18-5 IMPACT OF PRIOR JAK-INHIBITOR THERAPY WITH 09:15 - 09:15

RUXOLITINIB ON OUTCOME AFTER ALLOGENEIC STEM CELL
TRANSPLANTATION FOR MYELOFIBROSIS. A LARGE EBMT-
CMWP STUDY
Speaker: Nicolaus Kröger, DE

OS18-6 ADDITIONAL CHROMOSOMAL ABERRATIONS IN CML 09:15 - 09:15

PATIENTS UNDERGOING ALLOGENEIC HEMATOPOIETIC STEM
CELL TRANSPLANTATION
Speaker: Elena Morozova, RU

OS18-7 DONOR AGE, CD34 CELL DOSE AND NON-BLAST CRISIS ARE 09:15 - 09:15
PROGNOSTIC FACTORS FOR OUTCOME AFTER STEM CELL
TRANSPLANTATION IN PATIENTS WITH ADVANCE PHASE CML
Speaker: Christian Niederwieser, DE

OS18-8 OUTCOMES OF ALLOGENEIC HEMATOPOIETIC STEM CELL 09:15 - 09:15

TRANSPLANTATION IN PATIENTS WITH MYELOFIBROSIS
TREATED WITH RUXOLITINIB IN THE PRE-TRANSPLANT
PERIOD
Speaker: Anna Czyz, PL

Data Management
09:15 - 17:30 On-Demand Library
DM09 - Education session 9
This session is available in our on-demand library throughout the whole congress
DM9-1 Follow up forms - How to get a chronological overview of the -
patient history and follow up
Speaker: Elena Ferrer Martínez del Peral, ES

Lab Technicians Day

09:15 - 17:30 On-Demand Library
LT2 - Lab Technicians Day: Cell product testing, validation and characterization
This session is available in our on-demand library throughout the whole congress
LT2-1 Quality control assessment of ATMP phenotype and -
functionality using flow cytometry
Speaker: Willemijn Hobo, NL

229 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

LT2-2 Flow cytometry-based CD34 enumeration -

Speaker: Harry Dolstra, NL

LT2-3 Flow cytometric in-process and quality control for CAR T cell -
manufacturing
Speaker: Ulrike Köhl, DE

Lab Technicians Day

09:15 - 17:30 On-Demand Library
LT1 - Lab Technicians Day: Specialized cell processing
This session is available in our on-demand library throughout the whole congress
LT1-1 Bone marrow processing: Techniques and results -
Speaker: Boris Calmels, FR

LT1-2 Technical aspects and performance TCRab/CD19 depletion -

Speaker: Kasper Westinga, NL

LT1-3 Donor selection and GMP-compliant manufacturing of virus- -

specific T-cells
Speaker: Britta Eiz-Vesper, DE

Working Party Session

09:15 - 17:30 On-Demand Library
SAAWP - Severe Aplastic Anaemia Working Party Session
This session is available in our on-demand library throughout the whole congress
SAAWP-1 Introduction -
Speaker: Régis Peffault de Latour, FR

SAAWP-2 Registry Report -

Speaker: Antonio Risitano, IT

SAAWP-3 RACE – clinical update -

Speaker: Antonio Risitano, IT

SAAWP-4 RACE – what we learn on the biology of SAA? -

Speaker: Austin Kulakaseraraj, GB

SAAWP-5 Androgens in AA: Myth or reality in 2021? -

Speaker: Simona Pagliuca, US

SAAWP-6 GVHD and relapse free survival (GRFS) after HSCT for AA -
Speaker: Raynier Devillier, FR

Working Party Session

09:15 - 17:30 On-Demand Library
ALWP - Acute Leukaemia Working Party Session
This session is available in our on-demand library throughout the whole congress
ALWP-1 Introduction 09:15 - 09:15
Speaker: Mohamad Mohty, FR

ALWP-2 CAR-T cells in adult ALL 09:15 - 09:15

230 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

Speaker: Arnon Nagler, IL

ALWP-3 Transplant in refractory AML: Comparison of the different 09:15 - 09:15

FLAMSA approaches
Speaker: Mohamad Mohty, FR

ALWP-4 MRD in AML: Where do we stand? 09:15 - 09:15

Speaker: Ali Bazarbachi, LB

Nurses Group
09:15 - 17:30 On-Demand Library
NG21 - Clinical trials in a transplant setting
This session is available in our on-demand library throughout the whole congress
NG21-1 Antimicrobal Lock Therapy for Prevention and Treatment of -
Catheter Related Infections in Hematogical Patients
Speaker: Isabel Salcedo, ES

NG21-2 Convalescent plasma clinical trials for COVID-19 -

Speaker: Rocío Layunta, ES

NG21-3 Post transplant relapse -

Speaker: Stephanie Heyes, GB

Working Party Session

09:15 - 17:30 On-Demand Library
CTIWP - Cellular Therapy and Immunobiology Working Party Session
This session is available in our on-demand library throughout the whole congress
CTIWP-1 CTIWP Activity Report -
Speaker: Christian Chabannon, FR

CTIWP-2 Virus specific T cells post BMT- Broadening to SARS-CoV2 -

Speaker: Catherine Bollard, US

CTIWP-3 Are mesenchymal stromal cells the right arrow in the quiver to -
fight COVID-19?
Speaker: Rachele Ciccocioppo, IT

Special Session
09:15 - 17:30 On-Demand Library
SS10 - The HARMONY Alliance: Accelerating better and faster treatment for patients with blood cancer
This session is available in our on-demand library throughout the whole congress
SS10-1 General Overview of the HARMONY Alliance: Progress, -
Achievements & Results of HARMONY and HARMONY PLUS
projects
Speaker: Jesús Maria Hernández Rivas, ES

SS10-2 Envisioned contribution of the EBMT to the HARMONY Alliance -

Speaker: Guillermo Sanz Santillana, ES
Speaker: Yann Guillevic, CH

SS10-3 EBMT participation in the HARMONY Alliance -

231 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

Speaker: Anna Sureda, ES

SS10-4 HARMONY & HARMONY PLUS Research Projects / Outcomes -

definition
Speaker: Lars Bullinger, DE

SS10-5 HARMONY Platform -

Speaker: Ana Heredia Casanoves, ES

On Demand Library
09:15 - 17:30 On-Demand Library
On Demand Library

Educational
09:15 - 17:30 On-Demand Library
E08 - New challenges in infectious complications
This session is available in our on-demand library throughout the whole congress
E8-1 T-cell therapy for infections in SCT patients: An experimental -
treatment or a real choice for the practice?
Speaker: Patrizia Comoli, IT

E8-2 Infectious complications with new drugs in Hematology -

Speaker: Georg Maschmeyer, DE

E8-3 The blood virome of HSCT Recipients: Much more than viremia -
by CMV, EBV, HH6V and adenovirus
Speaker: Marie-Celine Zanella, CH

Data Management
09:15 - 17:30 On-Demand Library
DM05 - Education session 5
This session is available in our on-demand library throughout the whole congress
DM5-1 Hematopoietic Cell Transplantation-Comorbidity Index ‘Sorror -
Score’
Speaker: Bronwen Shaw, US

Nurses Group
09:15 - 17:30 On-Demand Library
NG23 - Oral session 2: Abstracts session
This session is available in our on-demand library throughout the whole congress
NG23-1 EFFICACY AND SAFETY OF A COLOSTRUM BASED ORAL 09:15 - 09:15
CARE PROTOCOL FOR THE PREVENTION AND TREATMENT
OF ORAL MUCOSITIS IN STEM CELL TRANSPLANT
RECIPIENTS
Speaker: Monica Guberti, IT

NG23-2 PATIENT-TO-NURSE STAFFING RATIO IN HEMATOPOIETIC 09:15 - 09:15

STEM CELL TRANSPLANT AND ADVANCED CELL THERAPY
UNITS IN SPAIN, HIGHLY NEEDED BUT CHALLENGING
Speaker: Julia Ruiz Pato, ES

232 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

NG23-3 ROOT CAUSE ANALYSIS TO IDENTIFY AND PREVENT FALL 09:15 - 09:15
CAUSES IN ALLOGENEIC HEMATOPOIETIC STEM CELL
TRANSPLANTATION PATIENTS
Speaker: Franziska Michaela Lohmeyer, IT

NG23-4 MAPPING THE NURSES' COMPETENCIES IN PAEDIATRIC 09:15 - 09:15

ONCO-HAEMATOLOGY AND HAEMATOPOIETIC STEM CELL
TRANSPLANTATION SETTING AND THEIR MAINTENANCE
OVER TIME
Speaker: Alberto Castagna, IT

NG23-5 EFFECTIVENESS OF AN EDUCATIONAL INTERVENTION FOR 09:15 - 09:15

INFLUENZA VACCINATION IN HEMATOPOIETIC STEM CELL
TRANSPLANT PATIENTS AND THEIR COHABITANTS
Speaker: Maria Teresa Solano Moliner, ES

Oral Session
09:15 - 17:30 On-Demand Library
OS02 - Oral session 2: CARs I
This session is available in our on-demand library throughout the whole congress
OS2-1 CARTITUDE-1: PHASE 1B/2 STUDY OF CILTACABTAGENE 09:15 - 09:25
AUTOLEUCEL, A B-CELL MATURATION ANTIGEN–DIRECTED
CHIMERIC ANTIGEN RECEPTOR T CELL THERAPY, IN
RELAPSED/REFRACTORY MULTIPLE MYELOMA
Speaker: Deepu Madduri, US

OS2-2 PROPHYLACTIC CORTICOSTEROID USE WITH 09:25 - 09:35

AXICABTAGENE CILOLEUCEL (AXI-CEL) IN PATIENTS WITH
RELAPSED/REFRACTORY LARGE B CELL LYMPHOMA (R/R
LBCL)
Speaker: Olalekan O. Oluwole, US

OS2-3 MATCHING-ADJUSTED INDIRECT COMPARISON (MAIC) OF 09:35 - 09:45

LISOCABTAGENE MARALEUCEL (LISO-CEL) VERSUS
AXICABTAGENE CILOLEUCEL (AXI-CEL) AND
TISAGENLECLEUCEL IN RELAPSED/REFRACTORY LARGE B-
CELL LYMPHOMA
Speaker: David Maloney, US

OS2-4 STRATEGIES TO INCREASE CAR T-CELL SAFETY AND TO 09:45 - 09:55

PREVENT EPITOPE MASKING IN CAR+ B-CELL LEUKEMIA
BLASTS
Speaker: Concetta Quintarelli, IT

OS2-5 CONTRIBUTION OF AGE AND THE HCT-CI TO PREDICT CRS 09:55 - 10:05
AND ICANS SEVERITY IN NHL PATIENTS RECEIVING CD19
CAR T-CELL THERAPY
Speaker: Jordan Gauthier, US

OS2-6 OUTCOMES OF TREATMENT WITH THE CHIMERIC ANTIGEN 10:05 - 10:15

RECEPTOR (CAR) T CELL THERAPY LISOCABTAGENE
MARALEUCEL (LISO-CEL) IN THE NONUNIVERSITY SETTING:
INITIAL RESULTS FROM THE OUTREACH STUDY

233 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

Speaker: John E. Godwin, US

OS2-7 BUILDING OF THE G0-CAR-T INITIATIVE TO PROMOTE USE OF 10:15 - 10:25

DATA COLLECTED FROM PATIENTS TREATED WITH CAR-T
CELLS AT EU OR EBMT AFFILIATED PROGRAMS
Speaker: Christian Chabannon, FR

OS2-8 ENGINEERED CAR.CD123 NK CELLS AS AN INNOVATIVE “OFF 10:25 - 10:35

THE SHELF” STRATEGY TO TREAT CD123POS CHILDHOOD
ACUTE MYELOID LEUKAEMIA
Speaker: Simona Caruso, IT

Oral Session
09:15 - 17:30 On-Demand Library
OS03 - Oral session 3: CARs II
This session is available in our on-demand library throughout the whole congress
OS3-1 CD19 CAR T THERAPY IN CHILDREN WITH R/R ALL: ADAPTIVE 09:15 - 09:15
SPLIT DOSING IMPROVES SAFETY AND MAINTAINS EFFICACY
OF THE APPROACH
Speaker: Olga Molostova, RU

OS3-2 CYTOKINE RELEASE SYNDROME IN PATIENTS WITH 09:15 - 09:15

RELAPSED/REFRACTORY MULTIPLE MYELOMA TREATED
WITH CILTACABTAGENE AUTOLEUCEL IN THE PHASE 1B/2
CARTITUDE-1 STUDY
Speaker: Andrzej Jakubowiak, US

OS3-3 PHARMACOLOGY AND EFFICACY OF KTE-X19 BY PRIOR 09:15 - 09:15

BRUTON TYROSINE KINASE INHIBITOR EXPOSURE OR
MANTLE CELL LYMPHOMA (MCL) MORPHOLOGY IN PATIENTS
WITH RELAPSED/REFRACTORY MCL IN ZUMA-2
Speaker: Michael L. Wang, US

OS3-4 REAL WORLD OF EXPERIENCE AXICABTAGENE CILOLEUCEL 09:15 - 09:15

FOR THE TREATMENT OF RELAPSED OR REFRACTORY
LARGE B-CELL LYMPHOMA IN SPAIN
Speaker: Mi Kwon, ES

OS3-5 HUMORAL RESPONSE TO PNEUMOCOCCAL ANTIGENS 09:15 - 09:15

DECLINES AFTER CD19-TARGETED CAR T CELL THERAPY
Speaker: Dasom Lee, US

OS3-6 DECREASED NEUROPROTECTIVE ANALYTES ON DAY OF 09:15 - 09:15

INFUSION OF CHIMERIC ANTIGEN RECEPTOR (CAR) T CELLS
ARE ASSOCIATED WITH NEUROTOXICITY
Speaker: Madhavi Lakkaraja, US

OS3-7 COMPARISON OF TWO KINDS OF ANTI-THYMOCYTE 09:15 - 09:15

GLOBULIN ON OUTCOMES OF HAPLOIDENTICAL STEM CELL
TRANSPLANTATION FOR REFRACTORY/RELAPSED AND HIGH-
RISK B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA AFTER CAR-
T THERAPY
Speaker: Zhao-Yanli Zhao, CN

234 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

OS3-8 THIRD-GENERATION GD2.CAR T-CELLS INCORPORATING 09:15 - 09:15

CD28.4-1BB COSTIMULATORY DOMAINS FOR TREATMENT OF
GD2+ SARCOMAS
Speaker: Antonio Camera, IT

Quality Management
09:15 - 17:30 On-Demand Library
QM5 - Quality Management Oral Abstracts
This session is available in our on-demand library throughout the whole congress
QM5-1 COMPLIANCE AND COST EFFICACY FOR CELLULAR 09:15 - 09:15
THERAPIES, CAN THESE TWO GO HAND IN HAND?
Speaker: Janik Adriaansen, US

QM5-2 HOW TO MAINTAIN A CONTINUOUS TRAINING PROGRAM FOR 09:15 - 09:15

NURSES IN TIMES OF PANDEMIC
Speaker: Sheila Saco, ES

QM5-3 THE RTN TRANSPLANT POLICY AND ACTIVITY DURING 09:15 - 09:15
COVID-19 PANDEMIC
Speaker: Antonio Bruno, IT

QM5-4 THE DISASTER PLAN ADJUSTMENT TO THE COVID-19 09:15 - 09:15

PANDEMIC AT AORN CARDARELLI TRANSPLANT PROGRAM
IN NAPLES, ITALY
Speaker: Lucia Ammirati, IT

Oral Session
09:15 - 17:30 On-Demand Library
OS10 - Oral session 10: COVID-19
This session is available in our on-demand library throughout the whole congress
OS10-1 A PHASE I DOSE-ESCALATION SINGLE CENTER STUDY TO 09:15 - 09:25
EVALUATE THE SAFETY OF ALLOGENIC MEMORY T CELLS
CONTAINING SARS-COV-2 SPECIFIC LYMPHOCYTES AS
ADOPTIVE THERAPY IN COVID19
Speaker: Antonio Pérez-Martínez, ES

OS10-2 THE IMPACT OF COVID-19 ON UNRELATED AND DONOR CORD 09:25 - 09:35
PROVISION TO UK TRANSPLANT CENTRES DURING THE 1ST
WAVE OF THE PANDEMIC: UK ALIGNED REGISTRY STUDY
Speaker: Angharad Pryce, GB

OS10-3 IMPACT OF SARS-COV-2 ON DELIVERY OF CAR T CELL 09:35 - 09:45

THERAPY IN EUROPE: A SURVEY FROM THE CELLULAR
THERAPY AND IMMUNOBIOLOGY WORKING PARTY OF THE
EBMT
Speaker: Sara Ghorashian, GB

OS10-4 OUTCOME OF COVID 19 IN ALLOGENEIC STEM CELLS 09:45 - 09:55

TRANSPLANT PATIENTS: THE SINGLE CENTER EXPERIENCE
FROM A SEVERELY AFFECTED AREA (BERGAMO)
Speaker: Maria Caterina Mico', IT

235 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

OS10-5 ALLOGENEIC STEM CELL TRANSPLANTATION IN ACUTE 09:55 - 10:05

LEUKEMIA PATIENTS AFTER COVID-19 INFECTION
Speaker: Maximilian Christopeit, DE

OS10-6 INFLUENCE OF THE SARS-COV-2 PANDEMIC ON BONE 10:05 - 10:15

MARROW TRANSPLANTATION CENTERS AND THE
PROTOCOLS ADOPTED IN BRAZIL BETWEEN MAY AND JUNE
2020
Speaker: Fernando Barroso Duarte, BR

OS10-7 CRYOPRESERVATION OF ALLOGENEIC HEMATOPOIETIC 10:15 - 10:25

PROGENITOR CELLS IN THE CURRENT SARS-Cov-2
PANDEMIC: EXPERIENCE OF A SINGLE CENTRE
Speaker: Dolores Moreno, ES

OS10-8 IMPACT OF COVID-19 PANDEMIC ON RELEASE OF FRENCH 10:25 - 10:35

CORD BLOOD UNITS. ON BEHALF THE AGENCY OF
BIOMEDICINE, EUROCORD AND THE SFGM-TC
Speaker: Hanadi Rafii - El Ayoubi, FR

Oral Session
09:15 - 17:30 On-Demand Library
OS07 - Oral session 7: Stem Cell Source and Donors
This session is available in our on-demand library throughout the whole congress
OS7-1 FUNCTIONAL MISMATCHING FOR HLA-DP REDUCES RELAPSE 09:15 - 09:25
RISK AFTER UNRELATED HEMATOPOIETIC CELL
TRANSPLANTATION: A STUDY FROM THE CELLULAR
THERAPY AND IMMUNOBIOLOGY WORKING PARTY OF THE
EBMT
Speaker: Annalisa Ruggeri, ES

OS7-2 POST-TRANSPLANT CYCLOPHOSPHAMIDE IN ONE-ANTIGEN 09:25 - 09:35

MISMATCHED UNRELATED DONOR TRANSPLANTATION
VERSUS HAPLOIDENTICAL TRANSPLANTATION: A
RETROSPECTIVE STUDY ON BEHALF OF THE ACUTE
LEUKEMIA WORKING PARTY OF THE EBMT
Speaker: Giorgia Battipaglia, IT

OS7-3 HLA EVOLUTIONARY DIVERGENCE (HED) INFLUENCES 09:35 - 09:45

OUTCOMES OF ALLOGENEIC HSCT FROM UNRELATED
DONOR (UD) IN PEDIATRIC PATIENTS AND YOUNG ADULTS
AFFECTED BY MALIGNANT DISORDERS
Speaker: Pietro Merli, IT

OS7-4 MANAGEMENT OF DONOR-SPECIFIC ANTIBODIES IN 09:45 - 09:55

HAPLOIDENTICAL TRANSPLANT: MULTICENTER EXPERIENCE
FROM THE MADRID GROUP OF HEMATOPOIETIC
TRANSPLANT
Speaker: Rebeca Bailén, ES

OS7-5 LONG TERM OUTCOMES AFTER INTRABONE UNRELATED 09:55 - 10:05

UMBILICAL CORD BLOOD TRANSPLANT IN PATIENTS WITH
HEMATOLOGICAL MALIGNANCIES: A EUROCORD, CTIWP-

236 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

EBMT ANALYSIS
Speaker: Jacopo Peccatori, IT

OS7-6 INFERIOR CLINICAL OUTCOMES IN RECIPIENTS OF 10:05 - 10:15

CRYOPRESERVED GRAFTS FOLLOWING REDUCED INTENSITY
ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION: A
SINGLE CENTER REPORT
Speaker: Andriyana Bankova, US

OS7-8 CLINICAL RESULTS OF PERIPHERAL BLOOD STEM CELL 10:15 - 10:25

TRANSPLANTATION WITH CRYOPRESERVED GRAFTS
DURING THE COVID19 PANDEMIC
Speaker: Maximilian Christopeit, DE

Oral Session
09:15 - 17:30 On-Demand Library
OS08 - Oral session 8: Graft versus Host Disease I
This session is available in our on-demand library throughout the whole congress
OS8-1 GVHD PROPHYLAXIS WITH POST TRANSPLANTATION 09:15 - 09:15
CYCLOPHOSPHAMIDE (PTCY) VERSUS CYCLOSPORINE A /
METHOTREXATE POST ALLOGENEIC TRANSPLANTATION
(HSCT) FROM MATCHED SIBLINGS FOR AML: FROM THE
ALWP/EBMT
Speaker: Arnon Nagler, IL

OS8-2 BELUMOSUDIL FOR CHRONIC GRAFT-VERSUS-HOST DISEASE 09:15 - 09:15

(CGVHD) AFTER 2 OR MORE PRIOR LINES OF THERAPY: THE
ROCKSTAR STUDY (KD025-213)
Speaker: Corey Cutler, US

OS8-3 A PERSONALIZED ORGAN-BASED APPROACH TO THE 09:15 - 09:15

TREATMENT OF CHRONIC GRAFT-VERSUS-HOST DISEASE
Speaker: Hanaa A. Fatoum, SA

OS8-4 RUXOLITINIB (RUX) VS BEST AVAILABLE THERAPY (BAT) IN 09:15 - 09:15

PATIENTS WITH STEROID-REFRACTORY ACUTE GRAFT-VS-
HOST DISEASE (SR-AGVHD): 6-MONTH FOLLOW-UP FROM
THE RANDOMIZED, PHASE 3 REACH2 STUDY
Speaker: Mohamad Mohty, FR

OS8-5 IMPACT OF CHRONIC GVHD SEVERITY AND STEROID 09:15 - 09:15

RESPONSE ON THE QUALITY OF LIFE IN PATIENTS
FOLLOWING ALLOGENEIC STEM CELL TRANSPLANTATION:
FINDINGS FROM A REAL-WORLD STUDY
Speaker: Sylvie Lachance, CA

OS8-6 SUCCESSFUL AND SAFE TREATMENT OF INTESTINAL GVHD 09:15 - 09:15

WITH POOLED-DONOR FULL ECOSYSTEM MICROBIOTA
BIOTHERAPEUTIC: RESULTS FROM A 29 PATIENT-COHORT
OF A COMPASSIONATE USE/EXPANDED ACCESS TREATMENT
PROGRAM
Speaker: Florent Malard, FR

OS8-7 REDUCED ACUTE GRAFT-VERSUS HOST DISEASE INCIDENCE 09:15 - 09:15

237 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

IN PATIENTS RECEIVING ANTI-T LYMPHOCYTE GLOBULIN IN

COMPARISON TO ANTI-THYMOCYTE GLOBULIN FOR THE
PROPHYLAXIS OF GRAFT-VERSUS-HOST DISEASE AFTER
ALLO-HSCT
Speaker: Marie T Rubio, FR

OS8-8 PATIENT-REPORTED OUTCOMES IN ACUTE GRAFT-VS-HOST 09:15 - 09:15

DISEASE: QUALITY-OF-LIFE FINDINGS FROM A REAL-WORLD
STUDY
Speaker: Nada Hamad, AU

Oral Session
09:15 - 17:30 On-Demand Library
OS11 - Oral session 11: Infectious Diseases I
This session is available in our on-demand library throughout the whole congress
OS11-1 POLYMORPHISMS WITHIN THE TNFSF4 AND MAPKAPK2 LOCI 09:15 - 09:25
INFLUENCE THE RISK OF INVASIVE ASPERGILLOSIS: A TWO-
STAGE CASE CONTROL STUDY IN THE CONTEXT OF THE
ASPBIOMICS CONSORTIUM
Speaker: Ana Moniz-Díez, ES

OS11-2 THE ASSOCIATION BETWEEN CYTOMEGALOVIRUS AND 09:25 - 09:35

INVASIVE FUNGAL INFECTIONS IN ALLOGENEIC
HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS: A
SYSTEMATIC REVIEW AND META-ANALYSIS
Speaker: Nipat Chuleerarux, TH

OS11-3 IMMUNE RECONSTITUTION DURING CMV PROPHILAXIS BY 09:35 - 09:45

LETERMOVIR: A SINGLE CENTER EXPERIENCE
Speaker: Ilaria Cutini, IT

OS11-4 LETERMOVIR PROPHYLAXIS FOR CYTOMEGALOVIRUS 09:45 - 09:55

REACTIVATION IN ALLOGENEIC STEM CELL
TRANSPLANTATION: A MULTICENTER ITALIAN REAL-WORLD
EXPERIENCE
Speaker: Massimo Martino, IT

OS11-5 PREVENTION OF INVASIVE FUNGAL INFECTION IN HAPLO 09:55 - 10:05

TRANSPLANTATION WITH POST-TRANSPLANTATION
CYCLOPHOSPHAMIDE. UNIVERSAL FLUCONAZOLE
PROPHYLAXIS AND A MOULD DIAGNOSTIC-DIRECTED
APPROACH. RESULTS IN 112 PATIENTS
Speaker: Amado Karduss -Urueta, CO

OS11-6 PATTERN OF FUNGAL INFECTIONS DURING THE INITIAL 100 10:05 - 10:15
DAYS IN CHILDREN UNDERGOING HEMATOPOIETIC STEM
CELL TRANSPLANTATION FROM A TERTIARY REFERRAL
CENTER IN INDIA
Speaker: Harika Varla, IN

OS11-7 THE MANAGEMENT OF CLOSTRIDIOIDES DIFFICILE 10:15 - 10:25

INFECTIONS IN PATIENTS AFTER ALLOGENEIC
HEMATOPOIETIC CELL TRANSPLANTATION: THE RESULTS OF

238 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

THE INFECTIOUS DISEASES WORKING PARTY EBMT SURVEY

Speaker: Agnieszka Piekarska, PL

OS11-8 CLINICAL DIAGNOSTIC AND THERAPEUTIC STRATIFICATION 10:25 - 10:35

OF INVASIVE FUNGAL DISEASE IN ADULT PATIENTS WITH
HEMATOLOGY MALIGNANCIES: A REAL-WORLD
OBSERVATIONAL STUDY
Speaker: Sizhou Feng, CN

Oral Session
09:15 - 17:30 On-Demand Library
OS09 - Oral session 9: Graft versus Host Disease II
This session is available in our on-demand library throughout the whole congress
OS9-1 GLUCAGON-LIKE-PEPTIDE-2 (GLP-2) ANALOGUE 09:15 - 09:15
TEDUGLUTIDE FOR GRAFT-VERSUS-HOST DISEASE IN
HUMANS
Speaker: Robert Zeiser, DE

OS9-2 RUXOLITINIB VS BEST AVAILABLE THERAPY IN PATIENTS 09:15 - 09:15

WITH STEROID-REFRACTORY/DEPENDENT CHRONIC GRAFT-
VS-HOST DISEASE (CGVHD): SUBGROUP ANALYSES OF
OVERALL RESPONSE RATE IN THE PHASE 3 REACH3 TRIAL
Speaker: Franco Locatelli, IT

OS9-3 DISCONTINUATION OF SYSTEMIC IMMUNOSUPPRESSIVE 09:15 - 09:15

THERAPY: NEW GOAL OF CHRONIC GVHD TREATMENT?
Speaker: Ivan Moiseev, RU

OS9-4 A PHASE 2, PROSPECTIVE, RANDOMISED, OPEN-LABEL 09:15 - 09:15

STUDY OF DEFIBROTIDE FOR THE PREVENTION OF ACUTE
GRAFT-VERSUS-HOST DISEASE (AGVHD) AFTER
ALLOGENEIC HAEMATOPOIETIC CELL TRANSPLANTATION
(HCT)
Speaker: Michelle Hudspeth, US

OS9-5 THE IMPACT OF GVHD ON OUTCOMES AFTER ADULT SINGLE 09:15 - 09:15
CORD BLOOD TRANSPLANTATION IN EUROPEAN AND
JAPANESE POPULATIONS: THE EUROCORD/ALWP EBMT AND
JSHCT/JDCHCT COLLABORATIVE STUDY
Speaker: Junya Kanda, JP

OS9-6 EARLY RECONSTITUTION OF CD6+ T CELLS AFTER 09:15 - 09:15

HEMATOPOIETIC CELL TRANSPLANTATION IDENTIFIES A
SUITABLE TARGET FOR ACUTE GRAFT-VERSUS-HOST
DISEASE TREATMENT USING ANTI-CD6 MONOCLONAL
ANTIBODY ITOLIZUMAB
Speaker: Benedetta Rambaldi, US

OS9-7 MICROBIAL-DERIVED METABOLITES INDUCE EPITHELIAL 09:15 - 09:15

RECOVERY VIA THE STING PATHWAY IN MICE AND MEN AND
PROTECT FROM GRAFT-VERSUS-HOST DISEASE
Speaker: Erik Thiele Orberg, DE

OS9-8 ASSOCIATION OF GENE POLYMORPHISMS IN 09:15 - 09:15

239 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

CYCLOPHOSPHAMIDE METABOLISM PATHWAY WITH

COMPLICATIONS AFTER HAPLOIDENTICAL HEMATOPOIETIC
STEM CELL TRANSPLANTATION
Speaker: Paula Muñiz, ES

Oral Session
09:15 - 17:30 On-Demand Library
OS20 - Oral session 20: Aplastic Anemia, Autoimmune Disorders, and others
This session is available in our on-demand library throughout the whole congress
OS20-1 HLA EVOLUTIONARY DIVERGENCE INFLUENCES 09:15 - 09:25
CHARACTERISTICS AND OUTCOMES OF PATIENTS WITH
APLASTIC ANEMIA AND PAROXYSMAL NOCTURNAL
HEMOGLOBINURIA
Speaker: Simona Pagliuca, US

OS20-2 OUTCOME OF NON-MYELOABLATIVE AUTOLOGOUS 09:25 - 09:35

HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR
MULTIPLE SCLEROSIS: A SINGLE CENTER SUMMARY OF 511
PATIENTS
Speaker: Richard K Burt, US

OS20-3 EARLY MORBIDITY OF AUTOLOGOUS HAEMATOPOIETIC 09:35 - 09:45

STEM CELL TRANSPLANTATION IN MULTIPLE SCLEROSIS- A
REAL WORLD EXPERIENCE
Speaker: Varun Mehra, GB

OS20-4 THE GENOMIC LANDSCAPE OF MYELOID NEOPLASMS 09:45 - 09:55

ARISING FROM APLASTIC ANEMIA AND PAROXYSMAL
NOCTURNAL HEMOGLOBINURIA
Speaker: Carmelo Gurnari, US

OS20-5 HIGH-DOSE IMMUNOSUPPRESSIVE THERAPY WITH 09:55 - 10:05

AUTOLOGOUS HEMATOPOIETIC STEM CELL
TRANSPLANTATION (AHSCT) IN MULTIPLE SCLEROSIS:
CHANGING APPROACHES IN SINGLE-CENTER EXPERIENCES
Speaker: Alexey Polushin, RU

OS20-6 HLA MUTATIONS IN PAROXYSMAL NOCTURNAL 10:05 - 10:15

HEMOGLOBINURIA: A POSSIBLE ALTERNATIVE MECHANISM
OF IMMUNE ESCAPE
Speaker: Carmelo Gurnari, US

OS20-7 HEMATOPOIETIC STEM CELL TRANSPLANT AS TREATMENT 10:15 - 10:25

OF REFRACTORY MYASTHENIA GRAVIS
Speaker: Claudia Lucía Sossa Melo, CO

OS20-8 IMPACT OF AHSCT ON FERTILITY IN MULTIPLE SCLEROSIS 10:25 - 10:35

PATIENTS
Speaker: Alice Mariottini, IT

240 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

Oral Session
09:15 - 17:30 On-Demand Library
OS21 - Oral session 21: Multiple Myeloma
This session is available in our on-demand library throughout the whole congress
OS21-1 MICROENVIRONMENT IMMUNE RECONSTITUTION PATTERNS 09:15 - 09:15
CORRELATE WITH OUTCOMES AFTER AUTOLOGOUS
TRANSPLANT IN MULTIPLE MYELOMA
Speaker: Harsh Parmar, US

OS21-2 AUTOLOGOUS HEMATOPOIETIC CELL TRANSPLANTATION 09:15 - 09:15

FOR RELAPSED MULTIPLE MYELOMA PERFORMED WITH
STEM CELLS RE-MOBILISED FOLLOWING A PRIOR AUTO-HCT
– A RETROSPECTIVE STUDY ON BEHALF OF EBMT CMWP
Speaker: Joanna Drozd-Soko?owska, PL

OS21-3 ISATUXIMAB PLUS CARFILZOMIB AND DEXAMETHASONE 09:15 - 09:15

VERSUS CARFILZOMIB AND DEXAMETHASONE IN RELAPSED
MULTIPLE MYELOMA PATIENTS WHO PREVIOUSLY
UNDERWENT TRANSPLANTATION: IKEMA SUBGROUP
ANALYSIS
Speaker: Mohamad Mohty, FR

OS21-4 AUTOLOGOUS-ALLOGENEIC VS AUTOLOGOUS TANDEM 09:15 - 09:15

STEM CELL TRANSPLANTATION AND MAINTENANCE WITH
THALIDOMIDE FOR PATIENTS WITH MULTIPLE MYELOMA
(MM) AND AGE <60 YEARS: A PROSPECTIVE PHASE II-
STUDY
Speaker: Nicolaus Kröger, DE

OS21-5 ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION 09:15 - 09:15

FOLLOWED BY BORTEZOMIB IN MULTIPLE MYELOMA: FINAL
RESULTS OF A PROSPECTIVE TRIAL HIGHLIGHTING A
STRONG PROGNOSTIC ROLE OF MEASURABLE RESIDUAL
DISEASE
Speaker: Jean Roy, CA

OS21-6 ACCEPTABLE TOXICITY AND GOOD HEMATOLOGICAL AND 09:15 - 09:15

RENAL RESPONSES AFTER AUTOLOGOUS HEMATOPOIETIC
STEM CELL TRANSPLANTATION IN MYELOMA PATIENTS WITH
RENAL INSUFFICIENCY: A PROSPECTIVE SFGM-TC STUDY
Speaker: laurent Garderet, FR

OS21-7 COAST (OP-501): FIRST IN MAN PHASE I MULTICENTER STUDY 09:15 - 09:15
EVALUATING OPD5 AS A MYELOABLATIVE CONDITIONING
REGIMEN IN RELAPSED REFRACTORY MULTIPLE MYELOMA
(RRMM)
Speaker: Sergio Giralt, US

OS21-8 CHARACTERISTICS AND TREATMENT PATTERNS OF TRIPLE- 09:15 - 09:15

CLASS-EXPOSED PATIENTS WITH RELAPSED/REFRACTORY
MULTIPLE MYELOMA WHO PARTICIPATED IN CLINICAL
TRIALS OF DARATUMUMAB
Speaker: Katja Weisel, DE

241 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

Oral Session
09:15 - 17:30 On-Demand Library
OS19 - Oral session 19: Lymphoma and Chronic Lymphocytic Leukemia
This session is available in our on-demand library throughout the whole congress
OS19-1 INTERIM ANALYSIS (IA) OF ZUMA-12: A PHASE 2 STUDY OF 09:15 - 09:15
AXICABTAGENE CILOLEUCEL (AXI-CEL) AS FIRST-LINE
THERAPY IN PATIENTS WITH HIGH-RISK LARGE B-CELL
LYMPHOMA (LBCL)
Speaker: Catherine Thieblemont, FR

OS19-2 LONG-TERM SURVIVAL AND GRADUAL RECOVERY OF B 09:15 - 09:15

CELLS IN PATIENTS WITH REFRACTORY LARGE B CELL
LYMPHOMA (LBCL) TREATED WITH AXICABTAGENE
CILOLEUCEL (AXI-CEL)
Speaker: Caron A. Jacobson, US

OS19-3 PRIMARY ANALYSIS OF ZUMA-5: A PHASE 2 STUDY OF 09:15 - 09:15

AXICABTAGENE CILOLEUCEL (AXI-CEL) IN PATIENTS WITH
RELAPSED/REFRACTORY (R/R) INDOLENT NON-HODGKIN
LYMPHOMA (INHL)
Speaker: Caron A. Jacobson, US

OS19-4 ONE-YEAR FOLLOW-UP OF ZUMA-2, THE MULTICENTER, 09:15 - 09:15

REGISTRATIONAL STUDY OF KTE-X19 IN PATIENTS WITH
RELAPSED/REFRACTORY (R/R) MANTLE CELL LYMPHOMA
(MCL)
Speaker: Michael L. Wang, US

OS19-5 VALIDATION OF GWAS-IDENTIFIED VARIANTS FOR CHRONIC 09:15 - 09:15

LYMPHOCYTIC LEUKEMIA: A STUDY IN THE CONTEXT OF THE
CRUCIAL CONSORTIUM
Speaker: Antonio José Cabrera-Serrano, ES

OS19-6 EVALUATION OF AUTOLOGOUS AND ALLOGENEIC 09:15 - 09:15

HEMATOPOIETIC CELL TRANSPLANTATION (HCT) IN
PATIENTS WITH HIGH-RISK ANAPLASTIC LARGE CELL
LYMPHOMA (ALCL)
Speaker: Natalie L. Smith, US

OS19-7 ECONOMIC ASPECTS OF STEM CELL TRANSPLANTATION BY 09:15 - 09:15

PATIENTS WITH RELAPSED DIFFUSE B-CELL LYMPHOMA
(DLBCL) IN A GERMAN TERTIARY HOSPITAL
Speaker: Bernhard Alexander Mörtl, DE

OS19-8 LONG TERM OUTCOMES OF ALLOGENEIC 09:15 - 09:15

TRANSPLANTATION IN LYMPHOMA: A SINGLE CENTRE
EXPERIENCE
Speaker: Alexander Glover, GB

Oral Session
09:15 - 17:30 On-Demand Library
OS06 - Oral session 6: Experimental Transplantation, Minimal Residual Disease, Immune Reconstitution and C
This session is available in our on-demand library throughout the whole congress

242 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

OS6-1 COMPARATIVE ANALYSIS OF IMMUNE RECONSTITUTION IN 09:15 - 09:15

HSCT PATIENTS WITH PT-CY OR ATG REVEALS DISTINCT T
CELL IMMUNE RECONSTITUTION PATTERNS
Speaker: Saskia Leserer, DE

OS6-2 MINIMAL RESIDUAL DISEASE AND CHIMERISM ANALYSIS 09:15 - 09:15

USING CIRCULATING CELL-FREE DNA AFTER ALLOGENEIC
HEMATOPOIETIC CELL TRANSPLANTATION
Speaker: Sandra Pennisi, DE

OS6-3 SEQUENTIAL QUANTIFICATION OF T-CELL RECEPTOR 09:15 - 09:15

EXCISION CIRCLES (TRECS) AND K-DELETING
RECOMBINATION EXCISION CIRCLES (KRECS) IN
ALLOGENEIC HEMATOPOIETIC STEM CELL
TRANSPLANTATION (ALLOHSCT) RECIPIENTS
Speaker: Carlos De Miguel Jiménez, ES

OS6-4 MUTATIONAL CONSEQUENCES OF HEMATOPOIETIC STEM 09:15 - 09:15

CELL TRANSPLANTATION IN HUMANS
Speaker: Mirjam Belderbos, NL

OS6-5 OVER-EXPRESSION OF HIF-1? IN MESENCHYMAL STROMAL 09:15 - 09:15

CELLS INCREASES HUMAN CD34+ CELLS CLONOGENIC
CAPACITY IN VITRO AND ENGRAFTMENT ABILITY IN A
XENOTRANSPLANTATION MODEL
Speaker: Silvia Preciado, ES

OS6-6 ALEMTUZUMAB BASED-CONDITIONING FOR NON-MALIGNANT 09:15 - 09:15

PAEDIATRIC DISEASES DEPLETES DONOR T-CELLS
ALLOWING EXCEPTIONALLY LOW RATES OF GVHD BUT
ALLOWS PERSISTENCE OF RESIDUAL, AUTOLOGOUS, VIRUS-
SPECIFIC T-CELLS
Speaker: Rubiya Nadaf, GB

OS6-7 TCR REPERTOIRE DYNAMICS AFTER HEMATOPOIETIC STEM 09:15 - 09:15

CELL TRANSPLANTATION IN MYELOID MALIGNANCIES
Speaker: Simona Pagliuca, US

OS6-8 DAY +60 WT1 ASSESSMENT ON BONE MARROW MIGHT 09:15 - 09:15
PREDICT RELAPSE AND MORTALITY AFTER ALLOGENEIC
STEM CELL TRANSPLANTATION
Speaker: Patrizia Chiusolo, IT

Nurses Group
09:15 - 17:30 On-Demand Library
NG17 - Care of the nurses
This session is available in our on-demand library throughout the whole congress
NG17-1 Mindfulness -
Speaker: Ana M. Muñoz Cobo, ES

NG17-2 Resilience and self-care -

Speaker: Christian Williams, GB

NG17-3 Tips and tricks for self care -

243 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

Speaker: Jane Keep, GB

Nurses Group
09:15 - 17:30 On-Demand Library
NG18 - Non-malignant diseases update
This session is available in our on-demand library throughout the whole congress
NG18-2 Multiple sclerosis 09:15 - 09:15
Speaker: Helen Jessop, GB

NG18-3 Sickle cell disease 09:15 - 09:15

Speaker: Jean-Hugues Dalle, FR

NG18-4 ITP 09:15 - 09:15

Speaker: Maria Luisa Lozano, ES

Nurses Group
09:15 - 17:30 On-Demand Library
NG14 - Nurses Education Day 2: Care of the vulnerable immunocompromised patients in critical care setting
This session is available in our on-demand library throughout the whole congress
NG14-1 Patient's experience -
Speaker: Ruth Tweedie, ES

NG14-2 Psychologist's point of view -

Speaker: Anna Lagerdahl, GB

NG14-3 Nurse's perspective -

Speaker: Núria Ballestar, ES

Nurses Group
09:15 - 17:30 On-Demand Library
NG22 - Quality processes in JACIE
This session is available in our on-demand library throughout the whole congress
NG22-1 Quality indicators for nurses -
Speaker: Louise McNamara, GB

NG22-2 JACIE: What's new? -

Speaker: Kim Orchard, GB

NG22-3 What is the nurse role as JACIE Inspector? -

Speaker: Eugenia Trigoso Arjona, ES

Educational
09:15 - 17:30 On-Demand Library
E10 - HSCT in paediatric non-malignant indications
This session is available in our on-demand library throughout the whole congress
E10-1 Haplo-identical SCT in hemoglobinopathy: Taking pole -
position?
Speaker: Josu de la Fuente, GB

244 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

E10-2 Mismatched family donors in inherited immune disorders: A -

new perspective
Speaker: Mary A. Slatter, GB

E10-3 HSCT for inherited bone marrow failure syndromes -

Speaker: Cristina Díaz de Heredia, ES

E10-4 Cord blood HSCT for non-malignant diseases in children -

Speaker: Vanderson Rocha, BR

Educational
09:15 - 17:30 On-Demand Library
E12 - Steroid-resistant/refractory GVHD
This session is available in our on-demand library throughout the whole congress
E12-1 GVHD - what’s in a name? -
Speaker: Helene Schoemans, BE

E12-2 Treatment of SR/R acute GVHD -

Speaker: Olaf Penack, DE

E12-3 Treatment of SR/R chronic GVHD -

Speaker: Zinaida Peric, HR

E12-4 New technologies in the approach to GVHD -

Speaker: Amin Turki, DE

Data Management
09:15 - 17:30 On-Demand Library
DM07 - Education session 7
This session is available in our on-demand library throughout the whole congress
DM7-1 Minimal residual disease (MRD) -
Speaker: Johannes Schetelig, DE

Workshop
09:15 - 17:30 On-Demand Library
W12 - Donor HLA assessment and matching for allogeneic HSCT
This session is available in our on-demand library throughout the whole congress
W12-1 HLA laboratory perspective and recommendations -
Speaker: Pascale Loiseau, FR

W12-2 Clinical perspective and recommendations -

Speaker: Francesca Lorentino, IT

W12-3 Selection of unrelated donors and cord blood units for -

Hematopoietic Cell Transplantation: Guidelines from
NMDP/CIBMTR
Speaker: Stephen Spellman, US

245 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

Working Party Session

09:15 - 17:30 On-Demand Library
CMWP - Chronic Malignancies Working Party Session
This session is available in our on-demand library throughout the whole congress
CMWP-1 Scientific activity of the CMWP 09:15 - 09:15
Speaker: Ibrahim Yakoub-Agha, FR

CMWP-3 Who and when in the course of disease to transplant? - 09:15 - 09:15
Myelofibrosis
Speaker: Donal McLornan, GB

CMWP-4 Is Chronic Myeloid Leukaemia still an indication for allo-HCT? 09:15 - 09:15
Speaker: Yves Chalandon, CH

CMWP-5 Is Chronic Lymphocytic Leukemia still an indication for allo- 09:15 - 09:15
HCT?
Speaker: Peter Dreger, DE

Working Party Session

09:15 - 17:30 On-Demand Library
IDWP - Infectious Diseases Working Party Session
This session is available in our on-demand library throughout the whole congress
IDWP-1 IDWP update -
Speaker: Rafael de la Cámara, ES

IDWP-2 Current scientific proposals of IDWP -

Speaker: Dina Averbuch, IL

IDWP-3 CMV T-cell immunity monitoring: is it time to incorporate it in -

clinical practices?
Speaker: Roy Chemaly, US

IDWP-4 What is new in the field of Gram-negative infections in SCT -

patients?
Speaker: Dina Averbuch, IL

IDWP-5 Seasonal human coronaviruses vs SARS-CoV-2 in allogeneic -

hematopoietic stem cell transplantation
Speaker: Jose Luis Piñana, ES

IDWP-6 Hepatitis C and hepatitis E in SCT -

Speaker: Malgorzata Mikulska, IT

IDWP-7 Central nervous system (CNS) complications following HSCT -

Speaker: Martin Schmidt-Hieber, DE

Oral Session
09:15 - 17:30 On-Demand Library
OS12 - Oral session 12: Infectious Diseases II
This session is available in our on-demand library throughout the whole congress
OS12-1 NOCARDIOSIS FOLLOWING HEMATOPOIETIC CELL 09:15 - 09:15
TRANSPLANTATION: 20 YEARS' EXPERIENCE. THE

246 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

INTERNATIONAL STUDY OF INFECTIOUS DISEASES WORKING

PARTY OF EBMT AND FRANCO-BELGIAN NOCARDIA STUDY
GROUP
Speaker: Dina Averbuch, IL

OS12-2 COLONIZATION-GUIDED PROTOCOL FOR EMPIRICAL 09:15 - 09:15

ANTIBIOTIC THERAPY IN ALLO-HSCT RECIPIENTS: FIRST
RESULTS OF A SINGLE CENTER PROSPECTIVE STUDY
Speaker: Marina Popova, RU

OS12-3 COLONIZATION BY MULTIDRUG-RESISTANT GRAM-NEGATIVE 09:15 - 09:15

BACTERIA IN EARLY PHASE OF HEMATOPOIETIC STEM CELL
TRANSPLANTATION
Speaker: Yuliya Rogacheva, RU

OS12-4 FAVOURABLE OUTCOME AND NO INCREASED RISK OF GVHD 09:15 - 09:15

IN PATIENTS DEVELOPING C.DIFFICILE INFECTION AFTER
HEMATOPOIETIC STEM CELL TRANSPLANTS
Speaker: Chiara Rosignoli, IT

OS12-5 CLINICAL IMPACT OF DE-ESCALATION/DISCONTINUATION OF 09:15 - 09:15

ANTIBIOTICS PRIOR TO NEUTROPHIL RECOVERY IN
PATIENTS UNDERGOING HEMATOPOIETIC STEM CELL
TRANSPLANTATION: A SINGLE-CENTRE EXPERIENCE
Speaker: Anke Verlinden, BE

OS12-6 COLONIZATION WITH MULTIDRUG-RESISTANT BACTERIA AND 09:15 - 09:15

DISEASE RISK INDEX ARE TWO INDEPENDENT FACTORS
THAT AFFECT THE SURVIVAL OF PATIENTS AFTER
ALLOGENEIC HAEMATOPOIETIC STEM CELL
TRANSPLANTATION
Speaker: Anna Czyz, PL

OS12-7 IMPACT OF FLUOROQUINOLONE PROPHYLAXIS IN 09:15 - 09:15

ALLOGENEIC HEMATOPOIETIC STEM CELL
TRANSPLANTATION; SINGLE CENTER EXPERIENCE
Speaker: Eshrak Al-Shaibani, CA

OS12-8 STRONG INFLAMMATORY CYTOKINE RESPONSE AFTER 09:15 - 09:15

HAPLOIDENTICAL HEMATOPOIETIC STEM CELL
TRANSPLANTATION WITH POST-TRANSPLANT
CYCLOPHOSPHAMIDE RELATES TO HUMAN HERPESVIRUS 6
REACTIVATION
Speaker: Kenichiro Takeda, JP

Oral Session
09:15 - 17:30 On-Demand Library
OS13 - Oral session 13: Transplant Complications I
This session is available in our on-demand library throughout the whole congress
OS13-1 FINAL PRIMARY RESULTS FROM THE DEFIFRANCE REGISTRY 09:15 - 09:15
STUDY: EFFECTIVENESS AND SAFETY OF DEFIBROTIDE FOR
TREATMENT OF HEPATIC VENO-OCCLUSIVE
DISEASE/SINUSOIDAL OBSTRUCTION SYNDROME AFTER

247 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

HAEMATOPOIETIC CELL TRANSPLANTATION

Speaker: Mohamad Mohty, FR

OS13-2 ASSOCIATION OF PRE-EXISTING COMORBIDITIES WITH 09:15 - 09:15

OUTCOME OF ALLOGENEIC STEM CELL TRANSPLANTATION.
A RETROSPECTIVE ANALYSIS FROM THE EBMT
Speaker: Olaf Penack, DE

OS13-3 DEFIBROTIDE PROPHYLAXIS FOR VENO-OCCLUSIVE 09:15 - 09:15

DISEASE/SINUSOIDAL OBSTRUCTION SYNDROME (VOD/SOS)
AFTER HAEMATOPOIETIC CELL TRANSPLANTATION (HCT):
ANALYSIS OF A MULTICENTRE, MULTINATIONAL,
PROSPECTIVE, OBSERVATIONAL REGISTRY STUDY (EBMT
PASS)
Speaker: Mohamad Mohty, FR

OS13-4 EBMT PASS: OUTCOMES OF DEFIBROTIDE-TREATED 09:15 - 09:15

PATIENTS WITH ANICTERIC/ICTERIC VENO-OCCLUSIVE
DISEASE/SINUSOIDAL OBSTRUCTION SYNDROME (VOD/SOS)
AFTER HAEMATOPOIETIC CELL TRANSPLANTATION (HCT)
Speaker: Mohamad Mohty, FR

OS13-5 EASIX SCORE PREDICTS OVERALL SURVIVAL, NON-RELAPSE 09:15 - 09:15

MORTALITY AND THE RISK OF INTENSIVE CARE UNIT
ADMISSION AT PRE-TRANSPLANT EVALUATION
Speaker: Marta Peña Domingo, ES

OS13-6 THE INCIDENCE OF SEVERE ORAL MUCOSITIS AND TASTE 09:15 - 09:15
DISTURBANCE IN PATIENTS UNDERGOING DIFFERENT
CONDITIONING REGIMENS IN HEMATOPOIETIC STEM CELL
TRANSPLANTATION
Speaker: Midori Nakagaki, AU

OS13-7 IMPACT OF SIROLIMUS/TACROLIMUS-BASED GRAFT-VERSUS- 09:15 - 09:15

HOST-DISEASE PROPHYLAXIS ON THE DEVELOPMENT OF
EARLY AND LATE TRANSPLANT-ASSOCIATED THROMBOTIC
MICROANGIOPATHY
Speaker: Aldo A Acosta-Medina, US

OS13-8 RISK FACTORS FOR SINUSOIDAL OBSTRUCTION SYNDROME 09:15 - 09:15

OF THE LIVER AFTER ALLOGENEIC HEMATOPOIETIC STEM
CELL TRANSPLANTATION IN CHILDHOOD
Speaker: Bernd Gruhn, DE

Oral Session
09:15 - 17:30 On-Demand Library
OS14 - Oral session 14: Transplant Complications II
This session is available in our on-demand library throughout the whole congress
OS14-1 PREGNANCY AND PREGNANCY OUTCOMES AFTER 09:15 - 09:15
HEMATOPOIETIC STEM CELL TRANSPLANTATION DURING
CHILDHOOD: A CROSS-SECTIONAL SURVEY OF THE EBMT
PEDIATRIC WP
Speaker: Tamara Diesch, CH

248 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

OS14-2 ONE THOUSAND VOICES ADDRESS PATIENT ENGAGEMENT IN 09:15 - 09:15

HEMATOPOIETIC STEM CELL TRANSPLANTATION AND CELL
THERAPY: RESULTS OF A SURVEY FROM THE EBMT
Speaker: Helene Schoemans, BE

OS14-3 CHRONIC KIDNEY DISEASE TEN YEARS AFTER PEDIATRIC 09:15 - 09:15
ALLOGENEIC HEMATOPOIETIC STEM CELL
TRANSPLANTATION
Speaker: Gertjan Lugthart, NL

OS14-4 NEUROLOGIC COMPLICATIONS AFTER ALLOGENEIC STEM 09:15 - 09:15

CELL TRANSPLANTATION: ANALYSIS OF RISK FACTORS. A
SINGLE CENTER STUDY OVER 20 YEARS OF FOLLOW-UP

OS14-5 AN UPDATED SYSTEMATIC REVIEW OF STUDIES ON 09:15 - 09:15

DEFIBROTIDE PROPHYLAXIS FOR VENO?OCCLUSIVE
DISEASE/SINUSOIDAL OBSTRUCTION SYNDROME (VOD/SOS)
Speaker: Selim Corbacioglu, DE

OS14-6 PROGNOSTIC BIOMARKER SIGNATURE FOR HEPATIC VENO- 09:15 - 09:15

OCCLUSIVE DISEASE/SINUSOIDAL OBSTRUCTION SYNDROME
(VOD/SOS) IN RECIPIENTS OF MYELOABLATIVE (MA)
ALLOGENEIC HAEMATOPOIETIC CELL TRANSPLANTATION
(HCT)
Speaker: Santosh Putta, US

OS14-7 OUTCOME AFTER ADMISSION TO INTENSIVE CARE UNIT (ICU) 09:15 - 09:15
IN HEMATOPOIETIC TRANSPLANT RECIPIENTS: SINGLE
CENTRE EXPERIENCE
Speaker: Isabel Iturrate, ES

OS14-8 DISTRIBUTION AND IMPACT OF ACUTE KIDNEY INJURY IN AT- 09:15 - 09:15
HOME ALLOGENEIC BONE MARROW TRANSPLANTATION
MODELS
Speaker: Marta Garcia-Recio, ES

Oral Session
09:15 - 17:30 On-Demand Library
OS15 - Oral session 15: Conditioning Regimens
This session is available in our on-demand library throughout the whole congress
OS15-1 BENDAMUSTINE-BASED CONDITIONING PRIOR TO 09:15 - 09:25
AUTOLOGOUS HEMATOPOIETIC CELL TRANSPLANT
IMPROVES OUTCOMES IN PATIENTS WITH ELAPSED-
REFRACTORY NON-HODGKIN LYMPHOMA
Speaker: Sylvie Lachance, CA

OS15-2 MICROBIOTA INJURY IS CONDITIONING REGIMEN- 09:25 - 09:35

DEPENDENT IN ALLOGENEIC HEMATOPOIETIC CELL
TRANSPLANTATION RECIPIENTS
Speaker: Roni Shouval, US

OS15-3 THE IMPACT OF PULMONARY FUNCTION IN PATIENTS 09:35 - 09:45

UNDERGOING AUTOLOGOUS STEM CELL TRANSPLANTATION

249 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

Speaker: Jesus Duque-Afonso, DE

OS15-4 HIGH INCIDENCE OF GVHD WITH TBF CONDITIONING IN 09:45 - 09:55

HEMATOLOGIC MALIGNANCIES: A SINGLE CENTER
EXPERIENCE
Speaker: Khalid Halahleh, JO

OS15-5 THIOTEPA BUSULFAN AND FLUDARABINE (TBF) PATIENTS 09:55 - 10:05

WITH ACUTE MYELOID LEUKEMIA IN COMPLETE REMISSION
:A RETROSPECTIVE ANALYSIS ON 221 PATIENTS AND 369
CONTROLS
Speaker: Federica Sora, IT

OS15-6 IMPACT OF THE ADDITION OF ANTITHYMOCYTE GLOBULIN TO 10:05 - 10:15

POST-TRANSPLANT CYCLOPHOSPHAMIDE IN
HAPLOIDENTICAL TRANSPLANTATION WITH PERIPHERAL
BLOOD COMPARED TO POST-TRANSPLANT
CYCLOPHOSPHAMIDE ALONE
Speaker: Giorgia Battipaglia, IT

OS15-7 HEMATOPOIETIC CELL TRANSPLANTATION COMORBIDITY 10:15 - 10:25

INDEX (HCT-CI) AND OUTCOME AFTER NON-MYELOABLATIVE
ALLOGENEIC STEM CELL TRANSPLANTATION IN ACUTE
MYELOID LEUKEMIA (AML) PATIENTS OLDER THAN 60 YEARS
Speaker: Donata Backhaus, DE

OS15-8 SEQUENTIAL FLAMSA-BU VERSUS FLUBU2 IN PATIENTS WITH 10:25 - 10:35

ACTIVE RELAPSED OR REFRACTORY ACUTE MYELOID
LEUKEMIA: A STUDY FROM THE ACUTE LEUKEMIA WORKING
PARTY OF THE EBMT
Speaker: Eduardo Rodríguez-Arbolí, ES

Oral Session
09:15 - 17:30 On-Demand Library
OS16 - Oral session 16: Acute Leukemia I
This session is available in our on-demand library throughout the whole congress
OS16-1 IMPACT OF CO-OCCURRING CYTOGENETIC ABNORMALITIES 09:15 - 09:25
ON TRANSPLANT OUTCOME OF TP53 MUTANT ACUTE
MYELOID LEUKAEMIA: REPORT FROM THE ALWP OF THE
EBMT
Speaker: Justin Loke, GB

OS16-2 IMPACT OF CYTOGENETIC CLASSIFICATION IN ALLO-HCT IN 09:25 - 09:35

PATIENTS WITH ACUTE MYELOID LEUKEMIA SECONDARY TO
MYELODYSPLASTIC SYNDROME: A JOIN STUDY BY THE
ALWP AND THE CMWP
Speaker: Eolia Brissot, FR

OS16-3 THE IMPACT OF CYTOGENETIC RISK ON OUTCOME OF NON-T 09:35 - 09:45

CELL DEPLETED HAPLOIDENTICAL STEM CELL
TRANSPLANTATION IN RELAPSED/REFRACTORY AML: A
STUDY FROM THE ALWP / EBMT
Speaker: Arnon Nagler, IL

250 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

OS16-4 NON-T DEPLETED HAPLOIDENTICAL STEM CELL 09:45 - 09:55

TRANSPLANTATION IN AML PATIENTS ACHIEVING FIRST
COMPLETE REMISSION AFTER ONE VS TWO INDUCTION
COURSES: A STUDY FROM THE ALWP/EBMT
Speaker: Arnon Nagler, IL

OS16-5 PREVALENCE AND OUTCOME OF CNS RELAPSE AFTER 09:55 - 10:05

ALLOGENEIC HEMATOPOIETIC STEM CELL
TRANSPLANTATION IN PATIENTS SUFFERING FROM AML AND
ALL. A STUDY FROM THE ALWP-EBMT
Speaker: Sabine Blum, CH

OS16-6 IMPACT OF ALLOGENIC TRANSPLANTATION IN THE 10:05 - 10:15

TREATMENT OF SECONDARY ACUTE MYELOID LEUKEMIAS.
COMPARISON BETWEEN MYELOABLATIVE VS REDUCE
INTENSITY CONDITIONINGS
Speaker: Claudia Núñez-Torrón, ES

OS16-7 THE DISEASE BURDEN PRIOR TO ALLOGENEIC 10:15 - 10:25

HEMATOPOIETIC STEM CELL TRANSPLANT IS MORE
RELEVANT IN PATIENTS WITH DE NOVO LEUKEMIA COMPARE
TO PATIENTS WITH SECONDARY LEUKEMIA
Speaker: Claudia Núñez-Torrón, ES

OS16-8 PROGNOSIS OF PATIENTS WITH ACUTE LYMPHOBLASTIC 10:25 - 10:35

LEUKEMIA RELAPSING AFTER AN ALLOGENEIC STEM CELL
TRANSPLANTATION. STUDY OF 132 PATIENTS
Speaker: Christelle Ferra Coll, ES

Oral Session
09:15 - 17:30 On-Demand Library
OS17 - Oral session 17: Acute Leukemia II
This session is available in our on-demand library throughout the whole congress
OS17-1 TRENDS AND PREDICTIVE FACTORS FOR OUTCOME OF 09:15 - 09:15
RELAPSED PHILADELPHIA POSITIVE ACUTE LYMPHOBLASTIC
LEUKEMIA AFTER ALLOGENEIC HEMATOPOIETIC CELL
TRANSPLANTION: IMPROVEMENT OF SURVIVAL IN RECENT
YEARS
Speaker: Ali Bazarbachi, LB

OS17-2 HOST IMMUNE GENETIC VARIATIONS INFLUENCE THE RISK 09:15 - 09:15
OF DEVELOPING ACUTE MYELOID LEUKAEMIA: RESULTS
FROM THE NUCLEAR CONSORTIUM
Speaker: José Sánchez Maldonado, ES

OS17-3 COMPARISON OF HAPLOIDENTICAL PERIPHERAL BLOOD 09:15 - 09:15

CELL TRANSPLANTATION USING POST-TRANSPLANT
CYCLOPHOSPHAMIDE WITH DOUBLE CORD BLOOD
TRANSPLANTATION IN ADULTS WITH ACUTE LEUKEMIA
Speaker: Annalisa Ruggeri, ES

OS17-4 REAL-LIFE EXPERIENCE OF SORAFENIB MAINTENANCE 09:15 - 09:15

AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL

251 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

TRANSPLANTATION FOR FLT3-ITD AML REVEALS HIGH

RATES OF TOXICITY-RELATED TREATMENT INTERRUPTION
Speaker: Sarah Morin, CH

OS17-5 VENETOCLAX COMBINED WITH HYPOMETHYLATING AGENT 09:15 - 09:15

(HMA) IS SAFE AND EFFECTIVE MAY BE A GOOD BRIDGE TO
TRANSPLANT IN HIGH-RISK ACUTE MYELOID LEUKEMIA
Speaker: Vincenzo Federico, IT

OS17-6 TKI MAINTENANCE AFTER STEM-CELL TRANSPLANTATION 09:15 - 09:15

FOR FLT3-ITD POSITIVE ACUTE MYELOID LEUKEMIA: A
SYSTEMATIC REVIEW AND META-ANALYSIS
Speaker: Nico Gagelmann, DE

OS17-7 STEM CELL TRANSPLANTATION FROM A HAPLOIDENTICAL 09:15 - 09:15

DONOR FOR PEDIATRIC PATIENTS WITH ACUTE
MYELOGENOUS LEUKEMIA: A RETROSPECTIVE NATIONWIDE
STUDY
Speaker: Charlotte Nazon, FR

OS17-8 COMPREHENSIVE GERIATRIC ASSESSMENT, ALLOGENEIC 09:15 - 09:15

HSCT AND SURVIVAL IN AML PATIENTS 65-75 YEARS OLD
Speaker: Gabriele Magliano, IT

Joint Session
09:15 - 17:30 On-Demand Library
JS05 - Joint session WBMT: COVID-19 Vaccination in HSCT
This session is available in our on-demand library throughout the whole congress
JS5-2 COVID-19 vaccination in HSCT 09:15 - 09:15
Speaker: Per Ljungman, SE

JS5-3 Global access to COVID-19 vaccines 09:15 - 09:15

Speaker: Susan Brown, US

Oral Session
09:15 - 17:30 On-Demand Library
OS05 - Oral session 5: Cellular Therapy, Gene Therapy and New Drugs II
This session is available in our on-demand library throughout the whole congress
OS5-1 HEMATOPOIETIC STEM CELL GENE THERAPY FOR 09:15 - 09:25
MUCOPOLYSACCHARIDOSIS TYPE I, HURLER (MPS-IH):
BIOLOGICAL EFFICACY AND PRELIMINARY EVIDENCE OF
EARLY CLINICAL RESPONSE
Speaker: Maria Ester Bernardo, IT

OS5-2 OVERALL SURVIVAL BY BEST OVERALL RESPONSE WITH 09:25 - 09:35

TABELECLEUCEL IN PATIENTS WITH EPSTEIN-BARR VIRUS-
DRIVEN POST-TRANSPLANT LYMPHOPROLIFERATIVE
DISEASE AFTER ALLOGENEIC HEMATOPOIETIC CELL
TRANSPLANT
Speaker: Susan Prockop, US

OS5-3 RESOLUTION OF SERIOUS VASO-OCCLUSIVE PAIN CRISES: 09:35 - 09:45

252 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

RESULTS FROM THE ONGOING PHASE 1/2 HGB-206 GROUP C

STUDY OF LENTIGLOBIN FOR SICKLE CELL DISEASE (SCD)
GENE THERAPY
Speaker: Markus Mapara, US

OS5-4 DURABLE CLINICAL OUTCOMES FOLLOWING 09:45 - 09:55

BETIBEGLOGENE AUTOTEMCEL (BETI-CEL) GENE THERAPY
WITH UP TO 6 YEARS OF FOLLOW-UP IN PATIENTS WITH
TRANSFUSION-DEPENDENT ?-THALASSEMIA (TDT)
Speaker: Franco Locatelli, IT

OS5-5 OPEN LABEL DOSE ESCALATION TRIAL OF AB-205 (E-CEL® 09:55 - 10:05
CELLS) IN ADULTS WITH SYSTEMIC LYMPHOMA
UNDERGOING HIGH-DOSE THERAPY AND AUTOLOGOUS
HEMATOPOIETIC CELL TRANSPLANTATION (HDT-AHCT)
Speaker: Carolyn Mulroney, US

OS5-6 IMMUNOTHERAPY IN ACUTE LEUKEMIA: A GITMO (GRUPPO 10:05 - 10:15

ITALIANO TRAPIANTO MIDOLLO OSSEO) SURVEY ON
EFFICACY AND TOXICITY OF DONOR LYMPHOCYTE
INFUSIONS AFTER ALLOGENEIC STEM CELL
TRANSPLANTATION
Speaker: Francesca Patriarca, IT

OS5-7 MONITORING PATIENT SARS-COV-2-T-CELL IMMUNE 10:15 - 10:25

RESPONSES AND GENERATING SARS-COV-2-SPECIFIC T
CELLS FROM CONVALESCENT DONORS; IMPLICATIONS FOR
THE IDENTIFICATION OF HIGH-RISK PATIENTS AND
TREATMENT WITH T-CELL IMMUNOTHERAPY
Speaker: Anastasia Papadopoulou, GR

OS5-8 NORMALISED LYSOSOMAL ACID LIPASE ACTIVITY CAN BE 10:25 - 10:35

ACHIEVED IN WOLMAN FIBROBLASTS VIA BOTH DIRECT
TRANSDUCTION AND CROSS-CORRECTION MECHANISMS
USING A LENTIVIRAL-MEDIATED GENE THERAPY APPROACH
Speaker: Jane E Potter, GB

Paed4-2 EARLY SAFETY AND EFFICACY RESULTS WITH A SINGLE 10:35 - 10:45
DOSE OF AUTOLOGOUS CRISPR-CAS9-MODIFIED CD34+
HEMATOPOIETIC STEM AND PROGENITOR CELLS IN
TRANSFUSION-DEPENDENT ?-THALASSEMIA AND SICKLE
CELL DISEASE
Speaker: Selim Corbacioglu, DE

Special Session
09:15 - 17:30 On-Demand Library
SS08 - Social Media Session: Do's and don'ts of the interaction in the social media for the HSCT and cell thera
community
This session is available in our on-demand library throughout the whole congress
SS8-1 Social media beyond twitter for the HSCT and cell therapy -
community
Speaker: Navneet Majhail, US

253 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

SS8-2 Do's and don'ts of interaction in social media: Nurse's -

perspective

SS8-3 Do’s and don'ts of interaction in social media: How social -

media can improve patient outcomes - The patient's perspective
Speaker: Gillian Adams, GB

Poster Sessions
09:15 - 17:30 ePoster Area
CAR-based Cellular Therapy – Preclinical
P026 NON-VIRAL SLEEPING BEAUTY TRANSPOSON ENGINEERED 09:15 - 09:15
CD19-CAR-NK CELLS WITH HIGH ANTILEUKEMIC EFFICIENCY
Speaker: Tobias Bexte, DE

Poster Sessions
09:15 - 17:30 ePoster Area
Cellular Therapies other than CARs
P027 PROLONGED REPEATEDLY ADMINISTERED LOW DOSE 09:15 - 09:15
DONOR LYMPHOCYTE INFUSION FOR PREVENTION OF
RELAPSE AFTER ALLOGENEIC STEM CELL
TRANSPLANTATION FOR PATIENTS WITH HIGH RISK ACUTE
LEUKEMIA
Speaker: Panagiotis Tsirigotis, GR

P028 CD8?-ENHANCED NY-ESO-1-SPECIFIC TCR T CELLS 09:15 - 09:15

(GSK3901961) IN HLA-A*02 PATIENTS WITH NSCLC: MASTER
PROTOCOL SUBSTUDY 1
Speaker: Mehmet Altan, US

P029 CLINIMACS PLUS® SELECTION AS A RELIABLE AND SAFE 09:15 - 09:15

ALTERNATIVE PROCEDURE FOR CLINIMACS PRODIGY®
TCR?? AND CD19 DEPLETION
Speaker: Katalin Dobos, HU

P031 COMPREHENSIVE ACTIVATION PROFILING OF 09:15 - 09:15

TABELECLEUCEL, AN OFF-THE-SHELF, ALLOGENEIC EBV-
SPECIFIC T-CELL IMMUNOTHERAPY
Speaker: Fiona Ruiz, US

P030 IMPACT OF CRYOPRESERVED PHOTOPHERESIS IN GRAFT 09:15 - 09:15

VERSUS HOST DISEASE FOR NON-MALIGNANT DISORDERS
AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL
TRANSPLANTATION IN PEDIATRIC PATIENTS

P035 BMT CTN 1803: HAPLOIDENTICAL NATURAL KILLER CELLS (K- 09:15 - 09:15
NK002) TO PREVENT POST-TRANSPLANT RELAPSE IN AML
AND MDS (NK-REALM)
Speaker: Sumithira Vasu, US

P034 NEW, LN2-FREE SOLUTION FOR CRYOGENIC TRANSPORT OF 09:15 - 09:15

CELL THERAPIES
Speaker: Julie Meneghel, GB

254 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

P032 DONOR LYMPHOCYTE INFUSION AFTER ALLOGENEIC STEM 09:15 - 09:15

CELL TRANSPLANTATION: A RETROSPECTIVE ANALYSIS
Speaker: Virginia Escamilla Gómez, ES

P033 DONOR LYMPHOCYTE INFUSION (DLI). A STRATEGY TO 09:15 - 09:15

PREVENT OR TREAT RELAPSE FOLLOWING ALLOGENIC
STEM CELL TRANPLANTATION. ONE SINGLE CENTER
EXPERIENCE
Speaker: Melissa Karina Torres Ochando, ES

Poster Sessions
09:15 - 17:30 ePoster Area
Data Management
P045 GENDER DISPARITY IN AUTOLOGOUS HSCT; FACT OR MYTH? 09:15 - 09:15
A BSBMTCT REGISTRY STUDY LOOKING INTO POSSIBLE
MALE PREDOMINANCE IN HSCT PARTICULARLY IN MULTIPLE
MYELOMA
Speaker: Ruth Paul, GB

Poster Sessions
09:15 - 17:30 ePoster Area
Experimental Stem Cell Transplantation
P046 SYNERGISTIC EFFECT OF ATG PLUS PTCY FOR DUAL T CELL 09:15 - 09:15
MODULATION IN HAPLOIDENTICAL STEM CELL
TRANSPLANTATION FOR POOR PROGNOSIS ACUTE
LEUKAEMIA
Speaker: Maryam Barkhordar, IR

P047 DAY 0 EASIX SCORE MIGHT PREDICT OVERALL SURVIVAL 09:15 - 09:15
AND TRANSPLANT RELATED MORTALITY AFTER
ALLOGENEIC STEM CELL TRANSPLANTATION: SINGLE
CENTRE EXPERIENCE
Speaker: Elisabetta Metafuni, IT

Poster Sessions
09:15 - 17:30 ePoster Area
Experimental Transplantation
P048 INFLUENCE OF POLYMORPHISMS RELATED TO DRUG 09:15 - 09:15
METABOLISM IN ALLOGENEIC BONE MARROW
TRANSPLANTATION
Speaker: Marta Santiago, ES

P049 REDUCED-INTENSITY UNMANIPULATED HAPLOIDENTICAL 09:15 - 09:15

STEM CELL TRANSPLANTATION FOR RELAPSED HIGH-RISK
NEUROBLASTOMA AFTER AUTOLOGOUS STEM CELL
TRANSPLANTATION
Speaker: Tahereh Rostami, IR

255 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

Poster Sessions
09:15 - 17:30 ePoster Area
Gene Therapy
P050 BETIBEGLOGENE AUTOTEMCEL (BETI-CEL; LENTIGLOBIN 09:15 - 09:15
FOR ?-THALASSEMIA) GENE THERAPY TREATMENT OF A
GREEK PATIENT WITH TRANSFUSION-DEPENDENT ?-
THALASSEMIA (TDT)
Speaker: Evangelia Yannaki, GR

Poster Sessions
09:15 - 17:30 ePoster Area
Graft-versus-Host Disease – Clinical
P051 EFFECT OF EXTRACORPOREAL PHOTOPHERESIS ON 09:15 - 09:15
ENRICHMENT, SURVIVAL AND CYTOKINE PRODUCTION
CAPACITY OF MONOCYTES FROM CHRONIC GRAFT VERSUS
HOST DISEASE PATIENTS
Speaker: Arun Alfred, GB

P056 REDUCED GVHD WITH TRIPLE PTCY BASED GVHD 09:15 - 09:15
PROPHYLAXIS, AS COMPARED TO TRIPLE ATG BASED
PROPHYLAXIS, IN HLA MATCHED TRANSPLANTS
Speaker: Elisabetta Metafuni, IT

P055 PROLONGED SUPPRESSION OF BUTYRATE PRODUCING 09:15 - 09:15

BACTERIA INDICATES DYSBIOSIS AND IS ASSOCIATED WITH
ACUTE GASTROINTESTINAL GRAFT-VERSUS-HOST DISEASE
AND TRANSPLANT RELATED MORTALITY AFTER
ALLOGENEIC STEM CELL TRANSPLANTATION
Speaker: Elisabeth Meedt, DE

P052 ACUTE AND CHRONIC GRAFT-VERSUS-HOST-DISEASE IMPAIR 09:15 - 09:15

B-CELL RECONSTITUTION IN ALLOGENEIC-TRANSPLANTED
PATIENTS AT DIFFERENT MATURATION STAGES
Speaker: Matthias Alexander Fante, DE

P057 THE SAME FOR LESS: 2.5MG/KG VS. 4.5MG/KG RABBIT ANTI- 09:15 - 09:15
THYMOCYTE GLOBULIN IN PATIENTS UNDERGOING
MATCHED UNRELATED DONOR ALLOGENEIC STEM CELL
TRANSPLANTATION FOR HEMATOLOGICAL MALIGNANCIES
Speaker: Osman Radhwi, CA

P060 A PHASE 2/3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, 09:15 - 09:15

PLACEBO-CONTROLLED STUDY OF ALPHA-1 ANTITRYPSIN
FOR THE PREVENTION OF ACUTE GRAFT VERSUS HOST
DISEASE FOLLOWING HEMATOPOIETIC CELL TRANSPLANT

P061 CHRONIC AND LATE ACUTE GVHD IN CHILDREN USING THE 09:15 - 09:15
NIH 2014 CONSENSUS CRITERIA
Speaker: Koray Yalcin, TR

P058 COMPARISON OF POST-TRANSPLANTATION 09:15 - 09:15

CYCLOPHOSPHAMIDE VERSUS ANTI-T-LYMPHOCYTE
GLOBULIN AS GVHD PROPHYLAXIS IN ADULT PATIENTS WITH

256 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

ACUTE LYMPHOBLASTIC LEUKEMIA UNDERGOING

ALLOGENEIC HEMATOPOIETIC STEM CELL
TRANSPLANTATION IN CR1
Speaker: Maximilian Christopeit, DE

P059 TRIPLE PTCY BASED GVHD PROPHYLAXIS: HLA MATCHED 09:15 - 09:15
VERSUS HLA HAPLOIDENTICAL TRANSPLANTS
Speaker: Eugenio Galli, IT

P063 A PHASE 1/2, OPEN-LABEL, SINGLE-ARM, STUDY OF 09:15 - 09:15

RUXOLITINIB ADDED TO CORTICOSTEROIDS IN PEDIATRIC
PATIENTS WITH ACUTE GRAFT-VS-HOST DISEASE AFTER
ALLOGENEIC STEM CELL TRANSPLANTATION (REACH4)
Speaker: Franco Locatelli, IT

P062 AREA UNDER THE CURVE BASED MYCOPHENOLATE MOFETIL 09:15 - 09:15
DOSAGE REDUCED THE INCIDENCE OF GVHD AFTER
ALLOGENIC HSCT IN PEDIATRIC PATIENTS: ONE FACILITY'S
EIGHT-YEAR EXPERIENCE
Speaker: Antonio Grasso, IT

P064 IBRUTINIB FOR STEROID REFRACTORY CHRONIC GRAFT 09:15 - 09:15

VERSUS HOST DISEASE: DATA AND CLINICAL EXPERIENCE
FROM A SINGLE CENTER
Speaker: Panayotis Kaloyannidis, SA

P065 ROUTINE USE OF THE AMICUS BLUE™ ONLINE ECP SYSTEM IN 09:15 - 09:15
PATIENTS WITH CHRONIC AND ACUTE GRAFT VERSUS HOST
DISEASE
Speaker: Angelo Ostuni, IT

P066 RUXOLITINIB OFF-LABEL USE IN STEROID-REFRACTORY 09:15 - 09:15

CHRONIC GRAFT VERSUS HOST DISEASE: A SINGLE CENTRE
EXPERIENCE IN 36 PATIENTS
Speaker: Maria Teresa Lupo Stanghellini, IT

P067 PHARMACOKINETIC MODELING TO GUIDE DOSE SELECTION 09:15 - 09:15

OF ALPHA-1 ANTITRYPSIN IN A STUDY OF GRAFT VERSUS
HOST DISEASE PREVENTION IN PATIENTS RECEIVING
ALLOGENIC HEMATOPOIETIC CELL TRANSPLANT
Speaker: Henry Hu, US

P068 BASILIXIMAB FOR THE TREATMENT OF PATIENTS WITH 09:15 - 09:15

STEROID REFRACTORY ACUTE GRAFT VERSUS HOST
DISEASE: LITERATURE REVIEW AND POOLED ANALYSIS
Speaker: Xiaodong Mo, CN

P069 FIRST LINE SINGLE-AGENT RUXOLITINIB FOR GRADE II-III 09:15 - 09:15
ACUTE GRAFT-VERSUS-HOST DISEASE IN PATIENTS WITH
SEVERE INFECTIOUS COMPLICATIONS: CASE SERIES
Speaker: Ivan Moiseev, RU

P070 A PHASE 2 OPEN-LABEL, SINGLE-ARM, MULTICENTER STUDY 09:15 - 09:15

OF RUXOLITINIB ADDED TO CORTICOSTEROIDS IN PEDIATRIC
SUBJECTS WITH MODERATE/SEVERE CHRONIC GVHD AFTER

257 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

ALLOGENEIC STEM CELL TRANSPLANTATION (REACH5)

Speaker: Franco Locatelli, IT

P071 PRE-TRANSPLANTATION PLASMA VITAMIN D LEVELS AND 09:15 - 09:15

ACUTE GRAFT-VERSUS-HOST DISEASE AFTER
MYELOABLATIVE ALLOGENEIC HEMATOPOIETIC CELL
TRANSPLANTATION
Speaker: Lars Klingen Gjærde, DK

P072 SEVERE REFRACTORY SKIN GVHD IN CHILDREN: SERIES OF 09:15 - 09:15

CLINICAL CASES

P073 Elevated REG3? predicts refractory aGVHD in Patients Who 09:15 - 09:15
Received Steroids- Ruxolitinib as the First Line Therapy
Speaker: Liping Dou, CN

Poster Sessions
09:15 - 17:30 ePoster Area
Graft-versus-Host Disease – Preclinical and Animal Models
P074 THE MAGNITUDE OF INTESTINAL T CELL INFILTRATION 09:15 - 09:15
DETERMINES EPITHELIAL REGENERATION DURING IMMUNE-
MEDIATED TISSUE INJURY
Speaker: Sascha Göttert, DE

P075 ITACITINIB ATTENUATES XENOGENEIC GVHD IN HUMANIZED 09:15 - 09:15

MICE

Poster Sessions
09:15 - 17:30 ePoster Area
Haematopoietic Stem Cells
P078 RESULTS OF SECOND ALLOGENEIC HEMATOPOIETIC STEM 09:15 - 09:15
CELL TRANSPLANTATION IN PATIENTS WITH
HEMATOLOGICAL DISEASES: RETROSPECTIVE ANALYSIS OF
OUR HOSPITAL
Speaker: Elena Paumard Rodríguez, ES

P076 LETERMOVIR PROPHYLAXIS REDUCES THE RISK FOR CMV 09:15 - 09:15
INFECTION AFTER STEM CELL TRANSPLANTATION
Speaker: Katrin Koch, DE

P077 KIR B HAPLOTYPES IN UNRELATED HEMATOPOIETIC STEM 09:15 - 09:15

CELL TRANSPLANTATION, REVISITED
Speaker: Kazimierz Halaburda, PL

P079 THE IMPACT OF AGE ON HEMATOLOGIC RECOVERY AFTER 09:15 - 09:15

ALLOGENEIC TRANSPLANTATION
Speaker: Sabrina Giammarco, IT

P081 OUTCOME OF SECOND ALLOGENIC STEM CELL 09:15 - 09:15

TRANSPLANTATION IN CHILDREN WITH PRIMARY IMMUNE
DEFICIENCIES
Speaker: Zohreh Nademi, GB

258 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

P080 HEMATOPOIETIC STEM CELL TRANSPLANTATION IN 09:15 - 09:15

PEDIATRIC ACUTE MYELOID LEUKEMIA WITH ABERRANT CD7
ANTIGEN EXPRESSION
Speaker: Danilo De Novellis, IT

P082 OUTCOME OF ALLOGENIC STEM CELL TRANSPLANTATION IN 09:15 - 09:15

ELDERLY PATIENTS: A SINGLE CENTER STUDY
Speaker: Eshrak Al-Shaibani, CA

P084 ALLOGENEIC HEMATOPOIETIC STEM CELL 09:15 - 09:15

TRANSPLANTATION IN PATIENTS OLDER THAN 65 YEARS
WITH AML AND MDS: RISK FACTORS FOR OVERALL
SURVIVAL AND DISEASE FREE SURVIVAL
Speaker: Simona Piemontese, IT

P083 ALLOGENEIC HEMATOPOIETIC STEM CELL 09:15 - 09:15

TRANSPLANTATION FOR PATIENTS 60 YEARS OR OLDER. A
SINGLE-INSTITUTION EXPERIENCE
Speaker: Marta Hidalgo Soto, ES

P086 EFFICACY OF MODIFIED FC/ATG PRETREATMENT IN HAPLOID 09:15 - 09:15

AND ALLOGENEIC HEMATOPOIETIC STEM CELL
TRANSPLANTATION FOR SEVERE APLASTIC ANEMIA
Speaker: Ma Liangming, CN

P085 IMPACT OF HUMAN LEUKOCYTE ANTIGEN ALLELE 09:15 - 09:15

POLYMORPHISMS ON THE OUTCOMES OF
TRANSPLANTATION FROM HLA-MATCHED UNRELATED
DONORS
Speaker: Anastasia Beynarovich, RU

P087 AUTOMATED DRY THAWING OF CRYOPRESERVED 09:15 - 09:15

HAEMATOPOIETIC CELLS IS NOT ADVERSELY INFLUENCED
BY CRYOSTORAGE TIME, PATIENT AGE OR GENDER
Speaker: Julie Meneghel, GB

P091 UNMANIPULATED HAPLOIDENTICAL STEM CELL 09:15 - 09:15

TRANSPLANTATION FOR PEDIATRIC PATIENTS WITH ACUTE
LEUKEMIA: AN EXPERIENCE FROM THE LARGEST
CHILDREN'S HOSPITAL IN IRAN
Speaker: Amir Ali Hamidieh, IR

P090 INDICATIONS AND SURVIVAL OF ALLOGENEIC TRANSPLANT 09:15 - 09:15

IN PATIENTS OVER 65 YEARS OLD
Speaker: Magdalena Corona de Lapuerta, ES

P089 LONG-TERM RESULTS OF HEMATOPOIETIC STEM CELL 09:15 - 09:15

TRANSPLANTATION FOR HODGKIN’S AND NON-HODGKIN’S
LYMPHOMA: EXPERIENCE OF A SINGLE CENTER IN
COLOMBIAN NORTHEAST
Speaker: Claudia Lucía Sossa Melo, CO

P093 HAPLOIDENTICAL STEM CELL TRANSPLANTATION IN AML 09:15 - 09:15

WITH T(6;9)(P23; Q34); DEK-NUP214 SHOWS A FAVOURABLE
OUTCOME: SINGLE CENTER EXPERIENCE

259 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

P092 ABSENCE OF INFLUENCE OF THE PRE- TRANSPLANT IMMUNE 09:15 - 09:15

STATUS OF RECIPIENTS ON SURVIVALS AND GVHD AFTER
ALLOGENEIC STEM CELL TRANSPLANTATION: A
RETROSPECTIVE STUDY OF 195 CASES
Speaker: Thierry Guillaume, FR

P097 DEFIBROTIDE AS TREATMENT FOR TRANSPLANT- 09:15 - 09:15

ASSOCIATED MICROANGIOPATHY (TA-TAM) IN PEDIATRIC
PATIENTS: A SINGLE CENTER EXPERIENCE
Speaker: Danilo De Novellis, IT

P096 IMPACT OF COVID 19 PANDEMIC ON HSCT ACTIVITIES: 09:15 - 09:15

REPORT FROM A SINGLE CENTER
Speaker: Sabrina Giammarco, IT

P095 IS HAPLOIDENTICAL HAEMATOPOIETIC STEM CELL 09:15 - 09:15

TRANSPLANTATION (HAPLO SCT) USING POST-
TRANSPLANTATION CYCLOPHOSPHAMIDE (PTCY) FEASIBLE
IN SUB-SAHARAN AFRICA?
Speaker: Justin du Toit, ZA

P099 IMPACT OF CYTOGENETIC AND MOLECULAR RISK AT 09:15 - 09:15

DIAGNOSIS ON TRANSPLANTATION RESULTS IN PATIENTS
WITH SECONDARY ACUTE MYELOID LEUKEMIA
Speaker: Claudia Núñez-Torrón, ES

P098 THE IMPACT OF CRYOPRESERVATION ON HAEMATOPOIETIC 09:15 - 09:15

STEM CELL GRAFTS DURING THE COVID-19 PANDEMIC AT
THE ROYAL MARSDEN HOSPITAL
Speaker: Sandra Easdale, GB

P102 EBV COLITIS POST HEMATOPOIETIC STEM CELL 09:15 - 09:15

TRANSPLANTATION IN PATIENT WITH APLASTIC ANEMIA
Speaker: Lucia Prezioso, IT

P100 BURNOUT SYNDROME IN ONCOLOGY PRACTICE: 09:15 - 09:15

EXPERIENCE OF A LARGE HSCT CENTER
Speaker: Irina Artemeva, RU

P103 MORBIDITY AND MORTALITY OF T- CELL LYMPHOMAS 09:15 - 09:15

UNDERGOING AUTOLOGOUS STEM CELL TRANSPLANTATION
(ASCT)
Speaker: Carolina Lilibeth Moreira-Ponce, MX

P101 FACTORS AFFECTING OUTCOMES IN CHILDREN WITH ACUTE 09:15 - 09:15

LEUKEMIA POST HEMATOPOIETIC STEM CELL
TRANSPLANTATION – A RETROSPECTIVE STUDY FROM A
TERTIARY REFERRAL CENTRE IN INDIA
Speaker: Rumesh Chandar, IN

P104 BRENTUXIMAB VEDOTIN STRATEGIES FOR RELAPSED OR 09:15 - 09:15

REFRACTORY HODGKIN'S LYMPHOMA AND HEMATOPOIETIC
STEM CELL TRANSPLANTATION
Speaker: Katheryn Garzón-Velásquez, MX

260 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

P106 EHEALTH AS A TOOL IN HEMATOPOIETIC STEM CELL 09:15 - 09:15

TRANSPLANTATION: A NARRATIVE REVIEW
Speaker: Claudia Lucía Sossa Melo, CO

P105 STAFF EXPERIENCES AND LEARNING FROM WORKING ON A 09:15 - 09:15

HAEMATOLOGICAL STEM CELL TRANSPLANT WARD DURING
COVID-19
Speaker: Sarah Airdrie, GB

Poster Sessions
09:15 - 17:30 ePoster Area
Haemoglobinopathy
P107 THE VALUE OF ROUTINE PRE-TRANSPLANT RADIOLOGICAL 09:15 - 09:15
SCREENING IN PEDIATRIC SICKLE CELL DISEASE PATIENTS:
A SINGLE CENTER EXPERIENCE
Speaker: Mohammed Essa, SA

P108 HOW TO FACILITATE DECISION-MAKING FOR 09:15 - 09:15

HEMATOPOIETIC STEM CELL TRANSPLANTATION IN
PATIENTS WITH HEMOGLOBINOPATHIES - THE
PERSPECTIVES OF HEALTH CARE PROFESSIONALS
Speaker: Hilda Mekelenkamp, NL

P109 ENDOCRINE SEQUELAE IN PEDIATRIC HEMATOPOIETIC STEM 09:15 - 09:15

CELL TRANSPLANT RECIPIENTS WITH SICKLE CELL DISEASE:
A RETROSPECTIVE COHORT ANALYSIS
Speaker: Richelle Waldner, CA

P110 DECISION-MAKING FOR HEMATOPOIETIC STEM CELL 09:15 - 09:15

TRANSPLANTATION IN PEDIATRIC, ADOLESCENT AND
YOUNG ADULT PATIENTS WITH A HEMOGLOBINOPATHY –
SHARED OR NOT?
Speaker: Hilda Mekelenkamp, NL

Poster Sessions
09:15 - 17:30 ePoster Area
Immunodeficiency Diseases and Macrophages
P111 CLINICAL MANIFESTATION AND MECHANISMS OF GRAFT 09:15 - 09:15
FAILURE IN PRIMARY IMMUNODEFICIENCY PATIENTS AFTER
HEMATOPOIETIC STEM CELL TRANSPLANTATION
Speaker: Aishat Idarmacheva, RU

P112 OUTCOMES OF HAEMATOPOIETIC STEM CELL 09:15 - 09:15

TRANSPLANTATION IN CHILDREN WITH ZETA CHAIN
ASSOCIATED PROTEIN KINASE 70KDA DEFICIENCY
Speaker: Liam Reilly, GB

P113 ALLOGENEIC HEMATOPOIETIC STEM CELL 09:15 - 09:15

TRANSPLANTATION IN A PATIENT WITH CLERICUZIO
SYNDROME (POIKILODERMA WITH NEUTROPENIA)
Speaker: Alexandra Burya, RU

261 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

Poster Sessions
09:15 - 17:30 ePoster Area
Stem Cell Source
P216 THE BLOOD DONATION BEFORE BONE MARROW HARVEST 09:15 - 09:15
HAS NO IMPACT ON EFFICIENCY OF COLLECTION
Speaker: Iwona Mitrus, PL

P217 UNMANIPULATED HAPLOIDENTICAL TRANSPLANTATION FOR 09:15 - 09:15

HIGH RISK ACUTE LEUKEMIA USING MOBILIZED PERIPHERAL
BLOOD STEM CELLS (PBSC) AS SOURCE OF GRAFT: A
SINGLE CENTER EXPERIENCE
Speaker: Vincenzo Federico, IT

Poster Sessions
09:15 - 17:30 ePoster Area
New Drugs- and Cell-based Immune Therapies
P160 INJECTION-SITE REACTIONS IN THE RANDOMIZED PHASE 3 09:15 - 09:15
PEGASUS TRIAL OF PEGCETACOPLAN COMPARED WITH
ECULIZUMAB FOR INDIVIDUALS WITH PAROXYSMAL
NOCTURNAL HEMOGLOBINURIA
Speaker: Vivek Sharma, US

P161 CLINICAL BURDEN OF ILLNESS SURVEY RESULTS FOR U.S. 09:15 - 09:15
PATIENTS WITH PAROXYSMAL NOCTURNAL
HEMOGLOBINURIA RECEIVING C5 INHIBITORS
Speaker: David Dingli, US

P162 IN ACUTE HSCT/BMT-TMA THE ACTIVATION OF THE LECTIN 09:15 - 09:15

PATHWAY INDUCES C5B-9 FORMATION ON ENDOTHELIAL
CELLS AND FAVORS MICROVASCULAR THROMBOSIS
Speaker: Miriam Galbusera, IT

P165 MEMORY-LIKE NK CELLS AS TREATMENT FOR PEDIATRIC 09:15 - 09:15

SARCOMA
Speaker: Carla Martín-Cortázar, ES

P163 POST-HEMATOPOIETIC STEM CELL TRANSPLANT 09:15 - 09:15

MAINTENANCE TKI'S IN PHILADELPHIA POSITIVE ALL: KING
HUSSEIN CANCER CENTRE EXPERIENCE

P166 PHASE 3 MULTICENTER, DOUBLE-BLIND, PLACEBO- 09:15 - 09:15

CONTROLLED TRIAL OF VIRALYM-M (ALVR105) FOR THE
TREATMENT OF VIRUS?ASSOCIATED HAEMORRHAGIC
CYSTITIS AFTER ALLOGENEIC HAEMATOPOIETIC CELL
TRANSPLANT (HCT) (STUDY DESIGN)
Speaker: Anna Thorner, US

P168 CLINICAL PHARMACOLOGY AND POPULATION 09:15 - 09:15

PHARMACOKINETIC/PHARMACODYNAMIC MODELING OF
LECTIN PATHWAY INHIBITION BY NARSOPLIMAB (OMS721)
Speaker: William Pullman, US

P167 WORK PRODUCTIVITY LOSS AND QUALITY OF LIFE IN 09:15 - 09:15

PAROXYSMAL NOCTURNAL HEMOGLOBINURIA AMONG

262 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

PATIENTS RECEIVING C5 INHIBITORS IN THE UNITED STATES

Speaker: David Dingli, US

Poster Sessions
09:15 - 17:30 ePoster Area
Myeloproliferative Neoplasm

Poster Sessions
09:15 - 17:30 ePoster Area
Myelodysplastic Syndromes
P156 THE ROLE OF AGE IN OUTCOMES OF BONE MARROW 09:15 - 09:15
TRANSPLANTATION IN PATIENTS FROM THE LATIN
AMERICAN REGISTRY
Speaker: Fernando Barroso Duarte, BR

P157 PRE-TRANSPLANT FERRITIN PREDICTS NON-RELAPSE 09:15 - 09:15

MORTALITY IN PATIENTS WITH MYELODYSPLASTIC
SYNDROMES UNDERGOING HEMATOPOIETIC STEM CELL
TRANSPLANTATION
Speaker: Isla Johnson, US

P159 SURVIVAL ANALYSIS IN ALLOGENIC HEMATOPOIETIC STEM 09:15 - 09:15

CELL TRANSPLANTATION IN MYELODYSPLASTIC SYNDROME
AND CHRONIC MYELOMONOCYTIC LEUKEMIA. IMPORTANCE
OF THE PREVIOUS SITUATION

P158 SECONDARY AND TREATMENT-RELATED ACUTE MYELOID 09:15 - 09:15

LEUKEMIA: ALLOGENEIC HEMATOPOIETIC CELL
TRANSPLANTATION REMAINS THE BEST AVAILABLE OPTION
Speaker: Ioanna Sakellari, GR

Poster Sessions
09:15 - 17:30 ePoster Area
Minimal Residual Disease, Tolerance, Chimerism and Immune Reconstitution
P143 EMPIRIC GRANULOCYTE-COLONY STIMULATING FACTOR (G- 09:15 - 09:15
CSF) ADVERSELY IMPACTS SURVIVAL AFTER ALLOGENEIC
STEM CELL TRANSPLANTATION (HCT) PERFORMED WITH
THYMOGLOBULIN: A CIBMTR ANALYSIS
Speaker: Nina Orfali, IE

P144 PREDICTIVE MEANING OF MRD CONVERSION ON DAYS +30 09:15 - 09:15

AND +100 IN PATIENTS WITH AML AFTER ALLO-SCT
Speaker: Nicolaus Kröger, DE

P145 IMPACT OF DIFFERENT T CELL DEPLETION PROTOCOLS ON 09:15 - 09:15

IMMUNE RECONSTITUTION FOLLOWING ALLOGENEIC
HEMATOPOIETIC STEM CELL TRANSPLANTATION
Speaker: Amandine Pradier, CH

P146 MRD VS CHIMERISM: ARE THEIR EFFECTIVENESS 09:15 - 09:15

COMPARABLE TO PREDICT AML RELAPSE?
Speaker: Valérie Dubois, FR

263 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

P148 CELLULAR CHIMERISM – DO REPEATED MARROW BIOPSIES 09:15 - 09:15

OPEN A WINDOW FOR RELAPSE INTERVENTION?
Speaker: Jan Morf, GB

Poster Sessions
09:15 - 17:30 ePoster Area
Stem Cell Mobilization, Collection and Engineering
P206 INTERIM ANALYSIS OF THE OPTIMOB STUDY: A NON- 09:15 - 09:15
INTERVENTIONAL STUDY ACROSS GERMANY TO EVALUATE
THE MOBILIZATION AND COLLECTION OF HSCS IN POOR
MOBILIZERS AHEAD OF ASCT
Speaker: Katharina Kriegsmann, DE

P207 TRENDS IN AUTOLOGOUS STEM CELL MOBILISATION 09:15 - 09:15

PRACTICES IN MYELOMA PATIENTS IN EBMT CENTRES
BETWEEN 2008 AND 2017
Speaker: James Dillon, IE

P208 THE IMPACT OF THE “NEW NORMAL” ON STEM CELL 09:15 - 09:15
LABORATORY PRACTICES
Speaker: Sanja Mazi?, HR

P210 AN ALGORITHMIC APPROACH TO PRE-EMPTIVE PLERIXAFOR 09:15 - 09:15

USAGE WITH GCSF ALONE FOR MOBILIZATION OF
PERIPHERAL BLOOD STEM CELLS IN MULTIPLE MYELOMA
Speaker: Mohamed Elemary, CA

P209 PLERIXAFOR MOBILIZATION OF HEMATOPOIETIC STEM 09:15 - 09:15

CELLS IN DIALYSIS DEPENDENT PATIENTS IS SAFE AND
FEASIBLE; A SINGLE CENTER ANALYSIS
Speaker: Moussab Damlaj, SA

P211 PROGRAM OF HEMATOPOIETIC STEM CELL MOBILIZATION 09:15 - 09:15

AND COLLECTION FOR CHILDREN OF FIRST YEAR OF LIFE
AND WITH LOW BODY WEIGHT: SINGLE CENTER EXPERIENCE
Speaker: Nara Stepanyan, RU

P212 A RETROSPECTIVE RECORD REVIEW OF MOBILIZATION 09:15 - 09:15

STRATEGIES WITH AND WITHOUT PLERIXAFOR FOR
AUTOLOGOUS STEM CELL TRANSPLANT IN PATIENTS WITH
MULTIPLE MYELOMA
Speaker: Joshua Richter, US

P213 PREDICTION OF THE MOBILIZATION SUCCESS FOR 09:15 - 09:15

AUTOLOGOUS PERIPHERAL BLOOD STEM CELL COLLECTION
IN PATIENTS WITH MALIGNANT HEMATOLOGIC DISEASES
Speaker: Maria Eduarda Couto, PT

P214 DOES USE OF BIOSIMILAR ZARZIO CHANGE PLERIXAFOR 09:15 - 09:15

UTILIZATION DURING STEM CELL MOBILIZATION FOR
AUTOLOGOUS STEM CELL TRANSPLANT?
Speaker: Pilar Velarde López de Ayala, ES

P215 AUTOLOGOUS PERIPHERAL BLOOD STEM CELL BACKUP 09:15 - 09:15

264 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

BEFORE HAEMATOPOETIC STEM CELL TRANSPLANTATION

FOR INTERMEDIATE OSTEOPETROSIS: A SINGLE CENTRE
EXPERIENCE
Speaker: Madeleine Powys, AU

Poster Sessions
09:15 - 17:30 ePoster Area
Nurses Posters – Adult
NP01 NURSES’ TRAINING NEEDS FOR ADVANCED THERAPY 09:15 - 09:15
MEDICINAL PRODUCTS EG CAR T: KEY FINDINGS FROM
QUESTIONNAIRE-BASED SURVEY ON BEHALF OF THE
NURSES GROUP OF THE EBMT
Speaker: Michelle Kenyon, GB

NP02 IMPROVEMENT OF ORAL MUCOSITIS IN HEMATOPOIETIC 09:15 - 09:15

STEM CELL TRANSPLANTATION USING POVIDONE-IODINE
MOUTHWASH UNDER DIRECT NURSING SUPERVISION
Speaker: Napassaya Khanthum, TH

NP03 COMPREHENSIVE GERIATRIC ASSESSMENT TO PREDICT 09:15 - 09:15

OUTCOMES IN OLDER PATIENTS RECEIVED CAR-T CELL
THERAPY
Speaker: Mercedes Montoro-Lorite, ES

NP04 CAR-T - RECOGNITION AND TREATMENT MANAGEMENT OF 09:15 - 09:15

NEUROLOGIC TOXICITIES AND CYTOKINE RELEASE
SYNDROME
Speaker: Naama Nevo, IL

NP05 HOME PLATELET TRANSFUSION IN AUTOLOGOUS STEM- 09:15 - 09:15

CELL TRANSPLANTATION: IMPROVING HOME-CARE
STRATEGIES DURING SARS-COV-2 PANDEMIC
Speaker: Laura Villa Rodríguez, ES

NP06 IMPROVING LONG-TERM QUALITY OF LIFE FOR PATIENTS 09:15 - 09:15

LIVING WITH MULTIPLE MYELOMA: A SERVICE EVALUATION
Speaker: Sarah Henshaw, GB

NP07 AT-HOME HEMATOPOIETIC STEM CELL TRANSPLANTATION 09:15 - 09:15

DURING SARS-CoV-2 PANDEMIC

NP08 THE NURSING SEARCH COORDINATOR (NSC) OF THE ROME 09:15 - 09:15
TRANSPLANT NETWORK (RTN), A JACIE ACCREDITED
METROPOLITAN TRANSPLANT PROGRAM
Speaker: Antonio Bruno, IT

NP10 PREVENTION OF NOSOCOMIAL SARS-COV2 INFECTIONS 09:15 - 09:15

AMONG HEMATOLOGICAL PATIENTS JUST BY FOLLOWING
WELL ESTABLISHED NURSING CARE STANDARDS
Speaker: Isabel Salcedo, ES

NP11 A TALE OF 2 COLLECTIONS: CAR -T ‘V' PBSC. OUR SINGLE 09:15 - 09:15
CENTRE EXPERIENCE
Speaker: Caroline Jupp, GB

265 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

NP12 CREATION OF THE FIRST COURSE ON HEMATOPOIETIC STEM 09:15 - 09:15

CELL TRANSPLANTATION (HSCT) NURSING IN LATIN
AMERICAN. ARGENTINE SOCIETY OF HEMATOLOGY
Speaker: Mariela Blanco, AR

NP13 MANAGEMENT OF PATIENTS SUFFERING FROM AN HEMATO- 09:15 - 09:15

ONCOLOGY MALIGNANCY AND THOSE UNDERGOING
HEMATOPOIETIC CELL TRANSPLANTATION DURING THE
COVID-19. HOW DO WE PROTECT THEM?
Speaker: Anna Serrahima - Mackay, ES

NP14 PREVENTION OF ORAL MUCOSITIS WITH CRYOTHERAPY IN 09:15 - 09:15

ADULT PATIENTS UNDERGOING HEMATOPOIETIC STEM CELL
TRANSPLANTATION
Speaker: Bakhtawar Altaf Hussain, PK

NP15 COVID-19 CHALLENGES – TO THE POINT OF CELL DELIVERY - 09:15 - 09:15

THE REALITY
Speaker: Lindsey Ashton, GB

NP16 TRANSITION FROM PAEDIATRIC TO THE ADULT CLINIC IN 09:15 - 09:15

SICKLE CELL DISEASE: THE ROLE OF THE SPECIALISED
NURSE
Speaker: Marijke Quaghebeur, BE

NP09 EBMT (GEC) & LABMT COLLABORATION PROJECTT. LABMT 09:15 - 09:25
NURSES GROUP 2020 CONTINUING EDUCATION PROGRAM
Speaker: Mariela Blanco, AR

Poster Sessions
09:15 - 17:30 ePoster Area
Stem Cell Donor
P203 HAPLOIDENTICAL VS HLA-MATCHED RELATED DONOR HSCT 09:15 - 09:15
FOR ACUTE LEUKEMIA AND MYELODYSPLASTIC SYNDROME:
A SINGLE-CENTER COMPARISON
Speaker: Alisa Lörsch, DE

P204 CLINICAL OUTCOMES IN ALLOGENIC HEMATOPOIETIC STEM 09:15 - 09:15

CELL TRANSPLANTATION FROM ALTERNATIVE DONORS:
SINGLE CENTER EXPERIENCE WITH 9/10 HLA-MISMATCHED
UNRELATED, DOUBLE UMBILICAL CORD BLOOD AND
HAPLOIDENTICAL DONORS
Speaker: Claudie Roy, CA

P205 HAPLOIDENTICAL STEM CELL TRANSPLANTATION WITH 09:15 - 09:15

POST-TRANSPLANT CYCLOPHOSPHAMIDE FOR PATIENTS
WITH HIGH-RISK HEMATOLOGIC MALIGNANCIES. A SINGLE
CENTER EXPERIENCE IN MEXICO
Speaker: Katheryn Garzón-Velásquez, MX

Poster Sessions
09:15 - 17:30 ePoster Area
Nurses Posters – Paediatric

266 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

NP17 NURSING INTERVENTIONS TO PREVENT HYPERTENSIVE 09:15 - 09:15

EMERGENCIES IN CHILDREN UNDERGOING HEMATOPOIETIC
STEM CELL TRANSPLANTATION
Speaker: Deepa Karmegam, IN

NP18 NEUROLOGICAL ASSESSMENT IN PAEDIATRIC PATIENTS 09:15 - 09:15

AFTER CAR-T INFUSION
Speaker: Giulia Del Giorno, IT

NP19 THE WORK OF THE REHABILITATION DEPARTMENT WITH 09:15 - 09:15

VOLUNTEERS DURING THE COVID-19 PANDEMIC
Speaker: Rashida Bikulova, RU

NP20 EVALUATION OF THE EFFECTIVENESS OF NASOGASTRIC 09:15 - 09:15

CATHETERIZATION AS A MEASURE OF NUTRITIONAL
SUPPORT IN PEDIATRIC PATIENTS UNDERGOING
ALLOGENEIC HEMATOPOIETIC STEM CELLS
TRANSPLANTATION
Speaker: Eugenia Trigoso Arjona, ES

NP21 NURSING CARE FOR ACUTE LEUKEMIA CHILDREN WITH 09:15 - 09:15
COMPLICATED BCG VACCINATION DURING CHEMOTHERAPY.
DESCRIPTION OF CLINICAL CASES
Speaker: Anton Silov, RU

NP22 INFUSION OF CHIMERIC ANTIGEN RECEPTOR T CELL (CAR-T 09:15 - 09:15

CELL) THERAPY IN PAEDIATRIC PATIENTS RECEIVING: ONE-
CENTER EXPERIENCE
Speaker: Alba Fernandez-Arroyo Garcia, ES

NP23 IMPLEMENTATION OF THE ADVANCED CELL THERAPY 09:15 - 09:15

PROGRAM:  EXPERIENCE AT LA PAZ UNIVERSITY
HOSPITAL
Speaker: Alba Fernandez-Arroyo Garcia, ES

Poster Sessions
09:15 - 17:30 ePoster Area
Nurses Posters – Research
NP24 ROLE OF NURSING IN THE CARE OF PATIENT’S SKIN WITH 09:15 - 09:15
CUTANEOUS CHRONIC GRAFT-VERSUS-HOST DISEASE
AFTER ALLOGENEIC HAEMOPOIETIC STEM CELL
TRANSPLANTATION: A QUESTIONNAIRE?BASED SURVEY
Speaker: Jacqui Stringer, GB

NP25 INTRAVENTRICULAR INJECTIONS VIA OMMAYA RESERVOIR 09:15 - 09:15

MAY BE PERFORMED BY A TRAINED NURSE AS A PART OF
PEDIATRIC NEUROONCOLOGY TRANSPLANT TEAM EFFORT
Speaker: Lubov Shepeleva, RU

NP26 THE ROLE OF A NURSE IN NUTRITIONAL COUNSELING 09:15 - 09:15

DEVELOPMENT IN HEMATOPOIETIC STEM CELL
TRANSPLANTATION: FROM PRACTICE TO SCIENCE
Speaker: Natalya Rotan, RU

267 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

NP27 LONG TERM SURVIVORS AFTER ALLOGENEIC 09:15 - 09:15

HAEMATOPOIETIC STEM CELL TRANSPLANTATION IN
CHILDHOOD AND ADOLESCENCE IN A DEVELOPING
COUNTRY: HOW ARE THEY NOW?
Speaker: Priscila Oliveira da Silva, BR

NP28 EPIDEMIOLOGICAL SCREENING FOR BACTERIAL DRUG 09:15 - 09:15

RESISTANCE IN CANDIDATES FOR ALLO-HSCT AND MEDICAL
EMPLOYEES OF HEMATOLOGICAL DEPARTMENTS
Speaker: Olga Prokofieva, RU

NP29 EARLY CORONAVIRUS WARNING SCORE IN HEMATOLOGY 09:15 - 09:15

DISEASES
Speaker: Silvia Sangüesa Domínguez, ES

Poster Sessions
09:15 - 17:30 ePoster Area
Pharmacology
P195 PRELIMINARY SAFETY AND EFFICACY OF ITOLIZUMAB, A 09:15 - 09:15
NOVEL TARGETED ANTI-CD6 THERAPY, IN NEWLY
DIAGNOSED SEVERE ACUTE GRAFT-VERSUS-HOST DISEASE:
INTERIM RESULTS FROM THE EQUATE STUDY
Speaker: John Koreth, US

P196 EVALUATION OF A LIMITED SAMPLING STRATEGY IN THE 09:15 - 09:15

THERAPEUTIC DRUG MONITORING OF BUSULFAN
Speaker: Bushra Salman, OM

P197 A NOVEL SHORT HALF-LIFE ANTI-HUMAN CD117-AMANITIN 09:15 - 09:15

ADC EXHIBITS DUAL HSCT CONDITIONING AND ANTI-
LEUKEMIA ACTIVITY AND EXTENDS SURVIVAL IN MULTIPLE
PRECLINICAL MODELS OF AML
Speaker: Leanne Lanieri, US

P199 PHARMACOKINETIC ANALYSIS OF BARICITINIB IN PHASE 1-2 09:15 - 09:15

STUDY FOR TREATMENT REFRACTORY CHRONIC GRAFT-
VERSUS-HOST DISEASE
Speaker: Sara M. Zimmerman, US

P198 THE IMPACT OF LETERMOVIR PRESCRIBING ON THE RATE OF 09:15 - 09:15

CYTOMEGALOVIRUS REACTIVATION FOLLOWING
ALLOGENEIC STEM CELL TRANSPLANTATION
Speaker: Siobhan Smith, GB

Poster Sessions
09:15 - 17:30 ePoster Area
Solid Tumours
P200 HIGH DOSE CHEMOTHERAPY AND STEM-CELL TRANSPLANT 09:15 - 09:15
FOR RELAPSED GERM CELL TUMORS: MULTICENTRIC REAL-
WORLD EXPERIENCE IN ARGENTINA
Speaker: Adriana Vitriu, AR

268 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

Poster Sessions
09:15 - 17:30 ePoster Area
Statistics
P201 EVALUATION OF MACHINE LEARNING ALGORITHMS 09:15 - 09:15
APPLICABILITY FOR GRAFT FAILURE PREDICTION
Speaker: Evgeny Bakin, RU

P202 WHITE MATTER DEVELOPMENT IN NEONATES WITH 09:15 - 09:15

INFANTILE KRABBE DISEASE
Speaker: Maria Escolar, US

Poster Sessions
09:15 - 17:30 ePoster Area
Non-infectious Early Complications
P169 POST HEMATOPOIETIC PROGENITORS TRANSPLANT 09:15 - 09:15
LYMPHOMA (PTLD) AND REPLICATION OF EPSTEIN-BARR
VIRUS (EBV): A CENTER'S EXPERIENCE
Speaker: Sara Garrido, ES

P171 CLINICAL OUTCOME OF PATIENTS WITH IMMUNE-MEDIATED 09:15 - 09:15

PLATELET REFRACTORINESS UNDERGOING HEMATOPOIETIC
STEM CELL TRANSPLANTATION. SINGLE CENTER
EXPERIENCE

P170 ANALYSIS OF THE GUT MICROBIOME IN PEDIATRIC PATIENTS 09:15 - 09:15

UNDERGOING ALLOGENEIC HEMATOPOIETIC STEM CELL
TRANSPLANTATION (HSCT) PRESENTING VENO-OCCLUSIVE
DISEASE (VOD/SOS) REVEALS AN IMPAIRED MICROBIAL
ECOSYSTEM
Speaker: Daniele Zama, IT

P172 HEMORRHAGIC CYSTITIS DURING ALLOGENEIC STEM CELL 09:15 - 09:15

TRASPLANTATION: A POSSIBLE ROLE FOR PROSTATIC
HYPERPLASI
Speaker: Eugenio Galli, IT

P173 THROMBOTIC EVENTS IN HEMATOPOIETIC TRANSPLANT 09:15 - 09:15

RECPIENTS: SINGLE CENTER EXPERIENCE
Speaker: Carlota Mayor Bastida, ES

P175 EVALUATION OF INTESTINAL PERMEABILITY IN CANDIDATES 09:15 - 09:15

FOR ALLOHCT AND IN EARLY POST-TRANSPLANT PERIOD BY
SUGAR ABSORBTION TEST: INTERIM ANALYSIS OF THE
SINGLE-CENTER PROSPECTIVE STUDY
Speaker: Grzegorz Basak, PL

P176 ANICTERIC PRESENTATION OF SEVERE HEPATIC VENO- 09:15 - 09:15

OCCLUSIVE DISEASE (VOD) WITH MULTIORGAN
DYSFUNCTION (MOD)- A PEDIATRIC CASE REPORT
Speaker: Zofia Szmit, PL

269 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

Poster Sessions
09:15 - 17:30 ePoster Area
Paediatric Issues
P183 POST-TRANSPLANT CYCLOPHOSPHAMIDE AFTER 09:15 - 09:15
ALLOGENEIC HEMATOPOETIC STEM CELL
TRANSPLANTATION FOR PEDIATRIC HODGKIN LYMPHOMA
Speaker: Andrey Kozlov, RU

P185 RISK FACTORS AND SURVIVAL OF GRAFT FAILURE IN 09:15 - 09:15

PEDIATRIC PATIENTS WITH HEMATOLOGICAL MALIGNANCIES
TREATED WITH ALLOGENEIC HEMATOPOIETIC STEM-CELL
TRANSPLANTATION FROM HAPLOIDENTICAL DONORS USING
EXVIVO T-CELL-DEPLETION
Speaker: Iván López Torija, ES

P184 FREQUENCY AND CAUSES OF DEATH AFTER 09:15 - 09:15

HEMATOPOIETIC STEM CELL TRANSPLANTATION IN
CHILDREN WITH NON-MALIGNANT DISEASES
Speaker: Koray Yalcin, TR

P186 SVEGF-R1 LEVELS ARE ASSOCIATED WITH ENDOTHELIAL 09:15 - 09:15

DYSFUNCTION AFTER PEDIATRIC HEMATOPOIETIC STEM
CELL TRANSPLANTATION
Speaker: Denise Elbæk, DK

P187 LATE ENDOCRINE EFFECTS AFTER HSCT IN CHILDREN WITH 09:15 - 09:15
NONMALIGNANT DISEASES: A SINGLE CENTER COHORT
ANALYSIS
Speaker: Joëll Esmée Bense, NL

P188 PROSPECTIVE MULTICENTER STUDY OF A REDUCED- 09:15 - 09:15

TOXICITY MYELOABLATIVE CONDITIONNING REGIMEN USING
FLUDARABINE AND FULL DOSES OF IV BUSULFAN IN
PEDIATRIC PATIENTS NOT ELIGIBLE FOR MYELOABLATIVE
REGIMENS
Speaker: Fanny Rialland, FR

P189 TCR ALFA/BETA DEPLETION FOR HSCT FROM UNRELATED 09:15 - 09:15
DONOR IN PEDIATRIC PATIENTS
Speaker: Luisa Sisinni, ES

P190 SARS-COV-2 SEROLOGICAL STATUS OF PEDIATRIC HSCT 09:15 - 09:15

RECIPIENTS: A SINGLE CENTER EXPERIENCE
Speaker: Charlotte Nazon, FR

P191 SAFETY AND PERFORMANCE OF CENTRAL VENOUS 09:15 - 09:15

CATHETERS IN PEDIATRIC LEUKAPHERESIS: A SINGLE
CENTRE EXPERIENCE
Speaker: Sofia Martin-Consuegra, ES

P192 TREOSULFAN – BASED CONDITION REGIMEN FOR STEM CELL 09:15 - 09:15
TRANSPLANTATION IN PATIENTS WITH DIAMOND –
BLACKFAN ANEMIA
Speaker: Svetlana Radygina, RU

270 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

P193 ALLO-HSCT IN TREATMENT OF TP53 MUTATION-RELATED 09:15 - 09:15

MDS/AML IN PEDIATRIC PATIENTS – REPORT OF TWO CASES
Speaker: Maksymilian Deregowski, PL

P194 CENTRAL LINE REMOVAL IN ALLOGENIC PEDIATRIC 09:15 - 09:15

HEMATOPOIETIC STEM CELL TRANSPLANT PATIENTS
Speaker: Taylor Fitch, US

Poster Sessions
09:15 - 17:30 ePoster Area
Non-infectious Late Effects, Quality of Life and Fertility
P177 IMPACT OF AGE IN EARLY AND LATE COMPLICATIONS AFTER 09:15 - 09:15
AN ALLOGENEIC TRANSPLANT IN ELDERLY PATIENTS
Speaker: Magdalena Corona de Lapuerta, ES

P178 OSTEONECROSIS IN PATIENTS UNDERGOING 09:15 - 09:15

HEMATOPOIETIC STEM CELLS TRANSPLANT: A SINGLE-
CENTRE STUDY OF INCIDENCE, RISK FACTORS,
CHARACTERISTICS AND EVOLUTION
Speaker: Giulia Prunotto, IT

P179 SECONDARY MALIGNANCIES AFTER AUTOLOGOUS 09:15 - 09:15

HEMATOPOIETIC STEM CELL TRANSPLANTATION
Speaker: João Gaião Santos, PT

P181 ANXIETY SYMPTOMATOLOGY PROGRESSION IN PATIENTS 09:15 - 09:15

WITH DIAGNOSIS OF MALIGNANT HEMATOLOGICAL
PATHOLOGY WHO ARE CANDIDATES TO RECEIVE INTENSIVE
CHEMOTHERAPY
Speaker: Walter Javier Zambrano Marquez, ES

P180 SECONDARY MALIGNANCIES AFTER ALLOGENEIC HSCT IN 09:15 - 09:15

CHILDREN
Speaker: Yulia Skvortsova, RU

P182 AN UNUSUAL PRESENTATION OF AUTOIMMUNE DISORDERS 09:15 - 09:15

AFTER ALLOGENEIC STEM CELL TRANSPLANTATION –
AMYOPATHIC DERMATOMYSISTIS, PRIMARY BILIARY
CHOLANGITIS AND AUTOIMMUNE HAEMOLYTIC ANAEMIA
Speaker: Pedro de Vasconcelos M, PT

Poster Sessions
09:15 - 17:30 ePoster Area
Multiple Myeloma
P149 HIGH-DOSE MELPHALAN AND AUTOLOGOUS STEM CELL 09:15 - 09:15
TRANSPLANTATION IN ELDERLY PATIENTS ? 70 YEARS IS
SAFE AND EFFECTIVE – A RETROSPECTIVE ANALYSIS
Speaker: Udo Holtick, DE

P150 PEGYLATED G-CSF VERSUS G-CSF FOLLOWING HD-CTX FOR 09:15 - 09:15
PBSC MOBILIZATION AND HEMATOPOIETIC RECONSTITUTION
AFTER ASCT IN NEWLY DIAGNOSED MULTIPLE MYELOMA

271 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

PATIENTS
Speaker: Meilan Chen, CN

P152 RECOMBINANT HUMAN THROMBOPOIETIN IMPROVED 09:15 - 09:15

PLATELET ENGRAFTMENT AFTER AUTOLOGOUS
HEMATOPOIETIC STEM CELL TRANSPLANTATION IN
PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA
Speaker: Jingli Gu, CN

P151 AUTOLOGOUS STEM CELL TRANSPLANTATION FOR ELDERLY 09:15 - 09:15

MULTIPLE MYELOMA PATIENTS – A SAFETY OPTION
Speaker: Rita Sousa Gomes, PT

P153 CLINICAL IMPLICATIONS OF ?? T CELL RECONSTITUTION 09:15 - 09:15

AFTER AUTOLOGOUS HEMATOPOIETIC STEM CELL
TRANSPLANTATION IN PATIENTS WITH MULTIPLE MYELOMA
Speaker: Carolina Afonso, PT

P155 INDUCTION RESPONSE SEEMS TO BE A PROGNOSTIC 09:15 - 09:15

FACTOR FOR PROGRESSION-FREE SURVIVAL AFTER
AUTOLOGOUS STEM CELL TRANSPLANTATION IN PATIENTS
WITH MUTIPLE MYELOMA
Speaker: Pilar Velarde López de Ayala, ES

Poster Sessions
09:15 - 17:30 ePoster Area
ePoster Area

Poster Sessions
09:15 - 17:30 ePoster Area
Acute Leukaemia
P001 MEASURABLE RESIDUAL DISEASE, FLT3-ITD MUTATION AND 09:15 - 09:15
DISEASE STATUS HAVE INDEPENDENT PROGNOSTIC
INFLUENCE ON POST-TRANSPLANT OUTCOMES IN
NPM1-MUTATED ACUTE MYELOID LEUKEMIA
Speaker: Rama Al Hamed, US

P002 ROLE OF ALLO-HSCT AS CONSOLIDATION OF MRD-NEGATIVE 09:15 - 09:15

REMISSION IN R/R B-ALL AFTER TREATMENT WITH
MONOCLONAL ANTIBODIES
Speaker: Inna Markova, RU

P003 AZACYTIDINE AND DONOR LYMPHOCYTE INFUSIONS (DLI) AS 09:15 - 09:15

SALVAGE TREATMENT IN PATIENTS WITH AML AND MDS
RELAPSED AFTER ALLOGENEIC STEM CELL
TRANSPLANTATION: A RETROSPECTIVE SINGLE CENTER
ANALYSIS
Speaker: Semra Aydin, IT

P004 T-CELL-DEPLETE ALLOGENEIC HAEMATOPOIETIC STEM CELL 09:15 - 09:15

TRANSPLANT AFTER REDUCED-INTENSITY CONDITIONING
FOR MYELOID MALIGNANCIES IN THE OVER-65S – A SINGLE
CENTRE EXPERIENCE OF 90 PATIENTS

272 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

Speaker: Alexandros Kanellopoulos, GB

P005 POST-REMISSION TREATMENT PATTERNS FOR PATIENTS 09:15 - 09:15

WITH NEWLY DIAGNOSED (ND) ACUTE MYELOID LEUKEMIA
(AML) IN THE CONNECT® MDS/AML DISEASE REGISTRY

P006 ALLOGENEIC STEM CELL TRANSPLANTATION IN FIRST 09:15 - 09:15

COMPLETE REMISSION IS ASSOCIATED WITH SUPERIOR
OUTCOMES IN ACUTE MYELOID LEUKEMIA INDEPENDENT OF
RECIPIENT AGE AND DONOR TYPE
Speaker: Tatiana Tzenou, GR

P007 GILTERITINIB MONOTHERAPY IN RELAPSED OR 09:15 - 09:15

REFRACTORY ACUTE MYELOID LEUKEMIA FLT3+ IN ADULT
PATIENTS
Speaker: Sergey Bondarenko, RU

P009 ZUMA-4: A PHASE 1/2 MULTICENTER STUDY OF KTE-X19 IN 09:15 - 09:15

PEDIATRIC AND ADOLESCENT PATIENTS WITH
RELAPSED/REFRACTORY B CELL ACUTE LYMPHOBLASTIC
LEUKEMIA (ALL) OR NON-HODGKIN LYMPHOMA (NHL)
Speaker: Alan S. Wayne, US

P008 VENETOCLAX COMBINED WITH AZACITIDINE OR LOW-DOSE 09:15 - 09:15

CYTARABINE FOR RELAPSED ACUTE MYELOID LEUKAEMIA
POST ALLOGENEIC STEM CELL TRANSPLANT
Speaker: Sandra Easdale, GB

P010 LONG-TERM OUTCOME OF ALLOGENEIC STEM CELL 09:15 - 09:15

TRANSPLANTATION IN PATIENTS WITH ACUTE MYELOID
LEUKEMIA – FOCUS ON MORTALITY
Speaker: Anna Lojko-Dankowska, PL

P011 SORAFENIB MAINTENANCE AFTER HEMATOPOIETIC STEM 09:15 - 09:15

CELL TRANSPLANTATION IMPROVES OUTCOME OF FLT3-ITD
POSITIVE ACUTE MYELOID LEUKEMIA
Speaker: Semra Aydin, IT

P012 BASELINE SOMATIC MUTATIONS PREDICT DISEASE FREE 09:15 - 09:15

SURVIVAL AFTER ALLOGENEIC STEM CELL
TRANSPLANTATION IN ACUTE MYELOID LEUKEMIA: A
RETROSPECTIVE MONOCENTRIC REPORT
Speaker: Elisabetta Metafuni, IT

P013 UNMANIPULATED HAPLOIDENTICAL HEMATOPOIETIC STEM 09:15 - 09:15

CELL TRANSPLANTATION IN ADULT PATIENTS WITH ACUTE
MYELOID LEUKEMIA
Speaker: Sergey Bondarenko, RU

P014 SURVIVAL OF PATIENTS WITH ACUTE MYELOID LEUKEMIA, 09:15 - 09:15

TAKEN TO HEMATOPOIETIC STEM CELL TRANSPLANTATION:
EXPERIENCE OF A CENTER IN COLOMBIA
Speaker: Claudia Lucía Sossa Melo, CO

273 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

Poster Sessions
09:15 - 17:30 ePoster Area
Conditioning Regimens
P036 OUTCOMES OF ALLOGENEIC HEMATOPOIETIC CELL 09:15 - 09:15
TRANSPLANTATION IN ELDERLY PATIENTS: IS AGE THE
LIMIT?
Speaker: Sara Fernández-Luis, ES

P037 THE IMPACT OF MELPHALAN DE-ESCALATION ON EFFICACY 09:15 - 09:15

AND SAFETY IN PATIENTS WITH MULTIPLE MYELOMA
UNDERGOING AUTOLOGOUS STEM CELL
TRANSPLANTATION: A SINGLE-CENTER EXPERIENCE
Speaker: Bartosz Malecki, PL

P038 CONDITIONING WITH HIGH DOSE TOTAL BODY IRRADIATION 09:15 - 09:15
AND POST TRANSPLANTATION CYCLOPHOSPHAMIDE IN
EARLY RELAPSED MULTIPLE MYELOMA PATIENTS
RECEIVING ALLOGENEIC STEM CELL TRANSPLANTATION
Speaker: Jaap van Doesum, NL

P039 PREVENTING AKI IN TRANSPLANT FOR PAEDIATRIC ALL 09:15 - 09:15

WITH TBI AND ETOPOSIDE CONDITIONING
Speaker: Jane E Potter, GB

P040 ENHANCED IMMUNOSUPPRESSION IN T-CELL REPLETE 09:15 - 09:15

HAPLOIDENTICAL TRANSPLANTATION WITH POST-
TRANSPLANT CYCLOPHOSPHAMIDE IS ASSOCIATED WITH
FAVORABLE OUTCOMES

P041 LONG-TERM SAFETY AND EFFICACY OF A MYELOABLATIVE 09:15 - 09:15

CONDITIONING REGIMEN OF REDUCED TOXICITY IN
ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION
Speaker: Ioanna Sakellari, GR

P042 TREOSULFAN VS. BUSULFAN-BASED REGIMENS IN 09:15 - 09:15

PEDIATRIC PATIENTS: A 7-YEAR RETROSPECTIVE STUDY
Speaker: Raquel Olivas-Mazón, ES

P044 POST-TRANSPLANT CYCLOPHOSPHAMIDE (PTCY) AS GVHD 09:15 - 09:15

PROPHYLAXIS FOR HEMATOPOIETIC STEM CELL
TRANSPLANTATION FROM MATCHED-RELATED SIBLING
DONORS
Speaker: Gabriella Storti, IT

P043 IMMUNE RECONSTITUTION AFTER SEQUENTIAL 09:15 - 09:15

CONDITIONING IN ELDERLY, HIGH-RISK AML AND MDS
PATIENTS: A MATCHED-PAIR ANALYSIS AMONG DIFFERENT
DONOR TYPES
Speaker: Alessia Fraccaroli, DE

Poster Sessions
09:15 - 17:30 ePoster Area
Lymphoma and Chronic Lymphocytic Leukemia
P134 RESULTS WITH ALLOGENEIC STEM CELL TRANSPLANTATION 09:15 - 09:15

274 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

IN PATIENTS WITH RELAPSED/REFRACTORY HODGKIN

LYMPHOMA TREATED WITH ANTI-PD1: A MULTICENTER
RETROSPECTIVE COHORT STUDY
Speaker: Fernando Warley, AR

P133 18FLUOROMETHYLCHOLINE PET/CT TO PREDICT OUTCOMES 09:15 - 09:15

OF PATIENTS PRE AND POST AUTOLOGOUS STEM CELL
TRANSPLANTATION(ASCT) FOR CNS LYMPHOMA – A NEW
CNS LYMPHOMA IMAGING TOOL
Speaker: Sandra Easdale, GB

P135 THE OUTCOMES OF ALLOGENEIC STEM CELLS 09:15 - 09:15

TRANSPLANTATION FOR RELAPSED/REFRACTORY CHRONIC
LYMPHOCYTIC LEUKEMIA IN THE ERA OF TARGETED
THERAPY: SINGLE CENTER EXPERIENCE
Speaker: Ivan Moiseev, RU

P137 STEM CELL TRANSPLANTATION IN MANTLE CELL 09:15 - 09:15

LYMPHOMA: POST-TRANSPLANT OUTCOMES OF TAIWAN
BLOOD AND MARROW TRANSPLANTATION REGISTRY
Speaker: Yu-Hung Wang, TW

P136 NIVOLUMAB 40 MG THERAPY IN RELAPSED AND 09:15 - 09:15

REFRACTORY CLASSICAL HODGKIN LYMPHOMA: RESULTS
OF A SINGLE CENTER MATCHED CASE-CONTROL STUDY
Speaker: Liudmila Fedorova, RU

P138 AUTOLOGOUS HEMATOPOIETIC CELL TRANSPLANTATION 09:15 - 09:15

FOR HIGH GRADE B-CELL LYMPHOMA WITH MYC AND BCL2
AND/OR BCL6 REARRANGEMENTS. A SINGLE INSTITUTION
EXPERIENCE
Speaker: Joanna Romejko-Jarosinska, PL

P142 SUCCESSFUL TREATMENT OF HEPATOSPLENIC T-CELL 09:15 - 09:15

LYMPHOMA WITH INTENSIFIED MYELOABLATIVE
CONDITIONING REGIMENS FOLLOWED BY UNMANIPULATED
HAPLOIDENTICAL HEMATOPOIETIC STEM CELL
TRANSPLANTATION
Speaker: Yan-Li Zhao, CN

P140 POLA-BR AFTER CAR-T CELL THERAPY FAILURE IN R/R 09:15 - 09:15
DIFFUSE LARGE B-CELL LYMPHOMA
Speaker: Ivan Moiseev, RU

P141 NODAL PERIPHERAL T-CELL LYMPHOMA – THE ROLE OF 09:15 - 09:15

CONSOLIDATIVE AUTOLOGOUS STEM CELL
TRANSPLANTATION IN COMPLETE OR PARTIAL FIRST
REMISSION: A 10-YEAR LESSON FROM SINGAPORE GENERAL
HOSPITAL
Speaker: Christopher Shwei Wen Tham, SG

P139 AUTOLOGOUS STEM CELL TRANSPLANT IN NON HODGKIN 09:15 - 09:15

LYMPHOMA AT AIIMS: TRENDS IN TOLERABILITY AND LONG
TERM OUTCOMES
Speaker: Sudhir Kumar, IN

275 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

Poster Sessions
09:15 - 17:30 ePoster Area
Infectious Complications
P118 COMPARISON BETWEEN PRIMARY PROPHYLAXIS AND PRE- 09:15 - 09:15
EMPTIVE THERAPY FOR CITOMEGALOVIRUS AFTER
HEMATOPOIETIC STEM-CELL TRANSPLANTATION
Speaker: Luisa Giaccone, IT

P119 INCIDENCE OF HEMORRHAGIC CYSTITIS FOLLOWING 09:15 - 09:15

HEMATOPOIETIC STEM CELL TRANSPLANTATION IN
PEDIATRIC PATIENTS BASED ON THE UNDERLYING DISEASE
Speaker: Amir Ali Hamidieh, IR

P120 EPIDEMIOLOGY OF RESISTANT AND REFRACTORY 09:15 - 09:15

CYTOMEGALOVIRUS INFECTION FOLLOWING SOLID ORGAN
OR HAEMATOPOIETIC STEM CELL TRANSPLANT: A
SYSTEMATIC REVIEW
Speaker: Aurore Bergamasco, FR

P122 EPIDEMIOLOGY OF INFECTIOUS COMPLICATIONS IN 09:15 - 09:15

PATIENTS WITH CHRONIC GRAFT-VERSUS-HOST DISEASE
Speaker: Aleksandr Siniaev, RU

P121 ANTIBACTERIAL PROPHYLAXIS IN PATIENTS UNDERGOING 09:15 - 09:15

HEMATOPOIETIC STEM CELL TRANSPLANTATION AND
DEVELOPMENT OF INFECTIONS BY ANTIBIOTIC-RESISTANT
BACTERIA
Speaker: Filippo Maraz, IT

P123 CLINICAL AND MICROBIOLOGICAL IMPACT OF 09:15 - 09:15

DISCONTINUATION OF FLUOROQUINOLONE PROPHYLAXIS IN
PATIENTS UNDERGOING HEMATOPOIETIC STEM CELL
TRANSPLANTATION: A SINGLE-CENTRE EXPERIENCE
Speaker: Anke Verlinden, BE

P124 IRON CHELATION WITH DEFERASIROX SUPPRESSES THE 09:15 - 09:15

APPEARANCE OF LPI DURING CONDITIONING
CHEMOTHERAPY PRIOR TO ALLOGENEIC STEM CELL
TRANSPLANTATION
Speaker: Sonja Essmann, DE

P125 SARS-COV-2 INFECTION IN A HEMATOPOIETIC STEM CELL 09:15 - 09:15

TRANSPLANT CENTER: A SINGLE CENTER EXPERIENCE IN
MEXICO
Speaker: Luis Manuel Valero-Saldaña, MX

P126 ANTIBIOTIC PROPHYLAXIS AND THE RATE OF BACTEREMIA 09:15 - 09:15

AND CLOSTRIDIUM DIFFICILE INFECTION IN PEDIATRIC STEM
CELL TRANSPLANTATION: A SINGLE CENTER
RETROSPECTIVE STUDY
Speaker: Mohammed Essa, SA

P128 TOCILIZUMAB IN POST HEMATOPOIETIC STEM CELL 09:15 - 09:15

TRANSPLANT COVID-19: A PEDIATRIC CASE REPORT
Speaker: Tahereh Rostami, IR

276 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

P127 HUMAN POLYOMA BK VIRUS AS A CAUSE OF HEMORRHAGIC 09:15 - 09:15

CYSTITIS: RETROSPECTIVE COHORT STUDY
Speaker: Nikola Pantic, RS

P132 CMV REACTIVATION AFTER ALLOGENIC HEMATOPOIETIC 09:15 - 09:15

STEM CELL TRANSPLANTATION - SINGLE CENTRE
EXPERIENCE
Speaker: Milena Todorovic Balint, RS

P129 PANDEMIC LESSONS OF COVID 19 IN NORTHEAST OF BRAZIL 09:15 - 09:15

Speaker: Fernando Barroso Duarte, BR

P131 SARS-COOV-2 INFECTION IN AN ADOLESCENT PATIENT 09:15 - 09:15

AFTER HAPLOIDENTICAL STEM CELL TRANSPLANTATION
Speaker: Maurizio Caniglia, IT

P130 CLINICAL CHARACTERISTICS AND OUTCOME OF 09:15 - 09:15

POLYMICROBIAL BLOODSTREAM INFECTIONS IN ALLO-SCT
PATIENTS: A MONOCENTRIC 5 YEARS SURVEY
Speaker: Gabriele Facchin, IT

Poster Sessions
09:15 - 17:30 ePoster Area
Inborn Errors
P114 ALLOGENEIC STEM CELL TRANSPLANTATION IN PATIENTS 09:15 - 09:15
WITH MUCOPOLYSACCHARIDOSIS TYPE I (HURLER) WITH
TREOSULFAN-BASED CONDITIONING
Speaker: Matthias Bleeke, DE

P115 LONG-TERM NEURODEVELOPMENTAL, 09:15 - 09:15

NEUROPHYSIOLOGICAL, AND NEURORADIOLOGICAL
OUTCOMES OF HEMATOPOIETIC STEM CELL
TRANSPLANTATION FOR TREATMENT OF LATE-INFANTILE
METACHROMATIC LEUKODYSTROPHY
Speaker: Maria Escolar, US

P116 OUTCOME OF HAEMATOPOIETIC CELL TRANSPLANTATION IN 09:15 - 09:15

CHILDREN WITH LYSOSOMAL ACID LIPASE DEFICIENCY: A
STUDY ON BEHALF OF THE EBMT INBORN ERRORS WORKING
PARTY
Speaker: Su Han Lum, GB

Poster Sessions
09:15 - 17:30 ePoster Area
CAR-based Cellular Therapy – Clinical
P016 HEALTH-RELATED QUALITY OF LIFE IN THE CARTITUDE-1 09:15 - 09:15
STUDY OF CILTACABTAGENE AUTOLEUCEL FOR
RELAPSED/REFRACTORY MULTIPLE MYELOMA
Speaker: Thomas Martin, US

P017 MANUFACTURING COMMERCIAL AXICABTAGENE 09:15 - 09:15

CILOLEUCEL (AXI-CEL) FOR EUROPEAN PATIENTS: A 2-YEAR

277 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

RETROSPECTIVE ANALYSIS
Speaker: Didier Hallard, NL

P015 RETREATMENT WITH AXICABTAGENE CILOLEUCEL (AXI-CEL) 09:15 - 09:15

IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) INDOLENT
NON-HODGKIN LYMPHOMA (INHL) IN ZUMA-5
Speaker: Julio C. Chavez, US

P019 COST-EFFECTIVENESS OF KTE-X19 CAR T THERAPY 09:15 - 09:15

FOLLOWING BRUTON TYROSINE KINASE INHIBITOR
TREATMENT FOR RELAPSED/REFRACTORY MANTLE CELL
LYMPHOMA IN ENGLAND
Speaker: Martin Brown, GB

P018 EXPANSION DYNAMICS DETECTED BY FLOW CYTOMETRY 09:15 - 09:15

CORRELATES WITH CLINICAL RESPONSE AFTER CAR-T CELL
THERAPY IN THE REAL WORLD SETTING
Speaker: Silvia monsalvo, ES

P020 PATIENT EXPECTATIONS AND PERCEPTIONS OF TREATMENT 09:15 - 09:15

IN CARTITUDE-1: PHASE 1B/2 STUDY OF CILTACABTAGENE
AUTOLEUCEL IN RELAPSED/REFRACTORY MULTIPLE
MYELOMA
Speaker: Adam D Cohen, US

P021 CHARACTERIZATION OF INFECTIONS AFTER CHIMERIC 09:15 - 09:15

ANTIGEN RECEPTOR T-CELL THERAPY IN PATIENTS WITH
LARGE B-CELL LYMPHOMA
Speaker: Pere Barba, ES

P022 CLINICAL APPLICATION OF HAPLOIDENTICAL DONOR- 09:15 - 09:15

DERIVED CD19 CAR-T CELLS MANUFACTURED FROM
MEMORY T CELL (CD45RA-DEPLETED) FRACTION
Speaker: Larisa Shelikhova, RU

P024 ICU RESOURCE UTILIZATION IN PEDIATRIC AND 09:15 - 09:15

ADOLESCENT YOUNG ADULT PATIENTS POST CAR-T
THERAPY
Speaker: Dristhi Ragoonanan, US

P023 HEMATOLOGIC RESCUE OF CAR T CELL-MEDIATED 09:15 - 09:15

PROLONGED PANCYTOPENIA USING AUTOLOGOUS
PERIPHERAL BLOOD HEMATOPOIETIC STEM CELLS IN A
LYMPHOMA PATIENT
Speaker: Udo Holtick, DE

P025 ZUMA-19: A PHASE 1/2 MULTICENTER STUDY OF LENZILUMAB 09:15 - 09:15

WITH AXICABTAGENE CILOLEUCEL (AXI?CEL) IN PATIENTS
WITH RELAPSED OR REFRACTORY LARGE B CELL
LYMPHOMA (R/R LBCL)
Speaker: Saad J. Kenderian, US

278 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

Multi-stakeholder Forum on Innovative Cellular Therapies

09:30 - 10:30 Auditorium 6
MSF1 - Multi-stakeholder Forum on Innovative Cellular Therapies - Session 1
Chair: Christian Chabannon, FR
Chair: Rafael Duarte, ES
MSF1-1 Real-world regulatory issues in the implementation of Advanced 09:30 - 09:44
Therapies
Speaker: Teresa Chavarria, ES

MSF1-2 Regulatory issues in a pandemic: The COVID-19 experience 09:44 - 09:58

Speaker: Cesar Hernandez, ES

MSF1-3 The development of new ATMPs from an academic perspective: 09:58 - 10:15
Hurdles and opportunities
Speaker: Collin de Haar, NL

MSF1-4 Q&A 10:15 - 10:30

Breaks
10:30 - 11:00 Auditorium 1
Coffee Break, Poster Viewing, Visit Exhibition

Educational
11:00 - 12:15 Auditorium 1
E07 - CARs in childhood malignancy
Chair: Selim Corbacioglu, DE
Chair: Jose M. Pérez Hurtado, ES
E7-1 CAR therapies for lymphoid malignancies and beyond 11:00 - 11:15
Speaker: Stephan Grupp, US

E7-2 Adapter CAR T-cells: Implications for childhood cancer 11:15 - 11:30
Speaker: Patrick Schlegel, AU

E7-3 CAR NK-cells: The next generation of Cellular Cancer Therapy 11:30 - 11:45
Speaker: May Daher, US

E7-4 Q&A 11:45 - 12:15

Workshop
11:00 - 12:15 Auditorium 2
W06 - Pretransplant risk management for allogeneic HSCT recipients and donors
Chair: Adrián Alegre, ES
Chair: Yela Figuera, ES
W6-1 Patient infectious risk factors: What they are and how to deal 11:00 - 11:15
with them
Speaker: Simone Cesaro, IT

W6-2 Patient comorbidity and organ issues 11:15 - 11:30

Speaker: Jaime Sanz Caballer, ES

W6-3 Donor issues posing a risk for themselves or for patients 11:30 - 11:45
Speaker: Nina Worel, AT

279 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

W6-4 Q&A 11:45 - 12:15

Nurses Group
11:00 - 12:15 Auditorium 3
NG09 - Research session
Chair: Sarah Liptrott, IT
Chair: Jacqui Stringer, GB
NG09-1 Hold on - A Swedish research study regarding support needs 11:00 - 11:15
among family caregivers in allo-HSCT
Speaker: Jeanette Winterling, SE

NG09-2 Getting involved in research: The experience of the junior 11:15 - 11:30
member of the Research Committee
Speaker: Marta Canesi, IT

NG09-3 A publication from scratch: My experience as the Infectious 11:30 - 11:45

Diseases Working Party Nurse
Speaker: Iris Agreiter, IE

NG09-4 EBMT Nurses Group guidelines for abstracts scoring: 11:45 - 12:00
Development and evaluation
Speaker: Isabel Salcedo, ES

NG09-5 Q&A 12:00 - 12:15

Speaker: Hilda Mekelenkamp, NL
Speaker: Sandra Schoenfeld, CH
Speaker: Jacqui Stringer, GB

How do I … ?
11:00 - 12:15 Auditorium 4
HDI4 - How do I... best select patients for CAR T therapies? - Supported through an unrestricted educational g
Chair: Alessandro Rambaldi, IT
HDI4-1 For NHL 11:00 - 11:25
Speaker: Peter Dreger, DE

HDI4-2 For Myeloma 11:25 - 11:50

Speaker: Philippe Moreau, FR

HDI4-3 Q&A 11:50 - 12:15

Data Management
11:00 - 12:15 Auditorium 5
DM02 - Education session 2 - Discussion forum - Med A Live session
Chair: Helen Baldomero, CH
Chair: Shelley Hewerdine, GB
DM2-1 Discussion forum - Med A 11:00 - 11:45
Speaker: Per Ljungman, SE
Speaker: Bertram Glass, DE
Speaker: Johannes Schetelig, DE
Speaker: Eolia Brissot, FR

280 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

DM2-2 Q&A 11:45 - 12:15

Multi-stakeholder Forum on Innovative Cellular Therapies

11:00 - 12:15 Auditorium 6
MSF2 - Multi-stakeholder Forum on Innovative Cellular Therapies - Session 2
Chair: Nicolaus Kröger, DE
Chair: Anna Sureda, ES
MSF2-1 EBMT Clinical Trials Office: Cell Therapy Data Capture 11:00 - 11:15
Speaker: Sofie Terwel, NL

MSF2-2 EMA's Patient Registry Initiative 11:15 - 11:30

Speaker: Xavier Kurz, NL

MSF2-3 How are new cellular therapies being rolled out? 11:30 - 11:45
Speaker: Ibrahim Yakoub-Agha, FR

MSF2-4 Pricing and real-life access to CAR-T therapy in the USA 11:45 - 12:00
Speaker: Inmaculada Hernández Delso, US

MSF2-5 Q&A 12:00 - 12:15

Breaks
12:15 - 13:00 Auditorium 1
Lunch Break, Poster Viewing, Visit Exhibition

Wellness session
12:20 - 12:50 Auditorium 1
Nutrition and healing: The anti-inflammatory plate

Meet the Expert

12:30 - 13:30 MTE rooms
Meet the Expert sessions
MTE-11 Post-transplantation cyclophosphamide as universal GVHD 12:30 - 12:30
prophylaxis - Room MTE1
Speaker: Ephraim Fuchs, US

MTE-12 Gene therapy for inborn errors ´come of age´ in 2021 - Room 12:30 - 12:30
MTE2
Speaker: Alain Fischer, FR

MTE-13 How can we manage DLBCL relapse after CART therapy? - 12:30 - 12:30
Room MTE3
Speaker: Catherine Thieblemont, FR

MTE-14 Managing thalassemia and other inherited disorders with HSCT 12:30 - 12:30
- Room MTE4
Speaker: Franco Locatelli, IT

MTE-15 Allogeneic HSCT in multiple myeloma in the era of new drugs - 12:30 - 12:30
Room MTE5
Speaker: Sergio Giralt, US

281 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

Special Session
13:00 - 14:00 Auditorium 4
SS05 - Health inequalities and equality, diversity and inclusion at EBMT
Chair: Raffaella Greco, IT
Chair: John Murray, GB
SS5-1 Progress in ED&I at the EBMT 13:00 - 13:10
Speaker: Ben Summerskill, GB

SS5-2 What have we learned? 13:10 - 13:20

Speaker: Silvia Montoto, GB

SS5-3 Patient perspectives on health inequalities 13:20 - 13:30

Speaker: Anne-Pierre Pickaert, FR

SS5-4 Health inequalities in BMT – A personal journey 13:30 - 13:40

Speaker: Soulaiman Elias, SY

SS5-5 Q&A 13:40 - 14:00

Data Management
13:00 - 14:00 Auditorium 5
DM03 - Education session 3 - Registry Upgrade and Data Collection news in the EBMT
Chair: Shelley Hewerdine, GB
DM3-1 Presentation 1 13:00 - 13:10
Speaker: Bas Middelkoop, NL

DM3-2 Registry Upgrade and Data Collection news in the EBMT 13:10 - 13:30
Speaker: Per Ljungman, SE

DM3-3 Q&A 13:30 - 14:00

Patient Advocacy Sessions

13:00 - 14:00 Auditorium 6
PA1 - Patient Advocacy: Gathering data and shaping the research via patient inputs
Chair: Andrea Linke, DE
Chair: Natacha Bolaños, ES
PA1-1 Shaping the research via patient inputs 13:00 - 13:15
Speaker: Lars Bullinger, DE

PA1-2 A patient inititated study in autoimmune disease 13:15 - 13:30

Speaker: Ellen Kramer, NL

PA1-3 Patient data and inputs: opportunities, challenges and a way 13:30 - 13:45
forward in 5 examples
Speaker: Hans Scheurer, BE

PA1-4 Round table discussion 13:45 - 14:00

Breaks
14:00 - 14:30 Auditorium 1
Coffee Break, Poster Viewing, Visit Exhibition

282 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

Plenary Session
14:30 - 15:45 Auditorium 1
P3 - Patient Reported Outcomes - A new paradigm in HSCT
Chair: Rafael Duarte, ES
Chair: Helene Schoemans, BE
Chair: Nicolaus Kröger, DE
P3-1 Do PRO predict HSCT outcome? 14:30 - 14:45
Speaker: Bronwen Shaw, US

P3-2 Optimizing the management of GVHD using PRO measures 14:45 - 15:00
Speaker: Rubeta Matin, GB

P3-3 PRO in CAR T-cell therapy 15:00 - 15:15

Speaker: Anna Barata, US

P3-4 Integrating the patient in HSCT research projects 15:15 - 15:30

Speaker: Linda Burns, US

P3-5 Q&A 15:30 - 15:45

Workshop
14:30 - 15:45 Auditorium 2
W07 - Controversies in patients with DLBCL
Chair: Anna Sureda, ES
Chair: Bertram Glass, DE
W7-1 Anything better than R-CHOP for first-line therapy? 14:30 - 14:45
Speaker: Umberto Vitolo, IT

W7-2 Has HSCT come to an end in relapsed disease? 14:45 - 15:00

Speaker: Bertram Glass, DE

W7-3 CAR-T cells in relapsed/refractory DLBCL and beyond 15:00 - 15:15

Speaker: Alberto Mussetti, ES

W7-4 Q&A 15:15 - 15:45

Nurses Group
14:30 - 15:45 Auditorium 3
NG10 - Oral session 1: Abstracts finalists
Chair: Isabel Salcedo, ES
Chair: Laura Vicente, ES
NG10-1 SUPPORTIVE AND PALLIATIVE CARE TEAM (SPCT) 14:30 - 14:40
INVOLVEMENT FOR PATIENTS ELIGIBLE FOR CAR T-CELL
THERAPY
Speaker: Debbie Yeatman, GB

NG10-2 IMPLEMENTATION AND EVALUATION OF A NURSE-ALLIED 14:40 - 14:50

HEALTH CLINIC FOR PATIENTS AFTER ALLOGENEIC
HEMATOPOIETIC STEM CELL TRANSPLANTATION
Speaker: Midori Nakagaki, AU

NG10-3 NURSES’ SLEEP QUALITY AND BURN-OUT LEVEL DURING 14:50 - 15:00

283 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

PHASE 2 OF COVID-19 EMERGENCY IN ITALY: A

MULTICENTRIC CROSS-SECTIONAL STUDY OF GRUPPO
ITALIANO TRAPIANTO DI MIDOLLO OSSEO
Speaker: Chiara Cannici, IT

NG10-4 THE IMPACT OF COVID-19 AND CHANGES TO CLINICAL 15:00 - 15:10

PRACTICE IN STEM-CELL TRANSPLANTATION - A
HEALTHCARE PROFESSIONALS PERSPECTIVE
Speaker: Hayley Leonard, GB

NG10-5 QUALITY OF LIFE FOLLOWING ALLOGENEIC STEM CELL 15:10 - 15:20

TRANSPLANTATION AT ALFRED HEALTH
Speaker: Bianca Cirone, AU

Q&A 15:20 - 15:45

Workshop
14:30 - 15:45 Auditorium 4
W08 - When modern hematology and antiinfective drugs meet at CYP450
Chair: Oliver Cornely, DE
Chair: Juan Diego Vélez, CO
W8-1 Is it time TDM our recent hematologic advances? 14:30 - 14:45
Speaker: Roger Brüggemann, NL

W8-2 Crossroads of life-saving drugs – Antifungal prophylaxis and 14:45 - 15:00

novel agents in oncology
Speaker: Jannik Stemler, DE

W8-3 Practical consequences of co-administration of life-saving 15:00 - 15:15

drugs
Speaker: Samir Agrawal, GB

W8-4 Q&A 15:15 - 15:45

Data Management
14:30 - 15:45 Auditorium 5
DM04 - Education session 4 - Data Managers' Discussion Forum: Centres, Registries and Study Offices
Chair: Helen Baldomero, CH
DM4-1 From computer to bed-side: improving patient care through 14:30 - 14:45
data collection
Speaker: Juana Schwartz Mota, ES

DM4-2 The BSBMTCT: The Role of National Registries in Data 14:45 - 15:00
Management – The UK Experience
Speaker: Julia Lee, GB

DM4-3 The EBMT Study offices: Using EBMT Registry data 15:00 - 15:15
Speaker: Steffie van der Werf, NL

DM4-4 Discussion forum - Being a data manager: Practical issues 15:15 - 15:40

DM4-5 Closing speech and thanks 15:40 - 15:45

284 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

Speaker: Shelley Hewerdine, GB

Patient Advocacy Sessions

14:45 - 15:45 Auditorium 6
PA2 - Patient Advocacy: Patient engagement in research: PRO, let’s talk about it
Chair: Guy Bouguet, FR
Chair: Anne-Pierre Pickaert, FR
PA2-1 CAB concept and implementation - Key achievement form CAB 14:45 - 15:00
program
Speaker: Natacha Bolaños, ES

PA2-2 Perspectives from a researcher against patient engagement 15:00 - 15:14

Speaker: Sam Salek, GB

PA2-3 Round table discussion with all participants: Arguments on 15:14 - 15:45
whether patient involvement in research is needed and efficient
Speaker: Pushpendra Goswami, GB

Breaks
15:45 - 16:15 Auditorium 1
Coffee Break, Poster Viewing, Visit Exhibition

Plenary Session
16:15 - 17:30 Auditorium 1
P4 - New developments in the field of CAR T cell therapy
Chair: Álvaro Urbano-Ispizua, ES
Chair: Christian Chabannon, FR
P4-1 CAR T cells to prevent antigen escape 16:15 - 16:30
Speaker: Marcela Maus, US

P4-2 Anti-CD123 CAR-T cells for plasmacytoid dendritic cell 16:30 - 16:45
leukaemia (BPDCN)
Speaker: Francine Garnache-Ottou, FR

P4-3 CRISPR-Case to engineer CAR-T cells 16:45 - 17:00

Speaker: Edward Stadtmauer, US

P4-4 Q&A 17:00 - 17:30

Workshop
16:15 - 17:30 Auditorium 2
W09 - HSCT for immune modulation of solid organ transplantation
Chair: Petr Sedlacek, CZ
Chair: Antonio Pérez-Martínez, ES
W9-1 Basis and opportunities of HSCT as a tool to induce 16:15 - 16:30
immunotolerance to SOT
Speaker: Megan Sykes, US

W9-2 HSCT to induce immunotolerance to lung transplantation 16:30 - 16:45

Speaker: Paul Szabolcs, US

285 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

W9-3 HSCT to induce immunotolerance to composite tissue 16:45 - 17:00

transplantation
Speaker: Sebastian Giebel, PL

W9-4 Q&A 17:00 - 17:30

Nurses Group
16:15 - 17:30 Auditorium 3
NG11 - Paediatric session
Chair: Hilda Mekelenkamp, NL
Chair: Teija Schröder, FI
NG11-1 Parent transplant decision making and good parent research 16:15 - 16:35
Speaker: Pamela Hinds, US

NG11-2 eHealth, home care and self-management in paediatrics 16:35 - 16:55

Speaker: Inger Kristensson Hallström, SE

NG11-3 Gamified mobile health intervention Triumf to prevent 16:55 - 17:15

psychological problems and support behavior change:
Learnings from a qualitative study among pediatric cancer
patients
Speaker: Kadri Haljas, EE

NG11-4 Q&A 17:15 - 17:30

Special Session
16:15 - 17:30 Auditorium 4
SS06 - COVID 2: The Impact of COVID-19 in HSCT and Cellular Therapy: a year from the start of the pandemic
Chair: Anna Sureda, ES
Chair: Rafael de la Cámara, ES
SS6-1 EBMT recommendations and prospective registry study 16:15 - 16:30
Speaker: Per Ljungman, SE

SS6-2 The challenge of COVID-19 a year on in Germany 16:30 - 16:45

Speaker: Lutz Müller, DE
Speaker: Judith Schaffrath, DE

SS6-3 The challenge of COVID-19 a year on in France 16:45 - 17:00

Speaker: Alienor Xhaard, FR

SS6-4 The challenge of COVID-19 a year on in the Netherlands 17:00 - 17:15

Speaker: Mette Hazenberg, NL

SS6-5 Q&A 17:15 - 17:30

How do I … ?
16:15 - 17:30 Auditorium 5
HDI5 - How Do I... manage stem cell mobilisation in special cases? - Supported through an unrestricted educa
by Sanofi
Chair: Nina Worel, AT
HDI5-1 Mobilisation of healthy donors - Standard procedures and 16:15 - 16:40

286 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

perspectives
Speaker: Kristina Hölig, DE

HDI5-2 Mobilisation in children 16:40 - 17:05

Speaker: Claudia Del Fante, IT

HDI5-3 Q&A 17:05 - 17:30

Joint Session
16:15 - 17:15 Auditorium 6
JS03 - Joint session EHA
Chair: Nicolaus Kröger, DE
Chair: John Gribben, GB
JS3-1 Update of European management recommendation for CAR T 16:15 - 16:35
cell therapies
Speaker: Ibrahim Yakoub-Agha, FR

JS3-2 CART, where are we going? 16:35 - 16:55

Speaker: Michael Hudecek, DE

JS3-3 Q&A 16:55 - 17:15

Nurses Group
17:30 - 18:00 Auditorium 3
NG12 - Nurses Closing Session
Chair: John Murray, GB
Chair: Klara Kabatova-Maxova, CZ
NG12-3 Best of the best: Abstract prizes 17:30 - 17:35
Speaker: John Murray, GB

NG12-4 Highlights from physician's sessions 17:35 - 17:50

Speaker: Anna Sureda, ES

NG12-5 Presentation of Prague 2022 17:50 - 18:00

Speaker: Klara Kabatova-Maxova, CZ

General
17:35 - 18:10 Auditorium 1
GS4 - Closing Ceremony
Chair: Nicolaus Kröger, DE
Chair: Rafael Duarte, ES
GS4-1 Presentation of the Springer Nature Poster Awards 17:35 - 17:40
Speaker: Nicolaus Kröger, DE

GS4-2 Congress President closing remarks 17:40 - 17:50

Speaker: Rafael Duarte, ES

GS4-3 Local Co-Presidents for EBMT 2022 Prague: Welcome 17:50 - 18:00
Speaker: Petr Sedlacek, CZ
Speaker: Pavel Jindra, CZ

287 / 288
Scientific program 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) 14-17 March Virtual

GS4-4 EBMT President closing remarks 18:00 - 18:10

Speaker: Nicolaus Kröger, DE

288 / 288